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DEVELOPMENT OF BIOCOMPATIBLE MULTI-DRUG CONJUGATED
NANOPARTICLES/SMART POLYMER FILMS FOR BIOMEDICINAL
APPLICATIONS

Kerriann R. Greenhalgh

ABSTRACT
It has been reported by the American Burn Association that 4,000 people die every year
due to burn injury. After survival of the initial trauma, the next major obstacle that must
be overcome is combating bacterial infection, the primary cause of mortality for burn
victims (Chapter 1). The polyacrylate nanoparticle drug delivery system was created to
provide a water-based solution for delivery of highly lipophilic antimicrobials; such as Nthiolated β-lactams, however, with the success of this system for these antimicrobials, it
was extended towards other, commercially-available water-soluble antimicrobials
through acrylation of the drug monomers, including those with observed bacterial
resistance (Chapter 2).
Various antibiotics were incorporated into this polyacrylate nanoparticle delivery system
by either encapsulation or covalent attachment, and the antibacterial activity was
determined in vitro (Chapter 3). Since current treatment of burn wound infections calls
for numerous antimicrobials in order to combat the vast array of microbes that may be
present in the wound, a multi-drug conjugated nanoparticle system was constructed and
analyzed for antibacterial activity against many pathogens commonly found in burn
wounds (Chapter 4). In vitro antibacterial assays suggest that the nanoparticle delivery
system rejuvenated the activity of penicillin-based antibiotics against formerly resistant
microbes, such as methicillin-resistant Staphylococcus aureus.
The multi-drug conjugated nanoparticle emulsion had the added benefit of forming a
drug-conjugated polyacrylate polymer film through air-drying and polymer coalescence.
Upon topical application to a skin abrasion in a mouse model, a protective barrier was
created over the wound. This film exhibits mechanical properties similar to elastin, a
pliant biological material, giving it the elasticity and flexibility required to move and
interact with the wound in the same fashion as intact skin (Chapter 5). This film also
xxv

permits diffusion of essential nutrients and small molecules (such as oxygen and water)
required for wound healing. The emulsion was able to be combined with other biological
materials, such as collage, to form a biocomposite material expressing the most optimal
properties from each constituent (Chapter 6). In vitro cytotoxicity analysis (Chapter 7)
and in vivo toxicity studies (Chapter 8) produced positive results indicating that the multidrug conjugated nanoparticle emulsion is a promising new treatment for the burn wound
and other topical skin and soft tissue infections.
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CHAPTER 1
BURN WOUND TREATMENTS AND COMPLICATIONS
1.1 Introduction
It has been reported by the American Burn Association that 500,000 Americans seek
medical attention, 40,000 are hospitalized, and 4,000 die every year due to burn injury.[1]
Children, who are at a higher risk of mortality from burn wounds due to weaker immune
systems and who have lower body surface area, often receive wounds covering a larger
area of the body, thus making treatment even more difficult, and have mortality rates
even higher than seen for adults, up to 84%.[2] Mortality rates due to burn wounds are
staggering when the total body surface area (TBSA) is greater than 50%, and even greater
when the majority of the wounds are third degree, extending through the dermal layer and
into the subcutaneous region. This is because the skin is an essential organ involved in
regulating body temperature, preventing fluid loss, and providing the body’s main
defense against infection, and when damaged, leaves the entire body vulnerable to
numerous pathological problems.[1] When patients are able to survive the initial trauma
and shock of a burn wound, the next major obstacle the patient must overcome is
combating bacterial infections, which is the primary cause of mortality for these
patients.[3]
Burn wounds must go through several stages before the wound can be fully healed, and at
each stage there are many complications, issues, and treatment options that must be
addressed in order for the wound to heal properly and have a low risk of hypertrophic and
keloidal scarring. Initially, burn wounds require cooling in order to terminate the
spreading of internal tissue damage.[4] Cooling the wound upon hospitalization has also
shown to improve wound healing and has been known to decrease local oedema at the
wound site,[4] which is why moist occlusive dressings, and more recently hydrogel sheets,
are used upon admittance to a hospital. Once cooled, the first stage a burn wound goes
through is often referred to as the infectious period,[5] where the wound is at its most
vulnerable state to microbial invasion. It is in this stage of healing that surgical options
are minimal, and the patient must rely upon topical antimicrobial treatments and
prophylaxis for wound protection. At this stage of wound healing is when the patient is at
the highest risk of mortality. Following this stage is when necrosis and agglutination
occur,[5] and the wound bed can undergo debridement procedures followed by surgical
grafting procedures to provide a more substantial wound coverage and treatment plan.
The final stage of wound healing only occurs once all infections have been cleared from
the wound and all necrotic tissue has been excised. At this stage re-epithelialization
occurs,[5] as cells are able to proliferate and wound contraction is observed. Proper cell
function and optimal healing conditions at this stage are crucial for minimizing scar
formation.
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While there are numerous treatments available for burn wounds and wound infection
prevention, the best course of treatment ultimately depends on the depth and severity of
the burn wound.[6, 7] First degree burn wounds, which only affect the epidermal layer of
skin, usually heal naturally within a few days and do not require any antimicrobial
treatments. These wounds are commonly inflicted by excessive sun exposure. Second
degree burn wounds that extend through the epidermal layer and affect the dermal region
of skin often require antimicrobial treatment and will produce blistering. These wounds
often take 2-3 weeks to heal, and if deep enough, can require debridement and grafting
and result in hypertrophic scarring if unattended. Third degree burns are the most severe
burn wounds that penetrate through the entire cutaneous region and into the subcutaneous
region. These burns produce scarring even with surgical intervention and treatment.
Some of the most commonly employed treatments for third degree or full thickness burn
wounds are surgical-based, including autografts, allografts from cadaveric skin, synthetic
wound dressings, and xenografts from porcine skin.[3, 6-28]

Figure 1.1. Anatomy of human skin and subdermal layers. Image obtained from the
National Library of Medicine.[29]

These aggressive surgical procedures are being continuously improved to enhance patient
care, and have been known to decrease pain, shorten hospital stays, assist infection
prevention, and decrease the number of operative procedures.[2, 8] Early wound
debridement has become one of the most common burn wound treatments since the early
1970’s, regardless of the degree of injury, and is essential for any surgical treatments to
be successful. Since its introduction to the medical field, debridement procedures have
been a major factor in decreasing mortality rates over the past three decades.[7, 10]
Mechanical/surgical debridement is the most frequently performed technique and uses a
scraping tool for removal of the necrosized tissue, which is one of the most painful
procedures performed on burn victims and is not a selective means of necrotic tissue
2

removal. Recently, biotechnical advances have been made that utilize the degratory
powers of enzymes to breakdown the damaged collagen, elastin, and fibrin molecules in
the wound bed, and companies now manufacture numerous enzymatic kits for such
purposes. While these surgical techniques, including skin grafting and debridement
procedures, assist in preventing loss of fluids, promote wound healing, and provide some
degree of protection from infection, many factors, such as time, patient stability, and
available donor skin, influence whether these procedures can be performed. [2, 10]
Inevitably, this influences whether the patient will be at a greater risk of developing
infection and sepsis.
When a burn occurs that is third degree (full thickness), the epidermis is completely
compromised, along with some of the dermis as well, leaving the underlying necrotic
burned eschar exposed, which is comprised of collagen, fibrinogen, fibronectin,
denatured proteins, mediators, and toxins.[10, 11] Many bacteria contain receptor proteins
that recognize and bind these cells, including Staphylococcus aureus strains that contain
receptors which interact exclusively with the exposed human cellular matrix
components.8 This allows S. aureus to inhabit and become one of the most common
pathogens found in burn wounds.8 Infections caused by these and other microbes can
slow healing, damage the remaining healthy tissue surrounding the wound, and lead to
infection in the blood stream, sepsis and toxic shock syndrome (TSS).[12] In order to
lower the morbidity and mortality rates in burn patients, an effective treatment is needed
that will prevent the spread of infection from the wound beds thereby preventing these
dire situations from developing.
While surgical graft procedures continue to rise in popularity, they require a high degree
of patient stability since anesthesia and major fluid loss is associated with such
procedures.[8] Patients often are not eligible for these surgical procedures until 6 to 10
days after the initial burn, during which time various wound dressings and antibiotic
treatments are commonly employed in an attempt to combat infection in the wounds.[13]
Research and development has moved further away from making improvements to
topical antibiotic therapies and has focused more on better surgical procedures, which are
only successful and can only be initiated after the patient has already recovered
sufficiently and exudation of the wound has lessened,[8] during which time the patient is
at a high risk of infection. A once booming area of research has thus been abandoned,
leaving behind a dire need for new and innovative antibiotic development. The
occurrence of nosocomial-based infections has continued to grow since this standstill,
and the predominance of multi-drug resistant bacteria infiltrating burn wounds has
continued to rise, while few new therapies have been explored in the past decade or
more.[8, 14] Thus new and improved analgesics, antibiotics, and immunity-promoting
therapies are urgently required for severe burn wound treatment.[8, 14]
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1.2

Wound Dressings for Infection Treatment and Prevention

1.2.1 Various Silver-Doped Dressings
Research to improve antimicrobial wound dressings have continued to be explored by a
select number of pharmaceutical companies and researchers, however, products have not
been significantly improved in the past 20 years. The mainstay of burn wound care has
revolved around silver-doped antimicrobial bandages as temporary wound dressings,
which has been the major topic in wound dressing research for the past 20 years. These
bandages contain antibacterial properties through the silver constituent, commonly
presented in the form of silver salt solutions, where silver sulfadiazine is the most
commonly used and is considered the benchmark for silver-containing dressings.[30] The
use of such metal-doped bandages is to reduce bacterial infection at the site of the wound
and also to aid in sepsis prevention.[30] Since the emergence of drug resistanct microbes
has limited the use of antimicrobials in wound dressings, many companies have begun
manufacturing wound dressing products containing various forms of silver salts as the
sole antimicrobial constituent. Some of these products include silver nylon
cloth/activated charcoal (Actisorb®),[31] silver sulfadiazine with cerium nitrate
(Flammacerium®),[30] silver absorbent wound dressing (SilvaSorb®),[31] silverimpregnated polyurethane (PolyMem Silver®),[31] and silver sulfadiazine-impregnated
lipidocolloid wound dressing (Urgotul SSD®).[30, 31] While these dressings display
antibacterial activity, they must be continuously changed due to a one time release of the
silver constituent into the wound bed. The process of changing dressings can be
extremely painful, potentially damaging, and highly risky.[30] The recently developed
nanocrystalline silver-coated dressings ActicoatTM and Silverlon® released onto the
market in 1999 have shown controlled, prolonged release of the silver constituent into the
wound area, thereby decreasing the frequency of dressing changes.[30, 32, 33] Unfortunately,
due to the controlled release of the silver, the levels of silver that is delivered to the
wound is below the bacteriocidal levels necessary to prevent resistance formation.[30]
Even though the need for frequent dressing changes has been reduced, daily application
of dressings is still required for this type of product; therefore, the heightened risk of
nosocomial-based infections and tissue damage still remains with this form of treatment.

1.2.1.2 Issues with Silver Dressings
Bacterial drug resistance towards the silver-based dressings has been shown to form in
clinical applications despite no observation of resistance in vitro. This development is
belived to form through one of two biochemical routes: bacteria can bind the silver once
inside the cell forming an intracellular complex, or the silver can be excreted from the
cells prior to invoking its antibacterial activity through the cell’s efflux systems.[30]
Another issue with the use of silver-containing dressings is the amount of silver available
in the wound and the inverse relationship with the concentration of silver required for
antibacterial activity. In all products described above, if the silver is delivered to the
wound in a burst effect, as is seen with silver salts, then the concentration in the wound
bed is high enough for bacteriostatic and bacteriocidal properties; however, this activity
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does not last long and the silver must be replenished often.[30] The other form of silver
delivery is through nanocrystalline silver delivered through a controlled release
mechanism, yet this does not provide the wound bed with a high enough concentration of
silver at a single time point to invoke a bacteriocidal effect, and thus allows the bacteria
to form resistance to the silver.[30] Recent studies have established that the use of
ActicoatTM with cultured keratinocytes and other cultured skin substitutes can be
cytotoxic within one day and can inhibit re-epithelialization,[30] while Silvazine® has
been shown to have the highest degree of cytotoxicity among the silver-containing wound
dressings.[30] One benefit of the silver substances for wound treatment, especially the
nanocrystalline silver incorporated in the ActicoatTM and Silverlon® wound dressings,
have been shown to promote wound healing through decreasing matrix
metalloproteinases (MMP), which are biomolecules known to cause tissue destruction
and cellular apoptosis.[30] However, not all silver-based complexes have these additional
beneficial properties and can even be detrimental to the wound healing process itself.

1.2.2 New Matrix Materials Promote Healing and Antimicrobial Delivery
Research has recently been conducted on different matrix materials for the delivery of the
silver complexes in order to increase antibacterial efficiencies and promote wound
healing in the wound dressing products. Absorbable collagen fiber matrices, synthetic
polymer-based materials, and chitosan-based biomaterials have all been incorporated into
wound dressings, each having its own advantages and disadvantages.[5, 30] The two main
ideas behind each of these new materials for wound dressings is to create a biodegradable
matrix to which the silver particles can adhere and be released, and provide a controlled
release of the metal or metal complex into the wound bed, thus extending the lifetime of
the dressing. These materials have also been chosen in order to increase the absorbability
of the dressing, which allows exudates from the wound bed to be removed without
invasive procedures, essentially cleaning out the wound bed.[5] Both of these properties
contribute to promotion of wound healing and reduced time before additional
reconstructive surgical procedures can be performed. However, with this absorption
property comes the risk of exudates sticking to both the bandage and the wound bed, thus
removing some healthy cells and tissue that have infiltrated the wound bed during
dressing changes. This can cause new trauma which reverses wound healing and causes
the area to have to start the wound healing process all over again.

1.2.3 Wound Healing-Promoting Dressings
Apart from antimicrobial dressings, research has also developed dressings that promote
wound healing by including extra cellular matrix (ECM) proteins and growth promoting
factors. Hybrid peptide synthesis has led to wound dressings that mimic the peptide
makeup of elastin and laminin, two major ECM proteins known for promotion of cellular
adhesion and proliferation. These peptides provide a facet for cellular attachments and
induction of otherwise inhibited wound healing.[34] When placed in conjunction with an
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alginate fibrous dressings, the hybrid-peptide dressing was able to promote granulation
tissue regeneration and epithelialization in the wound bed,[34] thus providing a new
approach to wound healing that does not involve artificial skin substitutes and is optimal
for chronic wounds where healing is highly impaired. However, this form of wound
dressing does not provide the wound with antimicrobial treatment, and thus must be used
with a topical antimicrobial agent that can impede peptide access to the wound bed and
limit the effectiveness of the dressing towards wound healing. Some types of wound
dressings provide the wound bed with a moist environment, which not only cools the
wound but also provides the moisture it needs for healing.[4] Most dressings applied
during this initial phase of treatment but often contain analgesics to help manage pain but
do not contain antimicrobails, which is why by the second or third day of hospitalization
the wound bed has succumbed to total microbial invasion. It is here that improvements
must be made to provide the wound not only with adequate moisture, but also with
antimicrobial therapy for bacterial eradication and wound coverage for protection from
translocation of opportunistic pathogens.

1.3 Current Antimicrobial Treatments
1.3.1 Silver-Based Creams
Silver-containing creams and solutions have been used for infection control since the
1880’s, where silver nitrate was the first silver salt used for such an application.[31] While
this silver salt was a successful bacteriocidal compound, it displayed caustic effects on
human tissue,[31] and thus other forms of Ag+ and other ways of delivering Ag+ to the
infection site have been an important research topic in infection treatment. The use of
silver as an antimicrobial died out at the onset of antibiotic discovery, but has recently
gained strength again due to the emergence of multi-drug resistant bacteria. Today, silver
sulfadiazine creams (Silvazine® and FlamazineTM) are common topical ointments that use
silver metal substrates as the antimicrobial for infection control, where Silvazine® also
has chlorhexidine digluconate as a drying agent and additional cleanser.[30, 31, 35] While
both silver sulfadiazine creams and silver nitrate solutions are used clinically, silver
nitrate solutions must be applied up to 12 times a day, while silver sulfadiazine creams
can be applied only twice a day.[30] Silver sulfadiazine has also been coupled with cerium
nitrate to provide even more efficient antibacterial activity, and in this formulation, has
shown to limit wound contamination even in cases where debridement cannot be
performed until over five days after burn injury.[36] Conventionally, these silvercontaining ointments are used with paraffin gauze dressing, although studies have shown
that this form of wound dressing with such topical antimicrobials is not optimal.[37] One
of the major drawbacks of using silver-containing topical ointments is the occurrence of
the light-sensitive formation of black colloidal Ag0 on the skin surface.[31] When this
happens, the skin becomes a dark bluish black color, which is irreversible and a
permanent cosmetic issue.[31] Companies producing these silver-containing creams and
solutions have attempted to overcome this issue with the addition of sulfadiazine to help
prevent this metal reduction by allowing the Ag+ to stay in the solution.[31] The efficacy
6

of any silver compound is greatly diminished by organic matter, i.e. burn wound
exudates, interacting with chloride ions present in the wound.[30]
Another drawback of these topical silver creams is delayed wound healing and eschar
separation, which prevents sloughing off of necrotic tissue from the wound bed.[30] These
creams also can produce toxicity when applied frequently over a long period of time over
a large surface area and can lead to hypertrophic scarring upon healing.[30] Silver nitrate
solutions and silver sulfadiazine creams have shown high levels of toxicity in vitro
against fibroblasts and keratinocytes and increased inflammation in clinical trials, where
inflammation is more than likely due to the cream base in silver sulfadiazine.[30] In vivo
and clinical studies have shown that silver can be taken up by epidermal cells and passed
on to the peripheral circulation where renal toxicity can then occur due to high
concentrations of silver in the blood and urine.[30] This observed toxicity is mainly due to
the fact that silver, when in simple salt form, cannot differentiate mammalian cells from
bacterial cells, and thus will accumulate in either; therefore, extended periods of topical
silver cream application over a large wound area can cause extensive damage to the
wound itself and to other systems in the body. The silver sulfadiazine creams, along with
commonly used mafenide acetate and gentamicin sulphate creams all have shown
bacterial resistance in clinical settings;[38] therefore, a new approach to antimicrobial
treatment in burn wounds needs to be brought to light.

1.3.2 Peptide-Containing Dressings
Recently, peptide research has looked into forming synthetic and naturally occurring
antimicrobial peptides for their antibacterial properties. Synthetic peptides such as
Novispirin G10[39] and natural host defense peptides (HDP)[38] have been explored for
such purposes. HDPs have been looked at because of their role in the innate immune
response to foreign pathogens and are transcribed in response to a pro-inflammatory
response initiated by pathogens.[38] After burn injury, local expression of HDP is greatly
reduced, which allows microbes to colonize the wound bed;[38] therefore, an obvious
method of treatment would be to re-introduce this peptide into the wound bed in an
attempt to make up for its lack of cellular production after burn trauma. A common mode
of action for antimicrobial peptides is to alter the permeability of the microbe’s
membrane, however, they also have great wound healing benefits and display a broad
spectrum antimicrobial activity.[39] While both naturally occurring and synthetic peptides
have their own benefits and flaws, naturally occurring peptides have shown cytotoxic
effects and have high costs associated with manufacturing processes,[39] therefore,
synthetic means of peptide manufacturing for antimicrobial applications may be the most
optimal form of antimicrobial peptides.
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1.3.3 Drawbacks of Current Topical Antimicrobials
The use of topical chemotherapy has helped to improve the survival of patients with
major burns and to minimize the incidence of burn wound sepsis, a leading cause of
morbidity and mortality in these patients.[30] Unfortunately, with the use of topical
ointments or creams for treatment of skin wound infections, frequent application and
scraping off of the wound region is required, often leading to increased pain and trauma
for the patient.[5, 31] This limits the use of topical creams, ointments, and gels for wound
infection management, especially in wounds that cover a large region of the body where
spreading on such treatments would cause more trauma and damage than is acceptable.
Added to this issue is the fact that many creams can form an overlying slough on the
wound bed that renders it difficult to assess the wound for its degree of healing.[37] It
should also be mentioned that in many hospitals, doctors will take the added precaution
of administering prophylaxis treatments of water soluble antibacterials while a patient is
in the infectious stage as a precautionary measure in case bacteria should migrate into the
blood stream where sepsis is initiated. This helps to decrease the occurrence of sepsis and
TSS in burn patients during this vulnerable time in the wound recovery process.
However, prophylaxis treatment is often ineffective once the bacterial load in a wound
has reached the blood stream, therefore, improvements must be made in topical
antimicrobials to make them more efficient at reaching bacteria deep in the burned tissue
as well as at the surface of the wound bed without having detrimental side effects to
wound healing.
Table 1.1. Ideal properties for biological-based temporary wound dressings.[23]
Optimal Properties for a Burn Dressing
Biocompatibile
Water Permeability and Heat Retention
Protective Barrier against Pathogens and Trauma
Reduces Pain
Adherent, yet Flexible and Conforming
Single Application
Moves with Patient
Low Cost
Long Shelf Life/ Simple Storage
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1.4 Skin Grafts as Prominent Treatment
1.4.1 Human Autografts as Treatment Mainstay
Immediate removal of necrotic tissue through wound debridement followed by effective
wound coverage is essential for adequate wound treatment and rapid wound healing.[9]
One of the best forms of permanent wound coverage and rapid wound repair currently
available to burn patients is human skin autografts,[13] where small patches of split
thickness skin from unburned areas of the patient are excised and permanently grafted
onto the wound bed.[2, 9, 13] These patches are often referred to as postage-stamp
autografts due to their postage-stamp-like size and shape.[13] This gives the skin cells a
matrix onto which new skin can grow. This technique is used to conserve the amount of
donor skin needed, and is preferably harvested from the scalp when available.[13] Since
the grafted skin is from the host itself, no rejection or immune response is observed with
this procedure, and thus the body immediately accepts the implanted skin and begins to
reconnect to it. This procedure minimizes the area of skin that must be rebuilt for the
burn to heal. Cellular migration, which normally must cover the entire wound, now only
stretches to the autografts, thereby decreasing the time required for wound healing. Also,
since the grafted skin is a living system and its cells are viable and unaffected by the burn
trauma, its cells can migrate outward into the wound bed and assist in the repair of the
wound and skin replacement. The expansion ratio of autografted tissue can range from
1:4 to 1:9 in the wound bed,[13] and thus a small skin sample can cover a large area after a
short period of time.

Expansion Ratio 1:4

Expansion Ratio 1:9

Figure 1.2. Depiction of postage-stamp autograft tissue expansion within wound bed.
Patchwork pieces of 1cm2 placed 1cm apart from one another produces an expansion
ratio of 1:4, whereas patchwork pieces placed 2cm from one another yields a 1:9
expansion ratio.[13]
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Autografts are generally only a few cell layers thick, which makes them fragile and
difficult to handle.[2] This also limits the durability of the graft and can cause it not to
fully adhere to the wound bed. These grafts, while being able to fully heal the wound
with time by expanding the skin sample into the wound area, do not cover the entire
wound initially and therefore must be used in conjunction with some form of allograft or
mesh to obtain maximal coverage of the wound.[13] These allografts are used as a
temporary protection only and can be used individually as well as in conjunction with the
autografts for wound protection, since autografts alone are extremely susceptible to
bacterial infestation.[13, 15]

Figure 1.3. Patchwork appearance of skin on the back of the legs upon postage-stamp
autografting procedure (left) and one year after procedure (right).[13] Reprinted from
Burns, Vol. 24, Pgs. 264-269, by Chang et. al. Copyright 1998 with permission from
Elsevier.

Some of the major drawbacks for this type of wound coverage treatment is the occurrence
of additional scarring and/or morbidity at the split thickness skin donor site.[9] Yet this
treatment remains the best option for wound coverage due to its permanent nature and the
ability of both dermal and epidermal skin layers to be grafted onto the wound bed.[9]
While this form of autografting can achieve significant expansion once grafted to the
wound bed, the grafting procedure itself is very difficult due to the fragility and
slightness of the postage-stamp sized skin samples and the grafted skin is easily
dislodged from the wound bed.[13] Due to the non-continuous coverage of postage-stamp
autografts, a patchwork design appears on the skin after wound healing due to
hyperpigmentation of areas receiving the grafts and pink-to-red discolorations in between
each skin graft area. [13]

1.4.1.2 Cultured Epithelial Autografts (CEAs)
While autografts remain the best form of surgical treatment for wound repair,
unfortunately, when the burn TBSA is over 50%, there is little donor tissue available for
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such a technique.[16, 17] Often times, this is the case for children and especially neonates
who have very little available skin for replacement, and scarring at the donor site can be
substantially increased with aging.[18] Thus an alternative to the conventional autograft
treatment was approached that still incorporates the patient’s own skin sample for
treatment, thereby maintaining the permanent aspect of the original wound coverage.[9, 16]

Figure 1.4. Cultured epithelial autograft treatment progress in clinical practice.[16] A and
B are examples of a cultured epithelium on a fibrin matrix for CEA treatment. C depicts
split-thickness meshed human cadaver allograft patches for temporary coverage prior to
CEA treatment. D shows CEA/fibrin-treated skin 3.5 years after procedure. Images
reprinted with permission from Transplantation, Vol. 70, Pgs. 1588-1598 by Ronfard et
al. Copyright 2000 by Lippincott, Williams, and Wilkins.

The cultured epithelial autograft (CEA) treatment relies on the culturing of epidermal
keratinocyte cells in vitro that are obtained from a small biopsy of the patient’s skin. The
area of skin needed for this procedure is extremely small, ranging from a 2 mm2 area to a
2-3 cm2 area, depending on the extent of damage,[9, 19, 20] and thus reduces the added pain
of skin harvesting as is the case for traditional autografts.[5] The biopsy sample is treated
to remove any subcutaneous tissue then the epidermal and dermal layers are separated so
that only the keratinocytes remain in the harvested skin sample.[9, 20] These cells are then
placed onto a biological matrix and allowed to expand onto the matrix to form a large
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sheet of epidermis, usually 8-10 cell layers thick.[8, 9, 16, 18-20] Many scientists have
identified numerous matrix materials for such applications, including polyurethane
membranes, silicon-collagen membranes, collagen only membranes, hyaluronic acidbased membranes, collagen sponges, and fibrin glue.[8, 9, 16, 20] These materials act to not
only provide a basis for the keratinocytes to replicate, but also as a pseudo-dermis when
applied to the wound bed. However, the lack of a true dermal layer has limited the use of
CEA in hospitals.[7, 8]

Scheme 1.1. Process for culturing CEA tissue, originally proposed by Rheinwald and
Green.[9, 20]

Since the discovery of this culture technique by Rheinwald and Green in 1975 and the
initiation of its clinical use by O’Connor et al. in 1981, this treatment has saved many
lives and improved the overall quality of life for thousands of burn victims.[9] This
treatment method has now become the one of choice for doctors around the world when
the TBSA is greater than 65-70%, where traditional autografts are not suitable treatment
options.[9] This treatment has shown in hundreds of patients the ability to shorten the time
required for wound healing through numerous advantageous properties, including the
ability to stimulate wound re-epithelialization from both wound edges and within the
wound bed itself,[19] and is able to regenerate itself many years after the transplant.[16]
Researchers are still looking to understand the full extent of this stimulatory action
exhibited by the CEA treatment.[19] The appearance of redness and scarring upon
complete wound contracture has been significantly reduced through this procedure as
well.[18] Burn areas covered with CEA, as opposed to split thickness autografts, have a
normal epidermal histology, a smoother surface, and elasticity in the skin after a few
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years of healing, indicating that the epidermis is able to regain its original biological
processes of continual regeneration.14 These grafts also have a higher probability of
“taking” or being accepted by the wound bed as compared to traditional allografts, by at
least 30%,[12] thus making them a much more permanent treatment for wound closure.
However, recent studies have reported that the meshed autograft still remains the best
option for full thickness burns in terms of length of hospital stay, procedural costs,
number of readmissions for re-opening of wounds and reconstruction of scar
contractures, and bacterial susceptibility.[7, 9] One drawback of this technology is that
only the epidermis can be reconstituted, and therefore it is not an approach that can be
used to treat large full thickness wounds that enter the subcutaneous region since no
keratinocytes are available in this area for the CEA to interact with.[7, 19] Even when it is
beneficial to use CEA as a means of permanent wound coverage, in order to obtain the
CEA tissue, a 3-4 week period of cell culturing for a decent size epithelium sheet to grow
is required,[9, 18] however, advances in the matrix used for epithelium construction have
recently shortened this time period to 2-3 weeks.[16] Within this time period a 3 cm2
biopsy of donor tissue cultured under these conditions can grow to be 5000–10,000-fold
larger, yielding a sample large enough to cover an entire adult[9] while the patient is
undergoing continuous treatment for burn shock, burn wound excision, and wound
preparation including bacterial eradication for the CEA graft.[21] There are still many
questions that need to be answered before this technique can become an optimal
treatment for burn wound closure, regardless of the degree of TBSA burned, including
issues of cellular confluency, optimal cell type for culturing, and optimal matrix
constituents, as well as gaining a better understanding of the benefits of this technology
on a cellular level.[9, 19]

Table 1.2. Comparison of patients treated with CEA versus traditional allograft
techniques used when TBSA >90%.[7]
Patients Receiving CEA
Treatments

1.4.2

Patients Receiving Other
Treatments

Total Operations

13

8

Days of Hospitalization

128

89

Cost per patient ($1k)

304

178

Donor Allograft Skin as an Alternative Treatment

For deep tissue burns where the dermal layer is compromised, full or split thickness
allografts are often used as temporary wound closures and for protection against bacterial
invasion and fluid loss.[6] Studies have established that when this treatment is performed
within six to ten days of the initial burn wound it can reduce the length of stay (LOS) at a
hospital by 15.7 days.[22] Yet, this treatment was not able to significantly reduce the
13

mortality rate in patients.[22] This again is due to the length of recovery time needed by
the patient prior to this treatment, during which time bacterial invasion is at its highest
probability. Skin and tissue banks have only recently began to harvest cadaver skin for
allograft purposes, some as recently as 1998,[22] thus the popularity and low cost
associated with this burn wound treatment has only recently been established in the
treatment of burn wounds. Of course, there are inherent issues when using donated
cadaveric skin for allografts, including discoloration of the skin post-mortem and
variances in skin texture and tone among races.[22] While tissue banks are growing in size
and number of donations daily, public awareness is still significantly low,[22] and large
strides need to be made in order to make this treatment more affordable and available to
patients in all areas of the world.
Adherence of human cadaver allograft skin (HCAS) to a wound bed has previously been
thought to signal physicians that a bacterial load in a wound bed is minimal, thereby
indicating when further permanent autograft treatment can be initiated.[15] However,
recent studies have shown that this is not the case, and that bacterial infections are still
able to manifest within the wound bed even with allograft coverage.[15] Dermal allografts
from human cadaver skin are also possible and can be used in conjunction with CEAs
and other epidermal-based grafts without any observed rejection.[8] There are many issues
that can arise when using HCAS, such as transfer of microbes, viruses, and viral diseases
from donor cadaver skin to burn patients, whose immune systems are already
compromised.[2, 8] The issue of host rejection of the allografts is currently being studied
and efforts are being made to suppress the host immune response to such grafts, thereby
extending the length of application of the allograft to the wound.[2] A topical treatment
containing cyclosporine A has been reported to give site-specific immunosupression
when applied to the graft, thereby extending the time of the graft placement on the host
by 50-75% over the norm.[2]

1.4.3

Porcine Xenografts as a Last Resort Treatment

As medicine has progressed so have the treatment options available for burn wound
management, yet in many cases the original treatment is still the best option. Xenografts,
or skin grafts originating from a different species, have been in use since the 16th century
and are often still the grafting technique of choice for many hospitals around the
world.[23, 24] This is especially true for third world countries and areas that cannot afford
expensive alternative treatments and when donor skin is limited.[22-24] Many regions
around the world do not have skin banks or places where they can obtain donor skin from
humans and they must rely solely on autografts, family members for donated skin, or on
xenografts for wound coverage.
The most frequently used skin type for xenografts is porcine skin, which is grossly
comparable to the anatomy of human skin and has been in use since the 1960’s,[23, 24]
however, pigs are not the only species whose skin has been used for wound coverage.
When xenografts first originated as a treatment option, skin from chickens, rats, pigeons,
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frogs, lizard, cats and dogs was used, and frog skin is still in use in some countries
today.[8, 23] One major benefit of using xenografts for burn wound treatment is the large
amount of tissue available for such procedures at a much lower cost than human cadaver
skin.[23] Since xenografts and allografts are not permanent additions to the body, as is the
case with autografts, they must be able to cover the entire wound for complete protection
from fluid loss and bacterial infection.[6] Both of these grafts are temporary covers for
burn wounds, but unlike allografts that are rejected by the body and undergo
devascularization, xenografts are ejected from the wound surface, which leads to a
shorter period of use and a higher number of surgical procedures.[13, 17, 23] However, both
grafting techniques are temporary and require more than one grafting procedure before
the wound can be completely healed in most full thickness wounds,[6] thus being able to
harvest a large amount of skin specimen is essential. This is often what limits the use of
allografts for these procedures and is why xenografts have remained in use since the 16th
century, even with the advance of newer technologies. Both HCAS and porcine skin
specimens are able to be preserved by glycerol, which reduces antigenicity, virality, and
bacterial loads inherent in the tissue;[8, 23] however, this procedure is very detrimental to
the HCAS due to loss of viability and vascularization.[8] While xenografts contain a
viable dermal matrix, they can never be used as a permanent treatment option due to the
inherent immune response and eventual ejection of the graft from the wound bed.[8]

Figure 1.5. Porcine skin xenograft covering a deep full thickness burn wound.[23]

Many companies have developed manufacturing processes for porcine skin so that it is
more readily available to hospitals and is treated for viral and microbial contaminants
prior to use, yet many hospitals around the world prefer to perform the xenograft
preparation themselves.[23] Companies specializing in xenograft manufacturing have also
looked into chemically modifying the skin specimens to reduce the antigenicity of them
in an attempt to increase their half life after grafting, which unfortunately also reduced
the binding efficiency of the graft to the wound bed.[23] While this method of treatment is
still of great importance in burn wound treatment, especially in Asia where xenografts are
highly preferred over HCAS, there appears to be many areas where this treatment method
can and needs to be improved to make this a more safe and effective method of treatment.
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1.4.4

Synthetic and Biological-Based Artificial Skin Grafts are Promising New
Treatment Options

Artificial wound dressings have been explored by burn specialists since the early 1970’s
as an alternative to xenograft and allograft treatments.[25] They can have various functions
in burn wound therapy depending on numerous factors, ranging from microbial
treatment, temporary wound coverage, permanent wound coverage, and promotion of
wound healing.[25] Due to recent advances in tissue engineering, artificial skin grafts are
being fervently studied in hopes of creating a permanent treatment option that combines
all of the advantages of each currently available graft type.[8] Many different types of
artificial skin grafts are currently being explored for treatment of deep tissue wounds,
including acellular grafts and biological-based full thickness bilayer skin equivalents,[8, 2628]
yet the use of these skin substitutes for burn wound treatment is still not widespread.[8]
Recently, bioengineered bilayer skin grafts have been formed from autologous
keratinocytes covering a layer of allo-based (originating from another human) dermal
fibroblasts in a native collagen matrix, which is set on top of a biological-based material
matrix, thus forming the first multi-layered artificial skin graft.[8, 26-28] One trademark
brand for this type of skin substitute is Apligraf, which has been FDA approved for use in
diabetic ulcers and has been shown to promote healing, yet is not a permanent
treatment.[28] Many of the autologous and allogous cell-based skin grafts have evolved
towards the use of matrix materials to enhance cellular delivery into the wound bed.[8, 2628]
Optimally these materials will be completely biocompatible and will be biodegradable
once applied to the wound bed, thus releasing the cultured cell(s) into the wound for
active proliferation and replication, thereby promoting wound healing. One commonly
used material for this matrix is hyaluronic acid (HA), which is a common extracellular
matrix component.[8] Gelatin scaffolds are also being explored for such basal matrices, in
combination with soluble collagen or by itself, and have shown good results in vitro and
in vivo thus far.[8]
Acellular artificial skin grafts are also a promising treatment option for wound
management. Many of the currently available grafts can work in conjunction with
cultured epithelial autografts,[8] instead of relying upon human cadaver allografts that are
limited by donor availability. The acellular skin grafts can be biological based, such as
using decellularized porcine skin to yield an acellular dermal matrix,[8] or completely
synthetic skin substitutes that can be formed from polymer, collagen, nylon, or silicone
films, to name a few.[8, 25] While these forms of artificial skin will not “take” as is seen
with living skin grafts nor will they make up for lost tissue layers by delivering tissue to
the bed for cells to adhere to, they can aide in wound contraction as well as help deliver
viable cells to the wound beds. Some of these forms of skin grafts, mainly the collagenbased grafts, have been shown to establish a “neodermal layer” in the wound bed when
the fibers are aligned properly.[10, 27] This provides a platform for cells to build the true
dermis and epidermis upon. Unfortunately, these forms of skin substitutes have not
shown nearly the high degree of protection from bacterial invasion as basic split
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thickness allografts in vivo,[25] and thus should only serve as a temporary means of wound
management.
One of the main drawbacks for using skin substitutes in any form of wound treatment is
the high costs associated with such materials.[26] Also, it has been shown that depending
on the matrix material often allo-based dermal and epidermal skin substitutes are rejected
or necrosized upon grafting to the wound bed,[28] thereby limiting the use of
manufactured skin substitutes. A secondary drawback for using artificial skin substitutes
as grafts is the lack of hair follicles in the graft, which essentially equals a lifetime of
hairlessness in that particular region of the body.[28] Until a skin substitute is created that
produces less scaring, is more durable, and requires no other surgical procedures for
recovery, the cost-to-benefit analysis will continue to be in favor of the more traditional
grafting procedures.

1.5 Conclusions
There are many different options available to burn patients today for treatment of burn
wounds. Surgical procedures have made many great advances recently and wound
management has now become multi-dimensional employing numerous techniques for
optimal treatmnet. With the various options available for grafting procedures, the patient
can choose which treatment plan will work best given the circumstances and the degree
of burn injury. However, these treatment options are only available once the patient has
survived the initial infection stage of wound healing, where morbidity and mortality are
at the highest occurrence rate.
A tissue that has been exposed to such heat as to cause second and third degree burns
requires cooling immediately after the trauma in order to stop the damage being caused
by the burn. It also calls for a moist environment initially as well as throughout the entire
treatment in order for the wound bed not to dry up and begin cracking or have wound
contraction begin prior to healing of the deeper tissue areas. Unfortunately, there are no
current treatments that provide the wound bed with the moisture it needs and provide it
with an antimicrobial to help control the onset of an infection in the wound bed. It is here
that improvements must be made to provide the wound with moisture and antimicrobial
therapy for bacterial eradication, and also protection from microbial translocation into the
wound bed.
While undoubtedly antimicrobial treatment is a must for initial burn wound infection
management, there are no currently available treatments that do not cause some
additional pain and trauma for the patient. The use of topical ointments and creams are
effective at controlling the infection at the wound site, however, their painful application
and cleaning process, which must be repeated continuously until surgical procedures can
be instilled, are very damaging to the patient and often times microbial resistance and
delays in wound healing accompany such therapies. While this issue is able to be avoided
through the use of antimicrobial bandages, often containing some form of silver species,
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the fact that these bandages must be changed frequently still poses a risk of wound bed
disruption. Use of either of these treatments yields an increased threat of nosocomial
infection due to the frequent hands-on interaction of the patient with the hospital staff.
In the next few chapters of this thesis, a hands-free water-based sprayable antimicrobial
system that allows for antimicrobial infiltration deep into the wound bed with targeted
drug delivery and high drug efficacy will be described, which provides wound bed
protection through a synthetic elastin-simulating polymer film formed on the surface of
the wound bed. This system combines the advantages of the moist hydrogels, the
antibacterial wound dressings, and the antimicrobial ointments without the occurrence of
any of the common drawbacks associated with these treatment options, thereby providing
a novel treatment for initial burn wound management that has all the benefits without any
apparent downsides.
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CHAPTER 2
ANTIMICROBIALS AND MRSA TREATMENTS
2.1 Introduction
Burn wounds provide one of the most optimal environments for bacterial cultivation.
Staggering amounts of bacteria initiate infection in burn wounds by the second or third
day after injury, and if left untreated, can infiltrate the blood stream and cause sepsis and
eventually death. Numerous bacterial species are typically involved in burn wound
infections; it has been found that up to 20 different species and strains of bacteria can
inhabit a burn wound at the same time.[1] Many of the bacteria found in burn wounds
usually live harmlessly on the surface of the skin, however, when an abrasion or wound
to the skin occurs, these opportunistic bacteria become pathogenic and invade the wound
or abrasion causing an infection. Bacteria like Staphylococcus epidermidis,
Staphylococcus aureus, and others that comprise the common skin flora turn deadly upon
wound infiltration. Upon initial thermal injury, gram positive microbes such as S. aureus
and S. epidermidis are prevalent, and resistant strains of these microbes quickly arise
during this time. However, as the wound progresses, gram negative microbes, especially
motile microbes such as Pseudomonas aeruginosa and Escherichia coli become
predominant within the wound due to their opportunistic and incursionary nature.[1] The
majority of these microbes come from the normal flora present within the gut and
intestinal lining, and migrate into the wound only a few days after injury. Therefore, the
need to treat these wounds with effective antimicrobials prior to bacterial resistance
formation and secondary gram negative invasion is paramount to expedited wound
healing and survival.
In 1998,[2] the Turos laboratory reported a new type of β-lactam antibiotic called Nthiolated β-lactams that possess good antimicrobial activity against select bacteria,
including methicillin-resistant S. aureus (MRSA). MRSA infections readily occur in burn
wounds and are a major threat to patients if optimal treatment cannot be provided. While
numerous penicillin-based analogues have been developed since the initial onset of
MRSA in the 1960s, relatively few are able to resist the ring-opening action of this
microbe’s penicillin defense enzyme, β-lactamase.
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2.2 Synthesis of N-Alkylthio β-Lactams
2.2.1 Introduction
Cl
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Figure 2.1. N-thiolated β-lactam structure.

Figure 2.1 shows the chemical structure of a typical N-thiolated β-lactam. The bioactivity
of these N-thiolated lactams is unlike all other β-lactam compounds previously studied,
which suggests a completely different mode of action than has been previously described
for this class of antibacterials.[3] The spectrum of antimicrobial activity has been largely
characterized,[3-9] however, no activity has been observed for gram negative bacteria or
most gram-positives. It is significant and very curious that only a select number of
pathogens are sensitive to the N-thiolated lactams, including staphylococci (S. aureus,
MRSA, and S. epidermidis) as well as numerous Bacillus species, including B. anthracis.
The activity of this class of drug seems to be insensitive to changes at the C3 and C4
centers of the lactam ring to an extent.[3-9] The original alkynyl substituents present at the
C4 position of the lactam ring has been substituted with E or Z alkenyl, alkyl, aryl, and
heteroaryl moieties without any apparent effect on the biological activity.[3] Yet what is
key for the activity of these compounds is the presence of a short chain alkyl group on the
N-thiolated portion of the ring structure. When the thiol group is removed,[6] or the alkyl
group is changed to a bulkier group, activity is lost. As well, the ring structure can also be
expanded to a 5-membered ring, such as in 2-oxazolidinones, and activity remains with
the existence of the N-thiolated portion for these as well (Figure 2.2).[3]
O

O

R

N

SR"

R'

Figure 2.2. Structure of N-alkylthiolated oxazolidinones.
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2.2.2 N-Alkylthio β-Lactams for Nanoparticle Encapsulation
The β-lactams discussed in this chapter are highly lipophilic molecules that are
completely insoluble in water, and only moderately soluble in dimethylsulfoxide
(DMSO), which displays cytotoxicity in mammalian fibroblasts when concentrations of
solutions contain greater than 10% of this solvent. Therefore, there is an obvious problem
when attempting to study the antibacterial activity of these drug monomers applied to in
vivo settings. Also, this solubility issue greatly limits the clinical potential of these
antibiotics. Since the β-lactams have shown potent anti-MRSA activity, and MRSA is
one of the leading causes of sepsis and toxic shock syndrome (both blood borne
infections) that are associated with high mortality rates, it is imperative that a delivery
system be established for these drug monomers in order to make them accessible to these
types of infections. Here, the synthetic design of these N-alkylthio β-lactams is described
that will later be incorporated into a water-based nanoparticle drug delivery system
(Chapter 3) that will provide the drug with systemic application capabilities as well as
treatment capabilities in lipophilic regions of the body where many life-threatening
infections are initiated.
Scheme 2.1. Synthesis of lactam monomers 2, 4, 6 and 10.
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N-Alkylthio β-lactams 2, 4, 6, and 10 were prepared by the series of reactions illustrated
in Scheme 2.1. The four step synthetic sequence was initiated by the synthesis of N-(4methoxyphenyl)imine 103 from o-chlorobenzaldehyde (101) and p-anisidine (102).
Staudinger coupling of alkoxyacetyl chloride (104) and imine 103 by a formal [2+2]
cycloaddition led to the formation of the racemic cis-(3S,4R)-substituted β-lactam 105.
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Removal of the p-anisidine protecting group through an oxidative cleavage mechanism
was accomplished with the use of ceric ammonium nitrate (CAN) in a strict volume:mass
ratio of the water and acetonitrile solvents per mg of reactant used (0.03mL CH3CN per
mg lactam and 0.00909mL H2O per mg CAN). The deprotected N-protiolactam 106 was
then thiolated using the synthesized sulfenylating reagent 107a or 107b to provide the Nthiolated β-lactams 2, 4, 6, and 10. Each reaction is further detailed in the following
subsections.

2.2.2.1 Synthesis of C-aryl imine 103
N-(4-Methoxyphenyl)imine 103 was prepared from the condensation of ochlorobenzaldehyde (101) and p-anisidine (102) (Scheme 2.2). Prior to the reaction, the
commercially supplied p-anisidine reagent was recrystallized using water heated to 60oC
and subsequently dried in vacuo in order to remove any impurities formed upon
packaging and storage of the reagent. The o-chlorobenzaldehyde was used without
further purification processes. Aldehyde 101 and p-anisidine (102) were dissolved in dry
dichloromethane. A catalytic amount of camphorsulfonic acid was added to the mixture,
which was then stirred at room temperature for 1-2 hours. However, in most cases the
condensation was completed within 30 minutes where progression of the reaction was
monitored by thin layer chromatography (TLC). The resulting imine was then
recrystallized in cold methanol to remove any excess anisidine and to obtain the pure
final product, N-(4-methoxyphenyl)imine 103.

Scheme 2.2. Synthesis of N-aryl imine 103.
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2.2.2.2 Synthesis of N-aryl protected β-lactams by Staudinger coupling
Staudinger coupling was employed for synthesis of the mono-cyclic β-lactam ring
formation, as has been previously reported.[2-9] This reaction involves a formal [2+2]
cycloaddition of an acetyl chloride (104a and 104b) to the prepared imine (103), to form
the N-aryl protected β-lactams 105a and 105b (Scheme 2.3).The imine was initially
deprotonated with triethylamine (TEA) at 0oC in dry dichloromethane, followed by
dropwise addition of the acid chloride and subsequent removal of the ice bath. After 3-4
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hours, the product was dried in vacuo and the lactam product was recrystallized in
methanol to afford a white crystalline solid in 60-80% yield depending on the alkoxy acid
chloride used.

Scheme 2.3. Staudinger [2+2] condensation of N-aryl imine 103.
OCH3

OCH3
Cl

O

N
H

103

Cl

+
RO

TEA, CH2Cl2
0 oC
RT

104

O

N

Cl

RO
105a: R=Ac, 65%
105b: R=Me, 74%

The mechanism proposed for the β-lactam formation is depicted in Figure 2.3.[8] The Naryl imine synthesized in Scheme 2.2 forms mainly in the E-configuration, which has
shown to lead mostly to the formation of the cis diastereomer of the racemic β-lactams.
This preference for the cis compound is thought to form through a kinetic pathway and is
often the single diastereomer observed when the acid chloride reagent is added in a
dropwise fashion to the reaction mixture (Figure 2.3). Proton NMR spectral analysis was
employed in order to determine the relative stereochemistry of the β-lactam, where the
cis β-lactam displays coupling constants for the C3 and C4 protons between 4 and 5Hz,
and the trans lactams display couplings constant between 2-3Hz.[8, 10]
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Figure 2.3. Theoretical mechanism for Staudinger-based ring closing reaction for
formation of the β-lactam ring.[5, 8]

Synthesis of the alkoxy acid chlorides (104a and 104b) is described in Scheme 2.4.
Acetoxyacetic acid (108a) was prepared from glycolic acid and acetyl chloride in
quantitative yields, whereas methoxyacetic acid (108b) was commercially available.
Compound 108a and 108b were reacted individually with thionyl chloride to form the
alkoxyacetyl chlorides (104a and 104b), yielding over 70% of each product after
distillation. Preparation of the acid chloride through this scheme was found to be more
cost effective than purchasing the acyl chloride and therefore was commonly employed
for the preparation of the C3-alkoxy β-lactams.
Scheme 2.4. Synthesis of alkoxyacetyl chlorides 104.
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2.2.2.3. Deprotection of N-protiolactam 105
Deprotection of the N-aryl lactam was accomplished using ceric ammonium nitrate
(CAN) in a ratio of water to acetonitrile (CH3CN) as the solvent system. For this reaction,
the lactam was dissolved in CH3CN (0.03mL CH3CN per mg lactam) and CAN was
dissolved in distilled water (0.00909mL H2O per mg CAN), then the CAN solution was
slowly added to the lactam solution (over 30-40 minutes) at -15oC. This slow addition of
CAN to the reaction mixture and the low temperature was critical for high product yields
with minimal by-product formation, and only an additional 20-30 minutes of stirring was
required after addition of the CAN. TLC analysis of the reaction mixture showed
complete conversion of starting material after only one hour reaction time. The overall
product yield was between 80-95%, depending on the R group.

Scheme 2.5. Removal of the N-p-methoxyphenyl protecting group from lactam monomer
105.
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2.2.2.4 Deprotection of the C3 alcohol acetoxy group on the lactam ring
In order to synthesize the N-methylthiolated lactam monomer 4, an additional step was
needed prior to thiolation of the lactam ring. Hydrolysis of the C3-acetoxy moiety was
accomplished under mild basic conditions in order to avoid ring-opening. Addition of
potassium hydroxide to the lactam acetate 106a dissolved in methanol afforded C3hydroxyl lactam 108 in 95% yield (Scheme 2.6).[11]

Scheme 2.6. Deprotection of C3-hydroxy group on lactam 106a.
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2.2.2.5 Thiolation of the N-protiolactams 106 and 108
Thiolation of the deprotected β-lactam ring was accomplished through the use of an Nthiolated phthalimide reagent prepared in house (Scheme 2.8). This method was first
reported by Miller et. al. and due to the good product yields and high purity after column
chromatography this procedure was established as the method of choice for thio transfer
reactions with the lactam ring.[8, 12] The β-lactam monomer (106, 108) was dissolved in
dry CH2Cl2 followed by addition of N-alkylthio phthalimide (107) and Hunig’s base
(diisopropylethylamine). The solution was refluxed at approximately 40oC for 24 hours
under a nitrogen environment in order to provide sufficient transfer of the thio group
from phthalimide to lactam. The N-protiophthalimide by-product was removed by
aqueous solvents to yield a solid white crystalline product in 50-85% yield, depending on
both R substituents present.

Scheme 2.7. N-thiolation of β-lactams 106 and 108.
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While the N-alkylthio phthalimide reagent is commercially available, it was more cost
effective to synthesize the reagent from the very inexpensive phthalimide reagent. An
alkyl disulfide reagent, either methyl or sec-butyl disulfide, was added to a slurry of
deprotonated phthalimide in CH3CN and pyridine, then 1.2 equivalents of liquid bromine
was cannulated into the flask to generate the N-thiolated phthalimide product in situ
(Scheme 2.8). A crystalline product was produced after crystallization of the oily product
in a solution of ethyl acetate and hexanes.

Scheme 2.8. Preparation of N-alkylthio phthalimide reagent.
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2.2.3

Synthesis of N-Alkylthio C3-Acrylated β-Lactams
β

While encapsulation is a well known means for incorporation of water insoluble drug
monomers into a liposomal or nanoparticle-based drug delivery system, covalent
attachment of these drug monomers had not yet been fully explored. Recently our lab has
shown that drug monomers are able to be co-polymerized in a microemulsion
polymerization in order to obtain drug-conjugated nanoparticles where the drug monomer
is covalently bound to the polyacrylate backbone. This is accomplished through the
addition of an acrylate or acrylamide moiety to the drug monomer, and both water
soluble and water insoluble drug monomers can be co-polymerized in this fashion. This
new and unique way to incorporate drug monomers into the nanoparticle means that not
only can the water insoluble drug monomers possibly exhibit controlled release, but also
that water soluble drug monomers can be incorporated to increase efficacy or stability.[13,
14]
This is accomplished through the acrylation of a free amine or alcohol present on the
antibiotic structure, and in some instances, an amide moiety, if other structures present in
the molecule are not sensitive to a strong base like sodium hydride. Other factors
influence the ability of the antimicrobials to be chemically modified in order to permit
covalent attachment of the drug to the nanoparticle, including the number of alcohol or
amine moieties present in the structure as well as the location of the moiety within the
structure. Presented in Scheme 2.9 is the synthetic route for modifying the N-thiolated βlactams in order to incorporate an acrylate moiety at either the C3 position of the lactam
ring or para to the lactam ring on the C4 phenyl substituent.

Scheme 2.9. General synthetic route for formation of acrylated N-alkylthio β-lactams.
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2.2.3.2 Acrylation of β-lactam monomers
Deprotection of the acetyl protecting group in lactam 105a was performed under the
same reaction conditions as described in Section 2.2.2.5. It was determined that
acrylation of the C3 substituent was required prior to removal of the anisyl protecting
group due to possible acrylation at the lactam amide, and also because it was determined
that acrylation after thiolation of the lactam ring caused the thio group to be hydrolyzed
from the lactam ring under the basic conditions required for hydroxyl deprotection and
subsequent acrylation. Therefore, the lactam was more stable to acetyl hydrolysis at this
stage of the synthesis, which afforded a more rapid and effective removal of the acetyl
protecting group.
Acrylation of the free hydroxyl group located at the C3 position of the β-lactam ring
yielded a yellow sticky solid, lactam monomer 110, in 45-60% yield after column
purification. Acryloyl chloride purchased from Sigma Aldrich was used without further
modification and was added dropwise to a solution of lactam monomer 109 in dry
dichloromethane after deprotonation of the alcohol with sodium hydride. The reaction
mixture was stirred at room temperature for 30 to 60 minutes, with progress continuously
monitored via TLC.

Scheme 2.10. Preparation of C3-acrylate β-lactam monomer 110.
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2.2.3.3. Attachment of C3 long chain acrylate substituent onto N-methylthio β-lactam 9
In order to explore the effect of different lengths of the acrylate linker to the nanoparticle
drug delivery system, lactam monomer 9 was synthesized and subsequently polymerized
(Scheme 2.11). Due to the higher product yields observed for the N-methylthio β-lactam
synthesis versus the N-sec-butylthio β-lactam synthesis, only the methylthiolated
monomer was prepared using the long chain acrylate. Lactam monomer 109 was used as
the starting material for synthesis of lactam monomer 9.
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Scheme 2.11. General scheme for the preparation of C3-long chain acrylate N-methylthio
β-lactam 9.
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Addition of the long acrylate chain to the free hydroxyl substituent at the C3 position of
the lactam ring was performed using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDCI) and 4-dimethylaminopyridine (DMAP) in dry dichloromethane. Deprotonation of
the alcohol group was accomplished with the bulky DMAP base, followed by coupling of
the deprotonated hydroxyl group with the acrylated succinate reagent.[7, 8] This reaction
yielded a colorless oil at 75-80% overall yield after column purification. The long chain
acrylated β-lactam was then carried through the customary deprotection of the pmethoxyphenyl (PMP) group using ceric ammonium nitrate followed by thiolation using
N-methylthiophthalimide 107a previously described to afford lactam monomer 9 in
yields equivalent to the lactam monomers previously described.

2.2.3.4 Synthesis of C4 acrylated N-methylthio β-lactam 5
It was hypothesized that the location of the acrylate linkage may also play a role in the
observed antibacterial activity when incorporated in the nanoparticle drug delivery
system,[14] thus lactam monomer 5 was synthesized where the acrylate linker was placed
at the para position of the phenyl ring located at the C4 position of the lactam. Again, due
to the ease in thiolation of the nitrogen present in the lactam ring when using Nmethylthiophthalimide instead of N-sec-butylthiophthalimide, only the N-methylthio
lactam was synthesized.
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Scheme 2.12. Synthesis of C4-acrylated N-methylthio β-lactam monomer 5.[5, 7, 8, 14]
OCH3

OCH3
OCH3

O

CHO

NH2

+

N

CSA

N

Cl
base

OH

OAc

114

Cl

MeO

O

CAN

N

MeO
117

O

N

H

MeO
118

N

O

O

O

OH

107a
base

116

OCH3

O
N

OAc

115

OCH3
O

N

MeO

OCH3
OH

KOH
MeOH

O

104b

O

O
119

SMe

MeO
O
O
5

Imine formation in the first step of this synthetic scheme was done under the same
reaction conditions as used in Scheme 2.2, with camphorsulfonic acid as the catalyst.
Protection of the p-hydroxy group of the imine was accomplished with acetyl chloride in
92% yield, and the imine was then cyclized using the Staudinger reaction under
previously established conditions (Schemes 2.3) to afford the cis β-lactam 116 in 78%
yield. Removal of the acetyl protecting group under basic conditions allowed the C4 phydroxy phenyl β-lactam 117 to be subsequently acrylated with acryloyl chloride using
the same reaction conditions as described in Scheme 2.10 to afford the C4 acryloyl N-aryl
protected β-lactam 118. Subsequent dearylation of the PMP protecting group followed by
methylthiolation using N-methylthiophthalimide (107a) produced the white solid C4
acryloyl N-methylthio β-lactam 5 in 89% yield.
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2.3 Modification of Commercially Available Antibiotics
2.3.1. Penicillin-Based Antibiotics
Many of the commonly used commercial antibiotics for treating burn wound infections
are water-soluble, such as the β-lactam antibiotics in Figure 2.4. Therefore, it was
necessary to chemically modify these compounds in order to incorporate them into the
nanoparticle framework. The choice of drug to be utilized was contingent on a few
factors, but first and foremost was the observance of a chemical moiety in the drug
structure that could be appropriately modified in order to add the acrylate or acrylamide
moiety to the drug. Acrylation of the drug monomers was simplest when a single
hydroxyl or amine group was present in the structure; therefore, the initial drugs chosen
for acrylation were penicillanic acid, amoxicillin, ampicillin, and cefaclor (Figure 2.4).
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Figure 2.4. Penicillin-based drug analogues considered for acrylation.

Penicillanic acid, ampicillin and cefaclor all possess a single free amino group that was
easily accessible to the acrylating agent, where penicillanic acid was the simplest of the
drug monomers chosen and possesses only the single amine located at the C3 position of
the lactam ring. These drug monomers were also chosen because they do not contain any
other structural moieties that would interfere with the acrylation procedure, such as an
alcohol or a secondary amine group. Initial trials determined that, in some instances, the
carboxylic acid moiety present on all of the lactam structures caused some problems with
the acrylation reaction, and in those cases, a silyl protecting group was employed for
temporary protection of the free acid (Scheme 2.13).
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Scheme 2.13. Acrylation of commercially available 6-aminopenicillanic acid.
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Penicillanic acid was the first penicillin analogue to be acrylated due to the bulk quantity
available and that this penicillin structure is commercially available as the free acid
instead of the water soluble potassium salt form, which would require acidification prior
to silyl temporary protection. Synthesis of the penicillanic acid acrylamide 11 was
accomplished through a two step process. First, the free carboxylic acid moiety was
temporarily protected with the use of a silyl protecting group, employing N,Obis(trimethylsilyl) acetamide in dry dichloromethane for 24 hours at room temperature.
The protected acid (120) was then taken directly to the acrylation step without an
intermediary work up, where the free amine located at the C3 position of the lactam ring
was acrylated using acryloyl chloride in the presence of a tertiary amine base (TEA).
Aqueous work up of the reaction mixture afforded the deprotected penicillanic acid C3acrylamide monomer 11 in 91% overall yield. Due to observed self-induced
polymerization of the acrylamide monomer at room temperature, the monomer was taken
directly to the emulsion polymerization without further purification (Chapter 3).

Scheme 2.14. Acrylation of cefaclor to yield monomer 17.
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The second generation cephalosporin antibiotic cefaclor was also commercially available
in the free acid form, and thus followed the same acrylation procedure as was used for
penicillanic acid (Scheme 2.14). The resulting cefaclor acrylamide monomer (17) was
produced as a sticky solid that quickly self-polymerized under ambient conditions;
therefore, purification processes were limited to an extractive work up of the reaction
mixture prior to product isolation.
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For the majority of the acrylated penicillin-based antibiotics (monomers 11, 16, 17, 18,
and 19), NMR analysis was difficult due to the insolubility observed in most deuterated
solvent systems. Therefore, product confirmation relied almost solely on TLC analysis,
which, when successful, showed spot to spot conversion of the commercially available
drug monomer to the acrylated form in a solvent system of 5:1 dichloromethane to
methanol.

Scheme 2.15. Acrylation of ampicillin sodium salt.
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Ampicillin was the most difficult of the initial penicillin-based monomers to acrylate due
to its low solubility in the organic media necessary for acrylation. Initial acidification of
the ampicillin carboxylate salt was attempted in order to make the ampicillin more
soluble in the organic solvent dichloromethane preferred for the acrylation reaction.
However, due to the free primary amine present in the structure, acidification using dilute
hydrochloric acid caused the amine to be protonated as well, which allowed the
ampicillin to remain positively charged and readily soluble in the water system.
Therefore, in order to perform the acrylation directly on the ampicillin sodium salt, a
phase-transfer reagent was used in a two phase (water/dichloromethane) mixture in order
to solubilize the drug in an organic solvent to permit silyl protection of the carboxylic
acid (Scheme 2.15). N,O-bis(trimethylsilyl)acetamide was the silylating agent of choice
for the acid protection step, and the reaction was carried out in a mixture of water and
dichloromethane, with the use of tetra-N -butylammonium bromide (TBAB) as the phase
transfer reagent. As has been previously established, once in the protected state, the
ampicillin was taken directly to the acrylation step after removal of the initial mixed
solvent system in vacuo. This procedure afforded spot to spot conversion of reactant to
product via TLC analysis, and the ampicillin acrylamide 16 was produced as a
yellow/brown solid in 52% yield.
The fourth drug chosen for polymerization was amoxicillin. Amoxicillin contains both a
free phenolic hydroxyl group and a free amine, both located along the C3 side chain away
from the lactam ring. These moieties allowed the drug to be either mono-acrylated using
one equivalent of acryloyl chloride to yield acrylamide 19, or di-acrylated to yield
product 18 by providing two equivalents of the acryloyl chloride (Scheme 2.16). This
aspect was intriguing because when monomer 18 was polymerized the polymer strands
would likely undergo additional cross-linking, which may or may not affect the
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antibacterial properties of the amoxicillin-based nanoparticle emulsion. These properties
were later explored in Chapter 3.

Scheme 2.16. Acrylation and diacrylation of amoxicillin (18 and 19).
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The final penicillin analogue chosen for this study was penicillin G, which is
commercially available as the potassium salt. The drug was chemically modified in order
to permit two acrylated forms of the drug (acrylation at the C3 amide to give acrylimide
13, or at the carboxylic acid moiety to give acrylate ester 12).

Scheme 2.17. Acrylation of penicillin G potassium salt.
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In order for acrylation of the C3-amide nitrogen on the lactam ring to be successful, the
penicillin monomer must be able to dissolve in dichloromethane, which means that the
drug must be acidified in order to convert the drug to its original free acid form (14). This
was accomplished by titrating dilute hydrochloric acid into a solution of the penicillin
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potassium salt in water. Addition of the acid was terminated upon precipitation of a
sticky yellow solid, followed by decanting of the water solution from the precipitated free
acid drug form and washing the solid 2-3x with water to remove excess HCl. The
acidified penicillin was allowed to dry overnight in vacuo in order to obtain a solid
crystalline powder (14), which was then protected with a trimethylsilyl group followed
by acrylation with acryloyl chloride. However, because the intended nitrogen for
acrylation is part of an amide system, a stronger base was needed than the previously
used tertiary amine base. Here sodium hydride was employed to deprotonate the amide in
order to make the amide nitrogen reactive towards the acryloyl chloride reagent. Aqueous
work up of the reaction was performed to remove the silyl protecting group, leaving the
water insoluble free acid acrylamide penicillin monomer 13 as a slightly yellow solid in
70% yield.

Scheme 2.18. Acrylation of penicillin G via the free acid.
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Scheme 2.18 shows the synthesis of pencillin G acrylate ester 12. In order for the
carboxylic acid on the penicillin to be acrylated, it was first converted from the sodium
salt to the free acid form. The free acid was then reacted with ethyl chloroformate at 0oC
for 30 minutes to yield the esterified acid 122, which was then directly reacted with 2hydroxyethyl acrylate in the presence of triethylamine to yield the penicillin G acrylate as
a yellow oil in 70% yield after column chromatography.
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Scheme 2.19. Esterification of penicillin G free acid 14.
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The long chain ester penicillin G analogue 15 was synthesized through EDCI coupling of
penicillin G in the free acid form (14) with 2-hydroxyethyl propionate following the same
reaction conditions as reported for Scheme 2.11 (Scheme 2.19).

2.3.2 Fluoroquinone-Based Antibiotics
The next commercially available antimicrobial examined for incorporation into the
polyacrylate nanoparticles was ciprofloxacin (Figure 2.5). Ofloxacin, an analogue of
ciprofloxacin, is sold as a racemic mixture of the chiral drug under the commercial names
Floxin® and Ocuflox® for treatment of bacterial infections, including bronchitis,
pneumonia, chlamydia, gonorrhea, skin infections, urinary tract infections, infections of
the prostate, and infections of the eye. The biologically active (S)-enantiomer of
ofloxacin, levofloxacin, has only recently been synthesized and has been approved for
medical applications under the brand name Levaquin in the U.S. (Figure 2.5).
Levofloxacin has shown to be twice as potent as the racemic ofloxacin due to elimination
of the (R)-enantiomer, which has no biological activity.
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Figure 2.5. Commercially available fluoroquinones considered for acrylation.

The second generation fluoroquinone, ciprofloxacin (cipro), is a potent broad spectrum
antibacterial whose activity is expressed by inhibition of bacterial DNA replication.
While this bacteriostatic antibiotic has been considered one of the work horses in
bacterial infection treatment, resistance has been observed for some microbes, especially
in hospital settings; therefore, this drug monomer was an excellent choice for
incorporation into the nanoparticle. Cipro was chosen over levofloxacin and the more
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readily available ofloxacin antibiotics due to the secondary amine located within the
cyclohexyl ring system of the drug monomer, which is replaced by a tertiary amine in
both ofloxacin and levofloxacin, making the amine unavailable for acrylation. Table 2.1
presents some of the microbes that are sensitive to cipro. Many of these microbes are also
commonly observed colonizing burn wounds, making cipro an optimal choice for
incorporation into the multi-drug conjugated nanoparticle delivery system for treatment
of burn wound infections.

Table 2.1. Antibacterial activity of ciprofloxacin.

Ciprofloxacin Antibacterial Activity

Gram Positive

Staphylococcus aureus: both
MRSA and MSSA
Bacillus anthracis
Streptococcus pneumoniae

Gram Negative

Pseudomonas aeruginosa
Enterobacteriaceae spp.
Escherichia coli
Neisseria gonorrhoeae
Neisseria meningitidis
Campylobacter spp.
Brucella spp.
Moraxella catarrhalis
Vibrio spp.
Haemophilus influenzae
Haemophilus ducreyi
Chlamydia trachomatis
Chlamydia pneumoniae

Ciprofloxacin was acrylated using two variations of the acryloyl chloride: the original
acryloyl chloride and methacryloyl chloride (Scheme 2.20). This afforded two different
analogues of the cipro acrylamide monomer to be used in the multi-drug conjugated
nanoparticle emulsion (Chapter 4).
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Scheme 2.20. Acrylation of ciprofloxacin.
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The commercially available ciprofloxacin hydrochloride monomer was dissolved in dry
dichloromethane, and the secondary ammonium proton was removed with triethylamine
(TEA) at room temperature over ten minutes. Acryloyl chloride was subsequently added
to the reaction mixture in a dropwise fashion, and the solution was then stirred at room
temperature for 24 hours. The resulting acrylamide product was immediately evaporated
in vacuo after aqueous work up in order to minimize polymerization observed upon
evaporation of the solvent from the product over a long period of time at 30oC. Once in a
dry yellow powder form, the cipro acrylamide monomers 7 and 8, produced in 75-90%
yields, were stable over long term storage in glass vials at room temperature.

2.4 Antibacterial Activity of Drug Monomers
Antibacterial assays were performed for the majority of the drug monomers synthesized.
Assays were performed against many Staphylococcal strains, including numerous strains
of MRSA. MRSA was either purchased from ATCC (43300 and 33591) or was obtained
from Lakeland Regional Medical Center as clinical isolates. The clinical isolates were
arbitrarily labeled USF652-659, and the ATCC purchased strains 43300 and 33591
correspond to the USF-designated 920 and 919, respectively. Methicillin-sensitive S.
aureus (MSSA) and Pseudomonas aeruginosa were purchased from ATCC as well
(ATCC 25923 and 10145, respectively) and Bacillus species were either provided by
Colorado Serum Co., Denver. CO. (B. anthracis-Sterne), purchased from ATCC
(Bacillus cereus: ATCC 14579, Bacillus subtilis: ATCC 19569, Bacillus megaterium:
ATCC 14581, Bacillus thuringensis: ATCC 10792), or provided by the Department of
Defense Reagents Program (Bacillus globigii). Both the Kirby Bauer and broth-dilution
minimal inhibitory concentration (MIC) antibacterial assays were performed for the drug
monomers dissolved in DMSO or water. Both of these assays are reputable for their
accuracy and ability to compare numerous antibiotics through the use of standardized
techniques described in the National Committee for Clinical Laboratory Standards
(NCCLS) handbook.[15] All broths and agars used in the antibacterial assays were
purchased from Fisher Scientific Company.
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2.4.1 Kirby Bauer Assay
Kirby Bauer assays were performed on the drug monomers dissolved in DMSO in a
1mg/mL concentration, and were added to the agar wells in 20µL volumes in accordance
with the guidelines recommended by the NCCLS handbook.[15] Results of this assay are
measured as the zone of bacterial growth inhibition (ZOI) in millimeters around the
center of the well where the dissolved drug is placed. The diameter of the zone in
millimeters is the value reported and partial growth inhibition zones are represented in
parentheses. These assays rely on the ability of the substance being tested to diffuse from
the well into the surrounding agar in a circular pattern in order for the drug to interact
with the bacteria present on top of the agar surface. However, there are many inherent
problems with this assay due to required diffusion of the drug monomer through the agar.
Often times highly lipophilic drug monomers will not diffuse through the agar or have
very limited diffusion due to positive interactions of the drug monomer with the agar
preventing drug migration, therefore, a second assay was employed for accurate analysis
of the antibacterial activity of the drug monomers synthesized here.

2.4.2 Broth Dilution Minimum Inhibitory Concentration (MIC) Assay
In order to establish the lowest drug concentration needed to prevent bacterial growth, the
drug monomers were analyzed for antibacterial activity at various drug concentrations
per mL of solvent (DMSO or water). Optical density measurements (540-550nm) were
employed to determine at what lowest drug monomer concentration the antibiotic inhibits
cell growth. The highest drug monomer concentration analyzed was 256µg/mL and
reached the lower limit of 0.125µg/mL through serial dilution. Mueller Hinton broth was
employed for the assay in accordance with the guidelines recommended in the NCCLS
manual for antibacterial testings.[7, 15]

2.4.3 β-Lactam Monomers
Due to the high lipophilicity of the lactams, the monomers were dissolved in DMSO for
both the broth-dilution MIC studies as well as in the Kirby Bauer assays. The
commercially available drugs analyzed for antibacterial activity (penicillin G potassium
salt and ciprofloxacin hydrochloride) were dissolved in nanopurified water for analysis.
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Figure 2.6. Kirby Bauer assay of β-lactam monomers against S. aureus. All N-thiolated
lactam monomers have anti-staphylococci activity, although lactam monomer 1 did not
have antibacterial activity in this specific assay.

As seen in Figure 2.6, the anti-Staphylococcal activity of a few of the lactam monomers
synthesized varied depending on the substituents present on the lactam molecule. The
weakest drug monomer synthesized, according to Figure 2.6, was lactam monomer 1,
which contained an acrylate moiety at the C3 position of the N-methylthio β-lactam. Also,
it was determined that the N-sec-butylthio lactam monomers (3 and 10) were more active
than the N-methylthio lactam monomers (1 and 6). This was also observed for the antiBacillus activity of the lactams presented in Table 2.2.
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Table 2.2. Zone of inhibition and minimum inhibitory concentration analysis of lactam
monomers. A 20µL volume of a 1mg/mL solution of lactam monomer in DMSO was
applied to the agar wells for ZOI analysis, and a 5.12mg/mL initial drug concentration
was the starting point of the MIC analysis.
B. anthracis- Sterne
Compound
Penicillin G

NA

MIC
(µg/mL)
NA

1

20

32

(12)

64

2

0

NA

(14)

NA

3

(25)

4

17 (22)

64

4

33

NA

18

32

5

15 (20)

32

(25)

128

6

23 (26)

4

31

32

9

(21)

NA

(15)

64

10

38

0.5

41 (45)

8

42 (45)

0.063

28 (34)

NA

Cipro

ZOI* (mm)

S. aureus
ZOI* (mm)
55 (61)

MIC
(µg/mL)
0.02

* ( ) = partial inhibition

Data presented in Table 2.2 shows that the lactam monomers display antibacterial activity
against both S. aureus and B. anthracis-Sterne. It was determined that the most potent
lactam analyzed was N-sec-butylthio lactam 10, where the MIC against S. aureus was
8µg/mL and 0.5µg/mL against B. anthracis. While none of the lactams were nearly as
potent as the commercially available drug monomer used for treatment of these microbes
in clinical settings (penicillin G or vancomycin for S. aureus and cipro for B. anthracis),
the bioactivity of the lactams remained constant against resistant strains of the microbe
(Figures 2.7, 2.8), which was not observed for the commercial drugs, specifically
penicillin G.
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Figure 2.7. Kirby Bauer assays comparing anti-Staphylococcal activity of lactam 10 to
penicillin G. Image to the left contains 100µg of β-lactamase spread over the agar. Image
to the right does not contain β-lactamase.

Figure 2.8. Comparison of zone of inhibition data for lactams 4 and 6 versus penicillin
G. Data presented for seven clinical isolates of MRSA (USF 652-659) and for MSSA
(ATCC 25923).
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As observed in Figures 2.7 and 2.8, lactams 4, 6, 10 and penicillin G all displayed
excellent activity against methicillin-sensitive S. aureus (MSSA), however, in the
presence of β-lactamase (Figure 2.7) or against MRSA (Figure 2.8), the activity of
penicillin G diminished greatly. In Figure 2.8, the observed activity for penicillin G
against the various strains of MRSA was measured as barely larger than the diameter of
the agar well (7-8mm), therefore, it can be concluded that when in the presence of βlactamase or against MRSA, for which penicillin G is not an effective antibiotic, the Nthiolated lactams are equally potent to these strains as they are towards MSSA.

2.4.2 Acrylated Monomers of Commercially Available Drugs
The penicillin G acrylamide monomer 13 displayed anti-Staphylococcal activity closest
to the commercially available penicillin G. Since penicillanic acid is a less effective
antibiotic than penicillin G, the activity of the penicillanic acid acrylamide 11 was
expected to be weaker than the acrylated penicillin G monomers 12 and 13, which was
observed in Figure 2.9.

Figure 2.9. ZOI data for penicillin-based monomers against S. aureus.
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Table 2.3. Antibacterial activities of ciprofloxacin acrylamide monomers 7 and 8 against
B. anthracis-Sterne, S. aureus (ATCC 25923) and P. aeruginosa (ATCC 10145). Drug
monomers were applied as a 1mg/mL concentration in DMSO, with 20µL of this solution
being added to each agar well for ZOI analysis.
B. anthracis-Sterne

S. aureus

P. aeruginosa

Sample
ZOI*
(mm)
42 (45)

MIC
(µg/mL)
0.063

ZOI*
(mm)
28 (34)

MIC
(µg/mL)
NA

ZOI*
(mm)
40

MIC
(µg/mL)
1

7

40

0.125

26 (29)

0.25

15

128

8

35

0.5

25

1

NA

128

Ciprofloxacin

* ( ) = partial inhibition

Ciprofloxacin acrylamide monomers 7 and 8 displayed nearly equipotent activity towards
B. anthracis and S. aureus as the unmodified ciprofloxacin antibiotic, but were inactive
against P. aeruginosa. This diminished activity was important because it enabled antiPseudomonal activity of the polymerized cipro acrylamide monomers (Chapter 3) to
establish that there is release of the un-acrylated (free) drug from the polyacrylate
backbone by the microbe.

2.5 Mode of Action of N-thiolated β-Lactams
The narrow scope of antimicrobial activity for the N-thiolated β-lactam monomers and
the fact that the lactams are bacteriostatic suggests that a reversible interaction of the drug
with a specific cellular enzyme in select microbes is occurring. There are many plausible
reaction mechanisms that could be the cause of the observed antibacterial activity, as seen
in Figure 2.10, however, recent studies in our lab have suggested that the majority of the
lactams interact with the susceptible microbes through a sulfenylation reaction.[3]
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Figure 2.10. Possible pathways for nucleophilic attack on the β-lactam structure. The
pathway highlighted in red has been established as the most plausible pathway.[3, 5]
Due to the unusual antimicrobial activity of these N-thiolated β-lactams,[4, 6, 7, 9, 11] plus
their antifungal activity against numerous Candida species, it seemed apparent that the
lactam structure is acting through a unique mode of action against these microbes. Initial
studies against S. aureus using a gram staining technique and SEM imaging of the treated
and un-treated bacterial cells determined that the cell wall of the bacteria was not the
target of this specific class of β-lactam drugs,[3, 5] even though all other β-lactam
antibiotics are well known inhibitors of cell wall biosynthesis for gram positive microbes.
Bacteria were exposed to the antibiotics via a Kirby Bauer assay, and the microbes
analyzed for imaging were taken from just within the edge of the zone of inhibition.
Radioactive studies by Timothy Long also supported this finding, as well as ruled out
other possible modes of action, such as DNA and RNA biosynthesis inhibition.[3, 5]
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Figure 2.11. Light microscopy images of S. aureus treated with various antibiotics.
Penicillin G and ampicillin were both analyzed using methicillin-sensitive S. aureus
(MSSA), while the mode of action of lactam monomer 6 was analyzed using methicillinresistant S. aureus (MRSA). Images taken by Dr. Timothy Long.[3, 5]

Gram staining studies using MSSA and MRSA strains of S. aureus were performed in
order to elucidate the mode of action of the mono-cyclic thiolated β-lactam monomers.
When the cell wall is intact for gram positive microbes, such as S. aureus, the microbial
cells stain purple in the gram staining analysis. However, if the cell wall is damaged, or a
gram negative bacterium is being analyzed, then the cells stain pink. The images in
Figure 2.11 show that the cell wall of the MRSA cells was un-affected by lactam 6,
observed by the purple gram staining. Penicillin G and ampicillin, two well-known
antibiotics whose mode of action is through inhibition of cell wall biosynthesis for gram
positive microbes, which caused the cells to stain mostly pink in color, as seen in Figure
2.11. Some of the penicillin-treated and ampicillin-treated cells were observed retaining
the gram stain, indicating that they were unaffected by the antibiotics or that the
antibiotics had not reached these microbes prior to harvesting for imagining. SEM
analysis also confirmed this finding, where the images showed intact S. aureus cells that
did not express any damage to the exterior of the cell wall.[3, 5]
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This gram staining study was also repeated with the spore-forming gram positive microbe
B. anthracis. This microbe is able to produce a highly potent toxin when in its natural
state; therefore, an attenuated strain of the microbe (Sterne) was used for this study. B.
anthracis is a rod-shaped, gram positive microbe that forms long chain-link structures
where the bacilli rods are attached to one another head-to-foot (Figure 2.12). This
bacterium is also able to form a highly impenetrable spore coating that protects it from
heat and allows the microbe to exist for years in environments with little to no
nutrients.[17] When sporulation occurs, the bacterium becomes highly insensitive to
normal antibiotic treatment, making it extremely difficult to treat.[19] The combination of
the highly toxic Ames strain of B. anthracis with the ability of the microbe to sporulate
makes it a potent and very dangerous microbe that can be used as a biological weapon.
Therefore, antibiotics powerful enough to eliminate the endospore form of the microbe or
antibiotics that can prevent sporulation are in dire need.

Figure 2.12. Light microscopy images of B. anthracis treated with various antibiotics.
All assays performed here used the attenuated Sterne strain of B. anthracis.

In Figure 2.12, it is clearly distinguishable that the Bacillus rods treated with either
ampicillin or penicillin G antibiotics exhibited damage to the bacterial cell wall apparent
by the pink staining of the rods. The untreated anthracis cells stained purple after gram
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staining analysis, indicating that when the bacilli are not treated with sub-lethal amounts
antibiotics there are no rods that stain pink in color. The bacilli treated with lactam 6,
however, displayed a mixture of pink and purple rods, where in some instances, a long
chain of rods would start out staining purple, but towards the end of the chain, stained
pink in color (Figure 2.12). Also observed were definitive regions of all pink-stained
bacilli as well as all-purple bacilli (Figure 2.13). One possible explanation for the
observed gram-negative staining result for bacilli (but not for staphylococci) is that the
drug is affecting the biosynthesis of the bacterial membrane, which is allowing
intracellular contents to leach out of some of the cells and, therefore, produce negative
gram staining in those affected cells. This hypothesis was supported by studies performed
by Dr. Seyoung Jang, that found that the N-thiolated β-lactams inhibit fatty acid
biosynthesis,[3,5] however the exact stage of this biosynthetic pathway where the lactams
exhibit their activity has yet to be elucidated. A secondary explination for the gram stain
results could be related to the ability of the anthrax to sporulate, which would also affect
the gram staining results.

Figure 2.13. B. anthracis treated with C3-methoxy N-methylthio β-lactam monomer 6.
A) Bacillus rods observed staining purple= gram positive. B) Bacillus rods observed
staining pink= gram negative.

Aside from the superficial effects the lactams imposed on the bacterial cells, little was
known of how the anatomy of the microbial cells was affected by the antibiotic.
Therefore, TEM imaging was performed on three different microbes sensitive to the Nthiolated β-lactams using lactam monomer 6, including the two gram-positive microbes
previously discussed (B. anthracis-Sterne and MSSA) and the fungal strain Candida
albicans, which is the leading cause of fungal infections colonizing burn wounds. The
broth culture containing the microbe was treated with lactam 6 for a 30 minute incubation
period (bacterial) or 1 to 4 hour period (fungi) at 37oC, and the cells were then crosslinked using gluteraldehyde in order to stop all cellular functions without damaging any
of the cellular components. This allowed the cells to be imaged in their natural state after
only a short antibiotic exposure.
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Figure 2.14. TEM images of B. anthracis cells. A) Untreated B. anthracis-Sterne cells.
A-Cell wall, B-Cell membrane, C-cytoplasm. B) Cells treated with N-methylthio βlactam monomer 6. C and D) Cells treated with penicillin G potassium salt. Arrow in C
points to a break in the peptidoglycan cell wall. Arrow in D points to a hydrated
endospore surrounded by many other encapsulated endospores and germinating bacilli.

The spore coat, the internal spore cortex, cellular membranes and the spore core were all
readily identified in the TEM images in Figure 2.14A of untreated bacilli through
negative staining (2% uranyl acetate).[18, 19] All of the bacilli cultures were stained with
osmium tetroxide coupled with lead citrate after sectioning of the embedded cells for
enhanced visibility of these structures, yet this caused the black metal precipitation
observed in some of the images. It has been noted that when bacilli and clostridial
(another sporulating microbe) cells are in an endosporic, dormant state, they exhibit
ultrafine (5-10nm) filamentous appendages on the exterior of the endospore that appear
hair-like in structure (Figure 2.14A).[17] These appendages were observed for many of the
bacilli imaged by TEM analysis, confirming the presence of the endospores in the
culture. The interior of the endospores, termed the protoplast, was clearly visible in many
of the bacilli imaged.
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Unlike the vegetative bacilli cells, the endospores shrink to less than 1µm in size upon
sporulation and are distinguished as small rounded cells containing numerous “rings,”
which represent the various layers of the spore coating anatomy.

Figure 2.15. TEM of B. anthracis treated with lactam monomer 6. Both images depict
deterioration of the bacterial cells and break down of the exosporium coatings of the
cells.

TEM imaging of the bacilli cells treated with lactam monomer 6 (Figure 2.14B, Figure
2.15) resulted in the observance of very few sporulated cells, where the cell culture that
was not exposed to lactam 6, or that was exposed to penicillin G possessed many
sporulated bacilli, as well as the observance of encapsulated endospores. This indicates
that the presence of the lactam monomer inhibits spore formation. In some instances, the
TEM images exposed a peptidoglycan outline of where the cellular contents used to be
housed, which further indicates that the lactams do not have a direct effect on the cell
wall of the microbes. It was assumed that the cellular contents were able to leach out of
the cell wall through interruption of the cellular membrane. Also, very few germinating
bacilli cells were observed in the lactam 6 treated cell culture, indicating that the
antibiotic prevents both endospore formation and blocks cellular germination of the
bacilli. One of the few spores observed in the lactam-treated culture (Figure 2.15, left)
showed damage to the inner and outer membranes of the cell (white arrow) and to the
spore cortex and sloughing off of the exosporium (black arrows) or external protective
coating of the bacilli spore.
As seen in Figure 2.14C, penicillin G caused many of the bacilli observed to have
breakdowns in the peptidoglycan cell wall, which caused cellular spillage visible in the
TEM. However, there were numerous bacilli endospores and germinating cells observed
for the penicillin-treated cell culture, indicating that until cell wall rupture occurs for the
bacilli, the cells are able to undergo normal cellular function (Figure 2.14D). The round
white spots located in the center of some of the cells in Figure 2.14D are due to hydration
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present within the bacterial cell that was not removed during the dehydration processing
of the cells prior to embedment in plastic for sectioning. When scanning the plastic
sections containing the penicillin-treated bacilli, there was a high degree of free-floating
peptidoglycan surrounding many of the cells, presumably having been degraded and
sloughed off the bacterial cell.

Figure 2.16. Overview of many bacilli present in penicillin-treated and untreated cell
cultures. Left image is untreated cells, and right image is cells treated with penicillin G.

Mesosomes, which have been observed in both gram positive and gram negative
microbes, are invaginations of the cellular plasma membrane that can form into vesicles
within the bacterial cell, and are thought to play some role in DNA replication and/or cell
division. As observed in Figure 2.16, both the penicillin-treated and untreated cells
displayed black clusters within the cells, mainly in the germinating cells, which are most
likely the mesosomes present within the prokaryotic cells. These black clusters were not
observed in the cells treated with lactam 6, further indicating that the N-thiolated βlactams inhibit fatty acid synthesis, which comprises the bacterial membranes present
within the cells and the aforementioned mesosome vesicles observed in the untreated and
penicillin-treated bacilli.
Imaging of S. aureus cells treated with β-lactam monomer 6 was also performed and
presented in Figure 2.19. While many TEM images were captured of the treated cellular
culture, very few cells were observed in an intact form. The majority of the cells
observed looked like ghost cells, with little cellular contents intact within the cell.
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Figure 2.17. S. aureus cells treated with lactam monomer 6. A and B) Cells treated with
lactam 6 for 30 minutes. C and D) Control cell culture that was not exposed to any
antibiotics.

The S. aureus cells treated with lactam monomer 6 showed a high degree of intracellular
damage, observed by the lack of intracellular mass within the bacterial cell wall. Even
thought it seems that most of the cellular contents have been destroyed and spilled into
the surrounding area, the bacterial cell wall appears to still be intact surrounding the
ghost cells. This was also observed in Figure 2.14B for the bacilli cells treated with this
lactam monomer in vitro. The untreated S. aureus cells appear to have intact intracellular
mass depicted by the gray matter within the intact cell wall, as seen in Figure 2.17C and
Figure 2.17D. Figure 2.17C shows germinating S. aureus cells that are in the process of
splitting, while the image in Figure 2.17D is of an intact vegetative cell. In both images,
the cell walls are whole and there is no observance of cellular spillage or deformation of
the cell morphology, indicating that the cellular destruction observed for the lactam 6
treated cells is a direct result of the drug’s antibacterial activity.
Candida albicans, the causative microbe for fungal infections such as athlete’s foot, is
also sensitive to the N-thiolated β-lactam antibiotics. Since fungi are eukaryotic
organisms, they possess many complex internal structures similar to mammalian cells,
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including a defined nucleus, mitochondria, cytoskeleton, and a network of internal
membranes for compartmentalization. Therefore, TEM analysis of these microbes was
performed so that a more complete mode of action for the drug monomers might be
defined due to the diverse ultrastructures present within the microbe, where many of
these structures are surrounded by phospholipid membranes.

Figure 2.18. Candida albicans cells treated with lactam monomer 6. A) Untreated
control cells. B and C) Cells treated with β-lactam 6 for 1 hour. D) Cells treated for 4
hours with lactam 6. Arrows point to cell membrane invaginations or disruptions due to
lactam treatment.

The images in Figure 2.18 show the fungal cells of C. albicans, where these cells are
much larger than the previously observed bacilli and staphylococci cells. Also seen in
these images are intact nuclei and mitochondrial membranes for both the lactam-treated
and untreated cells. However, arrows in Figure 2.18C and Figure 2.18D point to cell
membrane invaginations and disruptions due to lactam 6 exposure. The TEM and light
microscopy studies support previous works performed that suggest the N-thiolated βlactam antimicrobials act through inhibition of fatty acid biosynthesis, which in turn,
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disrupts the cellular membranes that are formed from the lipid bilayers that hold all of the
intracellular contents in place.

2.6 Conclusions
Antimicrobials were synthesized and acrylated to determine their antibacterial activity
and for subsequent incorporation in a nanoparticle delivery system (Chapter 3). Nthiolated β-lactam monomers were synthesized for both encapsulation and for covalent
attachment to the nanoparticle. Also, commercially available water soluble antibiotics
were chemically modified in order to afford an acrylate or acrylamide derivative, which
permits co-polymerization later in Chapter 3. All of the drug monomers synthesized here
displayed antibacterial activities against S. aureus and B. anthracis, and the N-thiolated
β-lactams synthesized had equipotent activity against methicillin-sensitive S. aureus as
well as methicillin-resistant S. aureus. It was also determined that acrylation of
ciprofloxacin removed its anti-Pseudomonal activity.
The mode of action of the N-thiolated β-lactams has recently been investigated by Revell
et al,[5] which established that the lactams act on the fatty acid biosynthetic pathway in
microbes that have coenzyme A-based thiol-redox buffer systems. In this chapter, various
imaging techniques observed that the N-methylthio β-lactam (6) disrupted the cellular
membranes of S. aureus, B. anthracis, and C. albicans, and in many cases, entire cellular
contents were destroyed leaving behind only the bacterial cell wall around ghost cells. NThiolated β-lactams also exhibit antimicrobial activity against the gram positive microbe
S. aureus, even in the presence of the β-lactamase enzyme, as well as MRSA, and acts
through a fatty acid biosynthesis pathway that causes microbial cell membrane
deterioration.

2.7 References
1.

2.
3.

4.

5.

Altoparlak, U., et al., The time-related changes of antimicrobial resistance
patterns and predominant bacterial profiles of burn wounds and body flora of
burned patients. Burns, 2004. 30(7): 660-664.
Ren, X.-F., et. al., Studies on nonconventionally fused bicyclic β-lactams. Journal
of Organic Chemistry, 1998, 63: 8898-8917.
Revell, K.D., et al., N-thiolated beta-lactams: Studies on the mode of action and
identification of a primary cellular target in Staphylococcus aureus. Bioorganic
& Medicinal Chemistry, 2007. 15(6): 2453-2467.
Coates, C., et al., N-thiolated beta-lactam antibacterials: Defining the role of
unsaturation in the C-4 side chain. Bioorganic & Medicinal Chemistry, 2003.
11(2): 193-196.
Long, T., PhD Dissertation. 2005: University of South Florida.
56

6.
7.

8.
9.

10.
11.

12.

13.

14.

15.
16.
17.

18.
19.

Turos, E., et al., N-thiolated bicyclic and monocyclic beta-lactams. Tetrahedron,
2000. 56(31): 5571-5578.
Turos, E., et al., N-thiolated beta-lactams: Novel antibacterial agents for
methicillin-resistant Staphylococcus aureus. Bioorganic & Medicinal Chemistry
Letters, 2002. 12(16): 2229-2231.
Wang, Y., PhD Dissertation. 2006: University of South Florida.
Long, T.E., et al., Effect of aryl ring fluorination on the antibacterial properties of
C-4 aryl-substituted N-methylthio beta-lactams. Bioorganic & Medicinal
Chemistry, 2003. 11(8): 1859-1863.
Carr, J.A., et al., Lipase-catalyzed resolution of 4-aryl-substituted beta-lactams:
effect of substitution on the 4-aryl ring. Tetrahedron, 2003. 59(46): 9147-9160.
Turos, E., et al., N-Methylthio beta-lactam antibacterials: Effects of the C-3/C-4
ring substituents on anti-MRSA activity. Bioorganic & Medicinal Chemistry,
2005. 13(23): 6289-6308.
Woulfe, S.R., H. Iwagami, and M.J. Miller, Efficient N-sulfenylation of 2azetidinones using S-substituted thiophthalimides. Tetrahedron Letters, 1985.
26(33): 3891-3894.
Turos, E., et al., Penicillin-bound polyacrylate nanoparticles: Restoring the
activity of beta-lactam antibiotics against MRSA. Bioorganic & Medicinal
Chemistry Letters, 2007. 17(12): 3468-3472.
Turos, E., et al., Antibiotic-conjugated polyacrylate nanoparticles: New
opportunities for development of anti-MRSA agents. Bioorganic & Medicinal
Chemistry Letters, 2007. 17(1): 53-56.
NCCLS, N.C.f.C.L.S., Methods for dilution of antimicrobial susceptibility tests
for bacteria that grow aerobically. , in NCCLS Document M7-A4. 1997, NCCLS
Ren, X.F., M.I. Konaklieva, and E. Turos, Synthesis of inversely-fused bicyclic βlactams. Journal of Organic Chemistry, 1995. 60(16): 4980-4981.
Panessa-Warren, B.J., G.T. Tortora, and J.B. Warren, High resolution FESEM
and TEM reveal bacterial spore attachment. Microscopy and Microanalysis,
2007. 13(4): 251-266.
Liu, H.B., et al., Formation and composition of the Bacillus anthracis endospore.
Journal of Bacteriology, 2004. 186(1): 164-178.
Zhang, J., et al., Supercritical carbon dioxide and hydrogen peroxide spore
structures associated with high killing rate cause mild changes in of Bacillus
anthracis. Journal of Microbiological Methods, 2007. 70(3): 442-451.

57

CHAPTER 3
NANOPARTICLE MICROEMULSION
POLYMERIZATION FOR DRUG DELIVERY
3.1 Introduction
New classes of antibacterial agents and alternative therapy protocols are in dire need in
this era of escalating drug-resistance among pathogenic bacteria. One of the most recent
forays in this area is the use of nanotechnology for both drug delivery platforms and as
therapeutic agents themselves. Nanoparticle-based antibiotics have provided antiinfectives with improved performance, sustained or controlled release, improved
solubility and stability, lower cytotoxicity, and in some cases, targeted drug delivery.
Since the first application of nanoparticles in therapeutics in 1976 by Kreuter and
Speiser,[1] nanotechnology has been applied to many areas in the medical field, including
imaging, anti-cancer therapies, and also antimicrobial therapy, although little effort has
been put towards improving antimicrobial efficacy thus far. With the increasing capacity
of microbes to develop resistance to the currently prescribed antibiotics, the need to
explore this form of advanced drug delivery for antimicrobials is paramount in
overcoming current bacterial resistances and also possibly improving the efficacies of
current antibiotics. That is the focus of this chapter, where the use of polyacrylate
nanoparticles synthesized through a microemulsion polymerization technique is explored
in order to increase the bioavailability of antimicrobials and also to rejuvenate some of
the current antibiotics such as penicillins that have become increasingly obsolete due to
the development of bacterial resistance mechanisms.

3.2 Penicillins and Bacterial Resistance
Since the initial discovery of penicillin by Alexander Fleming in 1928, and the first
synthesis of the antibiotic for pharmaceutical use, antibiotics have played a major role in
infection treatment. The penicillin antibiotics, and many of the other β-lactam-based
classes of antibiotics subsequently discovered, act by inhibiting the synthesis of the
bacterial cell wall. This thick cell wall, consisting mainly of cross-linked peptidoglycan
polymer chains, is found only in prokaryotic cells and is considered to be a very thick
protective layer in gram positive bacteria. While this layer is also present in gram
negative microbes, it is limited in its thickness and fortification.
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Figure 3.1. TEM of healthy Staphylococcus aureus cells. Left arrow indicates the
peptidoglycan cell wall that is present only in prokaryotic microbes.

This cross-linked cell wall is essential for microbes to retain their rigid cell structure and
morphology. When severely damaged, cytoplasmic leeching is observed, ultimately
killing the microbe (Figure 3.2). The penicillin class of antibiotics acts on cell wall
biosynthesis by preventing the inter-polymer strand cross-linking that gives the cell wall
its rigidity, through interactions with the bacterial enzyme glycopeptide transpeptidase.
As seen in Figure 3.2, S. aureus cells treated with penicillin G via a Kirby Bauer
diffusion assay caused the cocci to become wrinkled in appearance, concaved from their
inherent spherical morphology (darkened areas in center of cocci), and altered in size and
cohesiveness.[2]

Figure 3.2. SEM image of S. aureus treated with penicillin G. Image captured by Dr.
Timothy Long shows ruptured staphylococci at the bottom left and right of the image due
to a breakdown in the cell wall.[2]

However, with every great new discovery come new challenges and the establishment of
penicillin as an antibacterial drug was certainly no different. Over-usage and a lack of
public conscientiousness on how to properly administer this drug in terms of dosage
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regimens sparked a new phenomenon in bacterial infections and treatment, the era of
drug-resistant microbes. Almost as soon as penicillin was made available for use in
hospitals and clinics in the 1940s, bacterial resistance formed, especially in the gram
positive species Staphylococcus and Streptococcus, ultimately creating one of the most
dangerous microbes associated with human infection, methicillin-resistant S. aureus
(MRSA). In burn patients the risk of acquiring an MRSA-based infection is 45%, and is
one of the primary microorganisms contributing to infections associated with high
mortality rates in burn victims.[3] MRSA’s antibiotic defense works by exuding the
enzyme β-lactamase in the area immediately surrounding the microbe, which in turn
protects the microbe from β-lactam antibiotics. This enzyme, as seen in Figure 3.3, works
by effectively causing the ring opening of the β-lactam, which inactivates the drug’s
antibacterial activity.
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Figure 3.3. Inactivation of penicillin G by the β-lactamase enzyme.

Many new analogs of penicillin, including cephalosporins, carbapenams, penams,
nocardicins, and monobactams, have all been synthesized since the initial synthesis of
penicillin for antibacterial usage, and with each new class of antibiotics, an increase in
drug potency and broadening of the antibacterial activity towards gram negative microbes
was observed. However, none of these antibiotics were able to successfully resist the
enzymatic activity of the β-lactamase enzyme (Figure 3.3). However, clavulanic acid, a
low molecular weight molecule was later discovered that, when delivered in combination
with certain penicillins such as ampicillin and amoxicillin was capable of blocking the
activity of the β-lactamase in order for the antibiotic to reach the bacteria and evoke its
antibacterial activity. Since clavulanic acid has no antibacterial activity, only its ability to
enhance the activity of penicillin antibiotics, it is an important advance against drug
resistance. Nowadays, when penicillin antibiotics are prescribed, the drug often contains
clavulanic acid for this specific purpose. However, there are some disadvantages to this,
including further escalation of resistance from selective pressure on the microbe to overexpress the gene for penicillinase production (Figure 3.4). Also, since most antibiotics are
administered orally, poor stability and/or permeability in the digestive tract results in subtherapeutic concentrations of the antibiotic reaching the infection site. Since patients
often do not follow the recommended dosing regimen for oral antibiotics and stop
treatment once they begin to feel better, an even greater threat exists for development of
bacterial resistance to the drug. This is certainly the case for ear infections in young
children where use of clavulanic and (or other β-lactamase inhibitors) in combination
with a β-lactam antibiotic has led to severe antibiotic resistance.
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A

B

Figure 3.4. Antimicrobial resistance trends in pathogens found in burn wounds. A)
Resistance of S. aureus strains to antibiotics over time of treatment. B) Resistance of
Pseudomonas aeruginosa strains to antibiotics over time of treatment. Data reprinted
from Burns, Vol. 30, by Altoparlak et. al. Pages 660-664, Copyright 2004, with
permission from Elsevier.[3, 4]
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Studies have shown that, especially in burn treatment centers, patients who are
administered a regimen of β-lactam antibiotics have a nine-fold increase in the chance of
developing an MRSA infection over patients treated with the newer classes of
glycopeptide and fluoroquinone antibiotics.[5] However, glycopeptide antibiotics, such as
vancomycin and teicoplanin, are considered a last resort for treating S. aureus infections
since resistance has already been observed for these antibiotics as well. Also, while the
use of fluoroquinone antibiotics have been very effective broad spectrum antibiotics,
resistance has been observed for these antibiotics as well including in the gram negative
microbe Pseudomonas aeruginosa which is the most frequent pathogen found colonizing
burn wounds (Table 3.1).[6-11] Therefore, this work set out to establish a new and unique
drug delivery system that has the ability to shield antibiotics from resistance factors so
that they can maintain full antibacterial activity.
Table 3.1. Microorganisms commonly found in burn wound infections.[6-11]
Microbe Classification

Pathogen

Gram Positive

S. aureus: MRSA, MSSA
S. epidermidis
Streptococcus spp.
Pneumococcus spp.
Haemolytic streptococci
Bacillus spp.
Vancomycin-resistant Enterococcus
Enterococcus faecalis
Corynebacterium spp.
Neisseria spp.
P. aeruginosa
Escherichia coli
Klebsiella spp.
Enterobacter cloacae
Serratia marcescens
Proteus mirabilis
Acinetobacter calcoaceticus
Bacteroides spp.
Citrobacter fruendi
Candida spp.
Aspergillus spp.
Fusarium spp.
Alternaria spp.
Rhizopus spp.
Herpes simplex virus
Cytomegalovirus
Varicella-zoster virus

Gram Negative

Fungi

Viruses
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3.3 Nanoparticles as New Drug Delivery Vehicles
As detailed in Section 3.2, there are numerous antibiotics available to treat pathogens
commonly associated with burn wound infections. However, many of the potent
antimicrobials mentioned are water-soluble, which limits their use when the area of
infection is found within highly lipophilic regions of the body such as the skin and soft
(fatty) tissue. The level of antibacterial activity of the drugs is greatly diminished for such
applications due to the antimicrobials unable to penetrate into the tissue. While these
drugs can be successful for the initial superficial infections observed upon injury, they
cannot reach the deep fascia where bacteria typically colonize. Therefore, in order to
diversify the applications of these potent water soluble antibiotics, new drug delivery
vehicles must be explored. Previous work has made use of creams and ointments to
deliver multiple water insoluble antibiotics to skin and soft tissue abrasions and even
higher complexity burn wounds. These creams and ointments make use of numerous
types of drug delivery vehicles, including lyposomal and colloidal drug conjugates, as
well as emulsification processes and cross-linked polymer micelles.[12-18] While these
processes have yielded many commercial products, newer technologies (i.e.
nanotechnology) exist that may improve upon these drug carriers and make them not only
more versatile in application, but have also been shown to increase antibacterial
efficacy.[21]
Currently, nanoparticles have become one of the most heavily researched areas of drug
delivery. Many improvements have been made in this area, especially in cancer therapy,
targeted delivery of theraputic compounds, and medical imaging,[18, 22-26] yet up to now
little effort has been made towards applying nanoparticles to antimicrobial drug
therapy.[19-21, 27-35] Antibiotic-coated gold and silver-based metallic nanoparticles,[30, 32, 33]
antibiotic encapsulated polymeric nanoparticles and liposomes,[28, 34] and biodegradable
nanospheres[29, 35] have all been explored, yet little commercial development has been
seen thus far. Couvreur et al. developed a series of poly(alkyl cyanoacrylate)
nanoparticles which are bioresorbable and are currently being used as surgical glues[22]
and more recently as carriers of antibiotics (specifically ciprofloxacin).[28, 29, 31] This drug
delivery system provide the antibiotics incorporated within the particles with the ability
to overcome problems associated with oral administration, including stabilizing the drug
in the gastrointestinal tract and providing adequate adsorption into the blood stream.
Couvreur et al. has also shown that encapsulation of the ciprofloxacin monomer within
the poly(cyanoacrylate) nanoparticle has heightened the in vitro activity of this antibiotic
against S. aureus.
Some in vivo studies have looked into the effects of various nanoparticles, including
chitosan and metal-based nanoparticles, for burn wound treatment, and have found
positive results that show increased wound healing and enhanced cosmetic results.[27, 36]
Also, the commercially available ActicoatTM and Silveron wound dressings have utilized
nanocrystalline silver for topical application to burn wounds.[6] These dressings consist of
two sheets of high density polyethylene for antibacterial mesh that is coated with the
nanocrystalline silver, which affords moderate penetration of unexcised burn eschar, a
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highly lipophilic and extremely difficult tissue to penetrate, and controlled release over a
prolonged time frame.[6] Advances in nanotechnology have allowed these topical
antimicrobials to provide burn treatments with deep penetration of antimicrobial agents
and also extend activity of the antimicrobials. This has not only had benefits in
excavating infections below burn eschar prior to surgical debridement procedures, but has
also decreased the occurrence of nosocomial infections due to a decrease in the number
of dressing changes. Therefore, the work explored herein was established in order to
build upon the current advances and proven positive effects of nanotechnology coupled
with topical antimicrobial treatments for burn wound infections and create a new and
unique multi-drug containing nanoparticle delivery system for administration to burn
wounds immediately after thermal injury.
A previously described microemulsion polymerization process was chosen in order to
synthesize polyacrylate nanoparticles in a single step (Figure 3.6). Due to the highly
lipophilic nature and small size of the polyacrylate nanoparticles produced by emulsion
polymerization, the hope is that utilization of these nanoparticles as a drug delivery
system will allow the drug conjugate to penetrate deep into a wound bed and be able to
treat all of the infected tissue present, which most topical antimicrobials (even when
formulated in the currently used creams and ointments) are unable to achieve.

Figure 3.6. Nanoparticle containing emulsion, CNP5. This image depicts a freshly
prepared drug-free nanoparticle emulsion (20% solid content) in a 25mL glass vial.

3.4 Emulsion Polymerization
Emulsion polymerization has been utilized for many years for industrial development of
latex materials, adhesives, paints, paper and textile coatings.[37] The discovery of
microemulsion polymerization in 1943 by Hoar and Schulman allowed this technology to
expand towards drug delivery applications due to the formation of smaller, more stable
droplets suspended within the emulsion.[38, 39] The emulsion polymerization technique
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offers many advantages over other polymerization techniques such as reversible
addition–fragmentation chain transfer (RAFT) and block polymer formation, including
the use of water as the solvent system, formation of high molecular weight polymers with
the ability to limit the molecular weight range to a narrow distribution, and a resulting
low viscosity emulsion similar to water.[40] Both the macroemulsion and the
microemulsion polymerizations utilize surfactants to combine an aqueous phase (water)
with water insoluble liquid acrylate monomer(s) to produce the oil-in-water emulsion and
also to stabilize the polymeric particles that form from coagulating in the solution.
Radical initiation is the means for polymerization of the acrylate monomer(s) after the
initial micelle formation through the use of heat to generate the initial radical. For the
polymerization to be successful, free oxygen present in the emulsified solution must be
purged prior to addition of the radical initiator, since oxygen is a well known radical
scavenger that will inhibit polymerization.
In emulsion polymerizations, the choice of surfactant and radical initiator inevitably
dictates many of the physical properties of the resulting emulsion, including particle size
and morphology, surface charge, emulsion stability, and molecular weight of the polymer
chains. An anionic surfactant, dodecyl sulfate sodium salt (SDS), was chosen for these
specific emulsion polymerizations which established an overall negative charge for the
emulsion and subsequently, a low pH of 2 to 2.5. In order for the size distribution and
particle morphology to be uniform, polymerizations were carried out at or below the
critical micelle concentration, which is usually achieved by the addition of 1-6% (w/w)
surfactant to monomer in the emulsion formulation. All of the drug-free emulsions
synthesized here contained 1, 3, or 5% SDS in the formulation, and either 0.5 or 1%
radical initiator (Figure 3.7).
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Figure 3.7. Chemical structure of the surfactant, sodium dodecyl sulfate, and the radical
initiator, potassium persulfate, used in the emulsion polymerization.

In the instance of microemulsions, the micelles are subsequently transformed into solid
polyacrylate particles in the nanometer size range through radical-initiated
polymerization of the acrylate monomers within the micelles. The resulting emulsion is
typically optically transparent, isotropic, and thermodynamically stable, and contains
uniformly spherical particles of a narrow size distribution. Figure 3.8 is a representative
schematic of the microemulsion polymerization process, showing the emulsification stage
of micelle formation.
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Figure 3.8. Schematic of initial micelle formation during an emulsion polymerization.

3.4.2 Synthesis and Chemical Analysis of Drug-Free Nanoparticle Emulsions
In order to create the most optimal drug delivery system, numerous combinations of comonomers, surfactant, and radical initiator were used in the emulsion formulation. Four
different acrylate monomers were investigated in various combinations: butyl acrylate
(BA), styrene (Sty), methyl methacrylate (MMA), and ethyl acrylate (EA). The surfactant
used in the emulsion polymerizations was dodecyl sulfate sodium salt (SDS) and the
radical initiator was potassium persulfate. However, the concentration of these two
reactants used in each polymerization was varied from 0.5% to 5% of the total solid
content.

Scheme 3.1. Microemulsion polymerization of butyl acrylate and styrene co-monomers.
These two co-monomers were used in the drug-free emulsion formulations CNP5,
CNP7, CNP9, CNP10, CNP15, and CNP16.
Microemulsion
Polymerization

O
+

BuO

O Bu
BA

O

Water, 70oC, N2
CNP5, 7, 9, 10, 15, 16

Sty

Six different (drug-free) control nanoparticle (CNP) emulsion were formulated using BA
and Sty as the liquid acrylate monomers. Two different ratios of these monomers were
used for the emulsions, an 8: 2 ratio of BA:Sty (CNP7, CNP10), and a 7:3 ratio (CNP5,
CNP9, CNP15, CNP16). These emulsions are further distinguished from one another by
the content of surfactant and radical initiator in their formulations. CNP5 and CNP7
contained 3% SDS and 0.5% radical initiator, while CNP9 and CNP10 contained 5%
SDS and 1% radical initiator in the formulation. Both CNP15 and CNP16 nanoparticle
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emulsions contained only 1% SDS in their formulations, however, CNP15 contained 1%
radical initiator and CNP16 contained only 0.5% radical initiator.

Scheme 3.2. Microemulsion polymerization of butyl acrylate and methyl methacrylate
co-monomers. These two co-monomers were used in the drug-free emulsion formulations
CNP6, CNP12, CNP13, CNP14, and CNP17.
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Five different (drug-free) control nanoparticle emulsions were formulated using BA and
MMA as the liquid acrylate monomers. Two different ratios of these monomers were
used for the emulsions, an 8:2 ratio of BA:MMA (CNP6, CNP14), and a 7:3 ratio
(CNP12, CNP13, CNP17). These emulsions are further distinguished from one another
by the content of surfactant and radical initiator in their formulations. CNP12 and
CNP13 contained 3% SDS and 0.5% radical initiator, while CNP6 and CNP14 contained
5% SDS and 1% radical initiator in the formulation. The nanoparticle emulsion CNP17
contained only 1% SDS in its formulation and 0.5% radical initiator.
The drug-free nanoparticle emulsions (CNPs) were analyzed by analytical and chemical
means in order to characterize their physical, chemical, and mechanical properties.
Dynamic light scattering and imaging techniques were used to elucidate the physical
properties of the emulsions, nuclear magnetic resonance (NMR) spectroscopy and
Fourier transformed infrared (FTIR) spectroscopy and zeta potential analysis was used
for chemical analysis of the emulsions, and uniaxial tension analysis was performed to
determine the mechanical properties of the polymer films. NMR analysis was performed
on selected emulsions by pipetting between 1 and 1.5mL of concentrated (20% solid
content) nanoparticle emulsion onto a solid surface (glass or Teflon) and allowing the
solution to form a film through coagulation of the emulsion. The film was subsequently
placed in deuterated chloroform (CDCl3) in a thin glass NMR tube for NMR analysis.
Even though the polymer films were unable to completely dissolve, the films did swell
into a translucent gel-like material that was analyzed by proton NMR. Figure 3.9
provides a proton NMR spectrum obtained for the drug-free polyacrylate film sample
CNP5.
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Figure 3.9. NMR spectrum of CNP5 drug-free polyacrylate film samples.

3.4.3 Stability of the Nanoparticle Emulsions
Studies were performed on the nanoparticle emulsions in order to determine their stability
to changes in temperature (room temperature, physiological temperature, and
refrigeration storage temperature), changes in pH (from 1-12), aging, and stability to
blood serum. Results of these studies were recorded as visual observations by particle
size analysis of the emulsions by dynamic light scattering (DLS) analysis and by
antibacterial activity (Figures 3.10, 3.11, and 3.12). The BA:Sty emulsions and the
BA:MMA emulsions were visibly stable at pH 1 to pH 12, where the original
concentrated nanoparticle emulsions (20% solid content) exhibited pHs between 2 and 3
(Figure 3.10A). Stability of the emulsions over a wide pH range suggests that the
emulsions could tolerate post-polymerization chemical modification in order to add
additional functionality to the nanoparticle surface for biomedical applications. This was
not investigated further in this particular study.
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A

B

Figure 3.10. Stability of nanoparticle emulsion CNP5 at various temperatures and pH
changes. Data represents the average particle size for the emulsion at various pH values
(A) and for each solid content concentration at different temperatures for 3 days (B). In
each case, particle size was determined by dynamic light scattering.

As seen in Figure 3.10B, these nanoparticle emulsions are stable at low temperatures
consistent with refrigeration storage (5oC), as well as at physiological temperatures
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(40oC). The emulsions were also stable over extended periods of time, where in Figure
3.11 it was observed that the average particle size for all solid content concentrations
analyzed (1.5% to 10%) was the same when freshly prepared as it was after being stored
at room temperature for one month.

Figure 3.11. Stability of nanoparticle emulsion CNP16 upon aging for 30 days at room
temperature. Data represents the average particle size for each solid content
concentration. Samples were stored at room temperature while aging.

The nanoparticle emulsion CNP16, containing a 7:3 ratio of BA:Sty, 1% SDS and 0.5%
radical initiator, was stable over a minimum of one month. Moreover, visual observations
established that all of the emulsions containing 3% SDS or less showed no polymer
precipitation or surfactant settling for up to 2 years at room temperature. Figures 3.10 and
3.11 show that the nanoparticle size does not change upon dilution (from 20% to 1.25%
solid content concentration). It was expected that the particle size should not be
influenced by addition of more water to the emulsion, since the surfactant SDS should be
closely associated to the nanoparticles and feel no dilution effect.
The stability of the nanoparticle emulsion systems towards blood serum was analyzed
using the penicillin-containing nanoparticle emulsions NP13 and NP15 (described in
Section 3.5). NP13 contained encapsulated penicillin G in the free acid form, and NP15
was formulated with penicillin G acrylamide as one of the co-monomers for the emulsion
polymerization. Both emulsions have shown in vitro activity against S. aureus and
MRSA. Here, the emulsions were diluted to the appropriate concentration (5.12mg drug/
mL of emulsion) for minimal inhibitory concentration (MIC) serial dilution assays using
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fetal bovine serum (FBS) in place of aqueous buffer. The emulsions were incubated with
the serum for 24 hours at room temperature prior to antibacterial analysis. Table 3.2
provides the MIC values for the emulsions against S. aureus and MRSA before and after
exposure to the blood serum.

Table 3.2. MIC data for penicillin-containing emulsions NP13 and NP15 before and after
24 hour exposure to fetal bovine serum. MIC values are reported in µg of drug per mL of
emulsion. (S. aureus: ATCC 25923, MRSA: ATCC 63300).
Penicillin Samples
Untreated
Penicillin G
NP13
NP15
Treated
NP13
NP15

S. aureus

MRSA

0.012
2
64

16
2
64

2
8

2
8

The data in Table 3.2 show that the antibacterial activity of the penicillin G acrylamidecontaining nanoparticle emulsion (NP13) does not change upon exposure to the various
proteins, enzymes, and salts present in blood serum. This indicates that it is highly
probable that this emulsion formulation will be stable upon intravenous administration.
Visual observations for both emulsions diluted with FBS concluded that sedimentation
did not occur after 24 hours of exposure, nor did the appearance of either emulsion
change after initial dilution, which caused the emulsion to take on the brownish color of
the FBS. However, the MIC value for the penicillin G free acid encapsulated nanoparticle
emulsion NP15 drastically changed upon exposure to FBS, from 64 to 8µg/mL. The
dramatic increase in antibacterial potency for this emulsion could be the result of particle
degradation by biological molecules in the blood serum. When in the free polymer form,
the surfactant is not bound to the surface of the particles, which could then be allowing
the surfactant to exhibit toxicity against the microbes. A secondary explanation is that the
enzymes present in the blood serum promote the release of the drug from within the
nanoparticle more efficiently than when the nanoparticles are only exposed to the
microbial esterase and lipase enzymes. However, for a definitive answer, other studies
would need to be performed. Regardless of the variance in antibacterial activity for the
encapsulated penicillin nanoparticles, the covalently bound penicillin G acrylamide
nanoparticle emulsion was determined to be stable towards the blood serum, and thus was
used in the in vivo toxicology study defined in Chapter 8.
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3.5 Drug-Containing
Polymerization

Nanoparticle

Formation

by

Emulsion

Polymeric drug delivery was established almost 30 years ago and is still a heavily
researched area in drug design and delivery (Gombotz and Pettie, 1995; Sinha and
Khosla, 1998; Langer, 1998).[41] Polyacrylates have been a large part of this effort, due to
their lack of toxicity and optimal solubilizing properties.[12-17, 42-49] Polyacrylates have
been used in medicine in various forms, including polymer film coatings, gels, and in
liquid emulsions. Polyacrylate emulsions, and also lipid and other polymer-based
emulsions and colloidal drug carriers, have been investigated for many years to deliver
insoluble drug monomers to target sites and are frequently administered intravenously or
topically due to their high stability, ability to stabilize drug monomers for delivery, and
decrease irritation and pain at the application site.[12, 42-49] The emulsions have shown
numerous benefits when used for drug delivery, including delivering the dissolved drug
solely to its intended destination in the body, providing the drug with controlled release,
and increasing the uptake and efficiency of the drug.[12-17] Microemulsion polymerization
was explored in this study as a means for encapsulation of many water insoluble
antimicrobials, including the broad-spectrum antimicrobials amphotericin B,
erythromycin, and doxycycline, and also for covalent attachment of acrylated drug
monomers to the nanoparticle delivery vehicle. The application of these antimicrobials in
the nanoparticle emulsion was to improve upon the already established benefits of
emulsified drug delivery with the added benefit of the nano-size of the delivery vehicle as
a means to increase the overall efficiency and possibly provide the drug with new
medicinal applications.
Since incorporation of the drug monomers into the nanoparticle is essential for
antimicrobial activity, the co-monomers chosen must fully dissolve the acrylated drug
monomer prior to emulsification with water and surfactant. For most drug-containing
nanoparticle emulsions synthesized in this current study, BA and Sty were the comonomers of choice (Scheme 3.1). These two co-monomers were the best choice for
such polymerizations when used in a 7:3 ratio of BA:Sty because of the stability and
particle size of the resulting nanoparticle emulsion and also because this combination of
co-monomers dissolved the acrylated drug monomers being explored. Also, the initial
amount of surfactant used for these systems was 3% (w/w) because of the resulting
emulsion stability and particle size determined from the drug-free nanoparticle emulsion
systems. However, this amount of surfactant was later lowered to 1% (w/w) due to
observed cytotoxic effects of the 3% SDS emulsions on human dermal fibroblast cells
(Chapter 7). The amount of radical initiator utilized for this system was 0.5% (w/w).

3.5.2 Covalently Bound Drug-Conjugated Nanoparticle Formation by Emulsion
Polymerization
For a drug monomer to be incorporated covalently into the nanoparticle, it must contain a
chemical moiety similar to the ones present in the liquid acrylate co-monomers.
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Therefore, all of the drug candidates were converted to an appropriate acrylate or
acrylamide form. Schemes 3.3 through 3.9 depict the emulsion polymerization for each
drug acrylate monomer. These emulsions were subsequently tested for antibacterial
activity in vitro, along with their desiccated/coagulated polymer film.

Scheme 3.3. Emulsion polymerization of β-lactam monomer 1.
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Proton NMR analysis was performed by J.-Y. Shim in his dissertation research for NP1a
and compared the spectra obtained to that from lactam monomer 1 as well as poly(ethyl
acrylate) in order to establish the degree of lactam incorporation into the emulsion.
Integration of the peaks of the NMR spectrum from NP1a in Figure 3.12 showed that the
1:7 ratio of lactam 1 to EA was found in the solid content of the emulsion (polymer film),
indicating that all of the lactam monomer is covalently incorporated into the nanoparticle
polymer backbone. Figure 3.12 also shows the progression of lactam incorporation into
the nanoparticle emulsion as the amount of lactam is increased in the emulsion
formulation of NP1a from 20:1 EA: lactam up to 2.5:1 EA:lactam.
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Figure 3.12. NMR spectra of NP1a and poly(ethyl acrylate). NMR analysis showed that
the lactam monomer was incorporated into the nanoparticle emulsion, and that as the
amount of lactam monomer is increased in the emulsion formulation, signals from the
monomer become more apparent by NMR. NMR analysis performed by J.-Y. Shim.[20,40]

Proton NMR analysis showed signals at 2.6ppm, 5.6ppm and 6.1ppm that were assigned
to SCH3, C3-H and C4-H on the β-lactam respectively. The olefin protons of ethyl
acrylate and acrylated lactam monomer in the range of 5.6-6.1ppm were not visible in the
spectra indicating that all of the monomeric lactam acrylate and ethyl acrylate was
converted into polymeric particles. The aromatic protons from the ortho-chlorophenyl C4
substituent on the lactam ring was observed at 7.3ppm and the intensity of this signal
increased as the amount of lactam monomer 1 in the emulsion formulation increased.
While all of these respective signals for the acrylate monomers were observed, minus the
acrylate proton signals, the peaks presented by the polymer films were much broader than
the non-polymerized monomers individually, which is commonly associated with
polymerized samples.
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Table 3.3. Formulation for emulsion polymerization NP1a.
Reagent

Mass

Lactam
monomer 1
Ethyl acrylate
Water
Sodium dodecyl
sulfate
Potassium
persulfate

80 mg

Percent
(%)
2

Volume
(mL)
NA

0.28g

15.5

0.3

3.6g

80

3.6

7.2mg

2

NA

1.8mg

0.5

NA

The formulation for NP1a is defined in Table 3.3. NP1a was the first emulsion
polymerization formulated in this study and are the same as those previously established
by Dr. Jeung-Yeop Shim,3 where the acrylated β-lactam monomer 1 was co-polymerized
with ethyl acrylate. It was later determined that the physical and chemical properties of
these emulsions were not optimal in terms of particle size and emulsion stability,
antibacterial activity and biomedical application, thus the formulation was changed to the
one used for NP1 (Scheme 3.4, Table 3.4). The obvious difference between the two
emulsion formulations is the liquid acrylate monomers used for the new emulsion
formulation were butyl acrylate and styrene in a 7:3 ratio.

Scheme 3.4. Improved emulsion polymerization of β-lactam acrylate monomer 1.
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Table 3.4. Formulation for nanoparticle emulsion NP1 and all other drug-containing
emulsions.
Reagent

Mass

Percent (%)

Volume (mL)

Lactam
monomer 1

60mg

3

NA

Butyl acrylate

1.4g

1.57
13.5 or 15.5

Styrene

0.6g

0.66

Nanopure
Water

8.0g

80

8.0

Dodecyl sulfate
sodium salt

60mg

3 or 1

NA

Potassium
persulfate

10mg

0.5

NA

The emulsion formulation represented in Table 3.4 was employed for every other drugcontaining emulsion in this entire study (NP2-NP25), however, the amount of surfactant
was varied during the study with the initial surfactant concentration being 3% SDS and
later the concentration was reduced to 1%. A radical initiator concentration of 0.5% of
the solid content was also held constant throughout the entire study for all drugcontaining nanoparticle emulsions. The amounts of BA, Sty and radical initiator were
held constant at a 7:3 ratio and 0.5%, respectively, as seen in Table 3.4. Initial toxicity
analysis performed on the 3% SDS formulated emulsions resulted in slightly elevated
levels of fibroblast cytotoxicity (Chapter 7), which lead to the development of the 1%
SDS formulated emulsions. Herein, all of the physical, chemical and antibacterial data for
this drug-containing lactam monomer 1 is presented for the emulsion containing 1%
SDS.
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Scheme 3.5. Emulsion polymerization of β-lactam acrylate monomer 3 to form
nanoparticle emulsion NP3.
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Both of the ortho-chlorophenyl acrylate β-lactam monomers synthesized in Chapter 2
possess the same basic lactam structure and side chains at the C3 and C4 position of the
ring, yet they differ in the alkyl chain attached to the N-thiolated portion of the molecule
which is responsible for antibacterial activity. The difference in the alkylthio chain length
greatly influences antimicrobial activity, with these two derivatives showing, as well as
did changes to the C3 and C4 substituents (Chapter 2). Also polymerized individually
were lactam monomers 5 and 9 where the acrylate linker for both monomers was much
longer than for β-lactam monomers 1 and 3. Monomer 5 contained the acrylate linkage at
the C4 position on the lactam ring, as a para-substituent on the aromatic ring. Monomer 9
possessed a longer acrylate linkage at the original C3 position on the lactam ring. Both of
these lactam monomers were polymerized using the same formulation as described in
Table 3.4 to provide nanoparticle emulsions NP5 and NP9.
The acrylated form of several commercially available drugs (11, 12, 16, 17, and 19) were
also polymerized in order to define the antibacterial properties of the drugs when
incorporated in the nanoparticle delivery system. This was done to examine if
incorporation of various β-lactams in the nanoparticle could afford them with activity
against resistant microbes including MRSA. In order to analyze this, the acrylated form
of five different β-lactam drug monomers, ampicillin, amoxicillin, penicillanic acid,
cefaclor, and penicillin G were all individually polymerized with BA and Sty. All of the
drug-conjugated emulsions were formulated with 3% SDS (Scheme 3.6), except for the
penicillin G emulsions that contained only 1% SDS (Scheme 3.8).
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Scheme 3.6. Polymerization of penicillin-based acrylate monomers 11, 12, 16, 17 and 19
separately to afford NP11, NP12, NP16, NP17, and NP19.
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Staphylococcal resistance has been observed for all of the commercially available drugs
used to make the monomers chosen for polymerization; therefore, these antibiotics were
optimal choices for testing the ability of the nanoparticle to shield the incorporated drug
from β-lactamase produced by the microbe. All of these monomers were individually
polymerized using 3% SDS surfactant and 0.5% radical initiator in the emulsion
formulation, as well as a 7:3 ratio of BA:Sty.
As seen in Chapter 2, the commercially available penicillin-based antibiotic amoxicillin
was chemically modified to possess two acrylate moieties; therefore, both the monoacrylate and di-acrylate forms of this drug were individually polymerized to assess any
differences in antibacterial activity should the nanoparticles have more highly crosslinked matrices (Scheme 3.7).
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Scheme 3.7. Polymerization of amoxicillin diacrylate monomer 18 with BA and Sty.
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As seen in Scheme 3.7, having the di-acrylate moiety present in the drug monomer
provides cross-links between polymer strands. The heightened degree of cross-links over
the already present cross-links within the nanoparticles due to impurities within the liquid
acrylate monomers could indicate that the bacteria may have a harder time breaking
down the acrylate bonds with lipase and esterase enzymes, thereby making it more
difficult for the free drug to be released from the delivery system. The increase in amount
of cross-linking present could also cause the nanoparticles formed to be smaller in
diameter because they are being held together more tightly than when a mono-acrylated
drug monomer is incorporated. The antibacterial data may answer how the di-acrylate
moiety will affect the antibacterial activity of the drug-conjugated system.
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Scheme 3.8. Polymerization of penicillin G acrylamide monomer (13) with butyl acrylate
and styrene to give nanoparticle emulsion NP13.
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Penicillin G acrylamide monomer was likewise co-polymerized with the BA and Sty
liquid acrylate monomers using only 1% SDS in the emulsion formulation.

Scheme 3.9. Polymerization of acrylamide ciprofloxacin monomers 7 and 8 with butyl
acrylate and styrene (7:3) to give nanoparticle emulsions NP7 and NP8, respectively.
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Both ciprofloxacin acrylamide monomers 7 and 8 were polymerized using two different
formulations. These monomers were first polymerized using 3% SDS, then subsequently
polymerized with a decreased amount of 1% SDS. In both formulations, the amount of
BA, Sty, and radical initiator were held constant at a 7:3 ratio and 0.5%, respectively.
Initial toxicity analysis performed on the 3% SDS formulated emulsions resulted in
slightly elevated levels of fibroblast cytotoxicity (Chapter 7), which led to the
development of the 1% SDS formulated emulsions. Herein, all of the physical, chemical,
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and antibacterial data is presented for the emulsions containing 1% SDS for these two
drug monomers.

3.5.3 Drug-Encapsulated Nanoparticles by Emulsion Polymerization
There are many commercially-available antimicrobials that are water insoluble or highly
lipophilic including the widely used erythromycin and the potent antifungal amphotericin
B. While these antimicrobials have been effective in treating infections topically, they
have seen little use as prophylaxis treatments due to their lack of solubility in aqueous
systems. Therefore, in an attempt to diversify the use of these antimicrobials, experiments
were conducted to try to incorporate them into the polyacrylate nanoparticles as an
aqueous emulsion in an attempt to make these potent drugs accessible to blood borne
infections and other infections where only water-solubilized drugs can reach. Due to the
highly lipophilic nature of many of these drugs, no chemical modifications were
necessary prior to emulsion polymerization. Other commercially available antibiotics
required modifications due to manufacturing processes that have made them more water
soluble (i.e. penicillin G is sold as a potassium salt). Four N-thiolated β-lactam monomers
were chosen for nanoparticle encapsulation, along with two different variations of
penicillin G, and a few other commercially available antibiotics that are often associated
with treatment of burn wound infections or possess drug resistance (Figure 3.13 and
3.14).
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Figure 3.13. N-Thiolated β-lactam monomers encapsulated in the nanoparticle through
emulsion polymerization.

Of all of the N-thiolated β-lactam monomers synthesized in this study, including the
acrylate monomers intended for covalent attachment to the nanoparticle polymer
backbone, lactam monomers NP6 and NP10 displayed the most potent antimicrobial
activity against all of the microbes analyzed (Section 3.8), thus were chosen for
encapsulation in the nanoparticle delivery system. Lactam monomer 4 was also chosen
for encapsulation as a comparison of antibacterial activity to the covalently bound lactam
monomers 1. Should bacterial esterases or lipases cleaves the ester bond between the
nanoparticle matrix and the drug monomer in NP1, the active drug monomer released is
expected to be hydroxy lactam 4.
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Figure 3.14. Penicillin G monomers encapsulated in the nanoparticle through emulsion
polymerization.

Of all the commercially available antimicrobials, a select few were chosen due to their
known potency against the most common pathogens found in burn wounds, or their
possession of drug resistance. This property of the drug monomers was considered
because, as was performed for the covalently bound drug monomers, this study looked to
establish whether or not the nanoparticle delivery system could circumvent the already
formed bacterial resistance and protecting the antibiotic from resistance factors (i.e. βlactamases. Both of the water insoluble penicillin G monomers used in the
polymerizations of NP14 and NP15 represent structures similar to the covalently bound
penicillin G acrylated monomers after bacterial cleavage of the monomers from the
polymer backbone. Therefore, these two nanoparticle emulsions were polymerized in
order to determine whether or not covalent attachment of the penicillin analogue to the
polymer backbone is required for overcoming bacterial resistance, or if simple
encapsulation of the monomer within the nanoparticle delivery system can accomplish
this task.
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Figure 3.14. Commercially available drug monomers encapsulated in the nanoparticle
through emulsion polymerization.

The drug monomers presented in Figure 3.14 represent antibiotics commonly used to
treat burn wound infections due to their broad spectrum of, antifungal properties, and
water insolubility. All emulsions of encapsulated drug monomers were formulated with
7:3 ratio of BA:Sty, 3% SDS, and 0.5% radical initiator. Antibacterial activity and
particle size and stability data were obtained for these nanoparticle emulsions as well as
later cytotoxicity analysis using healthy human dermal fibroblast cells (Chapter 7).

3.6 Particle Size Analysis for Nanoparticle Emulsions
Particle size data was obtained for all of the drug-free nanoparticle emulsions synthesized
using a Honeywell Microtrac UPA, assuming a refractive index of 1.51 for the emulsions
and uniform particle size and morphology throughout the emulsion, as was observed by
TEM and SEM analysis. Data for each emulsion was obtained by averaging data from 3
runs of 180 seconds per run per sample. The lengthy time requirement for each run
correlates to the length of time needed for the particles to travel a sufficient amount in the
solution during analysis to obtain a series of data points for comparison and accurate
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calculation of the particle size. Analysis of a select few drug-conjugated nanoparticle
emulsions was also performed by Torrey DeLuca at Malvern Instruments using a
Malvern Zetasizer Nano ZS instrument for both particle size and zeta potential. This
additional testing on a secondary instrument was performed as a quality control and
unequivocally proved the accuracy of the Honeywell data.

3.6.1 Theory Behind Dynamic Light Scattering
Dynamic light scattering (DLS) has been used for analysis of particle size and
distribution for emulsions and polymerizations for many years and utilizes the principle
of light diffraction for measurement of particles in a solution. When particles are
suspended in a solution, they undergo random fluctuations through Brownian motion
defined by random collisions of the particles with one another, which inevitably causes
random migration patterns of the particles within the solution. Since the particle size is
inversely proportional to its migration (smaller particles migrate farther than large
particles), the average size of particles in a solution can be calculated, as seen in Equation
3.1. The diffusion coefficient (D) of the solution is used to correlate the particle size to
the migration aptitude of the particle, which is what the DLS instrument is capable of
measuring from light scattered from particles migrating through the solution under the
influence of Brownian motion.

Equation 3.1.

RH

=

kBT
6π
πηD

RH = Hydro-dynamic radius
D = Diffusion Constant
kB = Boltzmann’s constant (1.38 x 10-23 JK-1)
T = Temperature in Kelvin (K)
η= viscosity

DLS instruments used for this study were able to calculate the average particle size
present in a solution and was given as the mean volume (mv), mean area (ma), and mean
number (mn) for the solution. Two different light diffractions were taken into account by
the instrument for each sample analyzed. Rayleigh scattering, where light is diffracted
uniformly after passing through a solution of particles smaller than the light beam and
Mie scattering, where larger particles (greater than 250nm diameter) cause an intense
beam diffracted by the particles at independent angles.[20] Due to the limited ability of
these instruments to take into account more than one particle size range and
morphologies, a solution must contain particles of a uniform size and morphology. If
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various sized particles are present in the solution, then the average particle size obtained
from this type of instrument will not be accurate, which is why imaging analysis must
also be performed in conjuction with this technique to verify the constituents present in
the solution.

3.6.2 Analysis of Drug-Free Nanoparticle Emulsions
For the drug-free polyacrylate emulsions presented in this chapter, the particle sizes are
within a narrow size range. However, at high concentrations of solid content, the
emulsions are viscous since they contain both the spherical nanoparticles and long chain
polyacrylates that are not incorporated into the particles. This makes particle size analysis
at high concentrations of solid content very difficult, which is why the emulsions were
diluted prior to analysis. Dilution of the emulsion to approximately 1% solid content (one
drop of concentrated emulsion into 10mL water) allowed accurate analysis of the particle
size range. At this concentration, the data obtained from this instrument showed a narrow
range of particle sizes present in the emulsions (Figure 3.16, Table 3.5).

Table 3.5. Average particle size for the drug-free nanoparticle emulsions, determined by
dynamic light scattering.
Nanoparticle
Emulsion
CNP5
CNP6
CNP7
CNP8
CNP9
CNP10
CNP11
CNP12
CNP13
CNP14
CNP16
CNP17

Mean number
(mn)
42.0
65.6
29.3
48.1
49.8
45.1
42.6
64.0
50.4
50.2
78.1
75.6

Mean average
(ma)
42.45
72.2
33.6
52.7
52.5
49.1
45.5
67.1
59.7
59.6
86.3
84.4
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Mean volume
(mv)
46.8
76.9
35.9
55.1
53.8
51.3
47.0
68.7
61.4
62.3
91.5
89.2

Figure 3.16. Particle size analysis for drug-free nanoparticle emulsion CNP5. Data
presented is for the mv calculation for the emulsion, where the average particle size
reported here is 46.8nm.

The data for the nine drug-free nanoparticle emulsions is reported in Table 3.5, where
traditionally, only the mean volume particle size diameter is reported in the literature.
This data showed that the ratio of the co-monomers (whether it was BA:Sty or
BA:MMA) affected the particle size distribution, as did the concentration of surfactant.
Figure 3.16 distinguishes the difference in particle size between the 3% surfactant
emulsions (CNP5 and CNP7) and the 5% SDS emulsions (CNP9 and CNP10).
Emulsions having 3% SDS contained particles averaging between 30 and 40nm, whereas
emulsions formulated with 5% SDS contained particles around 50nm in diameter. The
data in this figure also determined that as the amount of styrene was increased, the
average particle sizes increased. Comparison between the 7:3 ratio of co-monomers
(CNP5 and CNP9), with styrene being the lower constituent, and the 8:2 ratio of comonomers, showed a slight decrease in average particle size (approximately 5nm) as the
amount of styrene was reduced. In fact, even though CNP8 was formulated with 3%
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surfactant, because of the ratio of co-monomers (5:5 BA:Sty), the average particle size
was on par with emulsions formulated with 5% SDS (approximately 52nm).

Figure 3.17. Effect of varying the ratios of butyl acrylate: styrene co-monomers and the
amount of surfactant on particle size.

3.6.3 Particle Size Analysis for Drug-Conjugated Emulsions
Particle size analysis was performed using DLS methodology on many of the drugcontaining nanoparticle emulsions synthesized. The average particle size for the
covalently bound drug-containing nanoparticle emulsions (NP1a, NP7, NP8, and NP11)
was a compilation of the data obtained for up to 3 separate batches of the emulsions,
where the data represented for NP7 and NP8 in Table 3.6 is the average for both the 3%
SDS and 1% SDS nanoparticle emulsions. Averaging of this data was possible since the
particle size ranges were parallel for both the 3% and 1% SDS formulated emulsions,
which then gave a more statistically significant particle size range for the emulsions. The
encapsulated nanoparticle emulsions containing either β-lactam drug monomers (NP2
and NP6) or commercially available drug monomers (NP23, NP24, and NP25) were also
analyzed for their average particle size, with the data presented in Table 3.6.
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Table 3.6. Average particle size data for drug-containing nanoparticle emulsions as
determined by dynamic light scattering.
Drug-Containing
Nanoparticle
Emulsion
NP1a

Mean number
(mn)

Mean average
(ma)

Mean volume
(mv)

87.5

123.9

147.2

NP2

49.3

53.7

56.3

NP6

47.7

53.5

56.4

NP7

55.6

61.4

64.4

NP8

51.7

57.3

60.5

NP11

58.8

67.2

71.7

NP23

63.2

67.3

69.4

NP24

69.8

77.3

81.4

NP25

101.9

140.9

157.3

Particle size analysis was performed on both covalently-bound and encapsulated drugcontaining emulsions. Also analyzed was the drug-conjugated emulsion NP1a that was
formulated with EA as the only liquid acrylate monomer along with acrylate lactam 1.
The average particle size (mn) for the EA:lactam emulsion was much higher than was
observed for the same monomer co-polymerized with liquid BA and Sty (NP1). The
other β-lactam containing nanoparticle emulsions also exhibited smaller particles on
average than NP1a as did the penicillin-containing emulsion NP11.
The encapsulated β-lactam nanoparticle emulsions NP2 and NP6 were within the same
particle size range as the covalently bound β-lactam nanoparticle emulsions (data not
shown). However, when the commercially available drug monomers amphotericin B,
erythromycin, and doxycycline were encapsulated within the nanoparticle emulsion
(NP25, NP23, and NP24, respectively) using the same 7:3 ratio of BA:Sty as the βlactam containing nanoparticle emulsions, the average particle size dramatically
increased from approximately 48nm to up to 102nm in diameter (Table 3.6).
Encapsulated amphotericin B drug monomer created the largest nanoparticles, with the
size ranging from 101.9nm for the mn value, to 157.3nm for the mv value. The smaller of
these commercially available encapsulated drug monomer nanoparticle emulsions was
erythromycin, with doxycycline only slightly larger. The average particle size for both of
these emulsions was only slightly higher than those observed for the commercially
available drug monomers that are covalently bound to the nanoparticles (NP11). This
observed increase in particle size, even though the emulsion formulation remained
exactly the same for all emulsions presented in Table 3.6 (aside from NP1a), is most
likely the result of the nanoparticle forming around the drug monomer, and therefore, the
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size, shape, and bulkiness of the drug incorporated is having a large effect on the
resulting particle size.

3.7 Zeta Potential Analysis for Nanoparticle Emulsions
Zeta potential analysis was performed for many of the nanoparticle emulsions
synthesized in order to establish the stability of the emulsions and also the surface charge
of the emulsions. Typically, a colloidal solution or one containing particles is considered
stable when its zeta potential is greater than the absolute value of 30mV (30mV and
above or -30mV and below). All of the emulsions that were analyzed were diluted to
solid content concentrations of 2.5% for standardized testing, which was a requirement of
the ZetaPlus Zeta Potential Analyzer manufactured by Brookhaven Instruments
Corporation. At this solid content concentration, all of the emulsions analyzed exhibited
numbers at or greater than -30mV.

3.7.1 Fundamental Aspects in Zeta Potential Measurements
Zeta potential is the measure of a solution’s overall charge and is most often determined
for aqueous solutions or solutions of moderate electrolyte concentrations. This
measurement is calculated from Henry’s equation represented in Equation 3.2, which
converts a solution’s electrophoretic mobility into zeta potential by taking into account a
solution’s dielectric constant (ε) and its viscosity (η).

Equation 3.2

Ue =

2εεz f(Ka)
3η

z = zeta potential
Ue = electrophoretic mobility
ε = dielectric constant
η = sample viscosity
ƒ(Ka) = Henry’s function

The analysis of the nanoparticle-based emulsions was performed under the assumption
that the emulsions act under the conditions of the Smoluchowski model. The instruments
used for these zeta potential measurements utilize the described equation and other
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external properties input into the software (such as dielectric constant, pH, and viscosity)
in order to produce the average zeta potential for the emulsions.

3.7.2 Zeta Potential Analysis of Drug-Free Nanoparticle Emulsions
Zeta potential analysis was performed for all of the drug-free polyacrylate nanoparticle
emulsions synthesized. Prior to testing, all of the emulsions were diluted to either 2.5% or
1.25% solid content in order to obtain the most accurate data that is comparable for all
emulsions tested. However, many of the drug-free emulsions were also tested at other
solid content concentrations in order to establish the occurrence of trends that may form
as a result of diluting the emulsions, which subsequently alters the bulk pH of the
emulsion.

Figure 3.18. Zeta potential data for drug-free poly(butyl acrylate-styrene) nanoparticle
emulsions at various solid content concentrations. Data was obtained as an average of
two-10 cycle runs per sample. The dispersant viscosity of all emulsions analyzed was
0.8872cP, the material refractive index was 1.59, the dielectric constant for the emulsion
medium was 78.55, and the zeta measurement was performed at 40V using the
Smoluchowski model.
.
The pHs of the nanoparticle emulsions were determined to be inversely proportional to its
solid content concentration where the highest solid content concentration (20%) had a pH
of approximately 2 and low solid content concentrations of 0.625% displayed pH in the
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range of 4 to 4.5. Although pH was taken into account for the calculations performed by
the ZetaPlus instrument, there still existed a distinct difference in zeta potential for the
emulsions at various solid content concentrations. However, in every instance analyzed,
the emulsions were most stable (displayed the largest zeta potential) at a solid content
concentration of 2.5%. This established the need to perform all zeta potential analysis at
this specific concentration, since the manufacturer’s guide for this particular instrument
suggests concentrations anywhere from 1% to 0.1%.
In Figure 3.18, the data suggests that the drug-free poly(butyl acrylate-styrene) emulsion
CNP7, formulated with only 3% surfactant, was much more stable that the two other
drug-free poly(butyl acrylate-styrene) emulsions CNP9 and CNP10, which both
contained 5% surfactant. This data clearly shows a significant increase in emulsion
stability in relation to a decrease in surfactant concentration. However, data obtained for
the drug-free poly(butyl acrylate-styrene) emulsion CNP16 that contains only 1%
surfactant was recorded as having an average zeta potential of -48.99mV +/- 1.29mV at
2.5% solid content. This data is similar to the data for the emulsion CNP9 that was
formulated with 5% surfactant and the same 7:3 ratio of co-monomers. This indicates that
the 3% surfactant in the emulsion formulation is the most optimal for stability purposes.
This trend was also observed for the drug-conjugated nanoparticle emulsions. When
ciprofloxacin acrylamide was covalently bound to the polymer backbone using 3%
surfactant in the emulsion formulation, the zeta potential was much larger (-83.91mV +/1.00) then when only 1% surfactant (-31.79mV +/- 1.75) was employed. At 2.5% solid
content only 0.75mg/mL of drug was present in the drug-containing emulsions.

Table 3.7. Zeta potential data for all of the drug-free nanoparticle emulsions analyzed.
Data presented is an average of 2-10 cycle runs for each sample analyzed and the values
obtained for each sample are in millivolts (mV).
Nanoparticle
Emulsion

Zeta Potential
(mV)

Standard Deviation
(mV)

CNP5
CNP7
CNP8
CNP9
CNP10
CNP16
CNP17

-34.29
-90.20
-84.45
-55.82
-73.81
-48.99
-39.71

0.22
6.89
11.74
21.32
5.44
1.29
2.27

The data in Table 3.7 shows a trend in zeta potential for the drug-free nanoparticle
emulsions. The data showed that as the amount of styrene in the emulsion formulation
was increased from 7:3 to 8:2, the zeta potential increases in negativity, following the
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trend of CNP5 and CNP9 < CNP7 and CNP10. Also, it was observed that an increase in
percent surfactant in the nanoparticle formulation from 3% to 5% SDS increased the zeta
potential substantially as was expected (CNP5 to CNP7, and CNP9 to CNP10), yet
when the amount of surfactant was decreased from 3% to 1% SDS (CNP5 to CNP16), the
zeta potential did not decrease in negativity as might be expected, but increased slightly.
Since data presented in Chapter 7 showed that at 5% SDS, there is a high percentage of
surfactant that is not coordinated to the surface of the particles, and is therefore often
observed sedimenting in the concentrated emulsion, the increase in negativity for the 5%
SDS formulated emulsion (CNP9 and CNP10) could be the result of the excess
surfactant, which is anionic in nature affecting the zeta potential and is therefore not a
direct measure of the emulsion’s stability. However, the data here shows that the drugfree nanoparticle emulsions containing 1 or 3% SDS possess zeta potentials that
indicative that they are highly stable.

Table 3.8. Comparison of the stability of drug-conjugated nanoparticle emulsions.
Values were obtained for each emulsion after dilution to 2.5% solid content.
Drug-Containing
Nanoparticle Emulsion

Zeta Potential
(mV)

Standard Deviation
(mV)

NP1a

-41.93

1.55

NP2

-76.27

1.88

NP6

-82.52

2.73

NP7

-45.49

2.86

NP8

-60.96

1.77

NP23

-44.47

2.59

NP24

-50.11

2.04

NP25

-40.84

3.01

The data in Table 3.8 shows that all of the drug-containing nanoparticle emulsions are
stable by means of zeta potential measurement. However, a correlation was observed that
directly linked the influence of particle size to the average zeta potential measured for an
emulsion. The nanoparticle emulsions containing larger particles (NP1a, NP23, NP24,
and NP25), are all on the lower end of the zeta potential spectrum, and that emulsions
containing smaller particle sizes (NP2, NP6, NP7, and NP8) all produced highly stable
emulsions in terms of zeta potential. Therefore, from this data, it appears that the smaller
the particle size, the more stable that emulsion is.
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3.8 Imaging and Analysis of Bacterial Interactions with Nanoparticles
3.8.1 Microscopy Imaging of Nanoparticle Emulsions
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM)
studies were performed on many of the nanoparticle emulsions synthesized. In order to
visualize individual nanoparticles using these instruments, the emulsions were diluted
3,000 fold for SEM and 10-10 for TEM analysis.

Figure 3.19. SEM and TEM images of β-lactam conjugated nanoparticle NP1a. Particles
range between 40-80nm in diameter. SEM image (left) taken by Dr. Jeung-Yeop Shim.3

SEM and TEM microscopy analysis of all emulsions analyzed confirmed that the
nanoparticles present in the emulsions are uniformly spherical with a small size range
distribution. However, for many of the nanoparticle emulsions analyzed, the particle sizes
were smaller by imaging analysis than they were via dynamic light scattering, which is
further explained below. Atomic force microscopy analysis was performed on the second
nanoparticle emulsion formulation for this lactam (NP1) that was formulated with a 7:3
ratio of BA:Sty co-monomers instead of only EA. Figure 3.20 shows that the average
particle size for this nanoparticle emulsion is much smaller than the average particle size
observed for NP1a.
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Figure 3.20. AFM analysis of NP1 nanoparticle emulsion. Images obtained using tapping
mode of AFM. Nanoparticles depicted displayed an average height between 15 and 26nm
from the surface of the glass slide. NP1 used in this analysis contained 1% SDS in the
formulation.

Figure 3.20 shows the array of data produced for nanoparticle NP1 by AFM analysis. The
original spectrum obtained for this emulsion (top left) contains a red line through the
center where the height for all of the particles which this line circumvents is plotted in the
bottom image in Figure 3.20. Also, a 3D image can be produced using the AFM software
of a selected number of particles, which produces a replication of the original image at
various angles.
AFM analysis of all of the emulsions presented herein displayed particles that were
significantly smaller than was determined by DLS analysis, with an approximate 2030nm difference in diameter between the two measurements. Figure 3.21 provides some
possible explanation for this observed difference in particle size analysis. Due to the
observance of thin polymer strands present in the emulsions via AFM and TEM analysis,
this would inevitably throw off the measurements by DLS. This is due to the nature in
which the DLS instrument performs its measurements, i.e. light diffraction. If there are
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other objects present in the emulsions that are not uniform with the nanoparticles’
morphology, it is very difficult to accurately calculate the average particle size by DLS.
While many of the DLS measurements were determined to be similar to the TEM and
SEM particle size analysis, AFM analysis showed much smaller nanoparticles than was
determined by these techniques. However, because AFM is a direct contact microscopy
analysis that has been shown to be able to detect objects at the molecular level, the data
obtained from AFM analysis was considered the most accurate performed for these
nanoparticle emulsions.
In order to explore the effect of the long chain polyacrylate strands on the dynamic light
scattering analysis, two drug-conjugated nanoparticle emulsions (NP1 and NP8) were
diluted to 1% solid content then centrifuged using a benchtop centrifuge at 14,500rpm for
50 minutes. A portion of the supernatant was then removed for DLS and AFM analysis.

Table 3.9. Comparison of DLS and AFM data before and after purification processes. All
of the data presented here is the diameter or height of the particles presented in
nanometers.
Sample

DLS-Before

DLS-After

AFM

NP1

NA

25.3

15-26

NP8

51.7

9-10

7-16

As seen in Table 3.9, the purification process performed on the two nanoparticle
emulsions drastically reduced the diameter measurement of the particles by DLS analysis.
By doing so, the measured diameters of the particles via DLS were within the observed
particle size range determined by AFM. These findings corroborate the initial theory that
the presence of long polymer strands in the emulsions causes the DLS measurements to
be inaccurate and by the data presented in Table 3.9 for the nanoparticle emulsion NP8,
the presence of the polymer strands caused an apparent inflation in the DLS data, by four
times the actual particle size. This shows that the nanoparticles present within the
emulsions are within the range of 10 to 40nm in diameter, instead of the original 4080nm particles previously described.[20,40]
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Figure 3.21. TEM image of drug-free nanoparticle emulsion CNP5. Particle sizes ranged
from 30-45nm in diameter by visual measurement. Arrows in image to right point to
polymer strands observed in the emulsion.

Figure 3.22. AFM image of drug-free nanoparticle emulsion CNP16. Both images are
3D replications of the original AFM image obtained, where the image to the right
provides an accurate height scale for the nanoparticles measured.

The average particle size measured by AFM for the drug-free BA:Sty emulsion CNP16
was 15.8 +/- 1.77nm (Figure 3.22). Images taken of the drug-free nanoparticle emulsions
showed that the emulsion contains both small nano-sized spherical polymer balls as well
as long chain polymer strands (Figure 3.21). These strands were also observed by AFM
analysis of the multi-drug conjugated nanoparticle emulsion MDNP2 (Chapter 4). These
visual observations of the emulsions confirmed the original notion that the polyacrylate
polymer films formed upon water loss from the emulsion is more likely due to the
presence of polymer strands interacting with one another than the aggregation of only
nanoparticles. This notion was built also upon the observed mechanical properties of
these polymer films, which is later defined in Chapters 5 and 6.
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Figure 3.23. TEM image of β-lactam encapsulated nanoparticle emulsion NP6.

TEM image of nanoparticle emulsion NP6 containing the encapsulated N-thiolated βlactam monomer 6 depicts nanoparticles that are not uniformly spherical (Figure 3.23). In
fact, the particles appear to be slightly oblong. This morphology was observed for many
of the drug-encapsulated nanoparticle emulsions, which could possibly be the result of
the nanoparticles forming around the drug monomer being incorporated, thus is more
likely to be non-uniform in nature.

Figure 3.24. TEM and AFM image of ciprofloxacin acrylamide conjugated nanoparticle
emulsion NP7. AFM image (right) was produced from the emulsion purified by
continuous extraction, as described in Section 3.7.2. Images were performed on
emulsions formulated with 3% SDS.
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As seen in Figures 3.24 and 3.25, both the TEM and AFM images for the ciprofloxacinconjugated nanoparticle emulsions NP7 and NP8 display a higher variability in particle
size than was observed for other emulsions. This variability is very pronounced in the
AFM image for NP7 (Figure 3.24) where there appears to be a few particles much larger
than the majority present within the emulsion, where the majority of the nanoparticles for
this emulsion were 23.7 +/- 2.7nm. The average particle size range for NP8 was also
within this same range, whereas the few sporadic larger particles present in the emulsion
are between 28 and 35 nm.

Figure 3.25. AFM image of NP8. Images are between 7 to 16nm in height, with some
observed larger particles between 28 to 35nm.

3.8.2 AFM Imaging of Polymer Films
In order to gain perspective on the anatomy of the polymer films formed from the
nanoparticle emulsions, AFM imaging was employed. A drop of the concentrated
emulsion was drop cast onto a glass coverslide and the polymer film was allowed to form
on the glass surface at room temperature prior to AFM analysis. AFM was performed
under tapping mode by dry imaging.
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Figure 3.26. AFM image of polymer film resulting from NP8 nanoparticle emulsion.
Image of the left is the original image obtained from the AFM. The right image is a 3D
replication of the original AFM showing the full topography of the film. The NP8
emulsion used for these images was formulated with ciprofloxacin methacrylamide and
used 1% SDS for the polymerization.

The AFM images taken from the polymer film sample NP8 shows large craters in the
topology of the polymer film. In the image on the left side in Figure 3.26, the white areas
are the raised portions of the polymer film, and the darker areas represent the lulls in the
film. This film was formed from the concentrated (20% solid content) emulsion, and
therefore, no nano-sized particles were observed due to the heavy degree of particle
coalescing into a solid polyacrylate film. However, in Figure 3.27, the polymer film was
formed using a more dilute sample of the drug-free poly(BA:MMA) nanoparticle
emulsion CNP17, and therefore, individual particles were observed in the film. This
indicates that when a reduced amount of solid content is used for the film formation, the
film becomes more of a compilation of particles closely packed together than it is a solid
film structure. This finding also concurs with the visual observations of the polymer film
samples formed from diluted emulsion samples where the film does not seem whole and
is very flimsy and weak. It also does not express the ability to withstand any deformation
as is observed for the films formed from the concentrated emulsions (Chapter 5).
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Figure 3.27. AFM images of CNP17 polymer film. Film was formed using 1% solid
content concentration of the poly(BA:MMA) emulsion.

In Figure 3.27, there is an obvious difference in the polymer film topology from that of
the NP8 film in Figure 3.26. Also, there is a large observed difference in the
concentration of the particles in Figure 3.27 versus Figure 3.25, prepared from a more
highly diluted sample of the nanoparticle emulsion NP8. Obviously, upon dilution, the
amount of nanoparticles present in solution is greatly reduced, along with the ability of
the emulsion to form a solid polymer film.

3.8.3 TEM Analysis of Nanoparticle Interactions with S. aureus
In Section 3.9, the antibacterial activity of these drug-conjugated nanoparticle systems
was explored and potent antibacterial activity in vitro was established for many of the
drug-containing systems. However, it was not clearly understood how the nanoparticles
were interacting with the bacterial cells in order to obtain this antibacterial activity. Two
possible concepts for the nanoparticle’s mode of action were originally visualized in the
schematic shown in Figure 3.28. The first idea was that the nanoparticles would collapse
upon initial contact with the cell wall and the antibiotic incorporated in the nanoparticle
delivery system would be released directly into the cell through the enzymatic activity of
enzymes present on the outside of the cell membrane (Figure 3.28). The second concept
relied more upon the bacteria cells to interact with the particles. Due to the small size of
the particles, it was surmised that the particles could be internalized by the bacteria cell in
order to release the bound or encapsulated drug through either endocytosis or
phagocytosis, depending on the particle size and its interactions with the macromolecules
present within the cell membrane. Therefore, the schematic drawing in Figure 3.27 was
formed for the potential modes of action of the nanoparticles.
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Figure 3.28. Schematic image of nanoparticle interaction with the bacteria cells.

In order to verify this, a TEM study was performed using S. aureus cells treated with the
drug-free nanoparticle emulsion CNP5. Cells were incubated with a the diluted emulsion
for 30 minutes then the solution was cross-fixed with gluteraldehyde to freeze all of the
metabolic and cellular functions. TEM imaging was previously performed to confirm that
the presence of gluteraldehyde in the emulsion would not affect the nanoparticles. The
cellular suspension was then analyzed “as is” (Figure 3.29) in order to observe the
external interactions of the nanoparticles with the bacteria cells, and after cross-sectional
preparation of the cell pellet embedded in plastic (Figure 3.30). This study confirmed that
both of the original modes of action concepts depicted in Figure 3.28 may be considered
for the drug-free nanoparticle emulsion CNP5.
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Figure 3.29. TEM images of whole S. aureus cells. A) TEM image of CNP5
nanoparticles. B and C) Images of S. aureus whole cells not treated with CNP5. D) S.
aureus cell with a CNP5 nanoparticle adhered to surface of the cell. Bacterial cells were
not dehydrated prior to TEM visualization; therefore, the whitening in the center of the
cells was caused by effervescing of the internal water by the electron beam.

In Figure 3.29A, the particles appear to be of normal size and morphology after treatment
with gluteraldehyde for fixation. As observed in Figure 3.29D, the nanoparticle is found
sticking to the surface of the bacteria cell, which confirms the initial concept of the
nanoparticle mode of action. However, in order to establish whether or not the
nanoparticles are internalized by the bacterium prior to particle degradation, crosssectioning of the bacterial cells after interaction with the nanoparticles was required.
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Figure 3.30. TEM images of sectioned S. aureus cells interacting with CNP5
nanoparticles. A-C) Cross-sections of S. aureus cells treated with CNP5. D) Crosssection of S. aureus cells untreated. All images were taken of cells without any staining
of the nano-thin cross-sections of the cells embedded in plastic to avoid metal
precipitation on the images.

TEM analysis of the cross-sections of S. aureus cells embedded in plastic showed that the
drug-free nanoparticles were found both adhered to the surface of the cells (Figure 3.30A
and B) and also within the cell wall (Figure 3.30C). No nanoparticle-sized materials were
observed in images of the cells that were not treated with the nanoparticle emulsion
(Figure 3.30D). Also, particles were not observed inside the cells further than just within
the cell membrane indicating that the bacteria may be able to degrade the particles once
within the cytoplasm of the cell. This study established that the bacteria cells are able to
internalize the nanoparticles, where once inside, could degrade the polymer matrix of the
particles thereby releasing the bound or encapsulated drug directly into the bacterium.
This essentially provides direct delivery of the drug to the bacterium without
encountering any degradation prior to internalization. This study was also performed
using N-thiolated β-lactam encapsulated nanoparticle emulsion NP6, however, upon
cross-sectional TEM visualization of the culture, most of the Staphylococcal cells were
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completely destroyed by the drug-containing nanoparticles and the few cells that were
observed by TEM did not show any nanoparticles within or adhering to the bacterial
cells. This observation indicates that drug cleavage and subsequent antibacterial activity
is extremely rapid following bacterial interaction with the nanoparticles. Since the
bacterial cultures were exposed to the nanoparticles for only a short period of time (30
minutes), many of the intact nanoparticles were observed in sections of the TEM grid far
removed from the few remaining bacterial cells indicating that these nanoparticles had
not yet interacted with the bacterial cells.

3.9 Antibacterial Activity of Nanoparticle Emulsions
Both the Kirby Bauer and MIC antibacterial assays were performed to determine
antibacterial properties of the nanoparticle-containing emulsions. The subsequent
polyacrylate films formed from the emulsions by air evaporation were analyzed only by
Kirby Bauer ZOI assays for determination of antibacterial activity. Both of these assays,
while being reputable for their accuracy and able to compare numerous antibiotics
through standardization of these assays, presented a challenge for accurate assessment of
the antibacterial activity for the drug-conjugated emulsions. However, this was overcome
by using the agar dilution MIC assay, described in NCCLS.[50]

3.9.1 Kirby Bauer Assay
Kirby Bauer assays were performed on the drug-conjugated nanoparticle emulsions and
the resulting drug-conjugated polymer films in accordance with the guidelines
recommended by the National Committee for Clinical Laboratory Standards (NCCLS).28
These assays rely on the ability of the substance being tested to diffuse from the well into
the surrounding agar in a circular formation in order for the drug to interact with the
bacteria present on top of the agar surface. However, there are many inherent problems
with this assay due to required diffusion. Often observed for these assays was the
appearance of a white ring surrounding the walls of the well where the emulsion was
added. This ring is presumably the long-chain polyacrylate strands present in the
emulsion that cause film formation. Since purification methods have shown that the large
polymer strands make up approximately half of the solid content of the emulsion, this
assay is only able to analyze the antibacterial activity of the nanoparticles and small drugbearing oligomers present in the emulsion indicating that the activity observed does not
fully represent the activity of the emulsion.

3.9.2 Agar Dilution Minimum Inhibitory Concentration Assay
In order to establish the lowest drug concentration needed to prevent bacterial growth, the
emulsions and drug monomers were analyzed for antibacterial activity at various drug
concentrations in µg drug per mL of emulsion or solvent (DMSO). Three different agars
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were employed here for these assays, the original Mueller Hinton agar that is described in
the NCCL manual for antibacterial testings[50] and a pH indicator-containing agar. All
agars used were purchased from Fisher Scientific and used without modification. The two
pH indicators used here were either bromothymol blue or phenol red. The phenol redcontaining agar was used for the Staphylococcal strains analyzed, and the bromothymol
blue-containing agar was used for the P. aeruginosa, E. coli, and B. anthracis assays.
These unconventional agars were used in order to provide a clearer identification of
bacterial growth inhibition since many of the samples analyzed, especially the β-lactam
and penicillin-containing emulsions, are bacteriostatic in nature. Therefore, they cannot
be analyzed for the presence of living microbes by secondary culturing on TSA agar
plates overnight as described in NCCL.[50] The pH indicator was employed to provide a
color change in the agar associated with the growth of bacteria present on the agar. These
color-changing MIC assays were compared with the traditional Mueller Hinton agarbased assay as a secondary experiment in order to verify the observed results.

3.9.3 β-Lactam-Containing Nanoparticle Emulsions
Antibacterial testing was performed on many of the drug-containing emulsions
synthesized in this chapter. Assays were performed against many Staphylococcal strains,
including ten strains of MRSA. MRSA strains were either purchased from ATCC (43300
and 33591) or were obtained from Lakeland Regional Medical Center as clinical isolates.
The clinical isolates were arbitrarily labeled 652-659 and the ATCC purchased strains
43300 and 33591 correspond to the USF-designated 920 and 919, respectively.
Methicillin-sensitive S. aureus (MSSA) was purchased from ATCC as well (ATCC
25923) and Bacillus species was either provided by Dr. Daniel Lim (B. anthracis-Sterne)
or purchased from ATCC.
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Figure 3.31. Kirby Bauer data for the β-lactam containing nanoparticle emulsions against
various clinical and ATCC strains of MRSA. Zone data is determined by measuring the
diameter in millimeters of the zone of bacterial growth inhibition.

Figure 3.31 compares the zone of inhibition (ZOI) data of three drug-containing (two
encapsulated and one covalently bound) nanoparticle emulsions, NP1a, NP2, and NP6
against 10 strains of MRSA. Interestingly, the anti-MRSA activity was drastically
different between these strains for β-lactam containing emulsion NP1a while the other
two β-lactam-containing nanoparticle emulsions (NP2 and NP6) displayed fairly
consistent zones of inhibition against all of the isolates and ATCC strains analyzed,
except for MRSA clinical isolate strain 653, which NP2 caused a much larger zone of
inhibition than was observed for any of the other MRSA strains.
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Table 3.10. MIC values for β-lactam-containing nanoparticle emulsions against various
bacteria. MIC values are reported in µg drug per mL of emulsion.[51] (ND= not done)
Nanoparticle
Emulsion
CNP5
NP1a
NP1
NP2
NP5
NP6
NP9

MRSA
(ATCC 43300)
>256
256
16
64
16
16
8

S. aureus
(ATCC 25923)
>256
256
16
64
16
8
8

B. anthracisSterne
>256
256
64
ND
ND
4
ND

Data presented in Table 3.10 showed that, when acrylate lactam monomer 1 is copolymerized with only ethyl acrylate as the sole liquid acrylate monomer, the
antibacterial activity of the monomer is almost completely lost (MIC is 256µg/mL).
However, when the monomer is formulated with butyl acrylate and styrene as the comonomers, the antibacterial activity is consistent with the lactam monomer dissolved in
DMSO. It was also observed that some of the lactam monomers’ activity was increased
when applied to the bacterial cultures in the nanoparticle delivery system (NP5 and NP9).
This supports the hypothesis that when the drug monomers are enzymatically cleaved
from the polymer backbone, the active drug monomer released is often more active than
the acrylate drug monomer. This was also observed in Chapter 2, where the lactam
monomers 6 and 10 were much more active than the acrylated versions 1 and 3.
However, since upon enzymatic cleavage of the acrylate moiety, the drug monomer is
reverted back to the free alcohol precursor 4. This is also supported by the fact that all of
the β-lactam containing emulsions displayed MIC values within the same range of
activity against S. aureus strains, including MRSA, except for lactam encapsulated
emulsion NP2, which contains the less active acetate moiety at the C3 position and is not
a precursor to the lactam monomers 1 or 3.
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Figure 3.32. Results of Kirby Bauer assay for NP1. Drug-conjugated emulsion NP1 is
formulated from acrylated lactam monomer 1 with ethyl acrylate.

Next, NP1 was tested against seven species of Bacillus as an aqueous emulsion. This Nthiolated β-lactam conjugated nanoparticle emulsion showed very good zones of
inhibition across the board for all of the Bacillus species tested in vitro. This agrees with
the MIC value of 16µg/mL reported for this emulsion in Table 3.10. The data in Table
3.11 shows that the other drug-containing lactam nanoparticle emulsions NP1a, NP2,
NP5, and NP6 displayed no or only moderate activity against B. anthracis via Kirby
Bauer analysis.
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Table 3.11. Kirby Bauer assay data for β-lactam-containing nanoparticle emulsions
against B. anthracis-Sterne. Data is reported as the diameter of the zone of inhibition in
millimeters.
Sample

ZOI* (mm)

NP1a

0

NP2

12 (17)

NP5

(21)

NP6

25

*( ) = partial inhibition

Again, as seen in Table 3.11, C3-acetoxy N-methylthio β-lactam encapsulated
nanoparticle emulsion NP2 displayed diminished activity against B. anthracis from the
other β-lactam emulsions. This was consistent with the Staphylococcal results as well,
indicating that this drug monomer encapsulated in the nanoparticle delivery system is not
a very potent antibacterial. The Bacillus data was also consistent for the C3-acrylate Nmethylthio β-lactam conjugated emulsion NP1a, where no zone of inhibition was
observed for this emulsion against the majority of the MRSA and S. aureus strains
analyzed. Both the C3-long chain acrylate and the C3-methoxy N-methylthio β-lactam
containing nanoparticle emulsions (NP5 and NP6 respectively) displayed excellent ZOI
data against B. anthracis (Table 3.11).

3.9.4 Nanoparticle Emulsions Containing a Commercially Available Drug
3.9.4.1 Penicillin-containing emulsions
All of the penicillin-containing nanoparticle emulsions were tested for antiStaphylococcal activity in vitro by both the Kirby Bauer and minimum inhibitory
concentration assays. The data is summarized in Table 3.12.
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Table 3.12. Anti-Staphylococcal activity of penicillin-based nanoparticle emulsions.
MIC values are reported as µg of drug per mL of emulsion. ZOI data is recorded for the
emulsions at 100µg drug in 100µL of emulsion.
Sample

CNP16
NP11
NP12
NP13
NP14
NP15
NP16
NP17
NP18
NP19
Penicillin G
Cefaclor
Amoxicillin
Ampicillin

S. aureus
(ATCC 25923)
ZOI*
MIC
(mm)
(µg/mL)
0
>256
9 (11)
64
45 (50)
16
(11)
2
ND
64
(15)
64
13
256
0
128
11 (14)
256
11
128
55 (61)
0.012
20
ND
41
ND
45
ND

MRSA
(ATCC 43300)
ZOI*
MIC
(mm)
(µg/mL)
0
>256
(18)
64
0
16
ND
2
ND
64
0
64
0
ND
ND
ND
0
ND
0
ND
10
16
(14)
ND
13
ND
15
ND

*( ) = partial inhibition, ND= not done

Many of the commercially available β-lactam drug monomers displayed no activity in
vitro when in the nanoparticle drug delivery system (NP16-19). The penicillin-containing
emulsions (NP11 through NP15) all displayed equal activity against MRSA as they did
against MSSA, where the penicillin G acrylamide nanoparticle emulsion NP13 was the
most potent emulsion analyzed in the MIC agar and broth studies, despite very
unimpressive zones of inhibition in the Kirby Bauer assay. This fact established the use
of this penicillin G acrylamide monomer in the multi-drug conjugated nanoparticle
emulsion MDNP1. The initial multi-drug conjugated nanoparticle system contained the
drug monomers 15-19, however, since these monomers did not display strong
antibacterial activity in vitro when in the nanoparticle delivery system, it was determined
that any antibacterial activity observed for this emulsion (MDNP2) was due to the
ciprofloxacin monomers present in the emulsion. This prompted the re-formulation of the
multi-drug conjugated system (Chapter 4), along with the need to decrease the amount of
surfactant present in the emulsion from 3% to 1% (w/w) due to observed toxicity
(Chapter 7).
Also observed in Table 3.12 is that the amount of surfactant present in the emulsion did
not cause the antibacterial activity observed. This is due to the fact that the most potent
anti-Staphylococcal emulsion, NP13, was formulated with only 1% SDS, whereas all of
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the other drug-containing nanoparticle emulsions presented in Table 3.12 were
formulated with 3% SDS. Therefore, the antibacterial activity would have been higher for
the other emulsions if the activity was due to toxicity caused by the surfactant present in
the emulsions.

Figure 3.33. Zone of inhibition assay for NP11 against S. aureus +/- 100µg β-lactamase.
Image on the left contains 100µg of β-lactamase, while the image of the right was not
treated with β-lactamase. R-11 represents NP11, and was added to the agar wells in either
20, 50, or 100µg of drug monomer in equal amounts of emulsion. Penicillin G was added
to the wells as 20µg drug monomer in 20µL water.

The Kirby-Bauer assay in Figure 3.33 shows that when 100µg of β-lactamase is spread
evenly over the agar plate prior to addition of S. aureus and subsequent well drilling, the
anti-Staphylococcal activity of penicillin G in the potassium salt form was completely
destroyed. However, the penicillanic acid acrylamide-conjugated nanoparticle emulsion
(NP11) displayed zones even at the reduced concentration of 20µg drug monomer in
20µL of emulsion. Since penicillanic acid normally displays weaker activity than the
penicillin G monomer against methicillin-sensitive S. aureus (MSSA), this indicates that
the nanoparticle delivery system is not only protecting the drug monomer from the
destructive β-lactamase, but is also enhancing the activity of the drug monomer in vitro.
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3.9.4.2 Ciprofloxacin-conjugated nanoparticle emulsions

Table 3.13. ZOI and MIC data for ciprofloxacin acrylamide nanoparticle emulsions NP7
and NP8. ZOI data performed on 20µg of drug monomer in 20µL of emulsion per well.
MIC data also based on the amount of drug monomer present per mL of emulsion
analyzed.
B. anthracis- Sterne

MRSA

S. aureus

Compound
ZOI
(mm)

MIC
(µg/mL)

ZOI
(mm)

MIC
(µg/mL)

ZOI
(mm)

MIC
(µg/mL)

38

2

26

4

26

1

31

1

28

2

30

2

42 (45)

0.063

28 (34)

1

ND

ND

NP7
O
COOH

F
H

N

N

H

N
O

NP8
O
COOH

F
CH3

N

N

H

N
O

Cipro
O
COOH

F
N

N

H

HN

*ND= not done

Table 3.13 reports both the zones of inhibition and the MIC values for the acrylated
cipro-conjugated nanoparticle emulsions NP7 and NP8, as well as the antibacterial
activity of the unmodified cipro drug. It was observed here that the cipro-conjugated
emulsions were highly potent towards S. aureus and B. anthracis, where ZOI data was
observed to be almost exactly the same for the cipro-conjugated nanoparticles as it was
for the commercially available cipro analogue. The MIC for cipro against S. aureus was
within the same range as the cipro-conjugated nanoparticle emulsions, indicating that
almost no antibacterial activity is lost for this drug when incorporated into the
nanoparticle delivery system. However, against B. anthracis, the original cipro drug has a
much lower MIC than either of the cipro-conjugated emulsions.
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Figure 3.34. Anti-Staphylococcal activity of ciprofloxacin-conjugated nanoparticle
emulsions. KG13 written on the plates represents NP7, KG11 represents NP8, and
KRG15 represents CNP15. Three amounts of drug were tested: 100µg, 50µg, and 20µg.

Figure 3.34 shows this pictorially for the zones of inhibitionf for NP7 (left) and NP8
(right) at different drug loading amounts. Both the cipro-conjugated nanoparticle
emulsions (Figure 3.34) and the polymer films (Figure 3.35) displayed excellent activity
against both MSSA and MRSA equally. The cipro-conjugated nanoparticle emulsions
yielded large ZOIs that were comparable to the free cipro drug and MIC values of
2µg/mL and 1µg/mL against B. anthracis for NP7 and NP8, respectively (Table 3.13).
Interestingly the activities (zone sizes and MICs) are only slightly diminished for MSSA
and MRSA.

NP11

NP13

CNP15

CNP15

Figure 3.35. Anti-Staphylococcal activity of the cipro-conjugated polymer films. A
0.5mL aliquot of each concentrated (20% solid content) emulsion was also used to form
the polymer films for ZOI analysis. KG13 written on the plates represents NP7, KG11
represents NP8, and KRG15 represents CNP15.
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Figure 3.35 shows a similar study for the drug-conjugated polyacrylate films from the
cipro-conjugated emulsions NP7 and NP8. A 0.5mL aliquot of concentrated (20% solid
content) emulsion was used to form the polymer films for ZOI analysis. The emulsions
were added on top of the already inoculated agar, and the polyacrylate films were
allowed to solidify in the biosafety cabinet prior to incubation for bacterial growth,
thereby allowing the solid polymer film to be interacting with the proliferating bacteria
and not the emulsion. The data presented in Figure 3.35 shows that the polymer films
formed from the cipro-conjugated nanoparticle emulsions (NP7 and NP8) displayed antiStaphylococcal activity, which was not observed for the drug-free polymer film formed
from the emulsion CNP15. Therefore, the observed antibacterial activity was not due to
leaching of the excess surfactant or radical initiator into the surrounding agar, but was
due to the direct interaction of the microbes with the polymer film formed from the
emulsion, since no bacterial growth was observed under the polymer film. The observed
zones of inhibition surrounding the polymer films may have been caused by diffusion of
the nanoparticle constituents present in the emulsions prior to film formation instead of a
direct interaction of the polymer film. Regardless of the reason for the observed zones of
inhibition, the films were determined to possess antibacterial capabilities in vitro. This
conclusion is also supported by the bacterial permeability studies and carbon source
assays described in Chapter 5.

Figure 3.36. Anti-MRSA activity of cipro-conjugated nanoparticle emulsions NP7 and
NP8. ZOI measurements are recorded for 20µg of cipro monomer in 20µL of emulsion.
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Figure 3.36 plots the measured zone sizes for the cipro-conjugated nanoparticle
emulsions NP7 and NP8 against different strains of MRSA. The MRSA strains marked
652-659 are all clinical isolates obtained from Lakeland Regional Medical Center, and
strain 919 was the ATCC strain 43300. Interestingly, five of the clinical MRSA strains
were completely resistant to NP7, while were still slightly susceptible to NP8. The
remaining three clinical isolates (657-659) and the ATCC strain (919) were all highly
sensitive to the cipro-conjugated nanoparticle emulsions, displaying zone sizes equal to
those observed for cipro in its commercially available form.
The cipro-conjugated nanoparticle emulsions NP7 and NP8 displayed potent activity in
vitro against the most common pathogen found in burn wound infections, P. aeruginosa
(Figure 3.36). In fact, the activity of the emulsions was comparable to that of the
commercially available ciprofloxacin, which is one of the most commonly prescribed
antibiotics for Pseudomonal infections. However, the acrylated ciprofloxacin monomers
alone did not appear to be very effective anti-Pseudomonal agents. This fact provides
further proof that the microbes are able to cleave off the drug (cipro) from the polymer
matrix, presumably inside the cell, in order for antibacterial activity to be manifested.

Sample

Trial 1

Trial 2

Cipro

1

1

7

256

128

NP7

4

2

8

128

128

NP8

8

4

Figure 3.37. MIC and Kirby Bauer data for ciprofloxacin-conjugated nanoparticle
emulsions against P. aeruginosa (ATCC 10145). MIC values are reported as the µg of
drug monomer per mL of emulsion or DMSO solvent. KG13 in the image represents
NP7, and cipro acrylate represents monomer 7.

In order to analyze the effect of purification processes on the antibacterial activity of the
drug-conjugated nanoparticle emulsions, Kirby Bauer assays were performed on equal
volumes and concentrations of the emulsion NP7 both before and after continuous
extraction for 72 hours of organic impurities present in the emulsion using cyclohexane.
Upon evaporation of the cyclohexane extract, it was determined that 33.3mg of impurities
was extracted from 10mL of the 10% solid content emulsion (2g total solid mass). The
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emulsion’s physical appearance was unchanged by the purification process, as
determined by AFM imaging, and the emulsion retained its ability to form a film.

Figure 3.38. Kirby Bauer assay using both the concentrated and diluted nanoparticle
emulsion NP7 before and after purification against S. aureus. The concentrated emulsion
used in the assay on the right contained 10% solid content (3mg ciprofloxacin acrylamide
monomer per 1mL emulsion), whereas the assay on the left represents the diluted
emulsion at 1mg drug monomer per 1mL emulsion. The zones on the top half of both
plates represent the purified emulsion (extracted with cyclohexane) and the zones on the
bottom half of the plates represent the original unpurified emulsion. (KG13: NP7).

For the zone of inhibition assay performed on the purified (top half) and unpurified
(bottom half) NP7 emulsion (Figure 3.37), the standardized assay (left) which
incorporates a 1mg drug per 1mL emulsion concentration at 20µL in each well was
supplemented with a more concentrated (3mg drug/mL) sample of emulsion (right). This
was done in order to magnify any observed differences in the measurements.
The zones of inhibition for the purified emulsion was 14-15% smaller than the zones
observed for the unpurified original emulsion at both 3.33% and 10% solid content
(1mg/mL and 3mg/mL drug concentration respectively). This indicates that some of the
acrylated drug monomer is not polymerized with the other two co-monomers and is most
likely remaining in suspension by either encapsulation within the nanoparticles or by
sticking to the surface of the nanoparticles. NMR analysis of the evaporated organic layer
after continuous extraction for 3 days displayed low intensity peaks in the region where
the acrylate peaks for the liquid acrylate monomers and the cipro acrylate monomer 7 are
normally found, between 5.9 and 6.5ppm. This indicates that a small percentage of the
acrylate monomers added to the emulsion formulation (33.3mg of the nominal 4.0g) was
not polymerized and remained suspended in the emulsion. Since the cipro acrylate
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monomers alone showed anti-Staphylococcal activity in vitro, the change in ZOI data
could be due to removal of the un-polymerized cipro acrylate monomer from the
emulsion. However, due to the small percentage of un-polymerized drug monomer
observed in the extracted organic layer, this may not be the only cause of the change in
antibacterial activity, and other issues (surfactant levels, ect) in changes to the
nanoparticles upon purification can not be ruled out.

3.10 Conclusions
The antibacterial containing nanoparticle emulsions synthesized here all contained
particles in the nano-size range. The emulsion formulation of a 7:3 ratio of BA:Sty liquid
acrylate monomers was the most optimal combination for both complete dissolution of
the drug monomers and also produced the most stable nanoparticle emulsions with a
small size range. Stability studies showed that this emulsion formulation was stable to
many different physical and chemical conditions, including a wide range of temperature
and pH changes, and also stable towards many biological molecules present in blood
serum. Purification processes showed that longer polymer strands present in the
emulsions can be removed through mild centrifugation processes, and that continuous
extraction of the emulsion using an organic solvent (cyclohexane) removes excess
acrylate monomers that were not polymerized from the emulsion. Encapsulation of larger
antibiotic monomers, such as amphotericin B and erythromycin, caused the resulting
nanoparticles to be larger in size and morphologically distorted, and encapsulation of
even the smaller β-lactam monomers resulted in particles of oblong morphology as
opposed to the uniformly spherical nanoparticles observed for the drug-conjugated and
drug-free nanoparticles.
Antibacterial and TEM analysis suggested that the drug-conjugated to the polymer
backbone must be cleaved in order for antibacterial activity to be observed, and also the
nanoparticles can deliver the bound or encapsulated drug monomers to the bacterium
either by collapsing upon interaction with the bacterial cell wall, or after incorporation
into the bacterium’s cytoplasma through either phagocytosis or endocytosis bacterial
invagination methods. The three most potent modified commercially available drug
monomers incorporated into the nanoparticle system were penicillin G acrylamide
monomer 13 and the two ciprofloxacin acrylamide monomers 7 and 8. Also, the most
potent N-thiolated β-lactam acrylated monomers synthesized that produced the most
optimal nanoparticle emulsions in terms of particle size, stability, and antibacterial
activity were 1 and 3. Therefore, these five acrylated drug monomers were chosen for the
multi-drug conjugated nanoparticle emulsion described in the next chapter (Chapter 4).
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CHAPTER 4
MULTI-DRUG CONJUGATED NANOPARTICLES FOR
BURN WOUND TREATMENT
4.1 Introduction
Burn wound infection sites are complex environments containing numerous pathogenic
microbes, many of which are commensal with the human body or comprise the normal
skin flora, such as Staphylococcus aureus, Staphylococcus epidermidis, and
Streptococcus pyogenes.[1-4] When an abrasion or disruption of the skin barrier occurs,
these persistant bacteria transform into opportunistic pathogens, causing many problems
that may delay healing and increase the risk of sepsis. Other bacteria and fungi that are
not part of the normal skin flora have been reported in burn wound infections, with
Pseudomonas aeruginosa and Escherichia coli topping the list, which has 22 different
strains and species of pathogens, including bacteria, fungi, and viruses.[1, 2, 5] Because of
the extremely nutrient-rich environment of a burn wound, especially prior to burn wound
excision when the burn eschar is still intact, it is an easily colonized environment that
calls many forms of microbes to immediately after thermal injury.[2] Some of the more
common infections associated with burn wounds are burn wound cellulites, burn wound
impetigo, open burn-related surgical wound infections, and invasive infections in
unexcised burn wounds.[5] All of these infection types have been known to contribute to
the more complicated bacterial infections, including bacteremia, sepsis, and toxic shock
syndrome if left untreated.[2, 5] These bacteria can originate from various other regions in
the body, including the nasal passages, the gut, and the blood stream, and can also be
transmitted to the wound through nosocomial contact with hospital staff. While many
precautions are taken at hospitals today to prevent such person to person spread of
pathogens, nosocomial infections still remain ubiquitous. In fact, nosocomial contact is
the number one cause of MRSA infections in hospitals and in burn wounds, where
transference of MRSA from the patient’s nasal passage to the burn wound is second.[4, 6-8]
Due to the highly drug-resistant nature of this pathogen, as well as the ability of
Pseudomonal strains to rapidly form resistances, application of more than one antibiotic
provides the best treatment and diminishes the likelihood for the microbe to develop
further resistance.[9, 10]
Also observed in burn wounds and in the underlying soft tissue is the presence of
biofilms. Biofilms are complex environments of microorganisms that work together in a
synergistic fashion in order to facilitate their growth and survival. These communities are
often found colonizing surfaces and are able to form a protective polymeric matrix
around the film that is extremely difficult for antimicrobials to penetrate. However, this
biofilm community has also been observed in burn wounds even though there is no solid
surface for the bacteria to adhere to in order to originate the biofilm formation. This is
most likely due to the high number of various microbes present in the wound
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environment and the endless supply of nutrients present in the site. P. aeruginosa, S.
aureus, and S. epidermidis are the leading microbes involved in biofilm formation in burn
wounds (Table 4.1).[2, 3] Since burn wounds provide an optimal environment for
microbial growth and colonization, it is not surprising that biofilm communities develop
here. Microbiological testing of burn wounds has shown that mature biofilms have been
observed in burn wounds after only 10 hours post-trauma.[2] The presence of such
bacterial organizations makes the infection even more difficult to treat with a single
antimicrobial, and is often even difficult to treat with multiple antibiotics, especially
when the drugs are not able to penetrate the outer layers of the protective film barrier.
Also, the entire biofilm takes on the characteristics of its strongest bacterium present,
therefore, if one microbe within the colony expresses multiple drug resistance, the entire
biofilm will experience this resistance. If only a single microbe or a few microbes survive
the initial antimicrobial treatment, those microbes, coined persister cells, can re-create the
entire biofilm community, where now every cell will express this multiple resistance.[2]
Therefore, a drug delivery vehicle is needed that can deliver more than one antimicrobial
deep into the tissue where the pathogenic microorganisms are cultivating, and penetrate
biofilms that may have already been established within the wound or surrounding tissue.
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Table 4.1. Common microbes found in many biofilms causing human infection. This
data was reprinted with the permission of the publisher.[3]
Infection or Disease

Common Biofilm-Causing Microbes

Dental caries

Acidogenic Gram-positive cocci (e.g.,
Streptococcus)
Gram-negative anaerobic oral bacteria
Non-typable strains of Haemophilus inßuenzae
Gram-positive cocci (e.g., staphylococci)
Group A streptococci
Enteric bacteria (e.g., Escherichia coli )
Various bacterial and fungal species
E. coli and other Gram-negative bacteria
Viridans group streptococci
P. aeruginosa and Burkholderia cepacia
Pseudomonas pseudomallei

Periodontitis
Otitis media
Musculoskeletal infections
Necrotizing fasciitis
Biliary tract infection
Osteomyelitis
Bacterial prostatitis
Native valve endocarditis
Cystic fibrosis pneumonia
Meloidosis
Nosocomial infections
ICU pneumonia
Sutures
Exit sites
Arteriovenous shunts
Schleral buckles
Contact lens
Urinary catheter cystitis
Peritoneal dialysis (CAPD)
peritonitis
IUDs
Endotracheal tubes
Hickman catheters
Central venous catheters
Mechanical heart valves
Vascular grafts
Biliary stent blockage
Orthopedic devices
Penile prostheses

Gram-negative rods
Staphylococcus epidermidis and S. aureus
S. epidermidis and S. aureus
S. epidermidis and S. aureus
Gram-positive cocci
P. aeruginosa and Gram-positive cocci
E. coli and other Gram-negative rods
A variety of bacteria and fungi
Actinomyces israelii and many others
A variety of bacteria and fungi
S. epidermidis and C. albicans
S. epidermidis and others
S. aureus and S. epidermidis
Gram-positive cocci
A variety of enteric bacteria and fungi
S. aureus and S. epidermidis
S. aureus and S. epidermidis
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4.2 Multiple Antimicrobials for Treatment of Burn Wound Infections
There is a well-known precedent for the use of multiple broad-spectrum antimicrobials
for topical treatment of burn wound infections, and has been shown to be the most
optimal choice due to the observed therapeutic value.[1] Topical creams, such as the
newest to the market, Flamazine, are now utilizing multiple antimicrobials in their
formulations in an attempt to combat the high variability of bacterial and fungal species
present in burn wounds. The leading antimicrobial currently used in such multi-drug
formulations is polymixin B due to its broad-spectrum antimicrobial activity and water
insoluble nature. Other anti-infectives used for these topical treatments are amphotericin
B, due to its potent antifungal activity, and many sulfa-containing antimicrobials.
Antimicrobial drugs for combination in topical anti-infective treatments must cover both
facultative and anaerobic microbes present in the intestinal and skin flora, which
commonly migrate into burn wounds after injury.[1] Skin and tissue banks often employ
the same mixture of antimicrobials as is used for mammalian cell culturing media to treat
incoming donated tiddue to prevent contamination, including various combinations of
penicillin, streptomycin, kanamycin, gentamicin, nystatin, tobramycin, co-trimoxazole,
vancomycin, and amphotericn B, to name a few.[9] The majority of these antimicrobials
are water-soluble, and thus are used to treat the excised tissues by soaking the tissues in
the solution. However, for topical burn wound treatment, this practice is not sufficient
due to the inability of the water soluble antimicrobials to penetrate the burn wound eschar
or reach deep into the wound bed, where the majority of the colonizing microbes lie.
Therefore, the currently used topical treatments for burn wound infections are limited to
the water insoluble antimicrobials, which may not be the most effective antimicrobials
for the highly resistant microbes often colonizing and forming biofilms in these wound
beds. Also, while the combination of multiple antimicrobials can have a synergistic effect
of the antibacterial activity, unwanted interactions have also been observed when drugs
are combined into a single antimicrobial formulation.[10] If not formulated properly,
resistance to the antibiotics can form faster than when using only a single antimicrobial in
the formulation.[10] Therefore, there is a dire need for a drug delivery system that will
allow the combination of both water-soluble and water-insoluble antimicrobials where
the antibacterial activity for the formulation has been optimized for synergistic activity.
Hospital studies have shown that gender, age, and also the geographic location of the
hospital heavily influences the strains and species of bacteria and fungi present in a burn
wound infection. However, in almost all studies performed, the two most predominant
pathogens found in nearly every burn wound examined were Staphylococcus aureus and
Pseudomonas aeruginosa. These two pathogens, while differing by gram distinction, are
both highly opportunistic and are able to cause severe infection, sepsis, and toxic shock
syndrome, and each produces high rates of morbidity when untreated. Both of these
microbes are also well known for their ability to rapidly develop resistance to antibiotics,
especially S. aureus, whose infamous antibiotic-resistant strain methicillin-resistant S.
aureus (MRSA) has been the cause of nearly 100,000 deaths each year in the United
States. Therefore, to develop a drug delivery system that possesses potent anti-MRSA
and anti-Pseudomonas activity our laboratory is examining nanoparticle polymers that
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contain at least one or more antibiotics active against each of these microbes that work
synergistically to optimize the antibacterial activity against these microbes.

4.3 Synthesis of Multi-Drug Conjugated Polyacrylate Nanoparticles
4.3.1 MDNP2
As discussed in Chapter 3, numerous single drug-conjugated nanoparticle emulsions were
successfully synthesized and their antibacterial activity assessed via zone of inhibition
(ZOI) and minimum inhibitory concentration (MIC) analysis. Many of the drugconjugated emulsions displayed antibacterial activity, even against microbes that were
inherently resistant to the antibiotic. However, in many instances, the ZOI assay was not
an effective means of antibacterial analysis. Ciprofloxacin-conjugated emulsions gave
zones of inhibition only slightly smaller in diameter than the original ciprofloxacin
monomer, yet the β-lactam conjugated nanoparticle emulsions (NP16-NP19) did not
show any antibacterial activity through ZOI analyses. It was unclear why this difference
in Kirby Bauer results occurred between the β-lactam and cipro-conjugated emulsions.
The antibacterial results shown in Chapter 3 promoted the incorporation of the penicillinbased antimicrobials in the first multi-drug conjugated nanoparticle formulation, due to
the observed activity against resistant microbes when in the nanoparticle delivery system.
Since this was the first of the multi-drug formulation emulsions, all of the acrylated
commercially available drug monomers were incorporated into the delivery system in
order to begin optimization of the system (Figure 4.3). This would establish whether the
individual emulsions synthesized or the combination of all the monomers in one
formulation would yield the most optimal antimicrobial activity in vitro.
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Figure 4.1. Acrylated drug monomers incorporated in MDNP2 nanoparticle emulsion.
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Figure 4.1 shows the structures for the six acrylated antibiotics used to prepare the multidrug conjugated nanoparticle emulsion MDNP2. Theoretically, the anti-Staphylococcal
activity of the first multi-drug conjugated system, which was formulated with four
different penicillin-based drug monomers, showed be extremely potent if all of the drug
monomers work in a synergistic fashion. The two ciprofloxacin acrylamide monomers (7
and 8) were chosen due to their exceptional antibacterial activity against P. aeruginosa.
The difference between cipro acrylamide monomers 7 and 8 was in the acrylyl side chain
(acrylamide versus methacrylamide), which allows for potentially different physical
properties of the resulting nanoparticle polymer. Therefore, the anti-Pseudomonal
activity of the multi-drug conjugated system MDNP2 should outweigh that observed for
the individual ciprofloxacin-conjugated emulsions if the two ciprofloxacin (cipro)
acrylate monomers are able to work synergistically against the microbe in the multi-drug
formulation. In addition, the four β-lactam analogues (11, 16, 18 and 19) were studied
due to their common utility as broad-spectrum antibiotics.

Table 4.2.Formulation of MDNP2 nanoparticle emulsion. The total weight of all the
drug monomers combined that were added to the emulsion polymerization was 132.9mg,
which contributed to 3.2% of the solid content of the emulsion (second table).
Acrylated Drug
Monomer
7

Weight
(mg)
40.0

% of Total
Drug
30.10

8
11
16
18
19
All 6 Drugs

20.0
10.0
40.0
20.0
2.9
132.9

15.05
7.52
30.10
15.05
2.18
100

Compound

Mass (g)

Percentage
(%)

Total Drug

0.133

3.2

Butyl acrylate

2.59

Styrene

1.11

Water

16.00

80

Sodium dodecyl sulfate

0.12

3.0

Potassium persulfate

0.04

1.0

12.8
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Table 4.2 shows the amounts of each antibiotic acrylate and formulation conditions. The
multi-drug conjugated emulsion MDNP2 was based on that of the drug-free poly(butyl
acrylate-styrene) emulsion CNP5 (page 69, Chapter 3), with the same ratio and amount
of co-monomers, surfactant, and radical initiator. Sodium dodecyl sulfate (SDS) and
potassium persulfate were the surfactant and radical initiators used for the
polymerization, where 3% surfactant and 1% radical initiator was employed in the
emulsion formulation. However, this amount of surfactant was found to be less than
optimal during initial in vitro cytotoxicity analyses (Chapter 7). Also, some of the
acrylated drug monomers utilized in this formulation were found to not exhibit
antibacterial activity when tested in vitro (Chapter 3), and therefore, the multi-drug
formulation was reformatted in order to include a less cytotoxic amount of SDS (1%) and
also include drug monomers that have shown better antibacterial activity when
individually polymerized within the nanoparticle delivery system.
AFM imaging analysis was performed for the resulting multi-drug conjugated
nanoparticle emulsion as previously described in Chapter 3. Figure 4.2 shows that the
resulting nanoparticles present in MDNP2 are uniformly spherical with a small size range
distribution, averaging 14 to 21nm in diameter.

Figure 4.2. AFM image of MDNP2. Image to the left is a full 5x5 µm scan of the
deposited emulsion. Image to the right is a focused scan of an individual particle
observed followed by 3D transformation of the scan using the IGOR software system.

AFM imaging was first performed on the multi-drug conjugated nanoparticle emulsion
over all of the other emulsions previously synthesized (Chapter 3), therefore, various
deposition techniques were performed for this emulsion in order to optimize imaging.
Imaging was performed for the deposited emulsion under both liquid and dry conditions,
and also after various deposition times and concentrations. Figure 4.2 shows one of the
original AFM images taken of the deposited emulsion on the glass coverslip, where a
128

longer deposition time was employed, along with no rinsing of the deposit prior to
nitrogen or air drying and imaging.

Figure 4.3. AFM of individual particle and polymer strands present in MDNP2. The
particle size is 14.7nm and the polymer strands (arrow) are approximately 0.8nm tall. Dry
imaging of the deposited emulsion using the AFM tapping-mode was utilized for these
images.

In Figure 4.3, both the long chain polymer strands (arrow) and the solid spherical
nanoparticle were observed in the emulsion. This data substantiated the TEM
observations reported in Chapter 3 for the drug-free emulsion, where the observed
polymer strands were poorly visible but still present in the emulsion. Here, the polymer
strands are clearly visible and well defined for the emulsion, indicating that both
constituents are present in the emulsions. Varying the deposition technique utilized for
AFM imaging allowed only the nanoparticle constituents to be visualized in the later
emulsions, where a short deposition time followed by rinsing of the deposition surface
afforded only the anionic nanoparticles adhering to the glass surface for imaging.

4.3.2 MDNP1
After analysis of MDNP2 by antibacterial assays in vitro (Section 4.4) and analysis of the
individual drug-conjugated nanoparticle emulsions in Chapter 3, it was determined that
this antimicrobial emulsion system was not working synergistically to afford heightened
antibacterial activity against the majority of the bacteria analyzed. Instead, what was
observed was a diminished activity when compared to the individually polymerized
cipro-containing emulsions, although the activity was greater for the multi-drug
conjugated emulsion than was observed for the individual penicillin-containing
emulsions. Also, the antimicrobial activity of the penicillin G acrylimide 13 was more
potent than all of the other acrylated penicillin analogues present in MDNP2, and
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therefore, 13 replaced all of the other penicillin analogues in MDNP2 to afford the new
multi-drug conjugated nanoparticle emulsion formulation MDNP1 (Figure 4.4).
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Figure 4.4. Acrylated drug monomers used to prepare multi-drug nanoparticles MDNP1.

Due to the inherent anti-MRSA activity of the N-thiolated β-lactam monomers
synthesized in Chapter 2, it was determined that incorporation of at least two of these
acrylated drug monomers in the new multi-drug formulation was necessary in order to
provide the emulsion with established anti-MRSA activity that does not rely solely on the
protective nature of the nanoparticle delivery system for activity, as was observed for the
penicillin G acrylamide monomer. These two β-lactam monomers were also chosen for
the second nanoparticle formulation due to their activity against the fungal species,
Candida, which is commonly found invading burn wounds and adding to the bacterial
infection load. These lactams have also proven to have activity against many of the gram
positive microbes found in burn wounds, including Staphylococcal species and some
Streptococcal species (Chapter 2).
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Table 4.3. Formulation for multi-drug conjugated nanoparticle emulsion MDNP1. The
total amount of all the drug monomers incorporated into the emulsion (120mg, first table)
totaled 3% (w/w) of the solid content of the emulsion (second table).
Acrylated Drug
Monomer
1
3

Weight
(mg)
10.0
20.0

% of Total
Drug
8.33
16.67

7

40.0

33.33

8

30.0

25.00

13

20.0

16.67

All 5 Drugs

120.0

100

Compound

Mass (g)

Percentage
%

Total Drug

0.120

3

Butyl acrylate

2.67

Styrene

1.15

Water

16.00

80

Sodium dodecyl sulfate

0.04

1

Potassium persulfate

0.02

0.5

15.5

The multi-drug conjugated emulsion MDNP1 was formulated after the drug-free
poly(butyl acrylate-styrene) emulsion CNP16, with the same ratio and amount of comonomers, surfactant, and radical initiator (Table 4.3). SDS and potassium persulfate
were again chosen as the surfactant and radical initiators, where only 1% surfactant was
employed in the emulsion formulation and 0.5% potassium persulfate. Further analysis of
this emulsion formulation showed optimal antibacterial activity in vitro and no toxicity in
either in vitro or in vivo settings.
AFM analysis was also performed for this multi-drug conjugated emulsion system and
yielded the same results as the MDNP2 nanoparticle emulsion, with uniformly spherical
nanoparticles within the same size range (Figure 4.5). Therefore, changing the amount of
surfactant (3% to 1% w/w) and radical initiator (1% to 0.5% w/w) did not alter the
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physical characteristics of the nanoparticles, nor did reducing the number of drug
monomers incorporated from six to five.

Figure 4.5. AFM image of MDNP1. The average diameter of the particles present in this
emulsion are 21.0nm +/- 5.3nm. The subset image to the right of a single particle is 36nm
wide and depicts a particle of 18nm in height.

AFM analysis of the multi-drug conjugated nanoparticle emulsion MDNP1 displayed
uniformly spherical nanoparticles present in the emulsion, with an average particle size of
21nm. This finding is comparable to the nanoparticle size range determined for MDNP2
by AFM analysis. Also, it was determined through this assay that the particle size range
for the multi-drug conjugated nanoparticles was equivalent to the size range observed for
the single drug-conjugated nanoparticle emulsions determined by AFM (Chapter 3).
Therefore, the addition of multiple antimicrobials to the nanoparticle drug delivery
system when the drug monomers are covalently bound to the polymer backbone does not
cause an increase in the average particle size. It is presumed here that if multiple
antimicrobials are added to the nanoparticle delivery system via encapsulation of the drug
monomer within the particle, the average particle size would be drastically increased due
to the data presented for the encapsulated drug monomer nanoparticles in Chapter 3.
Therefore, the choice of using the acrylated bound drug monomers for the multi-drug
containing nanoparticle system instead of opting for encapsulation of the monomers was
the most optimal.
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4.4 Determination of Microbiological Activity of Multi-Drug
Conjugated Nanoparticles MDNP1 and MDNP2
In order to determine the effectiveness of the multi-drug conjugated nanoparticle
emulsions MDNP1 and MDNP2 and the resulting polymer films, antibacterial assays
were performed against a variety of bacterial strains and species, by varying the amounts
of total drug concentration. Prior to analysis, the emulsions were diluted to 1mg total
drug weight per 1mL of emulsion with nano-pure water. This allowed equivalent
amounts of the total drug present in the multi-drug conjugated emulsion to be compared
to that of the single-drug conjugated emulsion, and also to the individual drug monomer
dissolved in DMSO or water. Although this is not a direct comparison, since it is the total
amount of drug being calculated in the dilution and not one individual drug, this still
provides the relationship necessary for accurate comparative analysis of antibacterial
activity.

4.4.1 Introduction
Antibacterial testing of the multi-drug conjugated nanoparticle systems was performed
against various strains of S. aureus, including numerous strains of MRSA. Other
microbes analyzed included Bacillus spp. and Pseudomonas aeruginosa, both of which
have been identified as two of the causative microbes in burn wound infections. Since P.
aeruginosa is the most consistently found and often the most deadly pathogen colonizing
burn wounds, it was imperative that sufficient activity be observed against this microbe in
order to consider the emulsion for topical application of burn wound infections. It has
been established that many of the pathogens found in burn wounds are able to form
complex cooperative environments known as biofilms within the wound in less than 24
hours post thermal trauma (Section 4.1), which are extremely difficult to treat; therefore
it was paramount that the emulsion be able to eliminate these microbes from the wound
as early as possible. Also, it is proposed that the polymer film that forms upon application
of the aqueous emulsion on the wound will protect the burn wound from these and other
invading pathogens. Therefore, the polymer films were analyzed for in vitro antibacterial
activity against these same microbes.

4.4.2 Antibacterial Activity of MDNP2
The original multi-drug conjugated nanoparticle emulsion formulated was the most
thoroughly analyzed of the two multi-drug systems, and therefore, more data is presented
here for this emulsion than is for MDNP1. This was due to the fact that the nanoparticle
formulation for MDNP2 was only later determined to be slightly cytotoxic to human
dermal fibroblast cells longer after the original nanoparticle formulation was synthesized
and analyzed. However, aside from this fact, which is explored later in Chapter 7, the
initial multi-drug conjugated nanoparticle emulsion (MDNP2) did not display the
antibacterial activity that was expected of it. This was due to the lack of antibacterial
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activity observed for the penicillin-based drug monomers that were incorporated into this
nanoparticle emulsion. As seen in Chapter 3, these acrylated monomers displayed little to
no antibacterial activity against the Staphylococcal strains when individually polymerized
in the nanoparticle emulsion system. Therefore, the observed antibacterial activity for
MDNP2 was the result of the ciprofloxacin acrylamide monomers present in the
emulsion. As seen below in Figure 4.6, activity was expressed for the emulsion and
polymer films against many of the bacterial species present in burn wounds at both the
onset of infection and also later in the infection development, but this activity was not
nearly as potent as the individually polymerized ciprofloxacin acrylamide nanoparticles.

100µL
MDNP2
50µL

20µL
CNP15

MDNP2

Figure 4.6. Antibacterial activity of multi-drug conjugated polymer film and emulsion
against S. aureus (ATCC 25923). In the plate shown to the left, 500µL of emulsion (20%
solid content) was added to the surface of the agar, and allowed to dry to form a thin
white film. KG32 represents MDNP2 in the assays, and KRG15 represents CNP15.

For the Kirby Bauer assays presented in Figure 4.6, the emulsion was added to the agar
wells based on the amount of total drug incorporated. A 1mg/mL concentration of total
drug in the emulsion was obtained by dilution of the concentrated emulsion. 100µg,
50µg, and 20µg of total drug in equal volumes of emulsion (100µL, 50µL, 20µL) was
analyzed by ZOI in order to present enough emulsion to the assay in order to observe the
antibacterial activity. This was done due to the inherent problems mentioned in Chapter 3
that go along with analyzing the nanoparticle emulsions by this assay. As previously
stated, due to the vast degree of long chain polyacrylate polymer strands present in the
emulsion that are not part of the nanoparticle, and since these long strands are not able to
diffuse through the agar apparent by the white ring coating the inside of the agar well in
Figure 4.6 only a portion of the drug content is diffusing into the agar.
A 0.5mL aliquot of concentrated (20% solid content) emulsion was used to form the
polymer films for ZOI analysis. The emulsion was added on top of the already inoculated
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agar, and the polyacrylate films were allowed to solidify in the biosafety cabinet prior to
incubation for bacterial growth, thereby allowing the solid polymer film to be interacting
with the proliferating bacteria and not the emulsion. The data present in Figure 4.6 shows
that the polymer film formed from the multi-drug conjugated nanoparticle emulsion
(MDNP2) displayed very good anti-Staphylococcal activity, which was not observed for
the drug-free polymer film formed from the emulsion CNP15. Therefore, the observed
antibacterial activity was not due to leaching of the excess surfactant or radical initiator
into the surrounding agar, but was due to the direct interaction of the microbes with the
both the nanoparticles that appear to have diffused into the agar prior to film formation
and from the polymer film, since no bacterial growth was observed under the polymer
film and since a zone of inhibition was formed surrounding the polymer film. The
bacterial permeability studies described in Chapter 5 also contributed to the
understanding of the antibacterial nature of the polymer films, as did the carbon sources
assays presented in that chapter as well. Therefore, it was concluded that both the
nanoparticle emulsion and the resulting polymer films possessed antibacterial activity.

Figure 4.7. Antibacterial activity of MDNP2 against P. aeruginosa. KG32 in the image
represents MDNP2. A 1mg/mL concentration of total drug in the emulsion was obtained
by dilution of the concentrated emulsion. 100µg, 50µg, and 20µg of total drug in equal
volumes of emulsion (100µL, 50µL, 20µL) was analyzed by ZOI.

The zones of inhibition measured for the multi-drug conjugated emulsion against P.
aeruginosa are described in Table 4.4, along with the MIC values for the emulsion, plus
the values of the ciprofloxacin acrylamide monomers that provide the emulsion with the
anti-Pseudomonal activity. Interestingly, the degree of anti-Pseudomonal activity for the
nanoparticle emulsion at 20µL volume did not produce a very large ZOI, whereas for the
staphylococci-based assays, the ZOI measurements for the 20µL volumes of emulsion
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were only slightly smaller than were observed for the higher volumes of emulsion in the
agar well.

Table 4.4. Anti-Pseudomonal activity of MDNP2 and ciprofloxacin acrylamide
monomers and emulsions. ZOI data is presented for 20µg of cipro monomer in 20µL of
emulsion or DMSO.
Sample

ZOI (mm)

MIC (µ
µg/mL)

Cipro

40

1

7

15

128

NP7

22

2

8

NA

128

NP8

21

4

11 (13)

4

MDNP2

The data in Table 4.4 makes a bold statement towards the ability of the Pseudomonal
bacterium to cleave the cipro drug monomer from the backbone of the polymer chain,
thereby releasing the active cipro monomer. Obviously, the commercially available form
of cipro has potent activity against Pseudomonal species and is one of the most
commonly prescribed antibiotics for these infections. However, after chemical
modification of this drug monomer into the acrylamide form (7 and 8), the antibiotic
loses almost all of its antibacterial activity against this microbe. Yet when copolymerized with butyl acrylate and styrene, the drug regains its activity against this
microbe and shows potent activity in vitro. This finding is the most persuasive data yet to
support the occurrence of bacterial cleavage of the drug monomer from the polymer
backbone, thereby releasing the active form of the drug monomer. This data also aids in
the confirmation that the observed antibacterial activity in the Kirby Bauer assays is not
due to the non-polymerized acrylate drug monomer dissolved in the emulsion, but that
the drug must be being cleaved off the polymer in order for the antibacterial activity to be
detected. The data in Table 4.4 and the ZOI assay shown in Figure 4.7 was repeated a
minimum of 3 times in order to verify these findings, and in each assay performed, these
findings were further solidified as accurate and reproducible. Therefore, in terms of in
vitro anti-Pseudomonal activity, the microbe must cleave the covalently bound cipro
monomer from the polymer backbone in order to release the active drug monomer.
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Figure 4.8. Analysis of drug-conjugated nanoparticle emulsions NP7, NP8, NP11, and
MDNP1 against various strains of MRSA. MRSA isolates 920 and 919 are ATCC strains
and strain 659 is a clinical isolate. KG32 in the images represents MDNP2, KG13
represents NP7, KG11 represents NP8, and KG30 represents NP11.

In Figure 4.8, it appears that there is a diminished degree of antibacterial activity against
MRSA for the multi-drug conjugated emulsion MDNP2 (KG32) versus the
ciprofloxacin-only conjugated emulsions NP7 and NP8 (KG13 and KG11 respectively).
This decrease in activity was attributed to the lowered amount of ciprofloxacin
acrylamide monomers present in the multi-drug conjugated emulsion versus the high
concentration of the monomers in the single-drug conjugated emulsions NP7 and NP8.
This also helped establish the fact that the other drug monomers in the emulsion (11, 16,
18, and 19) were not contributing to the anti-Staphylococcal activity to a large extent.
Since the single-drug containing emulsion NP11, NP16, NP18, and NP19 did not
produce large zones of inhibition against S. aureus, as shown in Chapter 3, this further
solidified this hypothesis. While the MIC data for these single drug-containing emulsions
did show some anti-Staphylococcal activity, the MICs were not very strong, indicating
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that the ciprofloxacin acrylamide monomers present in MDNP2 are the cause of the
observed anti-Staphylococcal activity for this emulsion.
Due to the diminished antibacterial activity observed for the MDNP2 nanoparticle
emulsion as compared to the individual ciprofloxacin-conjugated emulsions, it was
determined that the acrylated monomers incorporated into this delivery system should be
adjusted in order to provide a synergistic effect of the drugs present in the nanoparticle
formulation, rather than the observed diminished antibacterial activity. Also, in Chapter
7, it was determined that the nanoparticle emulsions formulated with 3% surfactant and
1% radical initiator inflict some toxic effects on human dermal fibroblast cells, even
when in the polymer film form, formulations containing more than 1% surfactant were
non-favorable in terms of cytotoxicity. Therefore, the need for a new multi-drug
conjugated nanoparticle formulation with no cytotoxic effects and a heightened
antibacterial activity against microbes commonly found in burn wounds was addressed.

4.4.3 Antibacterial Activity of MDNP1
MDNP1, formulated with 1% surfactant and 0.5% radical initiator, was analyzed for
antibacterial activity in vitro against some of the common pathogens present in burn
wounds. Prior to analysis, the emulsion was diluted to 1mg total drug weight per 1mL of
emulsion. This allowed the emulsion to be tested in vitro at the same drug concentrations
as the monomers dissolved in DMSO were previously tested, providing comparable
results to both the drug monomers, but also to the single drug-conjugated emulsions and
MDNP2.

Figure 4.9. Anti-Staphylococcal activity of MDNP1. Activity was tested against both S.
aureus (ATCC 25923) and MRSA (ATCC 43300). A 1mg/mL concentration of total drug
in the emulsion was obtained by dilution of the concentrated emulsion. Volumes of the
diluted emulsion (100µL, 50µL, 20µL) were analyzed by ZOI.
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The images in Figure 4.9 show that the multi-drug conjugated nanoparticle emulsion
MDNP1 is very potent even at a low total drug concentration of 20µg in 20µL emulsion.
This is most likely due to the potent effect of the multiple drugs on the bacteria, where all
of the drugs present in the emulsion have activity against S. aureus.

Figure 4.10. Kirby Bauer assay for MDNP1 against B. anthracis-Sterne.
The anti-Bacillus activity of the multi-drug conjugated emulsion was considered to be
extremely potent, and the degree of ZOI variance among the different volumes of
emulsion analyzed was almost none. This indicates that there is a higher degree of
nanoparticles present in the emulsion than there is the long polyacrylate strands.
However, these polymer strands are still present in the emulsion, as observed by the
white polymer rings surrounding the inside of the agar wells and also observed slightly
diffused into the surrounding agar. Since the non-particle based polymer strands are
required for the formation of the protective film for burn wound and other topical wound
applications, the presence of the white polymer precipitate in these Kirby Bauer assays is
a positive observation, regardless that this diminishes the ability of the assay to provide
an accurate antibacterial activity analysis.
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Table 4.5. Zone of inhibition data for MDNP1 nanoparticle emulsion. Emulsion is
applied to the agar wells in a 1mg of total drug per mL emulsion.
Volume of
Emulsion (µL)

B. anthracisSterne

S. aureus

MRSA

100

31 (33)

30

30

50

27 (30)

27

28

20

25

24

25

*( ) = partial inhibition

ZOI analysis of the multi-drug conjugated nanoparticle emulsion MDNP1 displayed
equal activity against S. aureus and MRSA, indicating that the penicillin-inactivating
enzyme β-lactamase has no effect on the activity of the antibiotics when in this delivery
system. It was determined here that the ZOI data observed for the emulsion at 20µL was
comparable to the ZOI data for the emulsion at 100µL against all 3 bacterial species
analyzed, indicating that only a small volume of the emulsion is needed to observe potent
antibacterial activity. Also, the data in Table 4.5 for the anti-Staphylococcal ZOI assay
showed that the emulsion MDNP1 was more potent than either of the individual
acrylated N-thiolated β-lactam monomers when applied to the assay dissolved in DMSO
(Chapter 2), therefore, addition of these monomers to the nanoparticle emulsion increased
the observed activity in vitro. The activity for MDNP1 against the various staphylococci
strains was much more potent than was observed for MDNP2, and was also more potent
than the individually polymerized cipro acrylamide emulsions (Chapter 3), indicating that
the mixture of antimicrobials present in MDNP1 possessed a synergistic effect in the
treatment of S. aureus and MRSA in vitro.

4.5 Conclusions
The multi-drug conjugated nanoparticle emulsion system MDNP1 appears to be an
optimal treatment for burn wound infections. This drug delivery system contains
antibiotics that are synergistic and provide overlapping activity against the pathogens
commonly found colonizing burn and other skin and soft tissue wounds and abrasions.
The equipotent activity in vitro of the emulsion against both MSSA and MRSA strains of
S. aureus makes this drug delivery system optimal for treatment of infections where
MRSA may be present. Also, the protective nature of the nanoparticle delivery system
and the fact that all of the antibiotics present in the nanoparticle emulsion are active
against S. aureus and MRSA should prevent the development of bacterial resistance to
one or more of the antibiotics present in the emulsion. Due to the highly potent anti140

Pseudomonal activity of the ciprofloxacin monomers present in the emulsion, and the
anti-fungal activity of the acrylated N-thiolated β-lactam monomers, this multi-drug
conjugated nanoparticle delivery system has the potential to eradicate the majority of the
microbes commonly found in burn wounds. This delivery system also has the potential to
treat biofilms formed within the wounds due to the highly lipophilic nature of the
nanoparticles, as well as the multiple antimicrobial treatment presented in the
nanoparticles that would be able to combat the various pathogens present in the biofilms.
Therefore, the multi-drug conjugated nanoparticle emulsion system has the potential to
revolutionize the treatment of burn wound infections and needs to be further explored for
in vivo efficacy and toxicity.
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CHAPTER 5
MECHANICAL PROPERTIES OF SMART
POLYACRYLATE POLYMER FILMS FOR
BIOMEDICINAL APPLICATIONS
5.1 Introduction
Biocompatible polymer films are of great utility in the medical field, including for
prostheses, sensors, and artificial skin development. These polymers have been
researched and optimized for many years in order to improve current biomedical devices,
and are now being applied to new biotechnologies such as sensors, microarrays, lab-on-achip technologies, immunoassays, protection from foreign body response, and as new
detection materials. Some of these biocompatible films are protein-based, as seen in
spider silk films,[1] and some are synthetic-based, such as polycarbonates, polyethylene
glycol (PEG), ε-caprolactone, poly (L-glactonic acid) (PLGA), porous poly (D,L- lactic
acid) (PDLLA), polylactic acid (PLA), polyglycolide (PGA) and the copolymer PGLA,
multilayer films, and poly (L-lactic acid) (PLLA).[2-7] Some of these synthetic polymers
can be made absorbable or biodegradable upon secondary chemical modifications, and
other bioabsorbable polymer materials have also been studied for medicinal uses,
including natural collagen-based sutures, and chitosan- and hyaluronic acid-based
polymers.[8]
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Figure 5.1. Structure of PLGA and PLA polymers.

Other well-known synthetic polymers, such as polyacrylates, have been used in medicine
in many applications since the 1960’s due to their lack of toxicity, especially in
prosthetics, bone cement, wound dressings, and absorbent materials.[9-15] Various forms
of polyacrylate polymers have been studied for biomedical applications, including
polymer films and coatings, gels, and liquid emulsions, and in delivery of insoluble drug
monomers to target sites within the body.[16-29] Since polyacrylates have been one of the
most widely used polymers for both commercial and biomedical applications to date, and
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is therefore of considerable interest to our laboratory for future developments in these
areas.
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Figure 5.2. Comparison of the tensile strengths of various biological materials.[30, 31]

5.1.2 Synthetic Polymers
Tissue engineering has been a widely growing area of research in the field of
biotechnology and has become the mainstay of bioengineering; a promising new
discipline that has already been integrated into many universities’s engineering colleges.
This interdisciplinary area of research revolves around the use of various cell types with
natural and/or synthetic materials to engineer matricies for partial or whole replacement
or improvement of biological tissues.[47] The products of this type of research play a
major role in advancing and optimizing burn wound treatment, heart valve and other
vascular replacements, and organ replacement systems, making this a major area of
interest in the biomedical engineering field. This field often requires biological and
synthetic-based systems to be combined in an effort to obtain scaffolds with equivalent
properties as the tissue it wishes to replace, therefore, an understanding of both systems
individually and in combination is critical.[32-39] Many of the aforementioned polymers
have been investigated for roles in tissue engineering, especially semi-synthetic polymers
that are bioabsorbable. However, for these polymers to be considered for tissue
replacement, the mechanical properties of the polymers must be known and be
compatible with the tissue in question. Many factors must be analyzed for a material prior
to its use in a tissue scaffold, including the length of time prior to complete
biodegradation, when the material loses its mechanical properties, and the point at which
the material is completely resorbed by the body.[6] Complete lack of cytotoxicity must
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also be a property of the polymer for such an application, since target cells also constitute
the scaffold, and it must promote cellular adhesion from the surrounding cells to aid in
scaffold integration, and the polymer must not be chewed apart by the body’s immune
system, as is often seen in breast implant materials.
Some of the most commonly used polymer structures for biomedical applications,
including tissue scaffolds, are aliphatic polyesters such as those containing lactic acid,
galactone, or glycolide as the base monomer (PGA, PLLA, PDLLA, PLGA, PLA, PEG),
or in a copolymer (PGLA).[3-5, 7] This is because these monomers, and in some instances
the polymer form as well, are often naturally occurring in the body, which makes them
non-toxic to mammalian systems, biocompatible, and often bioabsorbable.[3, 6]
Polycarbonate and ε-caprolactone polymer films have also been incorporated for
biomedicinal purposes, including tissue scaffolds due to the elastomeric property of the
polymer;[2, 6] however, the optimal mechanical properties of these films is highly
dependent on the molecular weight of the polymer, and is therefore difficult to maintain
batch-to-batch and in vivo.[2] The biocompatible nature of the polyesters has allowed
them to be incorporated into numerous sensor and microarray systems, as wells as
considered for tissue scaffolds, implants, and grafts, and research is still looking at
improving these films for optimization in such systems. The film structures are often
added to such systems using lithography, doping, or electrospinning techniques,[3, 7, 40]
and can be formed in a variety of different three dimensional patterns and with various
degrees of porosity on a surface of a membrane, sensor, array, scaffold, or other platform.
This provides even further utility of these types of synthetic-based polymer films in
biomedical applications.
Once added to the surface of the intended system, these polymer films can often be
further modified to provide additional utility to the system. This is often seen when these
polymer films are used as detection interfaces for biophysical and biochemical
applications.[7] When designing a mircoarray or other form of biological detection
system, films are frequently modified after application to the system to include the
addition of an enzyme or other biomolecule that binds to the surface of the film and
interact with what the system is trying to detect. These biomolecules are usually a
permanent addition to the film through either covalent or ionic bonding, and are able to
retain their native biological activity. Specific polymers can also be chemically modified
after synthesis to make them biodegradable, which allows them to be developed for tissue
engineering, or gives them additional utility in the system they are bound to.[2, 6]
However, the mechanical properties of the polymers must be in synch with the
application in order for it to be used. Many of the biodegradable polymers mentioned
above (PGA, PLA, PEG) do not have optimal mechanical properties for such applications
as tissue engineering due to their brittle nature,[6] indicating that they not function equal
to the native tissue. Other issues for these polymers come from the quickness with which
they are degraded in vivo, thus not making them the optimal choice for a long term in
vivo application, but a good choice for microarray detection materials due to their ability
to bind biological entities post-synthetically. Other issues arise when a polymer requires
cross-linking in order for it to retain the shape required or to maintain optimal mechanical
144

properties. Cross-linking, either through chemical or photochemical cross-linking, can
have very detrimental affects when in vitro and in vivo, and thus most research tries to
avoid this whenever possible.[2] Therefore, there is a great need for improvement still in
this area of research, and optimal synthetic materials still have yet to be found for
applications in tissue engineering and other biomedical applications.

5.1.3 Biorubbers
Within nature, there are many materials that are integral to life that behave as rubbers, or
elastic materials. These pliant materials, often referred to as biorubbers, work in
conjunction with many vital systems to support life through their elastic properties that
allow vital tissues to expand and retract continuously. There are three key biorubber
materials in living organisms: abductin in mollusks, resilin in arthropods and elastin in
echinoderms and mammals, and in each organism, proper function of this material is
critical for sustaining life.
The first type of naturally occurring biorubber belongs to the class of animals deemed
mollusks, specifically the bivalve shellfish. These animals possess a protein-based
material called abductin that is present in the ligament that acts as a hinge for the
mollusk. This hinge action provides the mollusk with the ability to open and close its
bivalve shell system rapidly, which allows the animal to not only feed itself, but also
provides rapid protection from invading predators by allowing the animal to close itself
off from its environment quickly through the elastic nature of the ligament. In winged
arthropods, the resilin protein is a major part of the ligament involved in flight. The
resilin component allows the elastic ligament to expand and contract rapidly, which in
turn expands and contracts the thorax of the arthropod. This movement is what indirectly
causes the wings that are attached to the thorax to move, creating the motion necessary
for flight.[41] The resilin-containing ligament must be able to extend and contract at very
high speeds for flight, where wing speeds have been reported as fast as 62,760 beats per
minute for some arthropods.[41-43] While these biorubbers obviously play a crucial role in
sustaining life for these animals, they appear to be involved in only one part of the
animal’s anatomy, typically involved in facilitating movement of the animal, making
their usefulness limited to those sole applications. However, in mammals, the biorubber
material present constitutes many of the animals’ vital organs and is involved in
numerous physiological aspects of life for mammals.
Elastin is a major component of human and mammalian tissue where elasticity is a
requirement, such as in elastic ligament, blood vessels, lungs, skin, and heart aorta
tissues.[33, 34, 44, 45] Its ability to undergo cyclic loading of stress and relaxation gives it its
unique viscoelastic property that is exploited by the mammalian anatomy.[44-46] Elastin is
an extra cellular matrix protein that exists as an array of cross-linked fibers in the
specified tissues and is formed from self-assembled tropoelastin proteins under
physiological conditions.[33] The physical properties and arrangement of these fibers
within the tissue it comprises varies from tissue to tissue, depending on the tissue’s need
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for elasticity and the amount of elastin present in the tissue. The degree of elasticity in a
single tissue (i.e. aortic heart tissue) can vary from animal to animal in mammals due to
the animal’s physiological requirements;[44, 45] however, in all animals, elastin fibers are
insoluble proteins that have been observed as having a half life of approximately 70
years, making it one of the most stable proteins present in mammalian systems.[33]
The mechanical properties of elastin and the other biorubber proteins describe a highly
viscoelastic material with a unique biphasic stress/strain curve that consists of an initial
linear region followed by an amorphic region. Elastin itself has shown tensile strengths
on the range of 0.5MPa and elastic moduli of approximately 1.5MPa.[45, 46] However, the
biological tissues that elastin comprises have shown tensile strengths up to eight orders
higher when tested, due to the presence of collagen in the tissue that provides strength for
the tissue.[44] Also, when elastin is present in fibrilar formation, such as seen in elastic
ligaments, the fiber is not only comprised of cross-linked elastin protein,[33] but also
contains microtubules, which in turn, alter the stress/strain curve characteristics for the
fiber yet do not affect its tensile strength.[44, 45] In terms of tissue engineering, elastin has
been able to be combined with numerous synthetic polymer systems and also various
solvents in order to increase its tensile strength in order to mimic the mechanical
properties of biological tissues where elastin is found.[33, 34, 46] This same type of
biocomposite engineering has also been applied to collagen, where collagen is the
biological material and a synthetic polymer is incorporated into a material that is an
attempt to emulate the mechanical properties of elastin.[32, 35-39] In this study, the polymer
film samples synthesized and analyzed displayed mechanical properties equal to those
observed for both elastin, and elastin fibers, where viscoelastic stress/strain data and
similar tensile strength and elastic moduli are observed. Also, the polyacrylate films
constructed herein display the same ability to undergo numerous stress/retraction cycles
as the elastin fibers, with deformations observed as high as 1000%, which is one order
higher than observed for elastin fibers that undergo only 150% deformation naturally.

5.2 Emulsion Polymerization
Polyacrylates have seen much use in industry and in the medical field since the late
1960’s,[10, 11] yet improvements in the polymer composition need to be made in order to
optimize the utility of the polymers in the medical field. Reducing foreign body responses
to the polymers, eliminating biofilm formation at the surface of the polymer, and
eliminating host-encapsulation of polymer-coated device or host cellular aggregation at
the surface of the polymer in vivo are just some of the goals of new medicinal polymers.
In order for polymers to be developed that meet the needs of these new medicinal
applications, they must maintain properties that are optimal for such uses, including
possessing properties parallel to the three goals previously listed. The polymers must also
abide by other parameters as well to be optimal for such uses, including displaying
appropriate pore sizes and physical and mechanical properties that cater to each specific
use. In the present study, a variety of polymer films formed through a single step
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emulsion polymerization process containing differing ratios of butyl acrylate (BA) to
styrene (Sty) and BA to methyl methacrylate (MMA) were synthesized. The physical and
mechanical properties of these films were analyzed in order to identify the most optimal
films for various medicinal applications. A total of 15 different films were formed and
the physical and mechanical properties were assessed, resulting in the development of
numerous new and unique elastomeric polymer films for various medicinal applications
that display unique properties consistent with biologically-based pliant materials.
Typically, this elastomeric property is seen when BA and Sty individual block or graft
polymers are blended together, where, as the amount of styrene is increased in the
mixture, the viscoelastic nature and adhesive properties of the films is lost, yet the tensile
strength of the films increases as does the elastic modulus.[9] Here, the polyacrylate films
are formed through a single step emulsion polymerization process, which provides more
control over the consistency and homology of the resulting emulsion and polymer films,
as well as easier handling that equates to lower costs associated with the material
production. The elastomeric property observed for the blended BA and Sty polymer films
is also found for the films obtained from the single-step emulsion polymerization, and
equal tensile strength and elastic moduli are also observed for these films as the blended
block polymer films, indicating that similar mechanical properties are observed for the
polymer films regardless of the polymerization technique utilized. The polymer films
were analyzed by uniaxial tension analysis, as shown in Figure 5.3 for determination of
the film’s tensile strength, elastic modulus, and maximum strain.

Table 5.1. Formulation of emulsion polymerizations containing butyl acrylate (BA) and
styrene (Sty) or methyl methacrylate (MMA).
Emulsion CoMonomer
CNP5
CNP6
CNP7
CNP9
CNP10
CNP12
CNP13
CNP14
CNP15
CNP16
CNP17

Sty
MMA
Sty
Sty
Sty
MMA
MMA
MMA
Sty
Sty
MMA

BA :Comonomer
ratio
7:3
8:2
8:2
7:3
8:2
7:3
7:3
8:2
7:3
7:3
7:3

Surfactant
(%)

Initiator
(%)

3
3
3
5
5
3
5
5
1
1
1

0.5
0.5
0.5
1
1
0.5
0.5
1
1
0.5
0.5
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Max
Stress
(MPa)
1.165
0.449
0.146
0.643
0.594
1.671
0.984
0.296
0.605
0.675
1.105

Young’s
Modulus
(MPa)
0.269
0.365
0.102
0.615
0.423
0.771
0.647
0.326
0.451
0.458
0.478

10mm

30mm

70mm

50mm

90mm

Figure 5.3. Images of polymer film before and during mechanical testing. Initial film
length placed between the clamps is approximately 10mm, and the film is stretch to
100mm, approximately a 1000% deformation.

5.3 FTIR Data and Analysis
5.3.1 Introduction
FTIR spectroscopic analysis was performed on poly(butyl acrylate-styrene) (CNP16) and
poly(butyl acrylate- methyl methacrylate) (CNP17) polymer films, and polymer films
containing BA, Sty, and covalently bound acrylated drug moieties (NP7, NP8, MDNP1).
Characteristic bands of all three co-monomers utilized in the emulsion polymerization
were present in all the spectrums; however, some of these peaks were weakened or
overshadowed in the polymerized form. Also, peaks from the drug moieties were not
observed, however, intensified peaks were observed when the drug possessed similar
moieties as the polymeric co-monomers. Spectra for the BA and Sty-containing polymer
film CNP16 were similar to that of the blended block polymer films described by
Cerrada et. al.[9]
5.3.2 Drug-Free Polymer Films
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Figure 5.4. FTIR spectra for polymer film samples CNP16 and CNP17.
CNP16 displays an obvious extra set of peaks in the 800-650 cm-1 region of the spectrum
from the C-H and ring bending absorption, indicative of the presence of an aromatic
constituent,[40] namely styrene. However, the commonly observed aromatic humps
normally observed for styrene in the 2500 cm-1 region are absent when the styrene
monomer is co-polymerized as the smaller side of the ratio with another acrylate
monomer.[9] Both samples display a strong, sharp signal in the 1700 cm-1 region,
characteristic of a strong C=O stretching, and a sharp peak at 1150 cm-1 representing a CO stretching,[9, 40] where both of these peaks appear even stronger for CNP17, which has
not one but two sets of acrylates in the sample, thereby causing the stronger absorption of
signals. The C=C stretching that would be observed for the vinyl group of the acrylate
and styrene monomers at 1640 cm-1 is absent, indicating a successful polymerization of
the monomers.
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5.3.3 Drug-Containing Polymer Films

Figure 5.5. FTIR spectra for NP7 and NP8.

The spectra in Figure 5.5 show the difference between the polymer films of NP7 and
NP8. While both of these emulsions contained acrylated ciprofloxacin drug monomers
and the same polymer formulation (7:3 BA:Sty, 1% surfactant, 0.5% radical initiator), the
difference between the two is that NP7 is straight ciprofloxacin acrylamide and NP8 is
ciprofloxacin methacrylamide. NP7 has a double peak at 2870cm-1 while NP8 has only a
single, sharper peak in this region. The C=O and C-O stretching peaks at 1700cm-1 and
1150cm-1, and all of the peaks for that matter below 2000cm-1 are stronger and sharper
for NP8 than they are for NP7, approximately a 5% transmittance difference in most
cases. However, these differences are minimal and difficult to detect due to the low
concentration of the drug moiety in the polymer film (15% of the solid polymer film).
Since the amount of drug is so small, there should be no difference between the two
spectra, which was the general results of the FTIR analysis, even though slight
differences were observed for peak intensities. Also, signals for the free carboxylic acid
moiety present on both cipro drug monomers incorporated in the polymers are missing
from the FTIR spectra in the 3300cm-1 region, further confirming that the amount of drug
present in the films was too low to be detected.
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Figure 5.6. Acrylated ciprofloxacin and β-lactam monomers polymerized in MDNP1.
This emulsion is formulated with the base acrylate monomers BA and Sty in a 7:3 ratio
and 1% surfactant. Monomers 1, 3, 7, 8, and 13 were individually used in the
polymerization of NP1, NP3, NP7, NP8, and NP13 respectively.

Figure 5.7. FTIR analysis of MDNP1.

In the FTIR spectrum (Figure 5.9) for the multi-drug conjugated polymer film MDNP1,
the peaks observed are the same as seen for NP7 and NP8, which is expected since
MDNP1 contains both ciprofloxacin drug monomers 7 and 8, yet it also contains two
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different β-lactam monomers (1 and 3) and the penicillin acrylamide monomer 11.
Therefore, since all 5 drug monomers (Figure 5.6) contain the acrylate moiety, the C=O
stretching peaks are much stronger and sharper than was observed for NP7 and NP8. The
split peak in the region of 2870cm-1 that was observed for NP7 is not seen here, and only
a sharper single peak of weak intensity was observed.
Since the amount of drug available in the polymer film samples is between 15-25% of the
solid content, it is reasonable that there would be a lack of drug monomer peaks observed
for the films analyzed. Since all five of the drug monomers contain aryl rings, these
moietied should exhibit overtones in the 1800-2200cm-1 range of the spectrum, yet this
was not observed in Figure 5.6, indicating that the drug monomers were not contributing
to the FTIR spectrum. However, intensified signals were observed for the drugcontaining films in the regions where C=O and C-O stretching is often found (1700cm-1
and 1150cm-1), therefore, the presence of additional carbonyl and/or acrylate structures is
likely in this analysis.

5.4 Tensile Strength Analysis
5.4.1 Stress versus Strain Data
Under uniaxial tension, many of the films analyzed here were able to withstand
maximum deformations of 100mm from originally 10mm long films, approximately 10
times their original length, without failure. On average, all films demonstrated a weak
tensile strength relative to other synthetic and natural polymers (Figure 5.2), with the
mean maximum stress observed for all films being around 0.7MPa. All films
demonstrated reversible extensibility in these experiments, retracting to approximately
150% more than their original lengths (~15mm) after full 1000% deformation, and
retracting to 100% of their original lengths (~10mm) after between 500-700%
deformation, on average. Also, all films were observed retracting to 100% of their
original lengths immediately after failure.
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Figure 5.8. The average elastic modulus at up to 10% deformation and maximum tensile
strength for each film based on an average sample size of 5 samples per film. Elastic
modulus is calculated for each film from the first 10% strain.

Figure 5.8 shows for 11 drug-free nanoparticle emulsion films the elastic properties and
maximum stress capabilities. Films containing 3% sodium dodecyl sulfate (SDS) as the
surfactant and a ratio of 7:3 with BA being the heavier side of the ratio (CNP5 and
CNP12) proved to be the strongest films, where the BA:MMA film (CNP12) was the
strongest of all of the films analyzed. On average, the BA:MMA films were stronger than
the BA:Sty films, with 3 of the top 5 film samples being BA:MMA copolymers. These
films often failed prior to maximum 100mm displacement, yet retracted to their original
shape upon failure faster than most films, especially CNP12 which retracted the fastest of
all the films analyzed. Films containing 1% SDS and the same amount of radical initiator
as CNP12 and CNP5 (0.5%) were the second strongest set of films (CNP16 and
CNP17). CNP15, which contained 1% SDS but also 1% radical initiator, was weaker
than CNP16, where the only difference between the two was the amount of radical
initiator present in the formulation, indicating that varying even the smallest constituent
in the emulsion formulation has an impact on the tensile strength of the resulting film.
The weakest films (CNP7 and CNP14) both contained 5% SDS, 1% radical initiator, and
a ratio of 8:2 BA to co-monomer. The elastic modulus did not follow the same trend
observed for the maximum tensile strength of the films, where many of the intermediary
films in terms of maximum tensile strength all displayed stress versus strain curves
exhibiting the same slope at 1% strain, which defines the Young’s Modulus of the film
sample analyzed.
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Figure 5.9. Quasi-static testing of BA:MMA polymer films during a single uniaxial
100mm deformation.

Figure 5.9 plots the stress-strain curves for films of CNP6, 12, 13, 14, and 17, as a result
of a single 100mm uniaxial deformation analysis.CNP12 possessed the highest degree of
tensile strength in this series of polymer films synthesized, at a maximum of 1.671MPa.
All other films’ displayed a maximum tensile strength within 0.2-0.4MPa of each other.
The stronger films in this series (CNP12 and CNP13) both broke after being displaced
approximately 50mm uniaxially on average. The weaker two films (CNP6 and CNP14)
either did not break or broke very close to the 100mm displacement mark, thus displaying
a higher tolerance for strain, but an overall lower tensile strength. CNP17 appears to be a
blend of the four other samples analyzed, displaying a high maximum stress yet without
premature failure. CNP12, CNP13, and CNP17 all were polymerized from a 7:3 ratio of
BA:MMA, whereas CNP6 and CNP14 contain an 8:2 ratio of the same monomers.
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Figure 5.10. Quasi-static testing of BA:Sty polymer films during a single uniaxial
100mm deformation.

The second set of films analyzed in the same fashion as the BA:MMA films (Figure 5.10)
contained co-monomers BA and Sty, in ratios of either 7:3 or 8:2 BA:Sty. The strongest
of this series of polymer films was CNP5, with a maximum stress of approximately
1.2MPa. CNP17 was the second strongest film in this series, with an average maximum
stress of approximately 0.90MPa, a value greatly reduced from CNP5. These two films
both contained a 7:3 BA:Sty ratio, however, their concentrations of surfactant used in the
initial micelle formation step varied from 3% for CNP5, to 1% for CNP17. The weakest
film analyzed was CNP7, which was determined to be very sticky and flimsy when
handled. However, this film was able to withstand the full 100mm displacement in every
sample analyzed.
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Figure 5.11. Quasi-static testing of all polymer films synthesized during a single uniaxial
100mm deformation.

Overall analysis of the 11 samples analyzed and compiled into a single stress-strain chart
(Figure 5.11) determined that CNP12 possessed the highest maximum stress of all the
polymer films synthesized, with CNP5 at a close second, yet both films displayed the
lowest maximum strains withstood. This indicated that the stronger the film is, the lower
the degree of strain it can withstand. However, not withstanding a high degree of strain
does not indicate that a film has a high maximum stress, as is observed for CNP13, even
though this film sample is one of the 5 strongest films analyzed. The two weakest films
analyzed were CNP14 and CNP7, both of which were synthesized using an 8:2 ratio of
co-monomers and underwent 1000% deformation without failure, consistently.
Curiously, both of these films were able to be displaced the full 100mm without failure,
however, their ability to retract was greatly weakened by this lengthy displacement.
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Figure 5.12. Stress-relaxation of CNP12. Stress was recorded for a 30mm displacement
and measurement of stress relaxation was recorded over one minute relaxation time.
Time points are arbitrary numbers corresponding to the point when that stress value was
obtained from the instrument.

Figure 5.12 shows a plot of the stress withstood by a control nanoparticle film, CNP12,
during two individual single-cycle analyses where the maximum deformation was 30mm
and the film was given a resting period of one minute between cycles. Many films
displayed similar maximum strains, which was due in part to a limitation in the
instrument’s ability to displace the films over 100mm. However, the BA:Sty films on
average were able to withstand a higher strain, yet displayed a lower tensile strength on
average than the BA:MMA films. Even with these variances, all films displayed a
consistent viscoelastic property, as depicted in Figure 5.12, and were able to exert a
memory-type property after initial and repeated displacements, and were able to retract
fully or, if extended the full 1000% deformation, to a close range from their nominal
lengths, usually within 50% of the original dimensions.

5.4.2 Cyclic Analysis of Film Samples
Cyclic analysis was then performed on each of the polymer film samples formed, using
an N of 5 for each sample. Data points were collected, and a moving average of these
points was plotted for the original 5mm ramp, followed by the 10mm cyclic analysis for
cycles 5, 10, 15, 20, 25, and the terminating 100mm ramp to failure. The tensile strength
for each film was compared before and after the 25 cycle analysis (Figure 5.9) in order to
determine how fatigue would affect the film’s mechanical properties. Also, the presence
of hysteresis was determined for certain films, and the observed degree of hysteresis was
analyzed at various strain velocities in order to determine the extent of hysteresis for the
film samples.
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Figure 5.13. Comparison of the mechanical behavior of CNP17 before and after 25
cycles of stress/relaxation.

Figure 5.13 plots the stress-strain curve for drug-free nanoparticle polymer CNP17
before and after 25 cycles of stress/relaxation testing. The cyclic analysis caused the
polymer film to slightly change its stress/strain curve; however, the viscoelastic nature of
the curve remained after cyclic analysis. Figure 5.14 expands on this to show cyclic
stress/relaxation experiments on four drug-free films, those of CNP5, 12, 16, and 17.
Each cycle provided the film with a 10mm stretch/relaxation, causing 100% deformation
at each cycle, followed by a final 100mm uniaxial deformation, causing 1000%
deformation. Analysis determined that the maximum stress or tensile strength of the
polymer sample was decreased for some samples after a 25 cycle analysis of 10mm
stretch/relaxation; however, when observed, this loss was minimal compared to the high
degree of maximum stress obtained by the films. All films displayed an active ability to
return to the original size and shape between each cycle, and most samples analyzed
retained the memory characteristic after all 25 cycles and the final ramp to failure, thus
making them prime materials for inclusion in such medical devices as artificial skin and
heart valve systems, where the elastomeric properties of the material is constantly taxed
and must not lose its original strength or ability to do so with time.
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Figure 5.14. Cyclic analysis of polymer films. Analysis of select films over a 25 cycle
period of 10mm deformation. Only cycles 1, 5, 10, 15, 20, and 25 were selected to be
graphed, along with the initial 5mm strain and the final ramp-to-failure. Time points are
arbitrary numbers corresponding to the point when that stress value was obtained from
the instrument.

All film samples analyzed in Figure 5.14 showed a slight decrease in force after each
cycle, but the strength at failure appears to be similar to that of an untested film sample,
as was also observed in Figure 5.13. It was also determined that the tendency of a film to
break prior to 1000% deformation is random; however, failure almost never occurs
before 700% deformation. CNP5 appeared to be affected the most by the continual cyclic
strain, where its stress dropped below 0MPa at about the fifth cycle and continued to do
so until the final ramp to failure. Therefore, this film formulation, while having a high
tensile strength, is easily fatigued and loses some of its elastomeric ability upon continual
strain/relaxation. CNP12 however does not appear to become fatigued between cycles
and keeps the same viscoelasticity throughout the cyclic analysis, making this
formulation optimal for applications such as artificial heart valve and skin tissue
replacement, although the final tensile strength of the film appears to have been lessened
by the cyclic analysis, making it equivalent to the tensile strength of its 1% SDS
counterpart CNP17. CNP17 on the other hand, while having a lesser tensile strength than
CNP12, did not lose any of its elastomeric properties upon cyclic analysis, nor was its
final tensile strength weakened by the cyclic fatigue. Therefore, CNP17 appears to be the
best overall film formulation for biomedical applications where the elastomeric property
of the film is continuous exploited.
In Figure 5.15, the occurrence of hysteresis was examined for CNP12 over numerous
cycles during the cyclic analysis of the film sample. All films analyzed by cyclic means
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displayed hysteresis to some extent; therefore none of the films are 100% elastic by
definition.

A

B

Figure 5.15. Hysteresis of CNP12 during cyclic analysis. A) Hysteresis at various cycles
during a 25 cycle analysis. B) Hysteresis at various strain velocities during a single cycle
analysis.
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Figure 5.15A shows that the relative degree of hysteresis displayed by CNP12 during a
25 cycle analysis stays consistent throughout the cycles, however, the maximum stress
observed after each cycle slightly decreases as the analysis proceeds while the maximum
strain endured remains constant. This was also determined from Figure 5.14A for CNP12
where the relaxation portion between each strain cycle progressively decreased
throughout the analysis. The gradual decrease in stress appears to halt once reaching a
certain point somewhere between the 10th and 15th cycle, where the cycle’s high point
does not decrease any further. The overall decrease in maximum stress observed in
Figure 5.15 between each set of 5 cycles appears to be approximately 0.1MPa, which is
minimal in relation to the observed maximum stress of 1.8MPa for the film upon uniaxial single strain analysis.
Figure 5.15B is a graph of a cyclic analysis of CNP12, where the relative velocity of the
strain and relaxation was adjusted to decrease between each cycle. In each cycle, the film
was stretched 30mm then returned to the original 10mm length, and the film was allowed
to rest between each cycle. This analysis showed that the observed hysteresis was not
eliminated by decreasing the relative velocity in which the cyclic analysis was performed.
Instead, the hysteresis reaches a “plateau” of sorts at 0.01Hz, where the observed loop
created upon cyclic analysis does not become any smaller as the frequency is reduced
during the cyclic analysis. This showed that the viscoelasticity observed cannot be
overcome and that the films are not able to achieve a pure elastic state, indicated by a
lack of hystoresis, even at reduced frequencies as low as 0.001Hz.
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5.4.3 Conditional Analysis of Tensile Strength

Figure 5.16. Comparison of the mechanical properties of CNP15 when the film is freshly
formed versus when it has been formed a month earlier.

CNP15 is not one of the strongest films analyzed in terms of tensile strength, and
therefore, it was hypothesized that age and exposure to a laboratory environment over a
certain amount of time would inflict a larger change in the maximum stress observed for
the film than it would for a film such as CNP5 that has a higher tensile strength. Visual
analysis of the film showed fibers and debris adhered to the surface of the aged film, and
some of its stickiness was also lost, most likely due to long term handling of the film
sample. Figure 5.16 shows a stress/strain curve for a freshly prepared sample versus an
aged sample (one month). The maximum tensile strength of the film was reduced by
0.25MPa after being exposed to the environment over one month time span. When the
original maximum stress is only 0.65MPa though, this degree of loss is quite significant,
with approximately one third of the original strength lost. This determined that in order
for a film to maintain a high tensile strength, handling prior to application must be kept at
a minimum. Also, the film should not be left on a bench top for extended periods of time
prior to application where work is being done and the occurrence of particulates in the air
is high.
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Figure 5.17. Effect of hydration on the mechanical behavior of CNP12.

Many of the biomedical applications proposed for these film samples involves the films
being exposed to a moist or wet environment. Therefore, it was necessary for the film
samples’ tensile strength to be analyzed after being fully hydrated. CNP12 was chosen
for this analysis due to its observed tensile strength being relatively high for these film
samples, which would hopefully allow any change in maximum stress to be more easily
observed. The tensile strength for the film sample was analyzed before and after being
hydrated in distilled water. Two sections of the polymer film sample were cut from the
original film formed and submerged under water for either 30 minutes or 48 hours (2
day), then analyzed for their maximum stress and strain (Figure 5.17).
Upon short term hydration, the tensile strength of the film increases significantly to above
2.0MPa. However in Figure 5.17, the maximum stress for CNP12 when dry (1.3MPa)
was less than that observed previously for this film formulation by approximately
0.3MPa. Upon hydration for an extended period of time (48 hours) there appears to be a
drop in tensile strength by approximately half of the maximum stress observed for the dry
film sample. Also interesting was the effect hydration inflicted on the maximum strain for
the film samples. The maximum strain increased slightly for the film upon hydration for
30 minutes from 4.3 to 5.6 strain, as shown for the yellow curve. However, the maximum
strain returned to slightly below it original dry film value after 48 hours of hydration. The
structure of the stress versus strain curve was the same for the wet and dry samples,
indicating that the viscoelasticity of the film samples is not altered upon hydration, and
all of the samples have failed well before 100mm displacement.
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5.5 Mechanical Analysis of Drug-Containing and Other Polyacrylate
Films
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Figure 5.18. Chemical structures of the drugs present in the films analyzed for
mechanical properties.

Figure 5.19 shows the stress/strain curve for some drug-containing polymer films. NP1a,
NP7 and NP11 all contained drugs that were covalently bound to the polymer backbone,
whereas NP2 and NP24 contained drug monomers that were encapsulated in the
nanoparticles. NP1a and NP2 contained N-thiolated β-lactam drug monomers and NP11
contained the penicillanic acid acrylamide β-lactam monomer. All of these resulting
polymer films displayed very low maximum stress values (approximately 0.4MPa),
although NP1a was not able to withstand nearly as great of a maximum strain as the other
two β-lactam containing films. NP1a, in this instance, was formulated using only ethyl
acrylate as the base polymer, which may explain the shortened maximum strain value.
All of the other drug-containing polymer films were formulated after CNP5, with a 7:3
ratio of BA:Sty.
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Figure 5.19. Stress versus strain curve for drug-containing polymer films. All emulsions
were formulated with 3% SDS and 0.5% radical initiator.

NP7, which contained covalently bound ciprofloxacin acrylamide, displayed the highest
maximum tensile strength of the covalently bound drug-containing films, which was
equivalent to the maximum stress observed for CNP16 (Table 5.1). Since NP7 and
NP11’s polymer formulation followed the formulation of CNP5 (Table 5.1), this data
indicates that the presence of a covalently bound drug moiety to the nanoparticles
decreases the maximum stress of the resulting polymer film sample. However, since all
of the drug-conjugated films were not analyzed, it cannot be determined whether or not
this is true for all of the films, or whether this is also the case for the multi-drug
conjugated polymer films.
The doxycycline encapsulated polymer film sample NP24 displayed the highest
maximum stress of the samples analyzed in Figure 5.19 at approximately 1.4MPa, which
was also seen for the erythromycin encapsulated film sample NP23 (data not shown) and
for the control film CNP5 (Table 5.1). Therefore, when commercially available drug
moieties are encapsulated in the nanoparticles without chemical modification, the
resulting polymer films retain the same maximum stress as the control film that the films
were formulated after. Interestingly, NP1a and NP7 were the only two film samples that
did not withstand the entire 100mm displacement and reached failure at approximately
half this distance.
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Figure 5.20. Cyclic analysis of polymer films containing drug monomers. Time points
are arbitrary numbers corresponding to the point when that stress value was obtained
from the instrument.

All of the drug-containing samples analyzed followed the emulsion formulation of CNP5
and, subsequently, all of their behaviors upon cyclic analysis were similar to that of
CNP5’s where a decrease in stress was observed between each cycle (Figure 5.20). NP24
lost some of its tensile strength after cyclic analysis, where its maximum stress at failure
was slightly below 1.2MPa. A non-fatigued sample of NP24 has a tensile strength of just
above 1.4MPa; therefore, the film sample loses approximately 0.2MPa upon cyclic
fatigue. All of the other drug-containing film samples analyzed for behavior upon cyclic
fatigue possessed similar maximum stresses before and after cyclic analysis. This could
possibly indicate that when a film sample has a low tensile strength, as is seen for NP5,
NP6, and NP7, and was previously seen for CNP17, that the film does not loses a
significant amount of tensile strength after cyclic fatigue and also retains the same degree
of stress between each cycle. However, film samples that originally have a larger tensile
strength tend to lose some of this strength upon cyclic fatigue. This is most likely due to
limitations of the instrument since the weaker film samples display maximum stress
values that are within the lower limits of the MTS machine’s capablilities. Therefore, it is
more difficult to distinguish changes at such a low value range than it is for the
instrument to detect changes at the higher tensile strength values seen for the stronger
film samples.
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5.6 Analysis of the Protective Capabilities of Polymer Film Samples
5.6.1 Introduction
When deciding upon a specific biomedical application for polymer films, there are
numerous factors and physical properties that must be clearly understood for the best fit.
Aside from the mechanical properties, which was first examined for the polymer films,
and the cytotoxicity of the films, other attributes of the film must also be established,
including pore size and diffusibility of the polymer films. One of the major reasons for
using the drug-conjugated and multi-drug conjugated nanoparticle emulsions for topical
treatment of skin/soft tissue and burn wound infections is the subsequent formation of a
polymer film over the wound. Therefore, the main objective of this study was to establish
whether or not the polymer films are able to prevent bacterial invasion of the wound,
either through its antibacterial activity or by providing a physical barrier for the burn
wound from its surrounding environment. If bacterial migration was observed, the next
step was to establish if this was due to large pores present in the films that permitted the
bacterial migration, or if it was the result of the bacteria’s ability to degrade the
polyacrylate strands, essentially eating their way through the films. This study also
determined if any of the microbes commonly found in burn wound infections were able
to utilize the polymer films as a carbon source for food and energy, which would
essentially be promoting bacterial growth in the wound bed. Also analyzed was the
ability of small molecular weight compounds to diffuse through the polymer films, and it
necessary to clarify what type and size ranges of the compounds are able to penetrate
these polyacrylate films.
Three different assays were developed and carried out under in vitro conditions to
address these issues. The first assay was developed to determine if motile bacteria (P.
aeruginosa, Escherichia coli, Citrobacter fruendii, Proteus mirabilis, Enterobacter
cloacae, and B. anthracis-Sterne) were able to penetrate the drug-free and drugcontaining polymer film samples. The second assay was developed in order to test, if
bacterial penetration of the film does occur, whether the bacteria are penetrating through
pores in the polymer films or if they are able to eat their way through the films by
degrading the polyacrylate strands within the films. The final assay was based on the
same premise of the initial assay, except instead of analyzing bacterial penetration of the
polymer films, small molecular weight dyes were used.

5.6.2 Bacterial Penetration Study
In order to accurately test the ability of motile bacteria to penetrate any form of material,
especially one formed from evaporation/coagulation of a liquid solution, in an in vitro
setting, an assay was developed using multiple layers of agar in either sterile test tubes or
Petri dish plates commonly used for Kirby Bauer assays, as illustrated in Figure 5.21.
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Figure 5.21. Representative of the multi-layered agar assay formed in a small Petri dish
(left) versus a test tube (right).

In each container, the nutrient free agar layer was inoculated with 5-10µL of saline
solution containing 105 CFU/mL of all six bacterial strains to be analyzed. The nutrient
rich agar used for this assay (Bacto Acetate Differential Agar, purchased from Difco
Company and used without modification) contained the pH indicator bromothymol blue
(3,3-dibromothymolsulfone phthalein, MW: 624.38g/mol), which when bacteria are
present in the agar and utilize the acetate nutrients for food the pH of the agar rises,
which turns the agar from green (neutral pH of 6.1 to 7.5) to blue (alkaline pH of 7.6 and
above). In the presence of the acidic emulsions (pH of approximately 2-2.5), the pH
indicator-containing agar turns yellow in color. The use of this agar allows the assay to
provide a visual detection of bacterial penetration without the need for analysis of the
agar or microscopic visualization for microbial detection.
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Figure 5.22. Images of multi-agar layered test tube-based polymer film permeability
assay. A) Test tubes prior to bacterial inoculation in top nutrient-free agar. B) After 4
days of incubation at 37oC of P. aeruginosa inoculated test tubes. C) After 7 days of
incubation at 37oC of P. aeruginosa inoculated test tubes
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As seen in Figure 5.22, the bottom agar containing the nutrient rich differential agar
remained green in color for all polymer films analyzed. In many of the test tubes, the top
agar (nutrient free M9 agar) either remained clear in color, as expected, or took on a
bluish tint after incubation of the inoculated test tubes. This development established the
ability of small molecules, including both the pH indicator and the acetate nutrients, to
pass through some of the polymer films analyzed. The agars which remained clear could
be the result of one of two things: either the pH indicator was unable to penetrate the
polymer film, or the acetate was not able to penetrate. Due to the relative molecular
weights of these two molecules (624.38g/mol indicator versus 82.02g/mol sodium
acetate), it is more likely that it is the pH indicator that was unable to penetrate all of the
films analyzed. This assay not only showed that some films are highly penetrable to even
small molecular weight molecules, but also that motile bacteria were not observed
penetrating the polymer films to get to the nutrient rich agar at the bottom. A positive
control where no polymer film was applied between the nutrient-rich and nutrient-free
agar layers resulted in bacterial presence throughout both agar layers, indicating that
when no obstructive material is placed between the two agar layers the microbes are able
to migrate freely throughout the agars.
Unfortunately, due to the aerobic nature of all the microbes analyzed here, it was very
unlikely that the microbes would wish to migrate deep into the agar where molecular
oxygen is limited; therefore, the assay was repeated using the small Petri dish plates and
the agar layers were reversed. Due to the ability to provide a larger surface area for the
agar layers using the Petri dish and the subsequent thinner layers formed, it is assumed
that the bacteria present in the lower layers of agar are more likely to encounter elemental
oxygen for respiration than they would in a test tube setting. This was an important aspect
of the assay since the bacteria need to be viable for motile activity to be expressed, and
therefore, for polymer film penetration to be observed. In this assay, the bottom layer of
nutrient free agar was inoculated with the bacterial solution by stabbing the agar with a
thin metal rod previously dipped in a mixed microbial-containing saline solution. The
emulsion was then added to the surface of this agar and allowed to transform into the
solid polymer film in a biosafety cabinet for 1-2 hours, then the nutrient-rich agar was
added to the surface of the solidified polymer film. After the top agar layer solidified, the
plates were incubated for up to 10 days to observe if the bacteria were able to penetrate
the polymer films over an extended period of time. Results from this assay confirmed the
original findings in the test tube-based assay, that none of the bacteria could pass through
the film barrier separating the agar layers.
A third assay was then performed using only two specific nanoparticle emulsions:
CNP15 and the multi-drug conjugated nanoparticle emulsion MDNP2 (described in
Chapter 4). This assay utilized a multi-diffusion chamber (Figure 5.23) to analyze ten
different locations throughout the film for bacterial penetration.
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Figure 5.23. Multi-diffusion chamber for polymer film diffusion/penetration studies. The
clear plastic lid closes over the top wells to seal in the microbial solution, and the
polymer film is placed between the single large bottom chamber and the multiple top
chambers.

Also employed for this broth-based assay was a Franz diffusion cell (Figure 5.24), where
a single film was placed over an opening in the cell below the solution containing a
bacterial culture. A sampling arm extending from the bottom chamber cibtaububg a
standard TBS solution (initially containing no bacteria) allows for sampling of the culture
daily to determine bacterial concentration. Swabs of the bottom chamber culture were
taken on days 1, 2, 3, 4, and 7 (final) from the Franz diffusion cell and only on day 7 for
the multi-diffusion chamber, and streaked onto the same Bacto acetate differential agar as
was used in the initial two assays for the presence of bacteria.

Figure 5.24. Franz diffusion cell. The top chamber is removable and the polymer film
(previously formed) is placed over the hole in the bottom chamber and is sealed in place
by the top chamber, thereby exposing the film to both the bacterial-free and bacterialcontaining solutions. (TSB: tryptic soy broth)
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Results of this study showed that for the MDNP2 polymer film, which was analyzed
using the Franz diffusion cell, no bacteria were present in the bottom chamber at any of
the days inspected, nor on the final day of the study (day 7). The lack of bacterial
penetration and presence in the bottom chamber solution could be the result of the
antibacterial activity of the polymer film (Chapter 4), or could be that the presence of
pores, if any, in the film were too small for bacterial penetration. In either scenario, this
assay, along with the initial two multi-layered agar assays, proved that the multi-drug
conjugated polymer films are able to prevent bacterial invasion of nutrient-rich
environments.
In the case of the drug-free polymer film CNP15, bacteria were present in the bottom
chamber for the multi-diffusion chamber on day 7. Since this chamber does not permit
sampling of the bottom solution prior to termination of the assay, the exact day of
bacterial infiltration could not be established in this scenario. This observed bacterial
penetration could indicate that either the chamber is not the most optimal apparatus for
this assay, and that some of the top chamber’s solution could have come in contact with
the bottom chamber’s solution when terminating the assay, or that the bacteria present in
the solution were able to penetrate the film either through pores or by microscopic
degradation of the film. The latter question was further explored in section 5.6.3 of this
chapter.

5.6.3 Carbon Source Assay
In order to establish whether a microbe can utilize a specific chemical, compound, or
material in order to create the energy it needs to sustain life, the bacteria must be grown
on media that contains no nutrients or carbon sources, i.e. minimal media. For this study,
a minimal media (M9 minimal salts agar) was purchased from Difco Company and used
without any modifications. Small Petri dish plates were filled with this agar, and after
hardening, 1.00mL of emulsion was added to the surface of the agar. After polymer film
formation was complete, a saline solution containing 105 CFU/mL was added to the
surface of the films by placing 5-6 drops of the solution on the film. Incubation was
performed at 37oC for all bacteria analyzed and the plates were incubated up to 7 days,
depending on the observance of bacterial growth. A positive control using tryptic soy
agar (TSA) was used to ensure that bacterial growth would occur when exposed to typical
nutrients, and a negative control using only the M9 minimal salts agar was also employed
to confirm a lack of bacterial on this media alone. The data reported in Table 5.2 is the
average of the results from three separate batches of emulsions per sample.
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Figure 5.25. Carbon source assay using P. aeruginosa (left side of plates) and E. coli
(right side of plates). A) The control plate showed no growth of either bacterial strains,
nor did the agar plate coated with a thick white film formed from the β-lactam conjugated
nanoparticle emulsion NP2 (KG9). B and C) P. aeruginosa displayed growth on all agar
plates coated with the more translucent drug-free polymer films (plates 1, 2, 3, and 4) and
no observable growth of E. coli. (Plate 1: CNP6, Plate 2: CNP12, Plate 3: CNP13, Plate
4: CNP14)

The results represented in Figure 5.24A showed that when no polymer film is added to
the minimal agar, no bacterial growth was observed after a 10 day incubation period, and
that no bacterial growth was also observed when a drug-conjugated polymer film was
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added to the agar surface. However, when poly(butyl acrylate: methyl methacrylate)
films free of any drug monomers was added to the agar, the P. aeruginosa was able to
utilize the polyacrylate films as a carbon source and displayed moderate to heavy
colonization on top of the films. Interestingly, since the N-thiolated β-lactam monomers
show absolutely no antibacterial activity against P. aeruginosa, and since all of the βlactam containing polymer films did not permit growth of this microbe, it appears that
this lack of growth is not due to the antibacterial nature of the drug-containing films,
which one would assume, but rather a change in the matrix of individual polymer strand
entanglement within the film formed, which appears to prevent the microbe from
utilizing the polymer as a carbon source. Another explanation for these results is that
when the drug monomer is present within the polymer film, either through copolymerization of the drug with the liquid acrylate monomers or through encapsulation
within the nanoparticles, the drug is able to block whatever interactions the microbe
utilizes in order for it to degrade the drug-free polymer film that allows it to be used as
nutrients. In either case, this assay has established that the drug-containing and therefore
the multi-drug conjugated polymer films cannot be utilized by P. aeruginosa as a carbon
source, and that E. coli cannot use any of the polymer film samples formulated with BA
and MMA. This is shown in Table 5.2 on the next page, with nine of the drug-free control
nanoparticle films and five of the drug-containing films being exaimened. Most microbes
do not grow on any of the films, but only the five drug-containing films prevent P.
aeruginosa from growing.
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Table 5.2. Carbon source assay data for all microbes and polymer films analyzed over 7 day incubation. M9 minimal agar was
the negative control employed, and TSA agar was the positive control. (+ represents observed bacterial growth, NG:no growth.
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Many other microbes commonly detected in burn wounds were analyzed in this fashion.
Here, it was determined that almost all of the microbes tested were unable to use the
poly(butyl acrylate:methyl methacrylate) films as a carbon source. All three of the
Candida fungal species tested were completely unable to utilize any of the polymer film
samples as a carbon source, along with Acinetobacter calcoaceticus, Bacillus anthracis,
Proteus mirabilis, Klebsiella oxytoca, S. aureus, and coagulase-negative S. aureus. Not a
single microbe was able to utilize any of the drug-conjugated poly(butyl acrylate:
styrene) polymer films as a carbon source, even though some of the microbes were able
to utilize the poly(butyl acrylate: styrene) polymer films when no drug was present in the
formulation, including E. coli and P. aeruginosa. Klebsiella pneumoniae, Citrobacter
fruendii, and Enterobacter cloacae all showed some sporadic, but reproducible, growth
on a few drug-free films analyzed.

5.6.4 Molecular Weight Cutoff Analysis
Two drug-free polymer films CNP6 and CNP7, formulated with either MMA or Sty
respectively, and two drug-encapsulated polymer film samples (NP23 and NP25)
containing encapsulated erythromycin and amphotericin B, respectively, were subjected
to these permeability studies in order to determine any differences between drugcontaining and drug-free films, and also any differences between films containing Sty or
MMA co-monomers. A capillary zone electrophoresis (CZE) instrument was used to
detect the disapperance of the various dyes from the top well of the diffusion chambers
(Figure 5.23), indicating their penetration through the polymer film samples. The CZE
instrument was used to analyze the retention time of each dye individually, followed by
analysis of all five dyes in a single solution, in order to provide CZE readings of each dye
prior to interaction with the polymer films. Thereafter, the multiple dye-containing
solution was added to the top of the individual chambers above the polymer film in the
multi-well diffusion chamber depicted in Figure 5.23 and after 24 hours, an aliquot from
each top chamber was removed and analyzed by the CZE for percentage of dye
remaining in the wells.
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Figure 5.26. Chemical structure of five pH indicators used for molecular weight cutoff
assays.

The dyes analyzed were all between 404 and 844g/mol, where the order of increasing
molecular weight is: cresol red, thymol blue, bromothymol blue, bromocresol green, and
methyl thymol blue. CZE analysis showed that the fastest dye to move through the
capillary was thymol blue, followed by bromothymol blue, then cresol red, bromocresol
green, and finally methyl thymol blue. Therefore, the size of the dyes was not the single
distinguishing factor for movement through the capillary, but also charge and perhaps
other interactions between the electrophoresis instrument and the dye ultimately
determined the rate at which each dye flowed through the capillary.
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Figure 5.27. Percentage of each dye analyzed that penetrated polymer film samples.
Dialysis tubing was used as a positive control, and a solid plastic material was used as a
negative control. Dyes are arranged from first to be read by the CZE instrument to last.

The data presented in Figure 5.27 shows that size, in terms of molecular weight, was not
the sole influence in molecule penetration. Methyl thymol blue, the largest dye analyzed,
had the highest percentage of film penetration for drug-containing poly(butyl acrylatestyrene) film samples NP23 and NP25, where NP25 showed penetration as high as 85%,
yet all of the other dyes analyzed for these two films were permeable at only 40-50%
penetration. However, this does show that the drug-encapsulated polymer film samples
are permeable to small molecular weight molecules, but the percentage of penetration is
highly dependent on the interactions between the molecule and the polymer film. This
property is highly favorable for applications such as wound dressings and artificial skin
and lung tissue grafts, where small molecular weight molecules, especially very small
molecules such as oxygen, carbon dioxide, and water, must penetrate the tissue as would
naturally occur. The ability to combine antimicrobial therapy to these artificial tissues has
yet to be explored, and the favorable properties of these drug-conjugated polymer films
seem to be an optimal prototype for such applications. The drug-free polyacrylate films
analyzed (CNP6 and CNP7) showed little to almost no penetration of the various dyes
after 24 hours of exposure. These film samples behaved more like the generic plastic
material used than a penetrable material. The plastic film used for the negative control
was approximately 1-2mm thick and was malleable, however, it was designed to be used
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as a containment plastic, therefore, should have been practically impenetrable by any and
all molecules. Since the percentages observed for dye penetration for the drug-free
polymer films was statistically similar to those observed for the plastic material, this
indicates that without the presence of drug, the poly(butyl acrylate-styrene) and
poly(butyl acrylate-methyl methacrylate) films are virtually impenetrable towards low
end molecular weight molecules. Further investigation should be performed to determine
the ability of essential small molecules, such as water, O2, and carbon dioxide, to
penetrate the films. Biomedical applications where no degree of molecular penetration
would be beneficial are areas along the lines of coatings for prosthetics and bone cement
and other biological glue-like materials that can hold in place biological sutures or
replacement materials. Thus, it is important to know which materials would be useful for
that versus as a burn wound treatment.

5.7 Conclusions
Mechanical analysis determined that the polyacrylate polymer films possess “memory,”
indicated by their ability to undergo large degrees of deformation followed by selfinduced retraction to their initial dimensions during a relaxation period. This property is
likely due to physical cross-linking between the single polymer strands tangled within the
film matrix that aid in film retraction, along with the presence of nanoparticles that allow
the strands to slide along side each other, aiding in the extensibility/retractability of the
films. The polymer films possess a viscoelasticity, evidenced by a high degree of
hysteresis when cyclically analyzed and a low maximum tensile strength (between 0.1
and 2.0MPa), and with minimal deformation observed upon cyclic fatigue. This observed
viscoelasticity relates these smart polymer films to materials that are often associated
with a class of pliant materials called protein rubbers or biorubbers, which includes
elastin, resilin, and abductin. Since elastin is a major constituent of elastic biological
tissues, such as elastic ligaments, skin, lung, and blood vessel tissue, this property may
allow many of these polymer film formulations to be used as the elastin constituent in
biocomposite material.
The polymer films, both drug-containing and drug-free, were able to physically prevent
the movement of bacterial migration into nutrient-rich media. Carbon source analysis
determined that the majority of the microbes commonly found in burn wounds were
unable to utilize these polyacrylate films for a source of energy, and that all microbes
analyzed were unable to grow in the presence of the drug-containing poly(butyl acrylate:
styrene) films in this assay. The degree of molecule penetration through the films will
ultimately determine the optimal emulsion formulation for each medical application.
Since the maximum stress that CNP12 and CNP5 are able to withstand is on par with
that of aortic tissue, which is mechanically similar to intact skin, this allows these
polyacrylate films to be considered as a new prototype for development of artificial
tissues. Thus, these new smart polyacrylate films offer a promising new material
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formulated from a single step emulsion polymerization process for numerous medical
applications ranging from treatment of burn wounds to tissue engineering and repair.
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CHAPTER 6
MECHANICAL PROPERTIES OF COLLAGENNANOPARTICLE EMULSION BIOCOMPOSITES
6.1 Introduction
In the past few years, collagen has been heavily studied for its application in tissue
engineering and is currently the most popular material being researched for such
applications.[1-5] Other naturally-occurring materials have also being explored, including
elastin, gelatin, chitosan, and hyaluronic acid. [6-9] All of these natural products have been
combined with various synthetic materials including various polymers and also numerous
organic solvents for artificial tissue construction. Additions of these biological-based
structures to currently used synthetic biomaterials have been studied for increasing
biocompatibility as well as improving the mechanical properties of the materials.[7]
Therefore, it is now common practice to use synthetic materials in combination with
collagen and other natural macromolecules to form biocomposites for tissue engineering
applications. In such cases, the most common natural products used for these
biocomposites are collagen fibers, fibrils, or individual macromolecules, where the
collagen is usually present in a lower quantity than the synthetic polymer constituent.[3]
When attempting to synthesize materials to emulate elastic tissues, such as ligaments,
blood vessels, lungs, skin, and heart aorta tissue,[7, 8, 10, 11] the collagen constituent must be
combined with a synthetic material that possesses elastomeric-like mechanical properties
to obtain an artificial tissue that closely resembles the elastic tissue.[1-5] The biocomposite
constituents can also be reversed, where the elastic constituent is provided through a
natural product like elastin, and the structural strength and integrity of the material is
provided through a mechanically strong synthetic material.[7-9] In either scenario, the
most optimal biocomposite must possess the strength of the collagen constituent and the
elasticity of an elastin constituent, which are both found in the representative tissue. The
aim is that the combination of the two materials in the biocomposite will provide the
mechanical and physical properties needed in order to closely resembles the natural
material being replaced.
Most of the recent biocomposites use collagen as the natural material, since this polymer
is present in most biological tissues, including the skin, ligaments, and tendons, which
often require artificial replacements when damaged. Therefore, the purpose of this study
was to combine one of the polyacrylate polymer film samples with native sea cucumber
collagen fibrils in order to develop a biocomposite fibrous material that has the elasticity
of the synthetic films combined with the high tensile strength of the collagen fibrils. Sea
cucumber collagen fibrils were chosen over native bovine collagen as a proof of principle
since we could obtain native intact collagen fibrils from the dermis of sea cucumbers.
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Also, sea cucumber dermal collagen fibrils possess a high aspect ratio making them
paramount in forming linear and various other arrays of smooth collagen fibers. Sea
cucumbers and sea urchins are the only two animals from which intact native collagen
fibrils can be extracted without damage to the collagen fibril, making sea cucumbers an
optimal and readily available source of collagen. The formation of collagen fibers from
fibrils has been established by Koob et. al. for both sea cucumber collagen and bovine
collagen,[12-15,18] and the sea cucumber fibers have been tested and proven to possess
similar mechanical properties as bovine collagen fibers; therefore, this was the best
choice as a model system for these initial exploratory experiments.

Table 6.1. Formulation for CNP3 nanoparticle emulsion.
CNP3

Percent (w/w)

Ethyl acrylate (EA): MMA, (4:1)

18.5%

Water

80%

Sodium Dodecyl Sulfate

1%

Potassium Persulfate

0.5%

6.2 Quasi-Static Analysis of Biocomposite Fibers
Uniaxial tension experiments on films formed from the poly(ethyl acrylate-methyl
methacrylate) nanoparticle emulsion CNP3 showed that this film formulation was
stronger and stiffer than all of the butyl acrylate: styrene and butyl acrylate: methyl
methacrylate polymer films synthesized in Chapter 5. This is due to the fact that when
polymerized, ethyl acrylate (EA) polymer films exhibit greater tensile strengths than
butyl acrylate polymer films, and since films containing methyl methacrylate were
stronger than ones containing styrene (Chapter 5), it was assumed that this formulation
would provide the strongest films so that the addition of the emulsion to the fiber
formulation does not diminish the tensile strength of the fibers too dramatically. Also,
since the intended use of this film formulation was to interact with collagen material for
use as artificial tissues, only 1% surfactant (SDS) was used in order to avoid unnecessary
toxicity.
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Figure 6.1. Uniaxial tension analysis of the poly(ethyl acrylate-methyl methacrylate) film
CNP3.

Stress/strain analysis of the polyacrylate film sample CNP3 (Figure 6.1) shows
mechanical properties very similar to those observed for elastin.[7, 8, 10, 11] However, the
average tensile strength of elastin itself is on the range of 0.5MPa and its elastic modulus
is approximately 1.5MPa.[9, 11] Therefore, the CNP3 polymer is slightly stronger than
elastin, yet, the elastic modulus is approximately equivalent, indicating that the behavior
of the two materials is the same. This data indicates that the polyacrylate film formulation
is equivalent if not better than the natural polymer, and thus is an optimal material for
combination with collagen in order to form a biocomposite material for elastic tissue
replacement.
The mechanical data presented in Figure 6.2 will be further explained in Section 6.3 of
this chapter. However, it should be mentioned here that the data presented in Figure 6.2,
and the data reported for all mechanical analyses in this chapter, are the result of the
averaged data for 3 fibers per formulation. This provided smooth lines for the graph, and
also explains the jumps in the graph of some of the formulations.
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Figure 6.2. Average of the uniaxial tension data for the biocomposite fibers formed from
concentrated CNP3 nanoparticle emulsion (20% solid content) and sea cucumber
collagen fibrils. Data is presented as the average of 3 samples per fiber formed up to
failure of the first fiber.

In order to establish the behavior of these biocomposite fibers, various volumes of
concentrated (20% solid content) CNP3 were employed in the fiber formulation. The
volume of sea cucumber collagen fibrils suspended in solution was also altered through
numerous dilutions with sterile water to determine if decreasing the amount of collagen
in the fiber formulation would improve the mechanical properties of the fiber construct
and possibly provide stronger elasticity. Therefore, the biocomposite fibers were formed
from either mixing a constant volume of the emulsion with percentages of collagen fibril
suspension, or mixing a constant volume of the fibrils with varying amounts of the
emulsion to provide alternative combinations of the two constituents.

186

A

B

Figure 6.3. Cyclic analysis of dry sea cucumber collagen fibers (A) and collagen/
emulsion biocomposite fibers containing 100µL of the nanoparticle emulsion CNP3 (B).
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Both the control collagen-only fibers and the biocomposite fibers were analyzed by a 25cycle stress/relaxation experiment, followed by a 10mm ramp to failure for the fiber
(Figure 6.3). Upon close analysis, the control fibers in Figure 6.3A displayed stress
relaxations below 0MPa as the number of cycles increased. The tensile strength of the
control fibers was not diminished upon fatigue, indicating that repeated uniaxial tension
on the collagen fiber did not affect the tensile strength of the fibers. However, no
elasticity was observed for these fibers, and when undergoing relaxation, the fibers were
observed lagging towards the center of the fiber. This property was not seen for the
biocomposite fibers, where the fiber was able to undergo stretching during the tension
portion of the cycle, and then retracted to the fibers original length upon relaxation. This
is why the cyclic stress/relaxation data for the biocomposite fiber in Figure 6.3B does not
show a decrease in stress upon relaxation throughout the cycles. However, the lull
between cycles did increase as the cycles progressed, which was also observed for the
control fibers, indicating that the fiber took progressively longer to react to the tension
being placed on the fiber at the onset of each cycle as the experiment progressed, for both
the collagen control fibers and CNP3.
The maximum tensile strength for the biocomposite fiber containing 100µL of CNP3 was
in the same range as the un-fatigued fiber (102 for the fatigued and 112MPa for the unfatigued fibers); therefore, cyclic fatigue did not alter the overall strength of the fiber
(Figure 6.2 and 6.3B). Little deformation was observed on the fiber by the repeated cyclic
displacement, and no lagging in the actual fiber was observed during the relaxation
period of the cycles. This is indicative of the elasticity of the biocomposite fibers, and is
also how the elastic biological tissues react towards fatigue, making the biocomposite
fiber optimal for such an application.

6.3 Mechanical Properties of the Biocomposite Fibers
Mechanical properties (average force, stress, strain, elastic modulus) were determined for
all the fiber formulations constructed, where 5 samples per formulation were analyzed.
Data for both the emulsion dilution fiber set and the collagen dilution fiber set are
presented in Table 6.2. The “control fibers” for the CNP3 emulsion dilution set of fibers
contained no CNP3 in the formulation and were formed from only sea cucumber
collagen fibrils. The fibers formulated with 100% collagen in the collagen dilution set of
fibers contained 100µL of CNP3 and 10mL of collagen fibril suspension, therefore, the
mechanical properties of these fibers should be equal to those seen in the emulsion
dilution set for the fibers containing 100µL of CNP3.
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Figure 6.4. Images of dry collagen (control) and biocomposite fibers (containing 25150µL of the emulsion).

In Figure 6.4, there is an observed increase in the diameter of the fibers as the amount of
CNP3 emulsion in the fiber formulation is increased. The fibers also appear smoother
when formulated with the CNP3 emulsion and appear more durable. In Table 6.2, the
control values are representative of sea cucumber collagen fibers without any emulsion
present. The volumes given are for the amount of concentrated CNP3 (20% solid
content) added to 10mL of collagen fibril solution prior to fiber formation. Once it was
determined that the most optimal amount of concentrated CNP3 emulsion added to the
fibril solution was 100µL, this volume was then used to determine if altering the
percentage of the collagen suspension would provide better mechanical properties than
the concentrated suspension. Dilutions of the collagen fibril suspension with distilled
water were made where collagen makes up 100%, 50%, 25%, 10% of the total
suspension, then was mixed with 100µL of concentrated CNP3 nanoparticle emulsion
prior to fiber formation and subsequent mechanical analysis.
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Table 6.2. Mechanical data for the collagen-CNP3 biocomposite fibers. The volume of
CNP3 was varied for each fiber formulation and the control fibers did not contain CNP3.

Wet
Force (N)
Stress (MPa)
Strain
Young's
Modulus (MPa)
% Swell
Dry
Force (N)
Stress (MPa)
Strain
Young's
Modulus (MPa)

Control

25µ
µL

50µ
µL

100µ
µL

150µ
µL

0.1311
1.1545
0.1874

2.2953
7.4585
0.7077

4.5260
36.0398
0.49052

4.2305
41.7555
0.4210

3.5169
32.9256
0.3703

37.27773
102.930

3.485523
36.8514

68.5623
56.7766

87.22434
33.5782

91.11033
23.2172

5.3695
222.972
0.3564

3.0522
44.1657
0.3785

5.0477
172.500
0.4395

3.7748
114.480
0.3720

4.8905
59.3254
0.4966

1392.754

83.94695

788.621

439.5076

199.127

Table 6.2 provides all of the mechanical properties observed for the biocomposite fibers
formulated from 10mL of concentrated collagen fibril suspension. Each of the individual
mechanical properties reported here are described in more detail below. However, the
most important finding presented in this table is that the mechanical properties for the
biocomposite fibers (containing 25-150µL of the emulsion) were not nearly as affected
by hydration as was observed for the control collagen-only fibers, indicating a higher
degree of mechanical strength retention for these biocomposite fibers.
Figure 6.5A shows that when dry, all of the biocomposite fibers containing CNP3 and
sea cucumber collagen fibrils displayed relatively similar maximum forces to fibers
containing only collagen (control) when analyzed under dry condition. However, when
hydrated, the control (collagen) fibers displayed almost no force tolerance, whereas the
biocomposite fibers displayed almost equivalent maximum forces as their dry
counterparts. This indicates that the presence of only a slight amount of nanoparticle
emulsion provides the collagen fibers with the strength it needs to be able to withstand
forces when hydrated similar to those observed for the dry fibers.

190

A

B

Figure 6.5. Average force in Newtons for CNP3-collagen fiber biocomposites. Data is
presented as an average of five samples per fiber formulation. A) Data obtained from
fibers containing 10mL of collagen suspension and varied amounts of CNP3 nanoparticle
emulsion. B) Data obtained from fibers containing 100µL of CNP3 nanoparticle
emulsion and various dilutions of the collagen suspension.
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The maximum force withstood by the collagen fibers in Figure 6.5B decreased as the
dilution ratio of collagen to water increased per fiber formulation. There was an
observable difference in the maximum force withstood by the dry and hydrated fibers
formulated with only 9% collagen, however, due to the high degree of deviation for the
average maximum force of the dry fibers, this difference is not statistically relevant. All
other fibers tested did not show any significant differences in the maximum force of the
hydrated and dry fibers, however, all fibers formed from diluted collagen suspensions
were not able to withstand forces nearly as high as those obtained from the undiluted
collagen suspensions. Also, the maximum force for the fibers formulated with only 9%
collagen resembled the maximum force observed for the control collagen-only fibers in
Figure 6.5A when hydrated (approximately 0.5N difference).
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A

B

Figure 6.6. Average stress in megapascals for biocomposite collagen/emulsion fibers. A)
Data obtained from fibers containing 10mL of collagen suspension and varied amounts of
CNP3 nanoparticle emulsion. B) Data obtained from fibers containing 100µL of CNP3
nanoparticle emulsion and various dilutions of the collagen suspension.
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In Figure 6.6A, the collagen fibers formulated with 50 and 100µL of CNP3 nanoparticle
emulsion appeared to possess the highest tensile strength properties, except for the
control collagen fibers. The 100µL CNP3/collagen fibers appeared to have more
consistent strength than the corresponding 50µL sample, even though the 50µL sample
displayed a higher maximum stress value. Figure 6.6A also shows that as the volume of
CNP3 nanoparticle emulsion was increased (25 to 150µL) in the fiber formulation, the
closer the maximum stress values were for the wet and dry fibers.
Analysis of the data in Figure 6.6B provided a clear observation for the tensile strength
trend for the fibers formed from diluted collagen suspensions that as the amount of
collagen present in the biocomposite fiber formulation decreases, the average tensile
strength for both the wet and dry fibers decreases. The non-diluted fibers formulated with
100% collagen and 100µL of CNP3 exhibited the highest average tensile strength for
both the wet and dry fibers analyzed, however, these fiber samples also displayed the
highest degree of deviation in the average tensile strength for the three fiber samples
analyzed under both wet and dry conditions. This high degree of deviation was also
observed in Figure 6.6A for the dry fibers containing 100µL of CNP3, but was not
observed for the wet fibers. All of the other fibers analyzed in Figure 6.6B did not show a
significant difference in tensile strength between the hydrated and dry fibers.
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A

B

Figure 6.7. The maximum strain observed for the biocomposite fibers. A) Data obtained
from fibers containing 10mL of the collagen suspension and varied amounts of the CNP3
nanoparticle emulsion. B) Data obtained from fibers containing 100µL of the CNP3
nanoparticle emulsion and various dilutions of the collagen suspension.
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The observed maximum strain for both the wet and dry biocomposite fibers were
statistically similar (Figure 6.7A), except for the fibers formulation with 25µL of CNP3,
in which case the hydrated fiber samples withstood greater maximum strains than the dry
fibers. All of the biocomposite fibers analyzed (fibers containing both collagen and
nanoparticle emulsion in the formulation) displayed strains significantly higher than those
observed for the control, collagen-only fibers. Also, Figure 6.7B shows that as the
amount of collagen in the fiber formulation was reduced, the maximum strain withstood
by the fibers increased. The fibers containing only 9% collagen in the formulation
withstood maximum strains three times greater than those withstood by the fibers
containing 100% collagen in the formulation (Figure 6.7B), and up to 4 times greater than
was observed for the control collagen-only fibers in Figure 6.7A. This indicates that the
elastic properties of the polymer film constituent are being incorporated into the
biocomposite fibers, which is allowing the fibers to endure higher degrees of deformation
than they would when formulated with only collagen fibrils. Also, the fibers were
observed displaying elastic stretching upon uniaxial tension, and were also observed
retracting back to their original length upon failure, indicating that memory property
observed for the polymer film samples analyzed in Chapter 5 was also incorporated into
the biocomposite fibers. This elastic property was not observed for the collagen-only
fibers, where the fibers did not stretch in any way under uniaxial tension. Also, the degree
of elasticity for the biocomposite fibers visibly increased as the amount of collagen
present in the fiber formulation decreased, which supports the data presented in Figure
6.7B.
The difference in strains observed between the wet and dry emulsion-containing fibers
was variable; however, this variance observed was not statistically significant. Thus,
neither the wet nor the dry fibers show predominantly higher maximum strains in Figure
6.7. The maximum strain measured for the biocomposite fibers containing 100%, 50%,
and 33% collagen in the uniaxial tensile test appeared to be statistically similar, with
maximum strains between approximately 0.4 and 0.8. The maximum strain observed for
the biocomposite fibers containing only 20% or 9% collagen were statistically similar as
well, with strains ranging between approximately 1.5 and 2.0. These results indicate that
there was a drastic change in the maximum strain withstood by the fibers between the
33% and 20% collagen dilutions. This drastic change in mechanical property may be
indicative of a change in the dominating constituent in the biocomposite, where the
mechanical properties expressed are originating more from the CNP3 nanoparticle
emulsion constituent in the biocomposite when only 20% collagen is used in the
formulation.
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Figure 6.8. The elastic modulus of the biocomposite fibers. A) Data obtained from fibers
containing 10mL of collagen suspension and varied amounts of the CNP3 nanoparticle
emulsion. B) Data obtained from fibers containing 100µL of CNP3 nanoparticle
emulsion and various dilutions of the collagen suspension.
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The elastic modulus or the stiffness of a given material observed for the biocomposite
fibers in Figure 6.8A is much lower than that of the dry, collagen-only control fibers, but
is substantially higher than the elastic modulus of the wet control fibers. Fibers
containing 50 or 100µL of CNP3 emulsion produced the highest modulus for the
biocomposite fibers, but 100µL displayed the least amount of variance between hydrated
and dry fibers analyzed. This drastic difference between the collagen fibers and the
biocomposite fibers when dry indicates that the fibers are displaying stress/strain curves
more closely resembling those observed for the CNP3 polymer films than they are for the
collagen fibers, since the elastic modulus is determined as the rate of change of stress
with strain for a given material. This data also shows that when hydrated, the fibers are
able to maintain much higher structural integrity than is observed for the collagen-only
fibers. This is most likely the result of the nanoparticle-based emulsions coating the
fibrils within the fiber construct and providing some degree of protection from water
damage for the fiber. Intriguingly, when 150µL of nanoparticle emulsion CNP3 was used
in the biocomposite formulation, the elastic modulus was nearly equal for the wet and dry
fibers. This observation sheds some light on which constituent is responsible for the
majority of the mechanical properties observed for this biocomposite fiber, since the
polymer film resulting from the nanoparticle emulsion CNP3 also expresses similar
elastic moduli when dry and upon short term hydration.
Statistically speaking, there is no difference between the elastic modulus for each of the
wet and dry fibers analyzed in Figure 6.8B. This also demonstrates that more of the
emulsion’s characteristics are being expressed by these fibers than the collagen’s. Again,
the dilution ratio of 1:2 for collagen appears to be the turning point where almost none of
the collagen’s mechanical properties are being expressed in the fiber constructs, and the
elastic modulus for these fibers is within only a few megapascals greater than the CNP3
films. Based on the data presented in Figure 6.8, the ratio of 10mL of undiluted collagen
fibril suspension to 100µL of CNP3 nanoparticle emulsion in the fiber formulation
appears to yield biocomposite fibers that express the strongest properties of each
constituent (high strength of collagen and elasticity of polymer).

6.4 Swelling Retardation of Collagen Fibers
One of the reasons that collagen has been more heavily studied when in combination with
other materials than it has alone for tissue engineering is due to the fact that when
hydrated, fibers formed from reconstituted collagen loses its structural integrity and the
maximum stress of the fibers dramatically decreases from 222MPa to less than 2MPa.
This is because during the extraction process, especially from mammalian sources, the
cross-linking and ionic interactions between the native collagen fibrils is broken, which is
what provides the structural integrity of the mammalian collagen in vivo.[13, 16, 18] In the
case of native sea cucumber dermal collagen, the structural integrity of the fibers is
thought to be due to the ionic interactions of anionic chondroitin chains bound to the
native fibrils interacting with the cationic sulfate molecules bound to the exterior of the
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collagen fibrils opposing the chondroitin.[18] Since any biocomposite material will be
hydrated when placed in a biological setting, this is an obvious problem that needs to be
addressed. In order to overcome this, research has focused on two different solutions: 1.
cross-linking the collagen fiber using a chemical cross-linking agent,[15-17] or 2.
combining the collagen with a synthetic material for support.[2-5] This study has chosen
the latter of the two options to try to overcome this hydration problem.

Figure 6.9. Images of biocomposite and collagen fibers when wet and dry. A and B) Dry
and wet (respectively) biocomposite fiber formulated with 100µL of CNP3 nanoparticle
emulsion. C and D) Control collagen-only fiber, dry and wet (respectively).

Figure 6.9 shows a comparison of collagen versus collagen-CNP3 composites when wet
versus dry. Data represented in Figure 6.6A showed that the dry control (collagen) fibers
depicted in Figure 6.9C are twice as strong as the dry collagen-CNP3 fibers depicted in
Figure 6.9A, but after hydration, the wet biocomposite fibers (Figure 6.9B) are up to 40
times stronger than the wet collagen fibers (Figure 6.9D). The mechanical properties of
the collagen fibers change drastically when hydrated, and a large degree of swelling
(100%) is observed for the fibers (C to D). When the collagen fibrils are combined with
any volume of CNP3 nanoparticle emulsion between 25 and 150µL prior to fiber
formation, the observed swelling is reduced drastically. Figure 6.10 shows that the largest
degree of swelling (60%) was observed for the fibers formulated with 50µL of CNP3
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emulsion and 10mL of undiluted collagen fibril suspension, and the lowest amount of
fiber swelling (2%) was observed for the biocomposite fibers formulated with only 9%
collagen fibril suspension diluted in water with 100µL of CNP3 emulsion in the
formulation. The degree of fiber swelling was determined by Equation 6.1 for each fiber
analyzed.
The diameter of the fibers was determined by measuring the width of the fiber at two
locations in the center of the fiber when dry or after being hydrated for one hour and
averaging these two measurements. The percent swelling for the fiber is then calculated
based on the following Equation 6.1.

Equation 6.1
Swelling % =

Average diameter of dry fiber

X

100%

(Diameter of wet fiber - Diameter of dry fiber)

As seen in Table 6.2, there are little to no differences observed in the mechanical
properties of the biocomposite materials when wet versus when dry, indicating that the
emulsion is creating an interaction between the fibrils in the fiber construct which is
unaffected by hydration. An explanation could be that the emulsion is actively blocking
the majority of the ionic interactions between the chondroitin molecules and the collagen
fibrils, which provides the native fibers with the observed structural strength, by coating
the fibrils within the construct. This would explain why the biocomposite fibers are much
weaker than the collagen-only fibers when dry. Also, if the emulsion is taking the place
of the inter-fibril ionic bonding, which is degraded upon hydration,[18] and the polymer
film is only minimally affected by hydration, this would explain why there is little
difference observed in the mechanical behavior of the dry versus hydrated biocomposite
fibers. In either case, the biocomposite is able to retain its mechanical properties in a
moist environment and is able to retard swelling of the fiber.
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B

Figure 6.10. Degree of fiber swelling upon hydration for the control collagen fibers and
the biocomposite fibers. A) Data obtained from fibers containing 10mL of collagen
suspension and varied amounts of CNP3 nanoparticle emulsion. B) Data obtained from
fibers containing 100µL of CNP3 nanoparticle emulsion and various dilutions of the
collagen suspension.
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All of the “collagen-only” fibers swelled to double their original diameter, which is
reported as 100% swell. The 25µL and 50µL biocomposite fibers produced a wide range
of hydration, indicated by the large deviation in the results. This is most likely due to the
variance observed for diameter of the fibers constructed from these formulations, where
some areas along the fibers were larger than others, providing a greater difference in the
diameter of the wet and dry fibers analyzed. Therefore, no conclusions can accurately be
drawn from the data presented in Figure 6.10A for the fibers formulated with 25µL or
50µL of CNP3. Fibers formulated with 100µL or 150µL of CNP3 sufficiently retarded
hydration of the collagen fibers over a one hour time period, producing between 28-35%
or 15-24% hydration swelling, respectively, as compared to the 100% hydration swelling
observed for the control collagen fibers.

Figure 6.11. Display of the variance along the length of the biocomposite fiber
formulated with 100µL of CNP3 nanoparticle emulsion and 9% collagen in the fibril
suspension. Images of dry pieces of fiber (top) and hydrated pieces of fiber (bottom), all
cut from the same parent fiber.

None of the fibers in Figure 6.10B swelled significantly after one hour of hydration.
Fibers formulated with very low concentrations of collagen fibrils in the suspension (22%
and 9% collagen-containing fibers) were not homogeneously spherical, as was the case
with the collagen fibers, which was due to the heightened emulsion content present in the
fiber. This caused the fiber to take on a flatter dimensional conformation upon drying,
which significantly altered the cross-sectional area of the fibers, as seen in Figure 6.11.
Therefore, the higher variability in swelling percentage for these fibers was more likely
due to this variance in fiber diameter throughout the length of the fiber than it was in the
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swelling difference of the fibers. The images of the single fiber formed from 9% collagen
in the fiber formulation showed that not only was no swelling observed for the fibers
(bottom images), but that throughout the length of the fiber, the morphology was
somewhat random due to the uneven distribution of emulsion throughout the length of the
fiber composition. Since the polyacrylate films take on whatever conformation they are
formed on, and since the biocomposite fibers are formed by hydraulically lifting the
fibers from the fiber-forming solution, the fibers do not take on a constant morphology
when air drying in the formulations with low collagen concentrations, hence the
inconsistent morphology. The fibers containing the original 100% collagen formulation
and the fibers containing 50% collagen in the formulation, as seen in Figure 6.10B,
displayed a consistent shape throughout the fiber, and thus the lack of swelling observed
for these fibers was significant and not a product of imperfections in the fiber formation.
This data suggests that, when combined with a polyacrylate nanoparticle emulsion,
collagen fibers can potentially be used for various biomedical applications without the
concern of structural degradation by the moist in vivo environment. This is due to the
observed retention of mechanical properties when the fibers are hydrated, as well as the
observed swelling retardation, yet the fibers still appear to be able to absorb some degree
of water. Also, for certain biomedical applications, such as ligament replacement,
swelling of the fiber can be useful when regulated so that swelling is not instantaneous,
but rather occurs over an extended period of time to allow for surgical manipulations. In
this case, these biocomposite fibers may be optimal because they will eventually swell to
a certain degree, but this does not occur upon immediate hydration, and even when
hydrated, these fibers do maintain mechanical properties. Applications where this
property would be useful is when artificial ligaments are being utilized for ligament
replacement, and instead of using a bone cement or glue to adhere the artificial ligament
to the bone, hydraulic fixation is utilized, where the fiber swells within a small hole
created in the bone and this swelling locks the fiber in place. This is just one example of
where regulated swelling/hydration of the fiber construct would be useful, however, in
each biomedical application proposed here, mechanical soundness of the biocomposite
fiber upon hydration or within a moist environment is paramount.

6.5 TEM Analysis of Biocomposite Fibers
In order to further understand the nature of the interactions between the collagen fibrils
and the nanoparticle emulsion, TEM analysis was performed on chemically fixed crosssections of the control collagen and biocomposite fibers (Figure 6.12). Fibers sections
were stained with both uranyl acetate and lead citrate in order to observe the individual
fibrils within the construct and their spatial orientations.
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B

C
Figure 6.12. TEM images of the cross-sections of control collagen and collagen/CNP3
biocomposite fibers. A) Collagen-only control fiber polymerized from sea cucumber
collagen fibrils. B) Biocomposite fiber containing 10mL of sea cucumber collagen fibril
solution and 100µL of CNP3 nanoparticle emulsion. C) Outer edge of control fiber. The
black arrow is pointing to a horizontally-oriented fibril in the fiber. Black dots within the
images are a product of stain precipitation during processing.

The control fiber appears to contain mainly linearly-arranged fibrils tightly packed in the
fiber in a longitudinal orientation, as evidenced from the “packing” of circular gray areas
in Figure 6.12A and C. This provides the fibrils with the orientation necessary for
interfibrillar interactions between the anionic chondroitin and the cationic collagen fibril
that provides the fiber with the high observed tensile strength when dry. However, the
tensile strength of the reconstituted fibrils is not completely on par with the native fibrils
in vivo, which is mostly likely due to the small percentage of fibrils in the fiber that are
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not in the same longitudinal arrangement as the majority of the fibrils are (Figure 6.12C
arrow). When hydrated, especially with phosphate-buffered saline or saline solutions, it is
likely that these ionic interactions are disrupted, possibly depleting the high tensile
strength previously observed for the dehydrated fiber (Figure 6.12C). Also, when
hydrated, it is presumed that the water molecules take up space in between the fibrils in
the fiber, interacting with the collagen fibrils, and thereby causing the observed swelling.
The emulsion-treated fibrils do not appear to have a linear arrangement; in fact, they
seem to be randomly oriented within the fiber cross-section in Figure 6.12B. The
collagen fibrils that are present are very loosely arranged within the fiber, indicating that
the emulsion is perhaps intertwining with the fibril and forming a protective film around
the fibrils. The random orientation of fibrils within the biocomposite fiber is most likely a
factor of the mixing performed when the emulsion is introduced to the fibril suspension
prior to fiber formation. The increased spatial distribution between the collagen fibrils in
the fiber composite does not permit the fibrils to interact with one another to the extent
that they do in the control fibers, which helps illustrate why there is an observed
difference in tensile strengths between the collagen and biocomposite fibers when dry.
Moreover, the variability observed for the individual fibrils’ spatial orientation within the
fiber explains the elasticity observed for the biocomposite fibrils and why the elastic
properties of the polymer film sample are also expressed in the biocomposite fiber. Since
most of the collagen fibrils present in the biocomposite fiber appear to be protected from
the environment by the emulsion/polymer, this could rationalize the observed retention of
mechanical properties upon hydration.

6.6 Calcium Deposition Analysis
It has been established since the 1960’s that the dermis of echinoderms is neurally
regulated, and that extracellular concentrations of calcium (Ca2+) has a large influence on
the stiffening of the dermis, which is a form of protection for these animals.36 While the
mechanism of this calcium interaction is still heavily debated, it has been established that
as the concentration of calcium presented to the dermis from the extracellular matrix
increases, so does the stiffness of the dermis. Therefore, since it has not yet been
established whether the stiffening is a result of a calcium-dependent cellular interaction,
or a direct calcium effect on the viscosity of the extracellular matrix,[12] the effect calcium
doping may have on these biocomposite materials was explored. The biocomposite fibers
formulated with 10mL of undiluted collagen fibril suspension and 100µL of CNP3
emulsion were fully submerged in a prepared solution containing 10mM calcium chloride
(CaCl2) or treated with ddi H2O for 24 hours. The diameter for both the treated and
untreated fibers was then measured and the fibers were characterized by uniaxial tension
analysis.
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Figure 6.13. Effect of calcium doping on the biocomposite fibers. A uniaxial tension
experiment was performed in order to establish the presence of a calcium-induced
stiffening effect on the biocomposite fibers containing 100µL of CNP3.

In Figure 6.13, both the calcium-doped (yellow line) and the undoped (green line) fibers
appear to display relatively similar mechanical properties, including maximum stresses
within 2-3MPa of each other and maximum strains within 0.05 of one another. The
stress/strain curves for the calcium-treated and the untreated control fibers were
comparative, however, the calcium-treated fiber (yellow line) did possess a larger elastic
modulus due to the slightly more linear stress/strain curve. Also observed was
inconsistent maximum strains for the calcium-treated biocomposite fibers, where failures
occurred between 0.3 and 0.6, which was not observed for the untreated biocomposite
fiber in Figure 6.13. While the calcium-doped fibers appeared to be slightly stiffer (less
strain observed), the maximum tensile strength for each set of fibers was equivalent, thus
the calcium treatment had minimal effects on the fiber’s overall stiffness. Further analysis
comparing the mechanical properties of the calcium-doped biocomposite fibers to the
collagen-only control fibers is needed to further appreciate any observed differences
presented here for the treated versus untreated biocomposite fibers.

6.7 Conclusions
The addition of nanoparticle emulsion CNP3 to the reconstituted collagen fiber
formulation ultimately established the development of a new biocomposite material that
may be ideal for artificial elastic tissue replacement. The biocomposite fibers expressed
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properties of both the emulsion and collagen constituents, and the expression level of
each was able to be regulated based on the relative amounts of emulsion and collagen
suspension in the fiber formulation. The most optimal biocomposite fiber formulation
was ultimately determined to contain 10mL of the sea cucumber collagen fibril
suspension and 100µL of CNP3 nanoparticle emulsion, as determined by both the
mechanical properties and the observed consistent morphology of the fibers formed from
this formulation. These fibers possessed the most consistent mechanical properties that
were closest to the control collagen fibers for the majority of the mechanical properties
defined in this study, which was a desirable feature. Also, these fibers displayed a limited
degree of fiber swelling upon hydration and minimal degree of variance observed for the
mechanical properties of the fibers when hydrated versus when in the original dry state,
another favorable outcome that the fibers formulated only from collagen fibrils did not
posses.
TEM analysis showed that the biocomposite fibers actively incorporated the emulsion
into the fiber formation, presumably in the solidified polymer film state, and that the
presence of the polymer surrounding the collagen fibrils and the random spatial
orientation of the fibrils within the biocomposite fiber ultimately diminished tensile
strength for the biocomposite fibers (when dry). However, upon hydration, these
interactions and spatial differences observed for the biocomposite fibers allowed them to
retain their full mechanical properties and retard or possibly even prevent swelling of the
fibers upon hydration, whereas the control, collagen-only fibers lost all of their stiffness
and observed tensile strength upon hydration and swelled to more than twice their
nominal cross-sectional area. The presence of the polymer in the fiber also provided the
biocomposite fibers with an elastic property that allowed the fibers to undergo cyclic
fatigue without any observed effect on the tensile strength of the fiber. It has been shown
that in the native echinoderm animal Cucumaria frondosa, from which the collagen
fibrils were extracted, calcium (Ca2+) influences dermal stiffening and creates a dramatic
increase in the stiffness of the dermal collage. However, calcium doping of the
biocomposite fibers appeared to have little effect on the tensile properties of the fibers,
where the only observed difference was slight variability observed for the maximum
strain withstood by the fibers.
In conclusion, the biocomposite collagen/emulsion fibers synthesized displayed
properties similar to many natural elastic tissues present in the body, including lung, skin,
blood vessel, and aortic heart valve tissue. Therefore, this new biocomposite material
would appear to be ideal for use in artificial tissue constructs for treatment of such
medical problems as artificial burn wound skin grafts or artificial ligament/tendon
replacement to name a few.
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CHAPTER 7
CYTOTOXICITY OF DRUG MONOMERS,
NANOPARTICLES AND FILMS
7.1 Introduction
In order for any drug to be established as a form of treatment outside of the lab, toxicity
analysis must be performed. Toxicity can be determined in a variety of different ways;
however, in order for any drug to be non-toxic, it must not have detrimental effects at the
cellular level. Therefore, in this chapter, cytotoxicity is analyzed for drug monomers used
in preparing nanoparticle emulsions, as well as the drug-conjugated and drug-free
nanoparticle emulsions, and drug-conjugated and drug-free smart polymer films. For the
toxicity experiments, human dermal fibroblast cells are used. Two different assays were
employed in this study to analyze the number of viable fibroblast cells after exposure to a
sample, a CyQUANT DNA binding assay, and an MTT colorimetric assay. Both assays
detect the number of viable cells through fluorescence absorption caused by interaction of
a colorimetric dye with viable cells. These assays not only give quantitative analysis of
cytotoxicity, but they can also be used to measure drug sensitivity, response to growth
factors, and cell activation. While these assays were chosen as the most optimal for the
present study, there are numerous others available for this type of analysis.

7.1.2 Trypan Blue Assay
There are a variety of cell growth and viability assays that quantify the amount of living
cells in a culture, some of those are spectrophotometric assays that require the use of a
spectrophotometer, and others use dyes that require only a light microscope for analysis.
One of the simplest cell viability assays is the trypan blue assay, where the solubilized
dye is added to the culture media and allowed to interact with the cells. Cells that are
viable have intact cellular membranes and do not take up the dye, thus displaying a blue
ring around the outside of the cells. In cells where the cellular membrane has been
compromised, indicating cell death, the dye will penetrate the membrane and bind to
intracellular contents, making the cells appear completely blue under the microscope.
While this assay is a relatively simple method that requires minimal instrumentation and
is fairly inexpensive, it is extremely difficult to differentiate between viable and nonviable cells, especially if the microscope being used for such an assay is not high
resolution. It is also a solely qualitative method of analysis and therefore can only tell the
user whether a cell is alive or dead, and indicates nothing about cellular function. Also,
this assay requires a person to count the number of viable cells and each test must be read
individually, which ultimately produces a higher degree of variability than other
instrument-based assays and does not permit high throughput screening.
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7.1.3 Radioactive H3 or C14 Thymidine Uptake Assay
There are numerous colorimetric and radioactive assays that require high powered
detection instruments that calculate the number of viable cells in a culture based on
comparison to a standardized curve. These assays are much more reliable, permit high
throughput screening due to the use of 96 well plates and versatile spectrophotometers,
and provide real-time quantitative analysis. The radioactive cell growth and viability
assay uses the radioactive agent H3-thymidine for detection of viable cells. Thymidine
uptake is not only a useful tool for cellular viability analysis, but it can also be used with
tissue cultures and to measure mRNA concentrations in vitro.[1] This assay requires
cellular manipulation in the form of cell harvesting and media changes for detection to
occur.[1] This inevitability increases the degree of variability in the results and the
possibility of error. However, recent advances by companies have made this assay much
more user friendly and reproducible.
Previously, cellular cultures were required to undergo harvesting in order to determine
the thymidine uptake levels, and also required the use of scintillation fluid for
radioactivity detection. However, recent alterations to the commercially available kits for
this assay provide the user with base plates that incorporate scintillants, therefore
eliminating the need for separation steps in the assay and expensive scintillation fluid for
detection, which is even more expensive to dispose of than it is to purchase. These assays
are now able to be read on microplate readers, which provide this assay with high
throughput capabilities. However, the fact still remains that this assay requires the use
and handling of radioactive materials, which most people would rather not use if at all
possible, and also calls for additional permits and safety approval for a lab. Therefore, if
cellular toxicity can be analyzed through the use of a safe dye instead of a radioactive
substrate, most researchers would probably choose the non-radioactive means of
measurement.

7.1.4 Cellular Toxicity Assays
There are also commercially available assays that determine the amount of cellular death
within a culture. These assays commonly use a dye whose fluorescence emissions can be
read by a spectrophotometer and that binds to an intracellular component of the cells. If
cells are necrotic due to interaction with a substrate, the cells will rupture, thereby
releasing the intracellular components into the media. Through the use of a standardized
calibration curve with known cell numbers that are lysed with a known cellular lysis
agent, the number of dead cells can be obtained through this assay. However, the number
of cells that are initially added to each experiment must be known, and a control well
must also be used to determine how many cells there would be after overnight culture in
order to obtain an accurate toxicity analysis. This, however, indicates that a simple
viability assay, such as the trypan blue assay, must be used in conjunction with this type
of assay in order to correctly analyze cellular toxicity.
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One example of this kind of kit is the lactate dehydrogenase cytotoxicity assay kit, which
detects the biochemical activity of the cytoplasmic enzyme after release into the
surrounding media following rupture of a cell’s plasma membrane. In this assay, an
aliquot of the media that the culture is grown in is centrifuged to remove any cellular
debris, and then the supernatant is combined with the enzyme in solution, followed
immediately by spectrophotometric analysis. This assay is a very good tool for
monitoring the progress of a cell culture over a long time period because the cellular
media can be sampled above where the viable cells are attached to determine cell death.
When determining cytotoxicity, it is also important to analyze the substrates interaction
with the cells over extended periods of time, and thus this assay is optimal for such a
study since the cells are not disrupted by the assay, and toxicity can be monitored daily so
that accurate analysis of when cellular death is initiated or at a maximum can be
determined.

7.1.5 MTT Colorimetric Assay
The MTT assay has recently been considered one of the best assays available for fast and
reliable detection of cellular growth and viability. Developed in 1983 by Mosmann,[2] this
assay was originally used to measure proliferation of lymphokines, mitogen stimulations
and complement-mediated lysis.[2] The success of this assay in current research practices
has largely been due to the spectrophotometric procedure used that can detect slight
changes in cell metabolism, making it much more sensitive than trypan blue staining, and
the colorimetric reagent used for the assay instead of a radioactive one, which makes this
procedure much safer than the older radioactive procedures.[1-3]
This colorimetric assay measures the amount of an insoluble formazan crystal that is
formed through the biochemical reduction of a yellow tetrazolium salt, 3-(4,5dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT), by the mitochondria of
viable cells.[3, 4] Cell cultures are incubated with the MTT reagent for 2-4 hours, then the
cells are lysed and any of the formazan crystal product is solubilized for detection. The
samples can then be analyzed by any spectrophotometer or multiplate reader that has
filters at a wavelength of 570nm. The amount of purple color produced by the dissolved
formazan crystal product is directly proportional to the number of viable cells.[3-5]
Detection levels for this assay range from as few as 1,000 cells to numbers as high as
5,000 cells per well.[1, 2] The reduction of tetrazolium salts is a safe and accurate
alternative to radiometric testing that provides a linear relationship between cell number
and absorbance, enabling accurate, straightforward quantification of changes in
proliferation.
The MTT system is a quantitative, more sensitive test than basic trypan blue or toxicity
assays because there is a linear relationship between cell activity and absorbance, thereby
allowing the growth or death rate of cells to be measured. This assay has also been
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extended to cytotoxicity analysis of new drug therapies for detection of anticancer
activity,[4, 6] making this assay a key tool for numerous kinds of drug development.

7.1.6 CyQUANT DNA Binding Assay
Another form of the colorimetric assay is the CyQUANT Assay. This assay analyzes cell
viability from a different perspective than the MTT assay because it does not measure
whether a cell is alive or dead, but measures the amount of DNA present in a culture
media, and has been shown to be more sensitive than both the trypan blue and the MTT
assays and also faster, requiring only one hour incubation with the cells or cellular
lysates. This assay has the capability of measuring 100 to 20,000 cells per well, thereby
giving it a wide detection range.[7] The CyQUANT assays are a fast and sensitive means
for counting cells in a population and measuring proliferation, however, its use is limited
to a microplate format due to the principle behind the assay. When fibroblast, and many
other cells types, are grown in culture, they have extracellular proteins and components
that allows them to attach to a substrate (i.e. the bottom of a microplate well). This assay
is built upon this principle and uses it to determine viable cell numbers in a culture. After
a culture of cells has been allowed to attach to the microplate and is subsequently
exposed to a sample of interest over a certain time frame, the media in each well is
removed from the culture, leaving behind only the cells that remained attached to the well
after exposure to the substrate.
After lysis of attached cells remaining after 24 hours of exposure to the substrate, the
lysate is combined with the DNA-binding dye, and fluorescence can be read at the
excitation wavelength of 485nm and at the emission wavelength of 530nm, and values
obtained can be compared to a standardized curve in order to estimate the absolute
number of viable attached cells in a well. Since only viable cells undergo cellular
attachment to surfaces, it is concluded that the number of cells measured by this assay
indicate the number of viable cells present in the culture. However, this is not a good
measure of the overall number of viable cells since cellular attachment can be disrupted
by some drugs, and yet the cells remain viable. Therefore, this assay is an indicator of the
overall biocompatibility of a substrate (i.e. whether a substrate has any negative effect on
a cell population) and does not determine the extent of toxicity or cell death, which is
why the MTT assay is often employed as a secondary assay.
As is often seen with fluorescence and absorbance measurements, which both the MTT
and the CyQUANT assays utilize, there is a high degree of variability in readings;
therefore it is necessary to perform multiple well readings for each sample. Also, if dead
or apoptosing cells or cellular DNA adheres to the attached cells and is not removed with
the culture media, then this will also skew the numbers obtained. Also, since this assay
can only measure the amount of DNA from cells that remain adhered to the well after 24
hours, this method is not recommended for cellular suspension analysis. This is why in
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this study, both the MTT and the CyQUANT assays were used to determine cytotoxicity
of the drug monomers, nanoparticle emulsions, and smart polymer films.

Figure 7.1. Standardized calibration curve for translation of fluorescence readings from a
CyQUANT assay to real-time cell numbers.

7.2 Cytotoxicity of Drug Monomers
To test the cytotoxicity of any drug monomer, it must be solubilized in a solvent in order
for it to interact with the cells on a molecular level. The most favorable solvent used for
such assays is water, but since all of the acrylated drug monomers synthesized are water
insoluble, another solvent was chosen that is the next best thing, dimethyl sulfoxide
(DMSO). DMSO is the second most common solvent for drug testing in antimicrobial,
anticancer, and cytotoxicity studies, yet it is also known to be cytotoxic at high
concentrations. Any concentration of DMSO above 10% in the culture medium is
considered toxic and can cause inhibitory effects on healthy mammalian cells, as well as
antimicrobial effects. Therefore, the amount of drug that can be tested in both the
antimicrobial studies and the cytotoxicity studies is limited by the amount of drug that
can be dissolved in 20% DMSO. Drug monomer fluorescence readings should be
compared to those obtained for cells treated with DMSO only and not with the control
cells.
In this study, acrylated drug monomers were tested against human dermal fibroblast cells
isolated from full thickness skin specimens obtained from the US Skin Bank, Cincinnati,
OH. Drug monomers were dissolved in DMSO at 1mg/mL concentrations, and tested
against the fibroblast cells at either 10 or 20µg/mL concentrations. Since most drug
monomers analyzed possess antimicrobial activity at or below 16µg/mL, these
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concentrations were deemed appropriate for cellular toxicity analysis, and samples were
obtainable at this concentration in aqueous DMSO.

7.2.1 β-Lactam Monomers

A

B

Figure 7.2. Cytotoxicity assay for β-lactam monomers in DMSO. A) CyQUANT assay
performed on 20µg of lactam monomer in 20% DMSO. B) MTT assay for either
10µg/mL or 20µg/mL lactam monomer in DMSO.
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The data obtained for lactams 1, 3, 4, 6, and 10 are plotted in Figure 7.2. The CyQUANT
assay was repeated numerous times for the β-lactam drug monomers over a six month
period. Upon initial assay, fibroblast cells were added to the wells at the same time as the
lactam drug monomers. Results showed that the lactams prevented the cells from
adhering to the bottom of the well, and the cells remained spherical in morphology. Since
the CyQUANT assay calls for cellular attachment in order for conclusive results to be
obtained, the assay was repeated with a slight modification in the procedure. For the
subsequent assay, the cells were allowed to grow and attach to the wells overnight prior
to exposure to the lactam monomers. Here, it was found that age of the monomer, purity
levels, and length of time in DMSO all influenced the toxicity of the monomers (Figure
7.2 and 7.3). This was illustrated by the difference observed for the toxicity results for
lactam 10 in Figure 7.2A and B, where in the CyQUANT assay, the lactam appeared to
cause a toxic effect, yet in Figure 7.2B, this was not the case, and treated cells appear to
be as numerous as was observed for the DMSO-treated cells. In Figure 7.2B, it was
determined that the lactam monomers yielded equal results for both the 10 and 20µg/mL
drug concentrations.

Figure 7.3. Analysis of toxicity of β-lactam 10 in DMSO by MTT assay over a 24 month
period. Control cells were exposed to only DMEM culture media.

Results of an MTT assay (Figure 7.3) showed that the older a drug sample was, or the
longer it was dissolved in DMSO, the more the drug caused the fibroblast cells to become
detached from the wells and revert back to the spherical shape. This spherical
morphology was often observed for the cells throughout the study when exposed to
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lactam monomers of low purity when not allowed to attach to the wells prior to exposure.
If the cells were allowed to attach prior to exposure, many would become slender and
attempt to detach from the wells. It was found after a few trials that when the lactam
monomer was prepared fresh and dissolved in DMSO only just before testing, the
monomers did not cause any visible toxic effects on the fibroblast cells (Figure 7.4), and
the cells remained attached and were able to proliferate equally to those of the control
cells. Also, as seen in Figure 7.3, the difference in toxicity between one and two years
after lactam 10 synthesis does not alter the toxicity of the drug, yet between one month
post-synthesis and one year, there is a marked increase in toxicity of the drug. This
indicates that drug monomers should be incorporated into nanoparticle emulsions
promptly after synthesis.

Figure 7.4. Images of fibroblast cells treated with lactam monomers 3 and 4. When
lactam monomers are prepared fresh and with high purity, fibroblast cells remain
elongated and viable, actively proliferating equal to control cells.

Assays were also performed with the cells being exposed to the lactam monomers over a
period of 7 days (Figure 7.5). However, this data may not be very accurate since media
changes were not performed due to the risk of losing viable cells that had detached from
the well surface and taken on a spherical morphology due to the lactam interaction with
the cells, causing them to be in the media suspension. Even in control wells where no test
substrates were added, cellular debris was present throughout the well and appeared
settled on top of the still viable cells, indicating that the cells were more vulnerable to
toxicity by the end of the study. The heightened toxicity observed for this assay was
therefore likely due to increased sensitivity of the cells to the drug monomers due to a
lack of fresh nutrients present for the cells. Also, in this assay, the fibroblast cells were
not allowed to attach to the wells prior to exposure to the lactam monomers, increasing
the likelihood of the cells to remain in the suspension.
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Figure 7.5. Fibroblast cells after treatment with β-lactam monomers over 7 days. Control
wells with only media present contained attached fibroblast cells (left arrow) and cells
detaching from the well (right arrow). Cells treated with lactam 1 mostly became
spherical and detached from the well, but some (arrows) remained attached and viable.
Lactam 6 produced no such effects and showed no toxicity.
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Figure 7.6. CyQUANT cytotoxicity analysis of fibroblast suspension mixed with lactam
monomers over 7 day incubation period.

In the extended exposure assay (Figures 7.5 and 7.6), lactam monomers 1 and 10 were
considered cytotoxic to the cells and caused the cells to remain in their spherical
morphology, whereas lactams 3 and 6 allowed the cells to attach to the well similar to the
cells exposed to DMSO. In this assay, lactams 1 and 10 were older samples that must not
have been of high purity, since numerous other assays showed these two monomers to be
non-cytotoxic to the fibroblast cells (Figures 7.2 and 7.3). Lactam 6 was freshly prepared
for this assay and was considered to be the purest sample analyzed for this monomer thus
far. The heightened number of control cells determined by the CyQUANT assay is most
likely due to the excess cellular debris caused from cellular lysis attaching to the attached
cells, thereby causing higher numbers from the fluorescence readings than were viable
cells. Also, since the cells exposed to 1 and 10 remained in suspension in the spherical
form, these cells were not able to be included in the CyQUANT assay since they were not
attached to the wells. Therefore, this data set is not as accurate as the other data sets, and
for an extended exposure time assay to be performed, many issues need to be resolved,
including changing the assay to the MTT assay, which was unavailable at the time of this
experiment.
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7.2.2 Acrylated Commercially Available Monomers
All of the acrylated drug monomers analyzed, except for the β-lactams, were prepared
from commercially available drug compounds whose toxicity has already been
established and deemed non-cytotoxic. Upon acrylation, the toxicity of the drug entity
may change. Therefore, it was necessary to analyze the cytotoxicity of the drug
monomers, even though it is believed that through the mode of action of the nanoparticle
delivery system the in its original commercially available form and thus should be nontoxic when used for infection treatment.
Figure 7.7 showed that all of the acrylated drug monomers, except the acrylate penicillin
G, were non-sytotoxic to the human dermal fibroblast cells. Interestingly, the
fluorescence results for the MTT assay shown in Figure 7.7B conclude that the
ciprofloxacin methacrylamide 8 was cytotoxic, yet the CyQUANT assay in Figure 7.7A
and visual observation of the treated fibroblast cells (Figure 7.8 and 7.9) indicate that no
toxic effects were caused by this drug. The batch of cipro monomer 8 used for the MTT
assay may have contained additional contaminents including remaining solvent or
unreacted reagents that was not present in the majority of the other batches of cipro
methacrylamide 8 synthesis, and therefore, is the drug is not cytotoxic when thorough
work up and evaporative processes are employed.

219

A

B

Figure 7.7. Cytotoxicity assays for acrylated commercially available drug monomers 7
and 8. A) CyQUANT assay data for 40µg of drug in 20µL DMSO. B) MTT assay data
for both 20µg and 10µg drug samples in DMSO.
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Figure 7.8. Images of fibroblast cells treated with acrylated commercially available
drugs. All cells imaged either resemble control cells or cells treated with DMSO only,
and therefore, all appear healthy and viable.
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Figure 7.9. Close up images of fibroblast cells treated with ciprofloxacin acrylated
monomers 7 and 8.

Images of the cells in Figures 7.8 and 7.9 that were treated with acrylated drug monomers
7 and 8 dissolved in DMSO showed that data obtained from the CyQUANT and MTT
assays is accurate and that the drug-treated fibroblasts were healthy and viable. Close up
images in Figure 7.9 depict healthy elongated fibroblast cells with intact nuclei present in
all of the cells. Although some cells took on a shortened, stubbier morphology, as was
seen with for the cells treated with DMSO in Figure 7.8, they were still viable,
proliferating cells that were attached to the wells. Therefore, all of the acrylated drug
monomers analyzed in either the MTT or CyQUANT assays were deemed non-cytotoxic
towards human dermal fibroblast cells.

7.3 Cytotoxicity of Nanoparticle-Based Emulsions
7.3.1 Drug-Free Polyacrylate Emulsions
Drug-free emulsions were analyzed for cytotoxic affects against the human dermal
fibroblast cells at various concentrations of solid content in order to determine at what
concentration, if any, the emulsions become cytotoxic. Since there were no drug
monomers in these emulsions to contend with, this gave the opportunity to determine if
the emulsion had inherent toxicity. All of the emulsions were first diluted prior to
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addition to the cells using nano-purified water, and all emulsions were analyzed at 20µL
volumes per well, regardless of the original solid content concentration.

Figure 7.10. CyQUANT cytotoxicity data for drug-free emulsions at 10% solid content.

Initial assays were performed on emulsions at 10% solid content, in which instance most
of the emulsions created cytotoxic effects on the fibroblast cells (Figure 7.10). This was
not easily determined due to the high amount of polymer and surfactant precipitation on
top of the fibroblast cells, creating almost an intact film covering the cells (Figure 7.11).
This sedimentation/film formation completely inhibited visualization of any fibroblast
cells that may have remained attached and viable, and thus accurate analysis of the
number of viable fibroblast cells in each well via the CyQUANT assay was not possible.
Also, when the films were able to be removed from the wells, fibroblast cells may have
adhered to the films, and would have been removed prior to assay analysis. Therefore,
accurate assessment of toxicity for these emulsions having a solid content of 10% or
greater is not feasible with either of the assays.
Although many of the control (non-drug containing) emulsions were not able to be tested
then, two samples (CNP16 and CNP17) were accurately tested since no precipitation was
observed in the treated cell-containing wells to interfere with the fluorescence assays and
these emulsions did not display any cytotoxicity at 10% solid content (Figure 7.10). This
is mainly because they contain only 1% SDS in their formulation, which resulted in less
surfactant and polymer sedimentation in the wells, presumably due to a higher degree of
nanoparticles present within the emulsion over the longer chain polyacrylate strands.
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Figure 7.11. Interaction of CNP12 at various solid content concentrations with human
dermal fibroblast cells. The emulsion, when applied to the cells at solid content
concentrations above 2.5%, precipitated on top of the cells, most likely along with excess
surfactant, thereby blocking accurate fluorescence measurements and visualization.
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Figure 7.12. CyQUANT assay analysis of dilution scheme for drug-free nanoparticle
emulsions CNP5 and CNP12. For both emulsions, 20% and 10% solid content
concentrations appear to be cytotoxic when applied to cultured fibroblast cells in a well.

The images in Figure 7.11 correlate well with the CyQUANT data obtained in Figure
7.12. The high variability for CPN12 at 5% solid content concentration is consistent with
the images of cellular debris and polymer and surfactant precipitate skewing the data.
Also, some cells may have still been attached to the wells under the precipitated material
in the case of the 10% and 20% solid content wells, which would explain the CyQUANT
data. The fact that any fluorescence was observed for cells treated with these
concentrations is more likely due to fluorescence being emitted by the polymer itself and
not from cellular DNA. In later experiments, this observed fluorescence was nulled from
the experimental data by analyzing the fluorescence emission observed for the emulsion
in the culture media when no cells are present in the wells and subtracting these values
from the values obtained for the actual cytotoxicity assays.
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Figure 7.13. MTT assay of multiple drug-free emulsions at various solid content
percentages.

In Figure 7.13, three different formulations of drug-free emulsions are analyzed at
various solid content concentrations for cellular toxicity via the MTT assay. CNP3 was
formulated with ethyl acrylate: methyl methacrylate, CNP16 was formulated with butyl
acrylate: styrene, and CNP17 was formulated with butyl acrylate: methyl methacrylate.
All three control emulsions analyzed contained only 1% SDS and 0.5% radical initiator,
and therefore, should be non-cytotoxic at solid content concentrations as high as 10% in
vitro. Figure 7.13 shows that the emulsions having a solid content concentration of 0.75%
to 2.5% were non-toxic. The data in Figure 7.10 corroborates this hypothesis, since in this
figure only the CNP16 and CNP17 formulations contained 1% SDS, whereas all of the
other emulsions contained either 3% or 5% SDS. Overall analysis of the data concluded
that all emulsions, regardless of the ratio and type of co-monomers used, ideally should
contain 1% SDS and 0.5% radical initiator for the most favorable properties in vitro.

7.3.2 Single Drug-Conjugated Emulsions
While it was established in the previous study that drug-free emulsions are non-cytotoxic
at concentrations at or below 5% solid content, this may not be the case when drug
monomers are covalently bound to the nanoparticles. Since drug monomers also can
display cytotoxicity at high concentrations, the concentration of the drug in the emulsion
must also be taken into account. Therefore, seven drug-conjugated emulsions were
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prepared and diluted to 20µg/mL or 10µg/mL (2.5% or 1.25%) solid content prior to
cytotoxicity analysis by CyQUANT and MTT assays in vitro.

A

B

Figure 7.14. CyQUANT and MTT assays for single drug-conjugated nanoparticle
emulsions. A) CyQUANT assay performed at 2.5% solid content. B) MTT assay
performed using 2.5% versus 1.25% solid content concentrations.
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All of the drug-containing nanoparticle emulsions analyzed in Figure 7.14 were
considered non-cytotoxic. The only nanoparticle formulation that showed some
cytotoxicity was NP1, but this was not a significant degree of variance from the control
data due to the high standard deviation observed when analyzed at 2.5% solid content.
Heightened fluorescence readings above those for the control cells could be a result of the
antibiotics present in the nanoparticle emulsions removing any bacteria that may have
infiltrated the cultures. Also, since the standard deviations for many of the emulsions that
produced high fluorescence readings are fairly large, the data falls within the same range
as the control readings. Other possible explanations for the increased fluorescence
readings for the 2.5% solid content emulsions could be due to small amounts of the
emulsion being analyzed by the spectrophotometer. Since the emulsions contain the
aromatic co-monomer styrene, plus some of the drug monomers express fluorescent
moieties, they could also be contributing slightly to the fluorescence readings, which
would produce values higher than cells not exposed to any emulsion or test substance
(control cells). Since previous data has shown that the higher the solid content
concentration, the more likely it is that some of the polymer/surfactant will precipitate in
the cell-containing wells, this explains why the fluorescence readings for NP8 and NP11
are higher for the cells exposed to the 2.5% solid content emulsions than they are for the
cells exposed to the 1.25% solid content emulsions.

7.3.3 Multi-Drug Conjugated Emulsions
The two different formulations, MDNP1 and MDNP2, were analyzed for cytotoxicity by
the MTT and CyQUANT assays. This was deemed necessary since the two formulations
not only contain different drug monomers in different concentrations, but also because
MDNP1 was formulated similarly to CNP16, where only 1% surfactant and 0.5% radical
initiator were used (Figure 7.15). MDNP2 was formulated after CNP5, with 3%
surfactant and 0.5% radical initiator, therefore, a difference in toxicity levels due to the
surfactant levels was expected (Figure 7.17).
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Figure 7.15. Acrylated drug monomers incorporated in MDNP1. The total amount of all
drugs incorporated in the emulsion is 5% of the solid content.
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Figure 7.16. CyQUANT assay for various solid content concentrations of MDNP1.
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B

Figure 7.18. Toxicity assays for both multi-drug conjugated nanoparticle emulsions. A)
CyQUANT assay at 2.5% solid content only. B) MTT assay of emulsions at both 2.5%
and 1.25% solid content concentrations.
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Figure 7.18B shows that the multi-drug nanoparticle formulation MDNP1 is the least
cytotoxic of the two formulations made, and displays almost no cytotoxicity at 2.5% solid
content concentration (Figure 7.16). This is most likely due to two factors: higher purity
of the drug monomers incorporated into MDNP1 and the fact that only 1% surfactant was
used for this emulsion as opposed to 3% that was used for MDNP2. The CyQUANT
assay showed no difference in toxicity levels between MDNP1 and MDNP2, but this
assay was only performed on the emulsions at 2.5% solid content, where at this
concentration in the MTT assay (Figure 7.18B), the fluorescence readings were also
equal. This indicates that if the CyQUANT assay was performed on the emulsions at
1.25% solid content, then a difference in cytotoxicity may have been observed in this
assay as well.

7.4 Cytotoxicity of Polymer Films
7.4.1 Drug-Free Polymer Films
Polymer films were able to be analyzed for toxicity in two ways: by formation of the film
on the bottom of the well prior to addition of fibroblast cells, and by addition of small
pieces of film samples to attached fibroblast cells in media. Both of these routes were
explored for the CyQUANT assay, however, only the addition of the small polymer film
pieces to the attached cells was analyzed for the MTT assay. This was due to some
experimental problems encountered when the polymer film was formed in the wells
before the assay was initiated.
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B

Figure 7.19. CyQUANT assay for drug-free polymer films. All films weigh
approximately 80mg. A) Initial assay using all polymer film samples. B) Assay on least
cytotoxic polymer films samples, all containing 3% surfactant or lower.
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In Figure 7.19, in the CyQUANT assay data, the films were not washed with ethanol
prior to addition to the fibroblast cells for removal of any bacteria or other debris that can
adhere to the films due to them being exposed to the environment for a long period of
time prior to analysis. Therefore, the CyQUANT assay was repeated where all the films
were dipped in 70% ethanol then allowed to air dry overnight in a biosafety class 2A
cabinet in order to remove all of the excess ethanol prior to addition to the assay. Also, in
the initial CyQUANT assay, the polymer films were formed on the surface of the wells
by addition of 50µL emulsion to the well then allowing it to dry overnight in the
biosafety cabinet. Since the CyQUANT assay determines the amount of attached cells,
the low fluorescence readings may be due to the fibroblast cells not being able to adhere
to the polymer films when greater than 1% surfactant is used in the emulsion. If this were
the case, then this would indicate that the fibroblast cells may not have been damaged by
any toxic effects from the films, but they were unable to adhere to the films, thus the low
fluorescence readings obtained from the assay; therefore, the second set of data shown in
Figure 7.19B is more reliable and was determined to be reproducible.
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Figure 7.20. Images of fibroblast cells that were exposed to 80mg pieces of control
polymer film samples.

As seen in Figure 7.20, the polymer film samples containing only 1% SDS did not appear
to have visibly affected the cells’ viability or altered their confluency. This supports the
data obtained in Figure 7.19B, which showed fluorescence readings for CNP16 and
CNP17 equal to those of the control cells. Polymer films that contained 5% SDS in their
formulation were only analyzed in the initial CyQUANT assay due to the observed
toxicity, and in many wells precipitated excess surfactant onto the fibroblasts. This was
most likely the cause of the observed toxicity, and therefore, only formulations
containing 3% SDS were further analyzed by the MTT assay. The films containing 3%
SDS (CNP7 and CNP12) in Figure 7.19 show viable cells present in the wells, but not as
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dense or confluent as the control cells or cells treated with CNP16 or CNP17. These cells
appear fatter than the control cells; however, they are all attached to the wells, indicating
cellular viability. These findings support the data obtained from the CyQUANT assay in
Figure 7.17B.
The data presented in this section supported the data in Section 7.3.1, that emulsion
polymerization formulations that contained 3% SDS or less are non-cytotoxic to dermal
fibroblast cells. This was not only true for the emulsions, but also for the polymer films.
The films displayed even less cytotoxicity than the parent emulsion, most likely due to no
chance of intercellular interactions with the polymer films, unless surfactant or radical
initiator is leeched from the films, as was seen for the 5% SDS films (CNP 9, 10, 13, 14).
Overall, when pieces of polymer film samples that are formulated with less than 5% SDS
are in direct contact with healthy human dermal fibroblast cells, no cytotoxic effects are
observed.

7.4.2

Drug-Conjugated Polymer Films

Figure 7.21. CyQUANT assay of drug-conjugated polymer films. All samples weigh
approx 80mg and are a mix between 3% SDS and 1% SDS films.

Figure 7.21 shows that many of the drug-conjugated films were non-cytotoxic at 80mg
pieces of film. The film samples were all washed for 2 hours with 70% ethanol then
allowed to air dry overnight in a biosafety class 2A cabinet to kill any microbes adhered
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to the film samples prior to analysis. Polymer films containing acrylated penicillins
(NP11, NP12, and NP15) and ciprofloxacin acrylated monomers (NP7 and NP8) all
displayed lower than normal fluorescence readings, while the lactam-conjugated film
NP1 displayed no cytotoxic affects, according to the data. However, visual observations
of the fibroblast cells (Figure 7.22) did not concur with the data in Figure 7.21, since,
upon observation, many of the wells containing these film samples possessed healthy
elongated fibroblast cells, and cells exposed to NP1 were not nearly as healthy as some of
the other treated cells (Figure 7.22).

Figure 7.22. Image of fibroblast cells exposed to NP1 and NP7 film samples.

Some samples caused a sediment to form on the cells, as was seen for many of the 3%
surfactant-containing films, yet the cells below the sediment all appeared viable and
attached to the wells. Cells exposed to NP7 and NP8 appeared to have the same density
of cell population as the control cells, and all were elongated and attached to the well,
with a few spherical but attached cells also observed (Figure 7.22), which is in complete
contrast to the data in Figure 7.21. This is just one of the inconsistencies observed with
data from this particular CyQUANT assay, which was not observed for any of the other
experiments using this assay. However, this assay also posed a problem when analyzing
the lactam monomers due to the spherical morphology observed for some of the treated
cells. Unfortunately, the MTT assay was not able to be used for the drug-conjugated and
multi-drug conjugated film samples, which may have most likely supported the visual
findings over the CyQUANT data. Therefore, no real conclusions can be made from the
presented data in this section due to the inconsistency of the findings. However, since
emulsions of these drug-conjugated nanoparticles were non-cytotoxic, and the drug-free
polymer film samples were non-cytotoxic (Section 7.4.1), it is reasonable to surmise that
the drug-conjugated polymer films are also non-cytotoxic.
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7.4.3 Multi-Drug Conjugated Films

Figure 7.23. CyQUANT assay on multi-drug conjugated polymer film samples.

Some cellular lysis debris was observed for cells exposed to MDNP2, but also in these
wells were healthy elongated cells, as well as some spherical cells, which are not
incorporated into the CyQUANT data since they do not adhere to the wells. This
indicates that the 3% surfactant in the MDNP2 formulation is slightly cytotoxic when
analyzed in vitro against healthy fibroblast cells. Therefore, the MDNP1 formulation,
which contains only 1% SDS, is the better choice than MDNP2 for biomedical
applications since it has been shown to be non-cytotoxic. Also, the data presented in
Figure 7.23 for MDNP1 did not concur with the visual observations of the cells exposed
to this film sample. The fibroblasts exposed to MDNP1 maintained an attached,
elongated morphology and the cell population in the wells appeared dense. While some
of the cells appeared fatter than the control cells, similar to cells exposed to DMSO in
Figure 7.8, these cells were still viable and should have been detected in the CyQUANT
data. Since cellular debris was observed in the control wells, the actual cell count
measured in these wells may be artificial and higher than expected due to the DNA from
the lysed cells contributing to the CyQUANT assay data. The data obtained for the
control cells and the cells exposed to MDNP1 are similar, indicating that the multi-drug
conjugated polymer film was non-cytotoxic to the healthy dermal fibroblast cells.
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7.5 Toxicity Analysis of Surfactant
After analysis of the drug-free emulsions and the drug-free polymer films, it became
apparent that the amount of surfactant was a contributor to the observed toxicity for some
of the formulations. CyQUANT analysis was therefore done on the free surfactant used,
dodecyl sulfate sodium salt (SDS), in order to determine the degree of toxicity. The hope
of this study was to determine at what concentration the SDS could be used in the
emulsions that would not produce a cytotoxic affect on the fibroblast cells.
Various concentrations of SDS dissolved in sterile saline were added to attached
fibroblast cells and allowed to incubate overnight. CyQUANT assay was then performed
on the attached fibroblast cells. Results showed that all levels of SDS were highly toxic to
the human dermal fibroblasts (Figure 7.24). While one percent surfactant displayed the
least amount of toxicity, the number of healthy attached cells for this concentration was
still drastically lower than the cells in the control wells.

Figure 7.24. CyQUANT analysis of SDS added to attached fibroblast cells in culture
media. Control cells were exposed only to the culture media, and SDS was applied to the
cells dissolved in double distilled water.

Since the drug-free emulsions did not exhibit toxic effects nearly as severe as the effects
observed for SDS alone, it was determined that in order to understand the toxicity
observed in the emulsions, the SDS should be analyzed in the presence of one of the least
toxic emulsions to determine if any interactions between the nanoparticles and the SDS
can decrease the observed toxicity.
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Various amounts of SDS were mixed with 0.1mL of an emulsion made with 5% solid
content to obtain the same concentrations as were tested for the SDS alone. At 5% solid
content, the amount of inherent SDS in the emulsion is 0.75%, therefore, this
concentration was adjusted by adding additional SDS to the emulsion to reach the
concentrations previously analyzed. The new emulsions were then added to the attached
fibroblast cells in 20µL volumes and incubated overnight. CyQUANT assays were then
performed on the attached cells.

Figure 7.23. CyQUANT analysis of SDS toxicity when added to attached fibroblast cells
in combination with CNP5 at 5% solid content. Control cells were exposed only to the
culture media, and SDS was added to the CNP5 emulsion after being diluted to 5% solid
content concentration to obtain the specified percentages of SDS in the emulsion.

Results in Figure 7.23 showed that when combined with control nanoparticles prior to
addition to healthy fibroblasts, the surfactant was much less toxic than when added to the
cells without the control nanoparticles, and showed only weak toxicity at 1%. At
concentrations of 7% and 9% SDS, all fibroblast cells were killed by the treatment. These
results for 1% SDS may be due to interactions of the surfactant with the nanoparticles,
which may prohibit the surfactant from interacting with the cells. Upon dilution of the
emulsion to 5% solid content, a great majority of the unused surfactant is removed,
thereby leaving behind room for more surfactant to be added to the emulsion. However, it
appears that the nanoparticles become saturated between 1 and 2% SDS, which would
explain the regained toxicity at 3% SDS. Subsequently, it also appears that at 3 and 5%
SDS, the surfactant is able to remain in solution for the most part, which would explain
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why some viable cells were observed. Yet at 7% and higher, all of the excess SDS most
likely precipitated onto the cells in culture, creating an extremely toxic environment for
the cells.
This study has lead to the conclusion that 1% SDS in the emulsion polymerization
process is optimal for in terms of minimizing cytotoxicity, and therefore, emulsions of
CNP15, CNP16, and CNP17 were prepared containing only 1% SDS. Also, due to the
results of this experiment, the multi-drug conjugated system MDNP1 made with 1% SDS
displayed less cytotoxicity than the 3% SDS-containing MDNP2. As seen in sections 7.3
and 7.4, these emulsions and polymer films were completely non-toxic to the fibroblast
cells, as determined by both CyQUANT and MTT assays. Therefore, this study was
crucial to obtaining an optimal emulsion formulation for the multi-drug conjugated
nanoparticles, as well as polymer film samples, for some of the intended biomedical
applications.

7.6 Conclusions
It was determined from various toxicity assays that the β-lactam monomers are noncytotoxic when prepared fresh, have not been dissolved in DMSO for a long period of
time, and are of high purity. Otherwise, the lactams cause the fibroblast cells to either
remain in the spherical morphology, or cause the cells to detach from the wells and return
to their spherical morphology. This is most likely caused by impurities in the lactam
samples interfering with the proteins and complexes involved in cellular adhesion.
However, when purified lactam samples are used, cytotoxicity can be avoided.
As was expected, all of the acrylated commercially available drug monomers were noncytotoxic based on both the MTT and CyQUANT assays. As was the case with the
lactam monomers, purity of the monomer and the DMSO it is dissolved in can cause
toxic effects on the fibroblast cells; however, when purified, and fresh DMSO is used, no
cytotoxic effects were observed for any of the commercially available drug acrylates.
Initial toxicity assays with CyQUANT DNA binding dye and the control emulsions
showed that the emulsions formulated with 5% weight percent of SDS caused toxic
effects in the fibroblast cells, as did the emulsions formulated with 3% SDS to some
extent. This was why the control emulsions CNP15, CNP16, and CNP17 were
formulated with 1% surfactant and then analyzed for cytotoxicity. After issues with
polymer precipitation in the cell culture wells were worked out by diluting the emulsions
to at least 5% solid content prior to exposure to the fibroblast cells, it was determined that
the emulsions containing 3% or 1% SDS were non-cytotoxic. It was concluded from this,
and from the SDS concentrations analysis, that 5% SDS was excessive for the emulsion
formulation since no detrimental effects are observed when all of the surfactant is utilized
by the nanoparticles. Therefore, all of the remaining drug-containing emulsions were
formulated with 1% SDS.
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All of the polymer film samples analyzed that contained less than 5% SDS were
completely non-cytotoxic to the fibroblast cells. Toxicity was observed for the polymer
films only when excess ethanol remained on the films, or when polymer films where not
allowed to fully form and some of the emulsion remained, which then precipitated in the
culture media and on top of the fibroblasts. Polymer films containing 5% SDS caused the
culture media to become cloudy white when added to the wells, further indication that
this amount of SDS in the formulation is excessive and causes toxicity. While conclusive
data was not obtained for any of the single or multi-drug conjugated polymer film
samples, visual observations of the cells showed little to no cytotoxic effects on the
fibroblast cells, depending on the surfactant concentrations of the films. Results from the
drug-conjugated emulsion in vitro assays also support the conclusion that these drugconjugated films are non-cytotoxic towards human dermal fibroblast cells when SDS
levels are below 3%.
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CHAPTER 8
In vivo BIOCOMPATIBILITY OF PENICILLINCONJUGATED NANOPARTICLE TREATMENT FOR
MRSA INFECTIONS
8.1 Introduction
Microbial drug resistance has become a widespread problem in hospital and non-hospital
environments, and currently used treatments for these infections have become less
effective.[1] One of the most predominant and deadly of these drug resistant microbes is
methicillin-resistant Staphylococcus aureus (MRSA), which is an opportunistic pathogen
commonly invading skin and soft tissue abrasions and wounds causing bacteremia and
eventually leading to sepsis and toxic shock syndrome, often resulting in morbidity for
patients.[2-4] In burn centers, it has been reported that patients treated with β-lactam
antibiotics for wound infection are nine times more likely to develop an MRSA strain in
the wound bed.[5] This is due to the rapid formation of Staphylococcal resistance when
exposed to this type of antibiotic. This problematic bacteria has been responsible for
nearly 4,000 deaths each year in the United States alone, and antibiotic therapy has been
reduced to only a select few approved therapies, such as glycopeptide-type drugs and
oxazolidinones, due to rapidly formed resistance that continues to evolve each year.[5-9]
As many bacteria, including MRSA, become increasingly resistant to commonly used
antibiotics, a growing need for new drug design, discovery, and delivery methods has
surfaced and requires immediate attention. While many water-soluble antibiotics are able
to act on microbial infections once they have reached the blood stream, these drugs are
not able to reach the root of the problem, which often occurs in areas where water-soluble
drugs are ineffective. Yet lipophilic antimicrobials are also ineffective here as well due to
a lack of initial uptake by the body in order to reach these sites.[10, 11] Often such systemic
infections, frequently caused by drug resistant bacteria, are initiated in fatty tissue areas,
such as skin and soft tissues or on the surface of implanted medical devices where highly
drug resistant microbial biofilms often form.[12] Being able to treat such infections not
only within the blood stream but also at the site of initiation with multiple drugs would be
optimal due to a reduction in the risk for cross-resistance that often occurs when using a
single antibiotic.
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Figure 8.1. Representation of the emulsion polymerization with acrylated penicillin G
monomer (13).

As described in Chapters 3 and 4, novel drug-conjugated nanoparticles synthesized
through a single step emulsion polymerization process are a promising new way to
combat this solubility and bioavailability issue against drug-resistant bacteria, including
MRSA.[12, 13] This nanoparticle delivery system has proven to be an effective way of
shielding the antibiotic from resistance factors prior to direct contact with the bacteria,
thus rejuvenating the activity of the β-lactam-based antibiotics against β-lactamase
producing bacteria such as MRSA.[13] This drug delivery system has been established in
vitro for nanoparticle systems containing both individual covalently bound antibiotics, as
well as with multi-drug conjugated nanoparticles, and has shown potent anti-MRSA
activity, as well as potent activity against P. aeruginosa and other common opportunistic
pathogens known to invade skin wounds. The anti-MRSA activity was observed even
when the usually inactive penicillin G is the bound drug, thereby providing a promising
new method for combating microbial drug resistance and many forms of Staphylococcus
infections.[13] The most common and dangerous route of infection for MRSA and other
opportunistic pathogens has been through dermal abrasions, which often lead to bloodborne systemic infections if left untreated. The biocompatibility of the single and multi
drug-containing nanoparticle emulsions has been established in vitro using human dermal
fibroblast cells, and results have shown that the acrylated drug monomers and the
resulting drug-containing emulsions have no toxic effects on the cells (Chapter 7). In
order to establish the efficacy of the nanoparticle system in treating MRSA infections in
an in vivo setting, biocompatibility of the most promising penicillin-containing emulsion,
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NP13, and the multi-drug conjugated emulsion MDNP1 was established in vivo. NP13
and its non-drug analogue, CNP16, were prepared as formulated in Table 8.1. NP13 has
5% by weight of penicillin G monomer 13.

Table 8.1. Formulations for CNP16 and NP13 tested in vivo.

Monomers in Emulsion

CNP16

NP13

0%

5%

18.5%

13.5%

Nano-purified Water

80%

80%

Sodium Dodecyl Sulfate

1%

1%

0.5%

0.5%

Penicillin G Acrylate
Monomer (13)
Butyl Acrylate: Styrene
(7:3 Ratio)

Potassium Persulfate

The biocompatibility of the drug-conjugated and drug-free emulsions (CNP16, NP13,
and MDNP1) was established in vivo by either intraperitoneal injection or by topical
application to a skin abrasion in mice models. For the multi-drug conjugated emulsion,
MDNP1, biocompatibility was only determined by topical administration and served as
an initial study for determining the efficacy of the emulsion for burn wound infection
treatment. To determine if the penicillin-conjugated nanoparticle emulsion could be used
as a prophylaxis treatment, systemic administration was one of the routes chosen for
toxicity analysis. Also, since one of the most dangerous routes of infection for MRSA is
through skin and soft tissue abrasions due to the high risk of sepsis and TSS forming,[2, 5,
8]
topical administration on the emulsion was also chosen as a route of administration.
However, since the emulsion would be applied to skin that is not intact and is therefore
more sensitive and vulnerable to toxicity when treating this form of infection, an abrasion
model was chosen to test the biocompatibility and/or toxicity of the emulsions when
applied topically. The dose concentration and regimen were varied for all three
nanoparticle-based emulsions administered, and saline controls were employed to provide
a base for the cytokine levels in blood serum, as well as to observe any variances in the
skin/soft tissue wound healing process. Biocompatibility was ultimately established by
determining cytokine levels in the blood serum of the mice at days 8 and 14 of the study,
which translates into detection of an inflammatory response at those time points. Toxicity
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and/or overall animal health and well being was determined visually by monitoring
animals for signs of pain, irritation, inflammation, discomfort, and distress.

8.2 Effect of Nanoparticle on Systemic Application in Mice Models
8.2.1 Visual Analysis of Toxicity
All mice injected into the peritoneal cavity with high concentrations of the emulsions
(>1.5 weight % of solid content), whether containing penicillin G or not, endured
polymer precipitation within the peritoneal cavity. However, the amount of precipitated
polymer observed decreased parallel to decreasing the solid content of the emulsions.
Polymer was observed trapped in the subcutaneous region of the abdomen as well as
attached to many vital organs, mucous membranes, and adipose tissue within the
peritoneal cavity, yet all organs and internal systems seemed to be healthy and appeared
consistent with normal size and coloring.

Figure 8.2. Effects of systemic nanoparticle administration. A) Subdermal area of mouse
treated with 5% solid content CNP16, unpurified. B) Polymer from 5% NP13 purified
emulsion clustered on the inside of the peritoneal cavity lining and various internal
organs. C) Polymer from 5% NP13 purified emulsion clustered in the fatty tissue
covering the lower abdomen and within the mucous membranes affixed to the large and
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small intestines. D) Peritoneal cavity of mouse treated with 0.25% NP13 unpurified. E)
Peritoneal cavity of mouse treated with saline solution.

It was determined that the precipitated polymer concentrated in highly lipophilic areas,
such as in the mucous membranes. At concentrations of 3% solid content and higher,
some abdominal distension was observed, however, this was not the case with all mice
receiving these concentrations, and no signs of pain were observed upon abdominal
examination. Mice receiving emulsions below 3% solid content showed no physical signs
of abdominal pain or distension, nor any signs of sensitivity or overall discomfort. At
concentrations below 1.5% solid content, little to no polymer precipitation was observed.

8.2.2 Biochemical Analysis of Blood Samples
Cytokine levels in the blood samples taken on days 8 and 14 of the study were analyzed
using an enzyme-linked immunosorbent assay (ELISA) kits for detection of interleukin 6
and tumor necrosis factor alpha. Both these cytokines are key factors in the innate
inflammatory response of the mouse, and an increase or decrease in the levels of the
cytokines in the blood relates directly to the toxicity of the treatment applied. Very little
variance in the levels of IL-6 were observed for any of the mice treated with the
emulsions, however, there were observed differences in the levels of TNF-α. At higher
solid content concentrations (5% and 3%), unpurified samples produced very low
concentrations of TNF-α as compared to the saline-treated mice. While a decrease in
these levels does not indicate an inflammatory response, this could mean that the
emulsions that precipitated in the peritoneal cavity may have affected other processes,
which caused the levels of TNF-α to drop in the blood serum. However, since the levels
of TNF-α were not raised, nor were the levels of IL-6, this implies that even with
polymer precipitated in the peritoneal cavity, that the polymer itself is biocompatible and
did not illicit an inflammatory response.
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Figure 8.3. Comparison of the levels of TNF-α to IL-6 in mice when 0.1mL of
unpurified NP13 emulsion is injected intraperitoneally twice a day for 8 days.
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A purification process for the nanoparticle emulsion, prior to injection in mice, using low
resolution centrifugation was employed in an attempt to reduce the degree of polymer
precipitation once administered. As shown in Figure 8.2, this process did not drastically
alter the amount of polymer precipitation upon intraperitoneal injection when analyzed at
5%, 3%, 2%, 1.5% solid content, although no polymer was observed outside the
abdominal wall or attached to the peritoneum at 3% solid content and below. Purified
solutions were more smoothly injected, however, and appeared to enter the peritoneal
cavity easier than the unpurified counterpart emulsions. As seen in Figure 8.4, the TNFα concentration for mice receiving 3% solid content was increased to match levels
observed for saline-treated mice by this purification process but not for the IL-6
concentration, where the purified and unpurified emulsions produced concentrations
comparable to that of saline-treated mice. At solid content levels below 3% (for the
centrifuged nanoparticle sample), there was no statistical difference between the
concentration of the cytokines for the saline-treated and the nanoparticle-treated mice.

Figure 8.4. Comparison of TNF-α concentrations for purified versus unpurified NP13
samples at various solid content concentrations.

Figure 8.5 illustrates that there was no difference in the levels of cytokines for mice
treated with CNP16 versus NP13. Polymer precipitation occurred for both of the purified
(centrifuged) formulations at the 5% and 2% solid content concentrations, regardless of
whether drug was present in the emulsion or not.
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Figure 8.5. Comparison of cytokine levels for purified NP13 and CNP16 emulsions.
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8.2.3 Analysis of the Findings
Systemic application of the nanoparticle-containing emulsions proved to be somewhat
problematic in terms of polymer coagulation upon injection into the mouse model.
Coagulation consistently occurred in highly lipophilic regions of the peritoneal cavity,
such as in the mesentery membrane of the intestines, the peritoneum, within adipose
tissue in the lower abdominal region, and on the exterior surface of the stomach, liver,
and pancreas. This is most likely due to the presence of non-SDS stabilized polyacrylate
strands in the emulsion that precipitate upon contact with mucous membranes.
This issue was resolved through purification processes and dilution of the solid content
concentration to below 1.5%. While these procedures reduced the amount of drug able to
be administered in a single dose, higher dose volumes and more frequent applications can
in principle be achieved at these lower concentrations. The presence of covalently bound
penicillin to the polyacrylates did not affect whether or not the polymer precipitated upon
intraperitoneal injection, and also did not appear to have any difference in cytokine levels
upon administration. Thus, the drug-conjugated and drug-free emulsions behaved equally
within the mouse model. Overall, the drug-conjugated nanoparticle system proved to be
completely non-toxic and biocompatible upon intraperitoneal injection when at solid
content levels below 1.5%, with or without post-polymerization purification.

8.3 Effect of Penicillin Nanoparticles upon Application to Dermal
Abrasion
8.3.1 Visual Analysis of Inflammation or Irritation
All mice responded well to the nanoparticle treatments, with no observed inflammation
or irritation on or around the abrasion throughout the study. Mice receiving only saline
treatments showed extended periods of irritation and inflammation due to bacterial
infection during the first few days of the study. These mice took an average of 3 days
longer to heal from the dermal abrasion than mice receiving emulsion treatments, usually
between days 6 and 8 of the study, with some taking even longer to heal.
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Figure 8.6. Mouse treated with saline solution three times a day. An obvious
inflammation appeared in the wound area on day 3, indicating a possible bacterial
infection. Wound healing was setback an additional 2 days, and was still not fully healed
by day 8.

The mouse in Figure 8.6 receiving saline treatments three times a day appeared to have
contracted an infection by day 3, apparent by the sudden redness and inflammation on the
abrasion area, thus the wound appears more prominent. The infection appeared to have
cleared by day 5, where the wound again looks similar to its progress on day 2. This kind
of setback in the wound healing process was not observed for mice receiving treatment
with any of the nanoparticle emulsions at any level of solid content studied.
The mouse in Figure 8.7 was likewise treated with the nanoparticle emulsion NP13
receiving 9% solid content by spraying the emulsion onto the area. The images of the
treated mouse showed healed abrasions as early as day 2 of the study when applied three
times a day, and by day 4 when applied two times a day. Mice receiving lower solid
content concentrations, (2% and 5% solid content) showed healed abrasions as late as day
5 and 6 of the study.
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Figure 8.7. Mice treated three times a day with 9% solid content NP13 (0.1mL). The
abrasion was almost fully healed by day 2, and fur re-growth was almost confluent by the
final day of the study (day 14).
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Figure 8.8. Mice treated two times a day with 9% solid content NP13 (0.1mL). The
abrasion was fully healed by day 5 and fur re-growth was almost completely confluent by
day 14.

Fur re-growth began on the final day of treatment for mice receiving nanoparticle
emulsions three times a day and even earlier for mice who received nanoparticle
treatments twice a day. All mice, including the saline-treated ones, displayed some fur regrowth by day 10 of the study. Polymer clumps formed on the surface of the abrasion
region after the abrasion was fully healed, indicating that the emulsion treatment was no
longer necessary. No precipitated polymer was observed below the dermis on the dorsal
area or within the peritoneal cavity. Pathology performed on the treated animals
confirmed that all internal organs appeared healthy and of normal size and color for all
emulsions examined.

8.3.2 Biochemical Analysis of Blood Samples
The levels of IL-6 in mice treated with either CNP16 or NP13 were not elevated beyond
those of mice treated with only saline. Since the earliest blood samples were taken on day
8 of the study, and any bacterial infections observed in saline-treated mice were cleared
by day 5, it is practical to believe that the levels of pro-inflammatory cytokines such as
IL-6 and TNF-α would be back to a normal level by day 8 for these mice.
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Figure 8.9. TNF-α concentrations in the blood serum of mice treated with various
concentrations of CNP16 and NP13 two or three times a day.
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Figure 8.10. IL-6 concentrations in the blood serum of mice treated with various
concentrations of CNP16 and NP13 two or three times a day.
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As observed in Figure 8.9, some variance was observed with the levels of TNF-α for the
treated versus untreated mice, where CNP16 showed elevated levels at 7% and 9% solid
content when treated 2x a day but not 3x a day, on the final day of the study as did NP13
at 9% solid content applied twice a day. However, since all of the treated and untreated
dermal abrasions were fully healed and all of the fur re-grown over the abrasion area
without any observance of redness or irritation, these elevated levels may have been
caused more directly by an environmental or metabolic factor and is not directly related
to the nanoparticle treatments. Also, since the nanoparticle treatments were stopped on
day 8, where no elevated levels of TNF-α were observed, this also further points to an
outside factor affecting the levels of TNF-α for these mice.

8.3.3 Analysis of the Findings
Application of the nanoparticle-containing emulsions to the dermal abrasions displayed
not only minimal toxicity, but also great advantages for the healing wound. Results of
this study showed that not only did the polymeric film that formed over the wound
protect it from invading pathogens, but also became an integral part of the freshly
forming skin layers. Removal of film-coated fur clumps stuck to the surface of the
abrasion due to the film binding the fur to the abrasion surface caused fresh abrasions to
appear within 8 hours, thus indicating infiltration of dermal fibroblast and epidermal
keratinocyte cells into the polymer film matrix.
All of the results for every concentration of emulsion produced no problematic effects on
the abrasion area. No redness, irritation, or inflammation was observed for any mice
treated with the emulsion, and all mice appeared healthy and active throughout the study.
Most mice did not appear to notice the film on the dorsal surface, and no mice were
observed rubbing the area against other objects in an attempt to remove the film. This
indicates that the mice were very tolerant of the film and did not feel any pain or
discomfort associated with the treatment. No polymer clumps were observed in the
subcutaneous region or below that, and no clumps were observed within the skin layers
as well. However, this does not preclude the fact that the nanoparticles may have been
able to migrate through some of the skin layers. Further studies need to be performed in
order to determine the extent of nanoparticle infiltration into the epidermal and possibly
the dermal layers or even if the nanoparticles in the emulsion are necessary.
As the polymeric film forms on the abrasion surface, the area does not dry out or become
rigid. In fact, the polymer film blended in smoothly with the skin and maintained the
same mechanical properties as the skin upon application, thereby allowing the animal to
move naturally. The fact that the skin area did not dry out or become rigid, indicates that
this treatment was able to provide the wound bed with the moisture and oxygen needed to
heal properly, which could be one of the reasons for the enhanced healing effect. Had no
oxygen or nutrients been able to penetrate the film and reach the wound bed, as needed
for healing, a delayed healing process would have been expected, which was not
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observed. With small abrasions, this is not that significant, but in the application of much
larger or deeper wounds, having uninhibited access to oxygen and nutrients from the
surrounding healthy tissue is vital for recovery.
These results demonstrate the biocompatibility of the emulsions and the ability of the
resulting polymeric film to serve as a foundation for regeneration of skin layers. Films
were never observed sloughing off the area, even upon complete wound healing, thus
further indicating the incorporation of the emulsion into the wound healing process and
absorption of the emulsion down into the freshly formed dermal and epidermal layers.

8.4 Affects of Multi-Drug Conjugated Nanoparticles on Dermal
Abrasions
8.4.1 Visual Analysis of Inflammation and Irritation
The multi-drug conjugated nanoparticle emulsion MDNP1 was applied to dermal
abrasions at 7% and 5% solid content three times a day for eight days. Mice receiving 5%
solid content took longer to heal (approx 7 days) than the mice receiving 7% solid
content. Neither emulsion caused any signs of inflammation or irritation in the abrasion
region or surrounding areas, and all mice formed healthy pink skin where the abrasion
was originated. After the abrasions fully healed, continued application of the emulsion to
the abrasion region caused clumps of polymer film to form in the area of application,
indicating that the emulsion treatment is no longer necessary (Figure 8.11, day 8). Mice
who received 7% solid content MDNP1 healed faster than mice receiving 9% solid
content of NP13 and CNP16 twice a day, and also faster than mice receiving 7% solid
content CNP16 three times a day, and were fully healed by the end of day 4 (Figure
8.11). This further suggests that application of the emulsions three times a day is most
optimal for fast wound healing and that the presence of antimicrobials does speed up
wound healing probably by eradicating bacteria from the wound. However, the treatment
should be discontinued upon complete wound healing in order to allow fur re-growth in
the abrasion area since application of the emulsions three times a day appears to inhibit
initiation of fur re-growth, while applications of emulsions only twice a day did not.
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B

Figure 8.11. Effect of MDNP1 on skin abrasions. A) Mice treated three times a day with
7% solid content MDNP1. B) Mice treated three times a day with 5% solid content
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MDNP1. Mice receiving 7% solid content are fully healed by day 4, and mice receiving
5% solid content were fully healed by day 7.

In Figure 8.10, the skin on the dorsal area is a healthy soft pink on days 8 for mice treated
with either 5% or 7% solid content. By day 2, wound contraction was visible for all mice
treated with MDNP1, and on day 3, slight scabbing was observed in the abrasion area for
mice treated with 7% solid content. Fur re-growth began on day 9 and reached
confluency by day 14 of the study.

8.4.2 Biochemical Analysis of Blood Samples
Biochemical analysis of the blood samples of topically treated mice further corroborates
the visual observations from this study (Figure 8.12). Levels of both IL-6 and TNF-α
were equal for mice receiving MDNP1 and saline only. The level of TNF-α on day 8 for
mice receiving 5% solid content were much higher than those observed for mice
receiving saline only or 7% solid content, but this is believed to be due to an infection in
the ear hole punch the mice received and not from the emulsion treatment, since the
cytokine concentration was dramatically reduced by day 14, long after the ear hole
infection cleared. This is mostly likely the cause of the variance in trend seen between
mice receiving 7% solid content and saline and mice receiving 5% solid content.
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Figure 8.12. Comparison of TNF-α and IL-6 concentrations for mice receiving MDNP1
three times a day.
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The levels of IL-6 were also slightly higher, on average, for mice receiving 5% solid
content, yet the trend in levels was the same for all samples analyzed. This heightened
cytokine level for mice receiving 5% solid content also supports the conclusions from the
TNF-α concentration abnormalities.

8.4.3 Analysis of the Findings
The data suggests that the multi-drug conjugated nanoparticles are completely non-toxic
to skin abrasions when applied topically at solid content concentrations as high as 7%. It
also suggests that the nanoparticles are extremely beneficial to skin wounds in terms of
eradicating bacteria from the wound and by protecting the wound from invading
pathogens. The fact that cytokine levels for mice receiving 7% solid content were not
significantly different from those in mice receiving sterile saline treatments further
identifies this nanoparticle system as an optimal treatment for all forms of skin and soft
tissue wounds, and appears to represent all of the optimal qualities of current topical
antimicrobials without any observed side effects or drawbacks. However, this system
must be evaluated in a basic wound infection model in order to determine the extent of
antimicrobial activity in vivo prior to any further explorations into treatment of multiple
bacteria-contaminating burn wound infections.

8.5 Conclusions
A total lack of toxicity and high biocompatibility was found for both intraperitoneal and
topical administration for the nanoparticle-containing emulsions. Despite the occurrence
of polymer coagulation within the peritoneal cavity upon IP injection of the emulsions,
cytokine levels remained statistically similar to those of saline-treated mice. However,
coagulation was not a favorable attribute of the emulsion treatment and, therefore, the
solid content concentration was lowered to levels below 1.5% to avoid this issue. When
applied topically, concentrations as high as 9% solid content did not produce any toxicity
or inflammatory responses and cytokine levels also remained similar to those of salinetreated mice. Beneficial properties were observed for the skin abrasion treatments as well,
where the average time required for healing was decreased by 2-3 days, on average, with
the application of the emulsion. The ability to treat numerous bacterial strains at once and
also provide a protective covering over an open wound, through a sprayable
administration route decreases the need for physical contact between the patient and
medical professional and in turn decreasing the risk of nosocomial infection, the multidrug conjugated nanoparticle system should be considered a potentially groundbreaking
new treatment option for burn wound and other acute and chronic skin-based infections.
Moreover, the data from this study suggests that the multi-drug conjugated nanoparticle
emulsions are may be effective treatments for skin/soft tissue infections as well as for
systemic-based infections. The next step to determine this is to examine the nanoparticle
emulsions in an MRSA animal infection model.
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CHAPTER 9
CONCLUSIONS AND FUTURE WORK
The work presented in this dissertation has investigated a potentially new approach
towards the treatment of burn wounds. Many of the current techniques and treatments
employed in hospitals around the world are leaving patients open to microbial infection at
the early stages after thermal injury, where patients are most vulnerable to pathogenesis
at the injury site. Chapter 1 looked at many of the current treatment options available
(skin grafts and wound excision) for burn wound management, and found that many are
only able to be performed once the patient has become stable, leaving the patient open to
infection and a high risk of mortality. Topical antimicrobial mixtures are frequently
applied to the wound site during this time where surgical treatment cannot be performed,
however, due to the mode of application (direct application of creams and ointments to
the wound) and the frequency required for continual treatment, this form of treatment
tends to be very traumatic for the patient, and also heightens the threat of nosocomial
infection.
In this work, a representative selection of antibacterial drugs were synthesized or
obtained commercially and converted to acrylate or acrylamide analogues in order to
incorporate them into a water-based nanoparticle emulsion. Eight N-alkylthiolated βlactam monomers, as well as the commercially available drug monomers erythromycin,
doxycycline, amphotericin B, ciprofloxacin, cefaclor, penicillanic acid, penicillin G,
amoxicillin, and ampicillin were all incorporated into the nanoparticle drug delivery
system individually and both the acrylated drug monomer and the drug-containing
nanoparticle emulsions were analyzed in vitro for antibacterial activity.
Initially, the nanoparticle emulsion was designed to provide a water-based delievery
system for the water insoluble N-thiolated β-lactams. In Chapter 2, the mechanism of
action of the N-thiolated β-lactams was studied, as well as the selective antibacterial
nature of this class of antibiotics. The antibacterial activity of the acrylated commercially
available drugs was also established here. The water soluble commercially available drug
monomers chosen for this study (ciprofloxacin, cefaclor, ampicillin, penicillin G,
penicillanic acid, and amoxicillin) were all chemically modified to incorporate an
acrylate or acrylamide moiety prior to subjection to the emulsion polymerization, which
allowed them to be co-polymerized with the liquid acrylate co-monomers and
subsequently covalently bound to the polyacrylate backbone of the nanoparticle. While
many of the acrylated drug monomers displayed antibacterial activity, some lost most
their potency upon acrylation. However, after co-polymerization, the antibacterial activity
of the original antibiotic was restored, indicating that the drug monomer was most likely
being enzymatically cleaved from the polyacrylate backbone to an anctive drug form
upon interaction with the microbe. It was also observed for many of the acrylate-bearing
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β-lactam monomers incorporated covalently in the nanoparticle that the antibacterial
activity of the drug monomers against both MSSA and MRSA strains increased after copolymerization into the nanoparticle system. Further ex vivo studies need to be performed
with these drug-conjugated emulsions using purified enzymes to confirm these findings
on a biochemical level.
Another major discovery for the drug-conjugated nanoparticle emulsion system described
in Chapter 3 was that upon incorporation of a penicillin, especially when modified to
contain an acrylate moiety for polymerization rather than encapsulation, antibacterial
activity against MRSA was recovered. This discovery led to the conclusion that the
nanoparticle delivery system is able to protect the drug from degradative enzymes exuded
by the microbe. This finding was supported by microscopy studies that analyzed the
interaction of S. aureus with the drug-free nanoparticle emulsion CNP5, which ultimately
determined that the nanoparticles can either collapse at the surface of the microbial cell
wall to present the conjugated or encapsulated drug monomer to the microbe, or the
nanoparticle is taken up by the microbe through either endocytosis or phagocytosis,
where the particle is enzymatically degraded and the drug is then released directly into
the cytoplasm of the microbe. Stability studies of the drug-conjugated nanoparticle
emulsions determined that the particles are stable to normal mammalian
biomacromolecules, including various enzymes, that are present within the blood serum,
and therefore, only interaction with the microbe elicits the release of the drug monomer
directly into the microbe itself.
In order to improve the current standards in treatment of burn wound infections, the
possibility of incorporating more than one class of acrylated drug monomers into the
nanoparticle delivery system was explored. This ultimately led to the formulation of two
multi-drug conjugated nanoparticle emulsion systems, MDNP1 and MDNP2, where
MDNP1 was preferred for biomedical applications. In this emulsion, two novel Nalkylthio β-lactam monomers were incorporated into the nanoparticle system along with
an acrylated form of penicillin G and two analogues of the modified ciprofloxacin
acrylamide monomer, accordingly the emulsion with a broad spectrum of antimicrobial
therapy which is necessary for treating multiple microbes present in burn wound
infections. These drugs were chosen based on their antimicrobial activity against the two
most common pathogens found colonizing burn wounds, S. aureus and P. aeruginosa.
Incorporation of the N-thiolated β-lactams also provided the emulsion with antifungal
capabilities, especially against Candida albicans, the leading fungal species and strain
present in burn wounds. Equivalent levels of activity against both methicillin-sensitive
and resistant strains of S. aureus made this the best candidate for topical treatment of
burn wound infections.
Chapters 5 and 6 analyzed the ability of the nanoparticle emulsions to form a film upon
drying on any surface, making this ideal for topical applications that require both
antimicrobial therapy and additional coverage for wound healing. The polyacrylate films
formed from both the drug-containing and drug-free emulsions all exhibit viscoelastic
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properties consistent with natural pliant materials, such as the elastic constituent in skin
and soft tissue, making them candidates for biomedical applications that require
continuous stress/relaxation cycles. It was also determined that combination of the
nanoparticle emulsions with native collagen fibrils created the formation of a
biocomposite material applicable towards many biomedical applications that call for both
strength and elasticity of the material. These films were also determined to exhibit
antibacterial activity (Chapter 3) as well as the ability to prevent bacterial penetration into
underlying nutrient-rich media while still permitting diffusion of nutrients and other
small molecules such as oxygen, water (Chapter 5).
Chapter 7 looked at in vitro cytotoxicity studies performed using human dermal fibroblast
cells. Here, it was determined that all of the acrylated commercially available drug
monomers maintained their biocompatibility after chemical modification, and when
incorporated into the nanoparticle emulsion drug delivery system using 1% surfactant and
0.5% radical initiator, no cytotoxic effects were observed. It was also determined that the
polyacrylate polymer films formulated with 3% surfactant or less were non-cytotoxic as
well. Chapter 8 focused on in vivo studies performed using a mouse model in order to
determine if the drug-conjugated, multi-drug conjugated, or drug-free nanoparticle
emulsions created any toxicity or inflammation upon systemic and topical application.
The drug-free nanoparticle emulsion chosen for this study was CNP16, the single-drug
conjugated nanoparticle emulsion analyzed was the penicillin G acrylamide nanoparticle
emulsion NP13, and the multi-drug conjugated nanoparticle emulsion analyzed was
MDNP1. CNP16 and NP13 were analyzed at various concentrations for systemic
application of the emulsion, and it was determined that at 0.25% solid content, the
emulsions do not precipitate within the intraperitoneal cavity of the body, yet at
concentrations as high as 5% solid content, there were no raised levels of TNF-α or IL-6,
indicating that no inflammatory response was caused by the emulsion. A dermal skin
abrasion was inflicted on the dorsal surface of the mouse in order to establish
compatibility of the nanoparticle emulsions for topical treatment of skin and soft tissue
infections. Upon topical application of all three emulsions to the skin abrasion, no
inflammatory response or visible irritation was observed for any of the emulsions at
concentrations as high as 9% solid content. It was also established here that application of
the emulsions aided the wound healing process by decreasing the observed time needed
for complete healing of the abrasion, and also appeared to prevent bacterial infiltration
into the wound bed. Therefore, the multi-drug conjugated nanoparticle emulsion has the
potential to revolutionize burn wound treatment and provide optimal infection control
and prevention immediately after thermal injury.
The evidence from these studies, taken collectively, indicates novel properties and
potential applications of N-thiolated β-lactams, acrylated commercially available
antibiotics, and polyacrylate nanoparticle emulsions in human therapy, most specifically,
in the treatment and prevention of drug-resistant bacterial infections. The application of
burn wound infection treatment and prevention is continuing to be investigated, and
additional functionality of the multi-drug conjugated nanoparticles is being explored for
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this specific application, as well as continued in vivo analysis of the treatment in treating
and preventing infections. A variety of new studies are underway in the Turos laboratory
to explore and enderstand these properties and future opportunities.

266

CHAPTER 10
MATERIALS AND METHODS
10.1 Synthesis of Drug Monomers
All reagents were purchased from Sigma-Aldrich or Acros Chemical Company and used
without further purification. Solvents were obtained from Fisher Scientific Company.
Thin layer chromatography (TLC) analysis was carried out using EM Reagent plates with
a fluorescence indicator (SiO2-60, F-254). Products were purified by flash
chromatography using J.T. Baker flash chromatography silica gel (40 µm). NMR spectra
were recorded in CDCl3, unless otherwise noted. 13C NMR spectra were proton broadband decoupled. Dichloromethane was dried for many reactions by distillation at 40oC.

10.1.1 Synthesis of C3-alkoxy N-thiolated β-lactam Monomers
10.1.1.1 N-Anisylimine Formation (103)
Commercially supplied p-anisidine reagent was recrystallized using water heated to 60oC
and subsequently dried in vacuo. Aldehyde 101 and recrystallized p-anisidine (102) were
dissolved in dry dichloromethane and a catalytic amount of camphorsulfonic acid was
added to the mixture, which was then stirred at room temperature for 1-2 hours, with
progression of the reaction monitored by TLC. The resulting imine was then
recrystallized from cold methanol to give the pure final product, N-(4-methoxyphenyl)
imine 103 in 95% yield.

Cl

OCH3

O
H

O
SO3H

+
NH2

101

OCH3

cat.

CH2Cl2, rt

102

Cl

N
H
103

(E)-N-(2-Chlorobenzylidene)-4-methoxybenzenimine (103): yellow crystalline solid,
mp 51-52oC. 1H NMR (250 MHz, CDCl3): δ 8.94 (s, 1H), 7.4-6.9 (m, 8H), 3.85 (s, 3H).
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10.1.1.2 Acid Chloride Formation (104a and 104b)
104a: To a flame dried 250mL round bottom flask containing glycolic acid (10g,
0.13mol), acetyl chloride (20g, 0.26mol) was added in a dropwise fashion at 0°C. The ice
bath was then removed and the resulting slurry dissolved within 30 minutes, followed by
the formation of a white precipitate after 1 hour. Benzene (50mL) was then added to the
mixture and the reaction stirred for an additional 12 hours. The resulting solid was then
filtered and washed with benzene and cold methanol to give pure product 108a in 80%
yield (mp 62-63°C). The solid product (108a) was then treated with thionyl chloride
(31.8 g, 0.24 mol) by dropwise addition at 0°C while stirring, followed by removal of the
ice bath. The slurry was then stirred for 24 hours at 30°C, followed by distillation of the
resulting liquid in vacuo to give the acetoxyacetyl chloride (104a) in 70% yield.
O
HO

OH

O

RCl
0 oC

RO

O

SOCl2
OH

108

0

30oC
75%

RO

Cl

104a: R=Ac
104b: R=Me

104b: To a 250mL flame dried round bottom flask containing methoxyacetic acid (31.4g,
0.35mol), thionyl chloride (41.4 g, 0.35 mol) was added in a dropwise fashion while
stirring over 30 minutes at 0°C. The ice bath was then removed and the mixture was
stirred for an additional 12 hours at 30°C. The pale yellow product was then distilled to
provide pure acid chloride 104a in 75% yield (bp 112-113°C).
10.1.1.3 Synthesis of N-4-Anisyl Azetidin-2-ones (105a and 105b)
Imine 103 (3.00g, 1.22mol) was dissolved in 75mL dry dichloromethane with
triethylamine (TEA) (7.92mL, 6.11mol) at 0oC, followed by dropwise addition of the acid
chloride (104a or 104b) (1.57mL, 1.47mol) and subsequent removal of ice bath. After 34 hours, the product was dried in vacuo and the lactam product was recrystallized in
methanol to afford a white crystalline solid in 60-80% yield, depending on the alkoxy
acid chloride used. TLC in 2:1 hexanes:ethyl acetate showed single product formation
after 3.5 hours (Rf 105a= 0.38, Rf 103= 0.66)
OCH3
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Cl
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N
H
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TEA, CH2Cl2
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N
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RO
105a: R=Ac, 65%
105b: R=Me, 74%
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(±)-(3R,4S)-3-Acetoxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one
(105a): white crystalline solid, mp 130-132oC. 1H NMR (250 MHz, CDCl3) δ 7.43 (1H,
d, J = 8.9 Hz), 7.32-7.23 (5H, m), 6.83 (2H, d, J = 8.9 Hz), 6.16 (1H, d, J = 5.0 Hz), 5.78
(1H, d, J = 5.0 Hz), 3.76 (3H, s), 1.76 (3H, s); 13C NMR (63 MHz, CDCl3) δ 168.6,
161.3, 156.6, 133.8, 130.1, 129.9, 129.7, 128.6, 126.7, 118.5, 114.4, 75.4, 58.1, 55.3,
19.8.
(±)-(3R,4S)-3-Methoxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one
(105b): white solid, mp 183-184°C. 1H NMR (250 MHz, CDCl3): δ 7.47 (d, 1H, J = 6.7
Hz), 7.39-7.27 (m, 3H), 6.97 (bs, 1H), 5.25 (d, 1H, J = 4.5 Hz), 4.83-4.82 (app m, 1H),
3.26 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.5, 133.7, 133.1, 132.9, 129.2, 128.2,
126.9, 86.9, 59.0, 55.9.

10.1.1.4 N-Dearylation of β -Lactam Monomers
Five hundred milligrams of lactam 105a or 105b (1.58mmol) was dissolved in 15mL of
acetonitrile (0.03mL CH3CN per mg lactam). Ceric ammonium nitrate (CAN) (2.60g)
was dissolved in 23.6mL of d.i. H2O (0.009mL H2O per mg CAN), then the CAN
solution was added dropwise to the lactam solution over 30-40 minutes at -15oC. Product
was extracted with ethyl acetate, which was then washed with 5% NaHCO3, 10%
NaHSO3, followed by 5% NaHCO3 again and finally with brine solution and dried over
sodium sulfate. Product was removed in vacuo to yield 80-95% pure product. TLC
analysis using 1:1 hexanes:ethyl acetate revealed spot-to-spot conversion of reactant with
no by-products observed after aqueous work up.
OCH3
O

N

RO
105

Cl

o

CAN, -15 C
CH3CN / H2O

O

H
N

Cl

RO
106a: R =Ac
106b: R=Me

(±)-(3R,4S)-3-Acetoxy-4-(2-chlorophenyl)azetidin-2-one (106a): White solid, 93%
yield, mp 100-101oC. 1H NMR (250 MHz, CDCl3) δ 7.30-7.21 (4H, m), 5.85 (1H, d, J =
5.1 Hz), 5.46 (1H, d, J = 5.1 Hz), 2.16 (3H, s); 13C NMR (63 MHz, CDCl3) δ 173.2,
165.2, 134.5, 129.2, 128.9, 128.7, 127.8, 126.7, 80.0, 60.8, 17.8.
(±)-(3R,4S)-3-Methoxy-4-(2-chlorophenyl)azetidin-2-one (106b): White solid, 89%
yield (mp 116-118oC). 1H NMR (250 MHz, CDCl3): δ 7.47 (1H, d, J = 6.7 Hz), 7.39-7.27
(3H, m), 6.97 (1H, bs), 5.25 (1H, d, J = 4.5 Hz), 4.83-4.82 (1H, d, J = 4.5 Hz), 3.26 (3H,
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s); 13C NMR (63 MHz, CDCl3): δ 168.5, 133.7, 133.1, 132.9, 129.2, 128.2, 126.9, 86.9,
59.0, 55.9.

10.1.1.5 N-Thiolation of Lactam Monomers 106 and 108
Dissolved 100mg of N-protiolactam monomer (0.40mmol) in 10mL of dry
dichloromethane and 0.2mL of Hunig’s base (1.2mmol) was added to the mixture. The
solution was heated to 40oC, and after addition of 84.15mg N-alkylthiophthalimide (107a
or 107b, 0.36mmol) and the reaction was refluxed at 40oC for 24 hours, with monitoring
of the reaction progress via TLC. Colum chromatography was performed using various
solvent systems, depending on the lactam monomer synthesized, for final purification of
the product.
O
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Cl
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CH2Cl2, reflux
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S R'
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Cl

RO
2, 4, 6, 10

107
107a: R'= Me
107b: R'= sec-butyl

2: R= Ac, R'=Me
4: R=H,
R'=Me
6: R= Me, R'=Me
10: R= Me, R'=sec-butyl

(±)-(3R,4S)-3-Acetoxy-4-(2-chlorophenyl)-N-methylthio-azetidin-2-one (2): Colorless
crystalline solid, 87% yield, mp:174-176oC (Rf = 0.8 in 40:1 CH2Cl2:MeOH). 1H NMR
(250 MHz, CDCl3) δ 7.30-7.21 (4H, m), 5.85 (1H, d, J = 5.1 Hz), 5.46 (1H, d, J = 5.1
Hz), 2.43 (3H, s), 2.10 (3H, s); 13C NMR (63 MHz, CDCl3) δ 173.2, 168.2, 135.5, 129.2,
128.9, 128.5, 127.9, 126.7, 80.0, 60.8, 22.0, 16.8.
(±)-(3S,4R)-4-(2-Chlorophenyl)-3-hydroxy-N-(methylthio)azetidin-2-one (4): White
solid. 1H NMR (250 MHz, CDCl3) δ 7.44-7.24 (4H, m), 5.37 (1H, d, J= 5.0 Hz), 5.29
(1H, d, J= 5.0Hz), 2.51 (3H, s).
(±)-(3S,4R)-4-(2-Chlorophenyl)-3-methoxy-N-(methylthio)azetidin-2-one (6): White
crystal, mp 71-73°C. 1H NMR (250 MHz, CDCl3): δ 7.35 (1H, d, J = 7.4 Hz), 7.24 (3H,
m), 5.29 (1H, d, J = 4.9 Hz), 4.80 (1H, d, J = 4.9 Hz), 3.16 (3H, s), 2.40 (3H, s); 13C
NMR (63 MHz, CDCl3): δ 170.4, 133.8, 131.4, 129.6, 128.9, 126.8, 86.7, 62.7, 58.9,
21.8.
(±)-(3S,4R)-N-sec-Butylthio-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (10): Light
yellow oil, 51% yield (Rf =0.7 in 2:1 hexanes:ethyl acetate). 1H NMR (250MHz, CDCl3)
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δ 7.4 (1H, d, J = 7.4 Hz), 7.3 (3H, m), 5.3 (1H, d, J = 4.7 Hz), 4.9 (1H, d, J = 4.8 Hz),
3.2 (3H, s), 3.0 (1H, m), 1.48 (1H, m), 1.2 (3H, dd, J = 6.8, 4.9 Hz), 0.94 (3H, q, J = 6.0
Hz); 13C NMR (63 MHz) δ 171.0, 133.8, 131.4, 129.5, 128.9, 126.8, 86.3, 64.1, 58.8,
48.1, 28.1, 19.0, 18.6, 11.1.

10.1.1.6 Preparation of N-Alkylthiophthalimide Thiolating Agents (107a and 107b)
An alkyl disulfide reagent, either methyl or sec-butyl disulfide, was added to a slurry of
N-protiophthalimide in CH3CN and pyridine, then 1.2 equivalents of liquid bromine was
cannulated into the flask to generate the N-thiolated phthalimide product in situ. A
crystalline product was produced after recrystallization of the oil product in a solution of
ethyl acetate and hexanes.
O
o

'R

S

S

R'

Br2, CH3CN, 0 C

N R'

O

O

NH , pyridine

107a: R= Me
107b: R= sec-Butyl

O

2-(Methylthio)isoindoline-1,3-dione (107a): white crystalline product in 83% yield, mp
175-176oC. 1H NMR (250 MHz, CDCl3) δ 7.82 (4H, m), 3.77 (3H, s).
2-(Butylthio)isoindoline-1,3-dione (107b): crystalline solid, mp 43-45oC. 1H NMR (250
MHz, CDCl3): δ 7.83 (4H, m), 3.21 (1H, m), 1.55 (2H, m), 1.24 (3H, d, J = 6.8 Hz), 1.04
(3H, t, J = 7.3 Hz).

10.1.2 Synthesis of Acrylated N-Alkylthio β-Lactams
10.1.2.1 Deprotection of C3-Hydroxyl Group from N-Aryl Protected Lactam 105a
To a solution of 105a (838mg, 2.43mmol) in 10mL of acetone was added a solution of
KOH (273mg, 4.86mmol) in 2mL of MeOH at 0oC. The hydrolysis was complete only
10 minutes after the addition of KOH/MeOH, indicated by TLC monitoring (2:1
hexanes:ethyl acetate). The reaction was quenched by adding an equal volume of water
and product was extracted with ethyl acetate, dried over sodium sulfate, and isolated in
vacuo to yield 700mg of the product in 95% yield. (Rf 109= 0.38, Rf 105a=0.56)
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(±)-(3R,4S)-4-(2-Chlorophenyl)-3-hydroxy-N-(4-methoxyphenyl)azetidin-2-one
(109): white solid, mp 193-194oC. 1H NMR (250 MHz, CDCl3) δ 7.48 (1H, d, J = 7.5
Hz), 7.33-7.22 (5H, m), 6.84 (2H, d, J = 8.9 Hz), 5.63 (1H, d, J = 5.1 Hz), 5.33 (1H, d, J
= 5.1 Hz), 4.88 (1H, brs), 3.78 (3H, s); 13C NMR (63 MHz, DMSO-d6) δ 166.6, 156.1,
133.1, 132.9, 130.9, 129.7, 129.6, 128.9, 127.3, 118.6, 114.9, 77.2, 60.0, 55.6.

10.1.2.2 Acrylation of C3-Hydroxy N-Aryl β-Lactam (109)
Lactam monomer 109 (500mg, 1.65mmol) dissolved in 20mL of dry dichloromethane
was treated with 99mg of NaH (60% oil immersion, 2.48mmol) and stirred at 0oC for 10
minutes. Acryloyl chloride (0.16mL, 1.97mmol) was then added dropwise to the reaction
mixture at room temperature and the reaction was stirred for an additional hour while
monitoring via TLC (2:1 hexanes:ethyl acetate). Product was washed with water 2x
(20mL each) and subsequently dried over sodium sulfate and evaporated in vacuo.
Column chromatography was performed on the product using 4:1 then 2:1 hexanes:ethyl
acetate, which yielded 74% pure white crystalline product that precipitated from a dark
yellow oil. (Rf 110= 0.65)
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(±)-(3R,4S)-4-(2-Chlorophenyl)-3-acrylate-N-(4-methoxyphenyl)azetidin-2-one
(110): white crystalline solid, 74% yield, mp 180-182oC. 1H NMR (250 MHz, CDCl3) δ
7.45-7.22 (6H, m), 6.88 (2H, d, J = 8.8 Hz), 6.31 (1H, d, J = 4.8 Hz), 6.11 (1H, dd, J =
4.8, 15.2Hz), 5.85 (1H, dd, J = 4.9, 15.4 Hz), 5.81 (1H, d, J = 5.0 Hz), 5.71 (1H, dd, J =
4.8, 15.2 Hz), 3.72 (3H, s). 13C NMR (100 MHz, CDCl3) δ 163.9, 161.6, 159.9, 132.5,
130.5, 130.3, 130.0, 128.8, 127.8, 127.0, 126.7, 119.0, 118.9, 114.7, 114.4, 58.5, 55.6,
30.0.
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10.1.2.3 Dearylation of N-Aryl C3-Acrylate β-Lactam 110.
Procedure was followed as described in Section 10.1.1.4, with 84% yield of pure solid
lactam product.
(±)-(3R,4S)-3-acryloyloxy-4-(2-chlorophenyl)azetidin-2-one (111): tan to white solid
product. 1H NMR (400 MHz, CDCl3) δ 7.41-7.22 (4H, m), 6.59 (1H, bs), 6.21 (1H, d, J =
5.0 Hz), 6.08 (1H, dd, J = 2.4, 10.8 Hz), 6.04 (1H, dd, J = 2.4, 10.0 Hz), 5.80 (1H, dd, J =
2.4, 10.8 Hz), 5.39 (1H, d, J = 4.8 Hz). 13C NMR (100 MHz, CDCl3) δ 164.8, 159.9,
132.5, 130.5, 128.8, 127.8, 127.0, 119.0, 118.9, 114.7, 58.5, 55.6.

10.1.2.4. N-Alkylthiolation of N-Protio β-Lactam 111.
Procedure was followed as described in Section 10.1.1.5.
(±)-(3R,4S)-3-Acryloyloxy-4-(2-chlorophenyl)-N-mehylthioazetidin-2-one (1): White
solid in yield, mp:87-88oC. 1H NMR (250 MHz, CDCl3) δ 7.31-7.20 (4H, m), 6.15 (1H,
d, J = 3.6 Hz), 5.98 (1H, dd, J = 2.4, 11.6 Hz), 5.75 (1H, dd, J = 2.2, 9.2 Hz), 5.62 (1H,
dd, J = 2.4, 9.6 Hz), 5.47 (1H, d, J = 3.2 Hz), 2.45 (3H, s).13C NMR (63 MHz, CDCl3) δ
168.5, 163.6, 132.8, 132.5, 130.7, 130.0, 129.7, 128.8, 126.9, 126.8, 62.4, 55.4, 22.1.
(±)-(3R,4S)-3-Acryloyloxy-4-(2-chlorophenyl)-N-sec-butylthioazetidin-2-one
(3):
Colorless oil in 82% yield (Rf =0.70 in 2:1 hexanes:ethyl acetate). 1H NMR (250 MHz,
CDCl3) δ 7.31-7.20 (4H, m), 6.15 (1H, d, J = 3.6 Hz), 5.98 (1H, dd, J = 2.4, 11.6 Hz),
5.75 (1H, dd, J = 2.2, 9.2 Hz), 5.62 (1H, dd, J = 2.4, 9.6 Hz), 5.47 (1H, d, J = 3.2 Hz), 3.0
(1H, m), 1.48 (2H, m), 1.2 (3H, dd, J = 6.8, 4.9 Hz), 0.94 (3H, q, J = 6.0 Hz).
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10.1.2.5 Synthesis of C4-Acrylate Acrylate Lactam (5)
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Synthesis of (±)-(3R,4S)-4-Acetoxyphenyl-N-(4-methoxyphenyl)imine (115): To a
solution of p-anisidine (1.08g, 8.81mmol) in 15mL of CH2Cl2 was added phydroxybenzaldehyde (1.07g, 8.81mmol), and a catalytic amount of (+)-camphorsulfonic
acid. The resultant mixture was stirred until TLC indicated the disappearance of starting
materials. The resulting imine was used for the next step without further purification. To
the solution of 4-hydroxyphenyl-N-(4-methoxyphenyl)-imine (114, 1eq) with 2eq of
TEA, acetyl chloride (1.5eq.) was added dropwise to the solution and the resulting
solution was stirred at room temperature for 15 minutes. The product was washed with
d.i. water (2×20 mL) and dried with sodium sulfate and the product was evaporated in
vacuo to afford 115 as a light yellow solid in 92% yield (mp 95-96oC). 1H NMR (250
MHz, CDCl3) δ 8.39 (1H, s), 7.84 (2H, d, J = 8.5 Hz), 7.20-7.11(4H, m), 6.86 (2H, d, J =
8.8 Hz), 3.77 (3H, s), 2.26 (3H, s). 13C NMR (400 MHz, CDCl3) δ 168.2, 161.2, 159.0,
157.3, 144.4, 129.9(2C), 128.8, 122.4, 122.2 (2C), 121.7, 114.6 (2C), 55.7, 21.4.
(±)-(3R,4S)-4-(4-acetoxyphenyl)-)-3-methoxy-N-(4-methoxyphenyl)azetidin-2-one
(116): White solid in 78 % yield, mp 94-96°C. 1H NMR (250 MHz, CDCl3): δ 7.33 (2H,
d, J = 8.4 Hz), 7.09 (2H, d, J = 8.4 Hz), 6.55 (1H, d, J = 17.3 Hz), 6.26 (1H, dd, J = 17.3,
274

10.4 Hz), 6.00 (1H, d, J = 10.4 Hz), 4.78 (1H, d, J = 4.5 Hz), 4.68-4.66 (1H, m), 3.11(3H,
s); 13C NMR (63 MHz, CDCl3): δ 168.0, 164.5, 150.5, 133.2, 132.9, 128.8, 127.7, 121.5,
116.0, 86.6, 58.2, 57.5.
(±)-(3R,4S)-4-(4-acryloylphenyl)-3-methoxy-1-methylthioazetidin-2-one (5): White
solid in 89% yield, mp 87-88°C. 1H NMR (250 MHz, CDCl3): δ 7.29 (2H, d, J = 8.4 Hz),
7.08 (2H, d, J = 8.4 Hz), 6.50 (1H, d, J = 17.3 Hz), 6.21 (1H, dd, J = 10.3, 17.1 Hz), 5.92
(1H, d, J = 10.4 Hz), 4.75 (1H, d, J = 4.8 Hz), 4.69 (1H, d, J = 4.8 Hz), 3.05 (3H, s), 2.26
(3H, s); 13C NMR (63 MHz, CDCl3): δ 170.3, 164.2, 150.9, 132.9, 131.1, 129.9, 127.7,
121.4, 86.5, 65.5, 58.3, 22.0.

10.1.2.6 Synthesis of C3-Long Chain Acrylate Lactam (9)
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Synthesis of (±)-(3R,4S)-3-Acryloyloxy ethyl succinate-4-(2-chlorophenyl)-N-(4methoxyphenyl) azetidin-2-one (112): To the solution of hydroxyl lactam 109 (500mg,
1.65mmol) in 5mL of CH2Cl2, 350mg of mono-2-(acryloyloxy)ethyl succinate (1.6
mmol) was added along with EDCI (310mg, 1.6mmol) and DMAP (196 mg, 1.6 mmol)
over ice. The solution was then warmed to room temperature and stirred overnight. The
product was purified by column chromatography using a 1:1 mixture of hexanes:ethyl
acetate to yield 77% lactam 112 as a colorless oil. 1H NMR (250 MHz, CDCl3) δ 7.277.21 (6H, m), 6.81 (2H, d, J = 8.8 Hz), 6.39 (1H, dd, J = 1.2, 10.8 Hz), 6.18 (1H, d, J =
4.8 Hz), 6.04 (1H, dd, J = 1.2, 10.4 Hz), 5.78 (1H, d, J = 4.8 Hz), 4.32 (4H, q, J = 5.2
Hz), 3.74 (3H, s), 2.42-2.39 (1H, m), 2.33 (2H, t, J = 6.8 Hz), 2.22 -2.18 (1H, m). 13C
NMR (250 MHz, CDCl3) δ 170.8, 169.9, 166.3, 161.8, 157.2, 134.1, 131.7, 130.1, 130.0,
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129.6, 129.4, 128.2(2C), 128.1, 127.1, 126.9, 118.9, 114.7, 62.6, 62.3, 60.0, 58.4, 55.7,
28.7, 28.6.
(±)-(3R,4S)-3-Acryloyloxy ethyl succinate-4-(2-chlorophenyl)azetidin-2-one (113):
Yellow oil in 86% yield. 1H NMR (250 MHz, CDCl3) δ 7.33-7.24 (4H, m), 6.70 (1H, bs),
6.39 (1H, dd, J = 2.4, 10.4 Hz), 6.15 (1H, d, J = 3.2 Hz), 6.12 (1H, dd, J = 2.2, 10.8 Hz),
5.83 (1H, dd, J = 2.4, 10.4 Hz), 5.36 (1H, d, J = 4.8 Hz), 4.29 (2H, t, J = 4.4 Hz), 4.24
(2H, t, J = 2.8 Hz), 2.42-2.36 (1H, m), 2.32 (2H, t, J = 6.4 Hz), 2.24-2.20 (1H, m). 13C
NMR (250 MHz, CDCl3) δ 170.8, 169.9, 166.3, 161.0, 134.1, 129.4, 127.6, 124.7, 124.6,
123.0, 121.8, 94.9, 80.1, 57.4, 57.1, 57.1, 28.7, 28.6.
(±)-(3R,4S)-3-Acryloyloxy ethyl succinate-4-(2-chlorophenyl)-N-methylthioazetidin2-one (9): Yellow oil in 72% yield. 1H NMR (250 MHz, CDCl3) δ 7.41-7.19 (4H, m),
6.35 (1H, dd, J = 2.2, 9.6 Hz), 6.11 (1H, d, J = 4.4 Hz), 6.02 (1H, dd, J = 2.4, 10.8 Hz),
5.73 (1H, dd, J = 2.4, 10.8 Hz), 5.42 (1H, d, J = 4.9 Hz), 4.28 (2H, t, J = 3.6 Hz), 4.24
(2H, t, J = 2.8 Hz), 2.44 (3H, s), 2.36-2.30 (4H, m). 13C NMR (250 MHz, CDCl3) δ
171.4, 169.9, 168.3, 166.0, 134.6, 131.6, 130.6, 130.3, 130.2, 130.1, 128.9, 128.1, 126.9,
62.6, 62.2, 28.6, 28.5, 22.1.

10.1.3 Modification of Commercially-Available Penicillin Monomers
10.1.3.1 Acrylation of 6-Aminopenicillanic acid (11), Amoxicillin (17), and Cefaclor
(19)
Five hundred milligrams of the penicillin (1.0eq) was dissolved in 20mL of dry CH2Cl2,
then 0.92mL of N,O-bis(trimethylsilyl)acetamide (1.1eq) was added to the solution and
stirred at room temperature for 24 hours. The reaction was then taken directly to the next
step by addition of 0.49mL TEA (1.5eq) followed by dropwise addition of 0.19mL of
acryloyl chloride (1.0eq). The mixture was stirred for 24 hours at room temperature,
followed by washing of the product with water and ammonium chloride. The product was
dried over sodium sulfate and the solvent was removed in vacuo. All reactions yielded
100% conversion of reactant to product (via TLC) in a 5:1 system of CH2Cl2:MeOH. 6Aminopenicillanic acid acrylamide was synthesized in 91% yield. Cefaclor and
amoxicillin acrylamide monomers were produced in less than 50% yields due to
undesired precipitation during the washing procedure of over half the product. Proton
NMR analysis was performed for all of the acrylated drug monomers in many deuterated
solvents in order to obtain a clear spectrum due to the limited solubility of the acrylated
products, however, due to solubility issues and issues with solvent purity and interference
in the spectral analysis, numerous peaks were observed for the monomers when analyzed
in deuterated methanol, acetone, and various mixtures of deuteratued chloroform with
methanol.
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10.1.3.2 Acidification of Penicillin G Potassium Salt (14)
Penicillin G potassium salt (2g) was dissolved in 10mL of d.i. water, followed by
addition of dilute HCl dropwise with swirling until a solid precipitate was observed in the
solution. The water was decanted from product, which then washed 3x with d.i. water
(10mL each) to remove excess acid. Product was dried over night in vacuo. (Rf =0.09 in
5:1 CH2Cl2:MeOH)
10.1.3.3 Synthesis of Penicillin G Acrylate (12)
The free acid monomer of penicillin G (14) (1.4g, 4mmol) in 20mL of dichloromethane
was treated at 0°C with TEA (0.67ml, 4.4mmol) and ethyl chloroformate (0.48mL,
5mmol). After stirring at 0oC for 30 minutes, was added a solution of 2-hydroxyethyl
acrylate (0.93g, 8mmol) and TEA (0.67ml, 4.4mmol) in 10mL of dichloromethane. The
ice bath was removed, and after storage for 3-4 hours, the mixture was washed with cold
water, dried over MgSO4 and column chromatography to give pale yellow oil of
penicillin G-acrylate monomer in decent yield (70% crude). 1H NMR (CDCl3, 250MHz):
δ 7.35-7.18 (5H, m), 6.38 (1H, d, J = 17.6 Hz), 6.05 (1H, dd, J = 17.6, 7.2 Hz), 5.80 (1H,
d, J = 7.2 Hz), 5.50 (1H, dd, J = 7.2, 2.4 Hz), 5.42 (1H, d, J = 2.4 Hz), 4.31 (4H, s), 3.67
(2H, s), 1.35 (6H, s).

10.1.3.4 Synthesis of Penicillin G Acrylamide (13)
Penicillin G free acid monomer (14) was dissolved in 40mL of dry dichloromethane
(1.00g, 3.37mmol) and 0.92mL of N,O-bis(trimethylsilyl)acetamide (3.71mmol) was
added to the solution and was subsequently stirred at room temperature for 24 hours.
Reaction was then placed over ice, and 202mg of sodium hydride (60% oil immersion,
5.06mmol) was added to the reaction. After bubbling ceased, the ice bath was removed
and the solution was stirred for 10 minutes, followed by addition of acryloyl chloride
(0.27mL, 3.37mmol) dropwise and stirring for 24 hours at room temperature. Product
was washed with water followed by ammonium chloride and brine, then dried with
sodium sulfate and solvent removal in vacuo to yield 95% yellow crystalline solid
product after washing with hexanes to remove any non-polar impurities. TLC analysis
showed spot-to-spot conversion of reactant in 5:1 CH2Cl2:MeOH (Rf prod=0.6857).
10.1.3.5 Acrylation of Ampicillin Sodium Salt (16)
To a solution of ampicillin sodium salt (500mg, 1.35mmol) dissolved in 15mL of water,
add 15mL CH2Cl2 and stir at room temperature. Next, tetrabutylammonium bromide
(435mg, 1.35mmol) was added and the solution was stirred until no separation of
solvents was observed. N,O-bis(trimethylsilyl)acetamide was then added (0.37mL,
277

1.50mmol) and the reaction was stirred for 24 hours at room temperature. The silylprotected ampicillin was then extracted with 20mL of CH2Cl2 and dried in vacuo to yield
700mg of the yellow silyl-protected solid intermediate, which was then re-dissolved in
20mL of CH2Cl2 and subsequently deprotonated using triethylamine (TEA) (0.28mL,
2.03mmol) and stirring over 10 minutes at room temperature. Acryloyl chloride (0.11mL,
1.35mmol) was then added dropwise to the reaction mixture and the reaction was then
stirred at room temperature for 24 hours. The mixture was washed with brine solution
then dried over MgSO4 to give a dark yellow solid in 52-70% crude yield. TLC in 5:1
mixture of CH2Cl2:MeOH showed spot to spot conversion of product with no by products
observed.

10.1.3.6 Diacrylation of Amoxicillin
Amoxicillin (100mg, 0.24mmol) was dissolved in 5mL of d.i. water, then treated with
0.48mL of 2M NaOH (0.60mmol) and stirred over ice for 10 minutes. Acryloyl chloride
(38.8µL, 0.96mmol) was added dropwise to the reaction mixture, which was then stirred
at 0oC for an additional 4 hours. The reaction was then terminated with the addition of
0.5mL of concentrated HCl, and the precipitated diacrylate free acid amoxicillin was
filtered from the solution. Product was a light yellow solid.

10.1.3.7 Acrylation of Ciprofloxacin
The commercially available ciprofloxacin hydrochloride monomer (500mg, 1.5mmol)
was dissolved in 15mL of dry dichloromethane and 0.63mL of TEA (4.50mmol) was
added to the solution then stirred at room temperature for ten minutes. Acryloyl chloride
(0.197mL, 3.0mmol) or methacryloyl chloride (0.29mL, 3.0mmol) was subsequently
added to the reaction mixture in a dropwise fashion, and the solution was then stirred at
room temperature for 24 hours. The resulting acrylamide product was immediately
recovered in vacuo after aqueous work up in order to prevent polymerization. A yellow
solid was produced in 75-90% yield, depending on the acryloyl chloride reagent used.
Ciprofloxacin acrylamide (7): Yellow solid, 74% yield. 1H NMR (250 MHz, CDCl3): δ
7.33-7.29 (2H, m), 6.5 (1H, m), 6.33 (1H, d) 6.26 (2H, d), 5.74 (1H, s), 3.87-3.69 (8H, d),
1.38-1.33 (1H, m), 1.30-1.18 (4H, s). 13C NMR (63 MHz, CDCl3) δ 187.0, 170.6, 164.7,
116.5, 141.2, 138.7, 135.6, 130.8, 129.1, 118.4, 111.6, 108.9, 99.0, 57.4, 49.0, 35.2.
Ciprofloxacin methacrylamide (8): Yellow solid, 90% yield.
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10.2 Antibacterial Assays
Media was purchased from Becton–Dickinson Laboratories, Cockeysville, MD, and
supplies were purchased from Fisher Scientific Company. Bacteria were purchased from
Hardy Diagnostics.

10.2.1 Culture Preparation
From a freezer stock in tryptic soy broth (Difco Laboratories, Detroit, MI) and 20%
glycerol, a culture of each microorganism was transferred with a sterile Dacron swab to
Trypticase® Soy Agar (TSA) plates (Becton-Dickinson Laboratories, Cockeysville,
MD), streaked for isolation, and incubated at 37oC for 24 h. A 108 standardized cell count
suspension was then made in sterile phosphate buffered saline (PBS, pH 7.2) and
swabbed across fresh TSA plates.

10.2.2 Kirby-Bauer Assay
Five milliliters of sterile phosphate buffered saline (PBS) was inoculated with the desired
bacteria and the concentration was adjusted to 0.5 McFarland Standard. The bacteriacontaining solution was then streaked evenly onto a Mueller-Hinton agar plate and wells
were drilled into the agar using sterile 1-30uL pipette tips. The wells were filled with
20uL of antimicrobial solution or nanoparticle emulsion which were at a 1mg/mL
concentration, and the plates were incubated for 24 hours at 37oC. Zones of inhibition
were determined for each well using a millimeter scale and measuring the zone through
the center of the well.
For antibacterial analysis of the polyacrylate films, instead of drilling wells in the agar for
addition of the emulsion, the concentrated (20% solid content) emulsion was placed on
top of an already inoculated Mueller-Hinton agar plate, where the volume of emulsion
added was dictated by the surface area of the agar plate used. The plates were then stored
uncovered in a biosafety class 2A cabinet to promote film formation for 30 minutes, then
were incubated at 37oC overnight. Zones of inhibition were determined for each film
using a millimeter scale and measuring the zone through the center of the film,
subtracting the film diameter from the measurement.

10.2.3 Agar Dilution MIC Assay
Antimicrobial concentrations were determined by the standard NCCLS protocol M7A2.28 The concentrations of the emulsions analyzed were based on the drug content
incorporated in the emulsions, and these concentrations were placed in a well of a 24 well
plate (Costar 3524, Cambridge, MA). Mueller Hinton agar was added to each well in
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liquid form to produce a total well volume of 1.5mL. The contents of each well were
thoroughly stirred to evenly distribute the antimicrobial within the agar. Using a sterile
inoculating loop, a small amount of each standardized bacterial strain cultured on TSA
plates for 24 hours was transferred into a sterile test tube containing 5mL TSB and
incubated at 37oC for 24 h. One microliter of each culture was then applied to the
appropriate well of solidified Mueller Hinton agar and incubated for 24 hours at 37oC.
Bacterial growth was assessed by visual observation and subsequent analysis on a TSA
plate if necessary.

10.2.4 Broth Dilution MIC Assay
MIC values were determined by broth serial dilution assay, according to NCCLS
protocols.28 The reported MIC values for emulsions analyzed were based on the
concentration of the drug incorporated in the emulsions, were the initial concentration of
drug was 512µg/mL emulsion, which was serially diluted in Mueller-Hinton broth, which
is subsequently inoculated with 5µL of bacterial culture in TSB. Bacterial
growth/inhibition was determined by optical density measurement at either 540nm
(Staphylococcal species) or 550nm (Bacillus species).

10.3 Nanoparticle Emulsion Polymerization and Analysis
10.3.1 Emulsion Polymerization Process
For the drug-containing emulsion polymerizations, a water insoluble drug monomer was
dissolved in a 7:3 (w/w) ratio of butyl acrylate and styrene, respectively, at 70oC. Nanopurified water was then added to the solution, followed by addition of sodium dodecyl
sulfate (SDS) as surfactant (5%, 3%, or 1% w/w). If no drug is added, the two comonomers, at their respective ratios, were heated to 70oC with stirring prior to addition of
surfactant and nanopurified water. The resulting mixture was stirred rapidly at 70oC
under a nitrogen atmosphere until homogenous micelle formation occurs (between 10 and
15 minutes). The radical initiator, potassium persulfate (1% or 0.5% w/w), was then
added to the emulsified solution and the solution was allowed to stir at 70oC for 6-8 hours
under a nitrogen atmosphere. The resulting emulsions are milky white to a white
iridescent solution, depending on amount of surfactant and the size of the drug monomer
incorporated.

10.3.2 Process for the Purification of Nanoparticle Emulsion NP7
A sample of the nanoparticle emulsion NP7 (20% solid content) was diluted to 10% solid
content concentration using nano-pure water. The emulsion (10mL) was then placed in a
continuous extractor and extracted for 3 days with refluxing cyclohexane. The emulsion
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was then removed from the apparatus and separated from the organic layer using a
separatory funnel. The extracted and non-extracted samples were then diluted to 1mg
drug content in 1mL of emulsion (the drug content for the washed emulsion was assumed
to be the same as the original unwashed emulsion) and the antibacterial activity was
analyzed by Kirby Bauer diffusion assay as described in Chapter 2.

10.3.3 Analysis of Particle Size Distribution by Dynamic Light Scattering
Dynamic light scattering data was acquired on a UPA Honeywell MicroTrac at the
University of Florida’s Particle Engineering Research Center (PERC). One drop of
concentrated emulsion solution (20% solid content) was placed in a 10 mL well filled
with nanopure water. Data was collected per sample over 3 runs of 180 seconds per run.

10.3.4 Zeta Potential Analysis of the Nanoparticle Emulsions
The zeta potential of each emulsion solution was obtained using a Brookhaven ZetaPALS
at PERC. The emulsion solution was diluted to 1.5% solid content (~ pH = 7) using
nanopure water for analysis. Two runs were performed per sample where each run
recorded 10 data points. The dispersant viscosity and dielectric constant of the poly(butyl
acrylate-styrene) emulsion solution used for analysis was 0.8872 cP and 78.55
respectively.

10.3.5 Film Formation and Characterization
An aliquot (~0.5-1.0mL) of concentrated emulsion solution was pipetted onto a glass or
Teflon surface and was allowed to sit at room temperature overnight. Film formation was
not solely dependant on evaporation of the water constituent of the emulsion, so film
formation was also performed under humid or moist atmospheres and at increased or
decreased temperatures. Body temperature (37oC) appeared to be the optimal temperature
for film formation however. Upon film formation, the emulsions turned from a cloudy
white liquid to a clear, translucent pliable film. Films were removed from glass surfaces
using a straight edge razor blade or peeled off manually from Teflon surfaces and further
manipulated.
Nuclear magnetic resonance (NMR) analysis was performed on some of the polymer
films synthesized by placing a small piece of the film in a slender tube containing
deuterated chloroform. While the chloroform did not dissolve the film, it caused the film
to swell and become translucent enough for NMR analysis. Fourier transform infrared
spectroscopy (FTIR) analysis was also performed on a Perkin Elmer Spectrum. Polymer
film samples were cut into 1 x 1cm2 pieces and analyzed with this instrument for sample
identification.
281

10.4 Microscopy Studies of Nanoparticles
All chemicals were purchased from Sigma-Aldrich Chemical Company, and the copper
grids for TEM imaging were purchased from Electron Microscopy Sciences.
Scanning electron microscopy (SEM) analysis of the nanoparticle emulsions was done in
the College of Engineering at the University of South Florida. The samples were prepared
by diluting the initial emulsion with nanopure water (3,000-fold), then evaporating the
aqueous content under a N2 stream prior to coating by gold sputter under high vacuum.
The gold-coated nanoparticles were then observed by SEM (Hitach S 800). Transmission
electron microscopy (TEM) analysis was performed on a FEI Morgagni 268D electron
microscope in the biology department at the University of South Florida. The initial
emulsion solution was diluted to a 10-10 concentration using nanopure water then the
solution was drop cast onto a formvar-coated copper grid (Electron Microscopy
Sciences). The water content was evaporated by applying a cool stream of air to the drop,
and the grid was subsequently viewed on the microscope. Atomic force microscopy
(AFM) analysis was performed with the aid of August Heim in the Department of
Physics at the University of South Florida. Glass slides were plasma cleaned to establish
a molecularly flat surface prior to emulsion deposition. A 5µL aliquot from the original
concentrated emulsion is placed in 5mL of nanopure water, then a 15µl aliquot is placed
on a round glass coverslip and the particles are allowed to sit uncovered for 1-2 minutes
in order for the particles to attach to the glass coverslip. Thereafter, the excess water was
shaken off the coverslip and any residual water was evaporated by applying a cool stream
of air to the drop. For liquid imaging, the coverslip containing the adhered nanoparticles
is submerged in DI water and then imaged. AFM imaging was performed using the
Asylum Research MFP-3D and µMasch cantilevers (nominal spring constants between
1–2 nN/nm) using the tapping mode of the instrument under ambient air at room
temperature and <45% humidity.

10.5 TEM Imaging of Bacterial Cell Interactions with Drug Monomers
and Nanoparticles
10.5.1 Whole Cell Imaging
S. aureus (ATCC 25923) was grown up on tryptic soy agar (TSA) plates overnight at
37oC. The bacteria were then carried through a series of dilutions in order to obtain a
concentration of 102 CFU/mL in trypticase soy broth (TSB). The cells were then exposed
to a 10-10 concentration of control nanoparticles for 30 minutes. Thereafter, the broth was
treated with 5mL of 2.5% gluteraldehyde for 4 hours at 4oC. A solution of 102CFU/mL S.
aureus in TSB was also treated with 5mL of 2.5% gluteraldehyde for 4 hours at 4oC and
served as a control for the experiment. The broth suspension was then drop cast onto a
formvar-coated copper grid and was allowed to dry at room temperature under a cool
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stream of air. The control cells and cells treated with control nanoparticles were then
observed on the FEI Morgagni 268D TEM.

10.5.2 Sectioned Cell Imaging
S. aureus (ATCC 25923), B. anthracis-Sterne, or Candida albicans was grown up on
TSA plates overnight at 37oC. The bacterial culture was then carried through a series of
dilutions in order to obtain a concentration of 107CFU/mL in TSB. The diluted samples
were then exposed to a concentration of 10-5 control nanoparticles or lactam monomer 6
dissolved in DMSO for 30 minutes (bacteria) or up to 4 hours (Candida) and then
centrifuged at 10,000xg for 5 minutes. The pellet was washed twice with PBS, then
resuspended in 5mL of PBS and fixed with 5mL of 2.5% glutaraldehyde for 4 hours at
4oC. The fixed cells were centrifuged at 10,000xg for 5 minutes and then resuspended in
PBS supplemented with 0.1 M sucrose. The cells were then centrifuged and resuspended
twice in PBS at 10,000xg for 5 minutes. The cells were then centrifuged again at
10,000xg for 5 minutes then the pellet was embedded in agar for easier handling. The
agar blocks were then washed with PBS and postfixed in 2% osmium tetroxide for 1 hour
at room temperature. The cells were then washed twice with PBS then once with 0.9%
saline and stained with 1.5% uranyl acetate. The cell-containing agar blocks were then
carried through a series of dehydrations using graded ethanol. The cells were then
infiltrated and embedded in Spurr’s Plastic and ultrathin sections were cut using a Sorvall
MT-2B ultramicrotome and placed on copper mesh grids. The grids were then examined
on the FEI Morgagni 268D TEM. No post-embedding staining was performed on the
sections in order to minimize any unnecessary metal precipitation that could be mistaken
as nanoparticles.

10.6 Mechanical Testing
All mechanical studies were performed at the Shriners Hospital for Children, Tampa, FL.
Each film was placed on a flat glass surface and cut into a rectangular shape of set
dimensions, which were then calculated with a dial caliper to the nearest 0.01mm in order
to calculate the cross-sectional area of the film. For cyclic, uni-axial analysis, the films
were analyzed as is. However, for measurement of tensile strength, a 3mm biopsy punch
tool was used to convert the film into a dumbbell shape by punching semi-circle holes on
either side of the center of the film. The width and thickness of the film was measured at
the center of the dumbbell at the thinnest point with the dial caliper in order to calculate
the cross-sectional area of the film at the most likely spot of failure.
This protocol was used for tensile strength measurements because, when the film is a
solid rectangular shape, failure occurred at variable locations, thereby decreasing the
accuracy of the measurement since the film’s width and thickness slightly varies
throughout the film. Actual clamp-to-clamp distance was measured after the film was
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loaded to the nearest 0.01mm with a dial caliper. The clamps were mounted in recessed
holes in aluminum jigs produced from 1/4 in stock. Uniaxial tensile tests were performed
on a tensiometer fabricated in the laboratory. The polymer film was stretched to 100mm
in length at a strain rate of 1mm/s, creating 1000% deformation under uniaxial tensile
load. Distance was continually measured with LVDT (Lucas Control Systems Products,
Schaevitz Sensors, Hampton, VA) mounted on the piston. Load was measured with an
LVDT force transducer (Lucas Control Systems Products, Schaevitz Sensors, Hampton,
VA).
To account for displacement of the force transducer core, an LVDT was placed in line
with the core and the distance was recorded. The mVolt analogue outputs were digitized
with a Quatec A-D PCMCIA card and imported directly into Microsoft Excel. Tensile
strength was taken as the highest load attained before failure normalized to the crosssectional area. The linear portion of the stress/strain curve was used to calculate the
elastic modulus. Due to the high number of measurements obtained, a moving average
was employed for each data set analyzed in order to visualize the data in a more seamless
fashion.

10.7 Bacterial Permeability Assays
The nutrient-rich agar used for this assay, 0.5% Bacto Acetate Differential Agar, was
purchased from Fisher Scientific, along with M9 minimal salts agar and tryptic soy broth
(TSB).

10.7.1 Multi-Layered Agar Assay
All agars were prepared following the manufacturer’s recommended procedure prior to
addition to the test tube or Petri dish. For each assay, each layer of agar or emulsion was
added to the test tube or plate and allowed to solidify in the biosafety cabinet until
completely hardened. Upon addition of the nutrient-free agar layer and subsequent
solidification, the agar was inoculated by dipping a thin metal rod into a saline solution
containing 105CFU/mL of multiple microbes prior to the next agar layer addition. Once
all layers solidified and the nutrient-free agar was inoculated, the assay was incubated at
37oC for 7 days, while monitoring the progress of the assay each day.
A positive control was used that represented a substance that does not permit bacterial
migration into the bottom agar layer, but does allow pH indicator and nutrients migration
into the nutrient-free agar layer. A 2% agar solution is prepared, autoclaved, and then a
1mL aliquot of the cooled solution was placed on top of the solidified bottom agar layer
and allowed to solidify overnight. Once solidified, the top agar layer was applied to the
tubes. Also, a negative control was used to represent a substance that did not permit
bacterial migration but allowed the flow of nutrients and pH indicator into the nutrient284

free agar layer. A 3x3cm square of double ply hospital-grade gauze was placed between
the nutrient-rich and nutrient-free agar layers at the same stage of assay preparation as
when the emulsions were added.

10.7.2 Broth-Based Diffusion Assay
A solution of TSB was prepared following the manufacturer’s recommended procedure,
then placed in the bottom chamber of either the diffusion chamber or the diffusion cell
used. A pre-formed polymer film sample (as described in Section 10.7.3) was placed over
the opening(s) of the diffusion apparatus so that no air bubbles were present between the
broth and the film, then was clamped in place by applying the top chamber to the
apparatus. The top chamber was then filled with a saline solution containing 105 CFU/mL
of multiple microbes, and the chamber was then sealed either by a lid or with parafilm
and incubated at 37oC for 7 days. For the diffusion chamber, at day 7, the apparatus was
dismantled, making sure not to contaminate the TSB in the bottom chamber, and a
sample of the TSB was then streaked onto an agar plate containing the Bacto acetate
differential agar. The inoculated plate was then incubated overnight at 37oC and any
observance of bacterial growth was recorded.

10.7.3 Carbon Source Assay
Small agar plates were formed using M9 minimal salts agar (1.5%). Once the agar
solidified, a 1.00mL aliquot of the emulsion sample was added to the surface of the agar
and the plates were left open overnight in a biosafety class 2A cabinet to permit film
formation. Once the film solidified, a microbial suspension containing 105 CFU/mL in
saline was added to the film surface by placing 5-6 drops (approximately 50µL each)
over the film. The plates were then incubated at 37oC for 7 days, checking the progress of
bacterial growth each day.

10.7.4 Molecular Weight Cutoff Analysis
In order to determine if small molecules, such as water, oxygen, and various nutrients, are
able to penetrate the polymer films to provide a wound bed, for example, with the
elements it needs to heal, a study was designed using dyes of various molecular weights
and microdialyzer chambers. These chambers allowed the polymer films to be exposed to
various dyes at once, and the subsequent percentage of each dye that penetrated the film
was analyzed by capillary zone electrophoresis (CZE).
Chambers used to determine the permeability of a few select polymer films samples was
similar to the chambers used by Ussing to test the permeability of egg capsules of marine
animals. (Ussing et al., ’52; Lombardi and Files, ’93). The top of the chamber has ten
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circular openings that, when placed on top of the bottom portion, create ten separate
wells, allowing for ten polymer film samples to be analyzed at once. The bottom portion
of the chamber has one large well containing phosphate buffered saline (PBS) solution
for the dyes that are able to penetrate the film samples to flow into. Dialysis tubing was
used as a positive control material, and a hard plastic material was used as a negative
control, with each sample being analyzed in duplicate. An N of 6 was used for the
polymer film samples analyzed. Once the bottom chamber was filled with PBS, the
materials were placed over each well so that there were no air bubbles between the
material and the PBS, then the top of the chamber was clamped into place over these
materials. Once secured, the material being analyzed separated the bottom well from the
top wells, and the top wells were subsequently filled a solution different molecular
weight dyes. Samples were taken from the top wells after 24 hours to determine whether
the different molecular weight materials were able to diffuse across the material.
PBS containing molecular weight materials ranging from 404 to 844g/mol was used to
determine the permeability of polymer film samples to low molecular weight materials.
The solution contained 1mM concentrations of each of the following materials: cresol red
(404g/mol), thymol blue (488g/mol), bromothymol blue (646g/mol), bromocresol green
(720g/mol), and methylthymol blue (845g/mol). Eighty microliter aliquots of the solution
were introduced into the top wells of the chamber so that the solution is in direct contact
with the film sample covering each well and the PBS solution in the bottom chamber was
stirred continuously for 24 hours. The amount of each dye was measured by removing an
aliquot of the solution from the top chambers after 24 hours using a capillary zone
electrophoresis system (Dionex) monitoring at an absorbance of 280nm.

10.8 Biocomposite Fiber Formation and Analysis
10.8.1 General Mechanical Analysis
Mechanical properties were established using a tensiometer fabricated in the laboratory at
Shriners Hospital for Children, Tampa, FL. The fibers were stretched to 10mm in length
at a strain rate of 1mm/s. Distance was continually measured with LVDT (Lucas Control
Systems Products, Schaevitz Sensors, Hampton, VA) mounted on the piston. Load was
measured with an LVDT force transducer (Lucas Control Systems Products, Schaevitz
Sensors, Hampton, VA). Displacement of the force transducer core was accounted for by
placing the LVDT in line with the core. The mVolt analogue outputs were digitized with
a Quatec A-D PCMCIA card and imported directly into Microsoft Excel. Tensile strength
was taken as the highest load attained before failure normalized to the cross-sectional
area. The linear portion of the stress/strain curve was used to calculate the elastic
modulus, and the maximum strain was obtained by the highest displacement before
failure normalized to the length of the fiber between the clamps of the instrument.
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10.8.2 Emulsion Dilution Biocomposite Fibers
Collagen fibrils were extracted from the echinoderms Cucumaria frondosa obtained from
Frenchman Bay in the Gulf of Maine. The extraction process was performed and reported
by Thomas Koob. [12, 13, 16, 18] Five-10mL aliquots of a sea cucumber collagen fibril
suspension were placed into 15mL centrifuge tubes, and either 0, 25, 50, 100, or 150µL
of CNP3 nanoparticle emulsion was added to the tube and the solution was gently mixed
to avoid fibril tangling. The mixture was then gently transferred to 10mm wide dialysis
tubing, placed in fiber-forming buffer (3% acetic acid), and stirred overnight at room
temperature. The fibers were then removed from the dialysis tubing and slowly lifted
from the fiber forming buffer over 4 hours to dry the fibers.

10.8.3 Collagen Dilution Biocomposite Fibers
A suspension of collagen fibrils in water was obtained as described in Section 6.8.2 and
10mL was transferred into one test tube, then 5mL, 4mL, 2mL, and 1mL into other
individual test tubes. The tubes containing 5mL or less of collagen was diluted with
deionized water to give dilutions of 1:1, 1:2, 1:4, and 1:10 collagen:water, which
corresponded to 50%, 33%, 20% and 9% collagen in the fiber formulation. If the dilution
volume was greater than 10mL, a 10mL aliquot was removed and placed in a fresh test
tube. A 100µL aliquot of CNP3 was pipetted into each test tube and gently mixed for
even distribution of emulsion. The mixture was then gently transferred to 10mm wide
dialysis tubing and placed in fiber-forming buffer (3% acetic acid) and stirred overnight
at room temperature. The fibers were then removed from the dialysis tubing and slowly
lifted from the fiber forming buffer over 4 hours to dry the fibers.

10.8.4 Fiber Analysis
Dried fibers were cut into 15mm long pieces and then ends of each piece were taped and
marked for identification. Half of the prepared fibers from a single formulation (3) were
hydrated with a drop of deionized water in the center of the exposed fiber for one hour,
and the other half were kept dry. The diameter of each fiber was then measured in
duplicate using a Nikon Eclipse E800M microscope and incorporated software. The
percent of fiber swelling was obtained for the hydrated fibers based on the measurements
in Equation 5.1. The fibers were then clamped in place on the tensiometer described in
Chapter 5, the length between the clamps was measured, and the fibers were tested under
uniaxial tension as described in Section 10.6.
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10.8.5 Calcium Doping Study
Biocomposite fibers containing 100mL of CNP3 and 10mL of sea cucumber collagen
fibril suspension were formed as described in section 6.8.1. The dry fiber was
subsequently cut into 8-10mm long segments and tape was placed on both ends of the
segments and labeled. Half of the fiber segments cut (5) were fully submerged in a
prepared solution containing 10mM calcium chloride (CaCl2) overnight, and the other
half were submerged in ddi H2O. The diameter of the fibers was then measured using the
Nikon Eclipse E800M camera/microscope in two locations towards the center of each
fiber segment, and the fibers were then analyzed under uniaxial tension by the MTS
instrument as described in Section 10.6.

10.8.6 TEM Analysis of Fibers
The TEM analysis procedure used for the collagen and biocomposite fibers was based on
numerous publications of imaging of biological tissues.37-39 A control, collagen fiber and
a biocomposite fiber formulated with 100µL of CNP3 nanoparticle emulsion and 10mL
of sea cucumber collagen fibril suspension were cut to 3mm in length and rinsed twice
with distilled water. The fibers were then rinsed with 0.1M sodium cacoldylate buffer
then submerged in a 0.1M cacoldylate buffer containing 3% gluteraldehyde and 0.5%
tannic acid overnight. The fibers were then rinsed again two times with 0.1M cacodylate
buffer then post-fixed using 1% osmium tetraoxide for one hour at room temperature.
Thereafter, the fibers were rinsed three times for 15 minutes each in double distilled
water (ddi H20), then submerged in 1% uranyl acetate in ddi H20 for two hours at room
temperature. The fibers were then rinsed twice with ddi H20, followed by total
dehydration of the fibers through an increasing gradient of pure ethanol, where the fibers
are first subjected to 30% ethanol for 5 minutes, followed by 50% ethanol for 5 minutes,
70% ethanol for 10 minutes, 95% ethanol for 10 minutes, and finally 100% ethanol twice
for 20 minutes each. The fibers were then submerged in propylene oxide twice for 10
minutes each to completely dehydrate the fibers. The dehydrated fibers were then
embedded in a specialized embedding plastic (Spurr’s Low Viscosity Embedding Media)
through a series of increasing concentrations of the plastic in propylene oxide, 1:2, 1:1,
2:1, and finally only Spurr’s plastic. The fibers sat in the different concentrations of
Spurr’s plastic: propylene oxide for 30 minutes each. The fibers in Spurr’s plastic were
then place into a rectangular mold containing a small volume of hardened Spurr’s plastic
so that the fiber would be in the center of the plastic, and the two plastics were allowed to
gel together sitting at room temperature for 4-6 hours. The fiber-embedded plastic was
then cured at 70oC for 8 hours. Once hardened, the plastic was removed from the mold
and sectioned into nano-thin cross sections with the fiber centralized in the plastic using
an ultramicrotome and a diamond-tip knife. The sections are then carefully transferred to
a TEM grid and subsequently viewed on a TEM.
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10.9 In vitro Cytotoxicity Assay using Human Dermal Fibroblast Cells
Human dermal fibroblast cells were a gift from the University of Cincinnati, College of
Medicine. All assays were performed with permission from the University of South
Florida’s Internal Review Board (IRB) for the use of human cell lines. All supplies were
purchased from Fisher Scientific Company, fetal bovine serum (FBS) was purchased
from Fisher Scientific (Hyclone), and the cellular media, contents and the CyQUANT
Cell Proliferation Assay Kit and the MTT Cell Proliferation Assay Kit were purchased
from Invitrogen. Fibroblast cells were incubated at 37oC with 5% CO2 for optimal growth
and proliferation.

10.9.1 Cell Culture Preparation
A vial of cryofixed or frozen yet still viable human dermal fibroblast cells in 10%
glycerol-containing media were plated out into 5 sterile flasks using Dulbeco’s Modified
Eagle Medium (DMEM) and incubated for 2-4 hours, then the media in each flask was
replaced with 20mL of DMEM containing 10% FBS and the cells were incubated for 3-4
days or until they reached confluence. The media was then removed and the cells were
treated with 10mL of 1% trypsin in phosphate buffered saline (PBS) for 10 minutes to
detach the cells from the flasks. The cell suspension was then centrifuged at 20,273 x g
for 15 minutes and the cellular pellet was re-suspended in 15mL DMEM containing 10%
FBS. The total number of cells in the suspension was then determined using a
hemocytometer (a cell counting instrument), and the number of cells per milliliter was
calculated in order to determine the number of cells that will be in each well for the
toxicity assay. The cell suspension was then diluted in DMEM in accordance with the
calculations in order to obtain the correct volume of cell suspension needed for the assay.

10.9.2 CyQUANT Cytotoxicity Assay
A cellular suspension in DMEM, as prepared in 10.9.1, was added in 2mL aliquots to
each well of a 24 well microplate and the cells were incubated for 24 hours in order for
the cells to adhere to the wells prior to sample exposure. Acrylated drug monomers
dissolved in DMSO or nanoparticle emulsions were added to the wells in 20uL aliquots,
or 80mg of disinfected polymer film samples were added to the wells and the cells were
incubated for 24 hours. The media was then removed, the cells were washed three times
with 2mL of PBS, then the cells were lysed using 0.5mL of 1% lysis buffer provided in
the CyQUANT kit followed by a series of freezing and defrosting at -108oC. A 100uL
aliquot from each well containing the lysed cells was placed in a 96 well plate and 100uL
of lysis buffer containing 1% CyQUANT DNA dye was added to each well. The amount
of fluorescence emission was then recorded for each well using the Victor Wallace 1420
spectrophotometer at 485nm excitation and 535nm emission.
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10.9.3 MTT Cytotoxicity Assay
A suspension of human dermal fibroblast cells in DMEM, prepared as described in
10.9.1, was added in 100µL aliquots to each well of a 96 well microplate, and the cells
were incubated for 24 hours in order for the cells to adhere to the wells prior to sample
exposure. Drug monomers dissolved in DMSO or nanoparticle emulsions were added to
the wells in 1µL or 2µL aliquots and the cells were incubated for 24 hours. The MTT dye
solution was then added to each well in 15µL volumes and the cells were incubated for 4
hours. The cells were then treated with 100µL of solubilization/stop solution provided in
the MTT kit and the formazan product was allowed to form for one hour. The amount of
fluorescence absorbance was then recorded for each well using the Victor Wallace 1420
spectrophotometer at 570nm.

10.10 In vivo Nanoparticle Toxicity Studies using a Mouse Model
10.10.1 Nanoparticle Synthesis
Synthesis of the penicillin G acrylamide monomer (13) is described in Section 10.1.3, as
well as synthesis of all the acrylated drug monomers that constituted MDNP1. The
emulsion polymerization process used to form CNP16, NP13, and MDNP1 is described
in Section 10.3.1.

10.10.2 Systemic Model for Toxicity Analysis of Nanoparticles
All animal procedures were conducted under the approval of the University of South
Florida Institutional Animal Care and Use Committee (IACUC). Female CF1 mice
weighing 25-27g (Harlan, Indianapolis, Ind., or Charles River Laboratories, Inc.,
Wilmington, Mass.) were acclimated upon arrival at the College of Medicine Vivarium at
the University of South Florida for 7 days prior to use.
Emulsions CNP16 and NP13 were diluted to solid content concentrations of 5%, 3%,
2%, 1.5%, 0.75%, 0.50%, or 0.25% using nano-purified water. The emulsions were then
either purified by low speed centrifugation using an Eppendorf desktop centrifuge 5415D
at 13.2K rpm (16.1K rcf) for 30 minutes in 2.0 ml Eppendorf Safe-Lock centrifugation
tubes or were used “as is” for the remainder of the study. A 0.1mL volume of either an
emulsion solution or a saline solution was administered to the mouse by intraperitoneal
injection twice a day for 8 days. Mice were also administered the analgesic ketoprofen at
the mouse dose rate of 10mg/kg body weight subcutaneously every 12 hours for the first
72 hours, then as needed per veterinary advice. The animals were monitored for 6
additional days after final sample injection for signs of pain, inflammation, toxicity,
irritation, discomfort, and distress. Blood samples were collected via submandibular vein
bleeds on the final day of treatment (day 8), and via cardiac puncture post-euthanasia
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(day 14). Samples were immediately centrifuged, and serum was stored at -20°C until
measurement of cytokine concentrations could be performed.

10.10.3 Tape-Stripping Abrasion Model for Toxicity Analysis of Nanoparticles
Mice were anesthetized using 3-5% isoflurane at a flow rate of 1L of O2 per minute and
received analgesic treatment via ketoprofen at the mouse dose rate of 10mg/kg body
weight subcutaneously every 12 hours for the first 72 hours, then as needed per
veterinary advice. Mice were kept on an isothermal warming blanket while under
anesthesia and during recovery to maintain normal body temperature. Mice were
removed from the blanket only after consciousness was regained. A 2cm2 area on the
dorsal surface was shaved and cleansed followed by administration of a skin abrasion
through the use of a recently popular tape stripping technique. This technique has been
histologically proven to create an abrasion by removal of most of the epidermal layers of
the skin, exposing the basal layer of epidermis, and in some instances, the upper dermis.
Nanoparticle-containing emulsions were then administered to the exposed area at 9%,
7%, 5%, or 2% solid content concentrations in 0.10mL doses two or three times a day for
8 days. The animals were monitored for 6 additional days after final sample
administrations for signs of pain, inflammation, toxicity, irritation, discomfort, and
distress. Blood samples were collected from each mouse via submandibular vein bleeds
on the final day of treatment (day 8), and via cardiac puncture post-euthanasia (day 14).
Samples were immediately centrifuged, and serum was stored at -20°C until
measurement of cytokine concentrations could be performed.

10.10.4 Biochemical Analysis of Mouse Blood Samples
Concentrations of TNF-α and IL-6 in serum were determined for all blood samples
obtained using an enzyme-linked immunosorbent assay (ELISA) kit (Endogen; Pierce,
Rockford, IL) following the manufacturer’s recommended procedure. Cytokine
concentrations were determined using three wells per serum sample, where a 10uL serum
aliquot was used per well.
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Appendix A: 1H and 13C NMR Spectra
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Spectrum 11.1: 1H NMR (250MHz, CDCl3) of β-lactam 103.

Spectrum 11.2: 1H NMR (250MHz, CDCl3) of β-lactam 105a.
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Spectrum 11.3: 1H NMR (250MHz, CDCl3) and 13C (63MHz, CDCl3) of β-lactam 105b.
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Spectrum 11.4: 1H NMR (250MHz, CDCl3) of β-lactam 106a.

Spectrum 11.5: 1H NMR (250MHz, CDCl3) of β-lactam 2.
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Spectrum 11.6: 1H NMR (250MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 106b.
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Spectrum 11.7: 1H NMR (400MHz, CDCl3) of β-lactam 107.

Spectrum 11.8: 1H NMR (400MHz, CDCl3) of β-lactam 10.
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Spectrum 11.9: 1H NMR (250MHz, CDCl3) and 13C (63MHz, CDCl3) of β-lactam 6.
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Spectrum 11.10: 1H NMR (250MHz, CDCl3) and 13C (63MHz, DMSO) of β-lactam 109.
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Spectrum 11.11: 1H NMR (250MHz, CDCl3) of β-lactam 108.

Spectrum 11.12: 1H NMR (250MHz, CDCl3) of β-lactam 4.
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Spectrum 11.13: 1H NMR (250MHz, CDCl3) and 13C (63MHz, CDCl3) of β-lactam 110.
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Spectrum 11.14: 1H NMR (250MHz, CDCl3) of β-lactam 111.

Spectrum 11.15: 1H NMR (250MHz, CDCl3) of β-lactam 3.
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Spectrum 11.16: 1H NMR (400MHz, CDCl3) of β-lactam 1.

303

Spectrum 11.17: 1H NMR (250MHz, CDCl3) and 13C (63MHz, CDCl3) of β-lactam 118.
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Spectrum 11.18: 1H NMR (250MHz, CDCl3) and 13C (63MHz, CDCl3) of β-lactam 119.
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Spectrum 11.19: 1H NMR (250MHz, CDCl3) and 13C (63MHz, CDCl3) of β-lactam 5.
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Spectrum 11.20: 1H NMR (250MHz, CDCl3) and 13C (63MHz, CDCl3) of ciprofloxacin acrylamide 7.
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Spectrum 11.21: 1H NMR (250MHz, CDCl3) of penicillanic acid acrylamide 11 and polymer NP11.
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Spectrum 11.22: 1H NMR (250MHz, CD3OD) of ampicillin acrylamide 16.

Spectrum 11.23: 1H NMR (250MHz, DMSO-d6) of amoxicillin.
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Spectrum 11.24: 1H NMR (250MHz, CD3OD) of amoxicillin diacrylate 18.

Spectrum 11.25: 1H NMR (250MHz, DMSO-d6) of cefaclor.
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Spectrum 11.26: 1H NMR (250MHz, Acetone-d6) of cefaclor acrylamide 19.

Spectrum 11.27: 1H NMR (250MHz, CDCl3) of poly(butyl acrylate) film CNP2.
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Spectrum 11.28: 1H NMR (400MHz, CDCl3) of poly(butyl acrylate:styrene) film CNP5.

Spectrum 11.29: 1H NMR (400MHz, CDCl3) of poly(butyl acrylate:styrene) film CNP7.
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Spectrum 11.30: 1H NMR (250MHz, CDCl3) of β-lactam:ethyl acrylate polymer NP1a.

Spectrum 11.31: 1H NMR (250MHz, CDCl3) of β-lactam encapsulated polymer NP6.
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Spectrum 11.32: 1H NMR (250MHz, CDCl3) of β-lactam encapsulated polymer NP2.

Spectrum 11.33: 1H NMR (250MHz, CDCl3) of ciprofloxacin:butyl acrylate:styrene polymer NP7.
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Spectrum 11.34: 1H NMR (250MHz, CDCl3) of doxycycline encapsulated polymer NP24.
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